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ABSTRACT 
 
The aim of this thesis was to validate the optimal surgical management of colorectal 
liver metastases (CLM) by using an evidence based approach. 
 
A meta-analysis comparing combined and sequential resection for synchronous CLM 
demonstrated that combined resection is associated with reduced hospital stay and with 
comparable perioperative mortality and morbidity, operative blood loss, and survival 
rates as sequential resection. Nevertheless, combined resection was associated with 
lower metastatic disease severity compared to sequential resection.  
 
A meta-analysis assessed liver resection for CLM in the presence of hepatic lymph node 
involvement and demonstrated that survival rates are lower in node positive disease 
patients compared to node negative disease patients, irrespective of whether the positive 
disease nodes were detected by routine or selective lymphadenectomy, or whether nodal 
involvement was microscopic or macroscopic.  
 
A network meta-analysis comparing different treatment strategies aiming to decrease 
operative blood loss found no difference in mortality, length of hospital stay or ITU stay 
between the treatment strategies. The use of radiofrequency dissecting sealer resulted in 
more serious adverse events compared to the clamp-crush method in the absence of 
vascular occlusion and fibrin sealant. Simple methods, such as clamp-crush method, 
gave overall equivalent outcomes to methods which require special equipment.  
 
Not reporting the period of follow-up was investigated as a potential source of study 
bias. Overall analysis did not identify a significant difference in mortality and disease 
recurrence, but sensitivity analysis of more recent reviews and larger reviews showed 
that the trials reporting the period of follow-up had a significantly lower hazard ratio for 
disease recurrence compared to trials not reporting the period of follow-up. 
 
A network meta-analysis comparing interventions aiming to decrease ischaemia-
reperfusion injury during liver resection, demonstrated that ischaemic preconditioning 
resulted in fewer serious adverse events, lower operative blood loss, fewer transfusion 
proportions, and shorter operative time.  
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1.1 COLORECTAL LIVER METASTASES 
 
Cancer is one of the leading causes of death worldwide, accounting for 8.2 million 
deaths in 2012.1 Worldwide, colorectal cancer is the second most common cancer in 
women (614,000 cases diagnosed every year, 9.2% of all cancer diagnoses),1 and the 
third most common in men (746,000 cases,10.0% of all cancer diagnoses).1 Every year, 
approximately 1.3 million people are diagnosed with colorectal cancer.1, 2 Almost 55% 
of all cases of colorectal cancer are diagnosed in the more developed countries.1 
Importantly, colorectal cancer is the fourth most common cause of cancer death 
worldwide after lung, stomach, and liver cancer,3 resulting in about 694,000 deaths 
every year.3  
 
In England and Wales, colorectal cancer is the second most common cancer after lung 
cancer, in terms of both incidence and mortality.4  Each year, over 30,000 new cases of 
colorectal cancer are diagnosed in England and Wales, and colorectal cancer is 
registered as the underlying cause of death in about half this number.4 In the United 
States (US) colorectal cancer is the third most prevalent form and has the second 
highest mortality rate of any cancer.5 It is estimated that 142,820 new cases and 50,830 
deaths occurred due to colorectal cancer in 2013 in the US.6 
 
Approximately 50% to 60% of patients with colorectal cancer will develop colorectal 
liver metastases (CLM) during their lifespan.7-9 In some people with colorectal cancer, 
the liver spread is present at the time of diagnosis of the primary tumour (synchronous 
metastases) and in others, the liver spread is identified at a later stage (metachronous 
metastases). Approximately 15% to 25% of patients with colorectal cancer have 
detectable liver metastases at the time of presentation (synchronous CLM) and a further 
20% to 25% of patients will develop metastases during the course of their disease 
(metachronous CLM).10-13  
 
The presence of CLM is a poor prognostic indicator with the median survival for 
untreated disease ranging between six to twelve months.14, 15 Removal of part of the 
liver to which the cancer has spread (liver resection), the only curative option for people 
with CLM, is indicated in the 20% to 30% of patients in whom the metastases are 
confined to the liver.7, 16-18 Five-year survival for patients with CLM who undergo liver 
resection, ranges between 32 and 58%,19-27 and 10-year survival ranges between 22 and 
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28%.20-22, 25-27 Table 1.1. shows the 5-year and 10-year survival for patients with CLM 
who underwent liver resection with curative intention from studies published in the 
literature. 
 
 
 
 
Table 1.1: Five-year and 10-year survival for patients with CLM who underwent liver 
resection with curative intention from studies published in the literature (NR=not 
reported). 
 
Author Year Participants 5-year survival 10-year survival 
Gayowski et al.23 1994 204 32% NR 
Scheele et al.26 1995 350 39% 24% 
Fong et al.21 1999 1001 37% 22% 
Choti et al.20 2002 226 40% 26% 
Abdalla et al.19 2004 190 58% NR 
Pawlik et al.24 2005 557 58% NR 
Wei et al.27 2006 423 47% 28% 
Fortner et al.22 2009 293 35% 24% 
Pulitano et al.25 2010 309 32% 23% 
 
 
 
  
 
For patients with unresectable CLM, modern systemic neoadjuvant chemotherapy can 
be used to downsize the liver metastases so that an R-0 resection (negative tumour 
margins) is possible, and allows approximately 12.5% of patients with unresectable 
CLM to be rescued by liver surgery.16, 28, 29 Furthermore, the use of modern adjuvant 
chemotherapy for patients with CLM who underwent liver resection with curative 
intent, may result in improvement of disease-free survival and overall survival.30-34 
Along with the benefits of chemotherapy, chemotherapeutic agents can cause liver 
parenchymal injury, known as chemotherapy-associated steatohepatitis (CASH), which 
results in increased postoperative morbidity in patients who had undergone 
hepatectomy.35, 36 
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The imaging modalities most frequently used for detection, staging, and determining 
resectability of CLM are computed tomography (CT), magnetic resonance imaging 
(MRI) which is liver specific, and 18-fuorodeoxyglucose (FDG) positron emission 
tomography CT (PET-CT) which is patient specific.37-40 The use of all three imaging 
modalities as a triple liver assessment is associated with low futile laparotomy rates, and 
is considered routinely in all patients being considered for hepatectomy.37-39 A study by 
Dunne et al. suggested that with modern imaging, the potential yield of staging 
laparoscopy is low, and that staging laparoscopy should not be used routinely.37 
According to Yip et al., assessment of initial CT, followed by a multidisciplinary team 
(MDT) discussion of patients with CLM, with subsequent PET-CT and MRI imaging 
thereafter (hybrid model), is associated with the shortest time-to-decision and lowest 
cost.39 
 
Patients suffering with CLM should be managed by a MDT at centres specialised in the 
diagnosis, staging, and oncological and/or surgical treatment of CLM. Management of 
patients suffering with CLM without the involvement of a specialist liver MDT, or 
tumour board, may lead to inappropriate management of these patients and is associated 
with lower resection rates, and patients being inappropriately denied potentially curative 
treatments.39, 41 Consequently in the United Kingdom (UK) it is now seen as the 
standard of care that a specialist liver surgeon and specialist liver MDT should assess all 
patients suffering with liver limited metastases from colorectal cancer.39, 42 
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1.2 LIVER RESECTION 
 
Liver resection, or hepatectomy, refers to removal of part of the liver. The liver is a 
common site for both primary and secondary malignancy. Hepatic resection is the main 
curative treatment for primary and metastatic cancer of the liver. Unfortunately, only 10 
to 20% of patients are candidates for this treatment.43, 44 For the remaining patients the 
main alternative treatment would be palliative chemotherapy. Tumour ablation (e.g. 
radiofrequency ablation, microwave ablation, high-intensity focused ultrasound, 
cryoablation, chemical ablation, selective internal radiotherapy treatment) has emerged 
as a promising alternative treatment, and in a few cases may downstage patients to 
allow a potentially curative hepatectomy.43 
 
The most common reasons for liver resection are CLM, hepatocellular carcinoma 
(HCC), cholangiocarcinoma, and benign liver tumours.45, 46 Anatomically, the liver can 
be subdivided into eight segments as described by Couinaud,47 based on the fact that 
each has its own vascular inflow, outflow and biliary as well as lymphatic drainage. In 
the centre of each segment there is a branch of the portal vein, hepatic artery and bile 
duct; in the periphery of each segment there is vascular outflow through the hepatic 
veins.47 Each Couinaud segment can be removed individually, or in combination, by 
right hemi-hepatectomy (Couinaud segments 5 to 8), left hemihepatectomy (segments 2 
to 4), right trisectionectomy (segments 4 to 8), or left trisectionectomy (segments 2 to 5 
and 8 ± 1) (see Figure 1.1).48 Although every liver resection is considered major 
surgery, major hepatectomy is defined as a right or left hemihepatectomy (or 
lobectomy), or extended hemihepatectomy (or extended lobectomy), or resection of 
three or more liver segments according to Couinaud.47 
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Figure 1.1: Anatomically, the liver is subdivided into eight segments as described by 
Couinaud. In the centre of each segment there is a branch of the portal vein, hepatic 
artery and bile duct; in the periphery of each segment there is vascular outflow through 
the hepatic veins (figure by Schiff et al.).49 
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Liver resection is feasible, and safely performed, as an open operation, laparoscopically, 
or with a robot. At first, laparoscopic liver resection was looked upon with scepticism 
because of concerns regarding parenchymal transection, bleeding control, bile leakage, 
incomplete tumour resection, air embolism, and difficult retraction and liver 
mobilization during laparoscopy with the risk of injuring major adjacent structures.50-54 
Nevertheless, studies comparing laparoscopic versus open liver resections have shown 
that laparoscopic hepatectomy is a safe and feasible option, and demonstrated no 
significant difference in operating time, postoperative adverse events, extent of 
oncologic clearance, disease recurrence, or overall survival between laparoscopic and 
open hepatectomy.53, 55-57 Furthermore, laparoscopic liver resection was shown to result 
in significantly lower operative blood loss, fewer patients requiring blood transfusion, 
and shorter length of hospital stay.53, 56, 57 Moreover, studies comparing laparoscopic 
versus robotic liver resection demonstrated no difference between the two minimally 
invasive techniques in operative and postoperative outcomes (as measured by 
intraoperative blood loss, transfusion rate, negative margin rate, postoperative liver 
function tests, postoperative intensive care unit admission rate, length of hospital stay, 
and 90-day mortality).58-60 Robotic hepatectomy resulted in significantly longer 
operative times59 and higher costs;60 however, it also allowed for an increased 
percentage of major hepatectomies to be performed in a purely minimally invasive 
fashion.59 
 
Over the years, indications for liver resection have been broadened and the number of 
liver resections performed has increased. The number of liver resections performed in 
the UK has more than doubled over the last 10 years, from around 1000 in 2003, to 
around 2400 liver resections in 2013.61, 62 This increase is probably due to the existence 
of cancer networks, regional referral guidelines, MDTs, and published results on 
surgical outcomes. It is also due to advances in diagnostic and imaging techniques, 
operative and anaesthetic methods, neo-adjuvant therapy, improvements in the 
perioperative care, better patient selection, and better understanding of hepatic anatomy 
resulting in anatomically based resections.45, 46, 63 Despite these advances, liver resection 
remains a major surgical procedure with significant mortality of around 4% and 
morbidity of around 40%.45, 46, 63 
 
Intraoperative haemorrhage remains one of the major risks during liver resections, and 
operative blood loss and perioperative blood transfusion are two of the most important 
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factors affecting perioperative morbidity and mortality.45, 46, 64, 65 Therefore, minimising 
blood loss is of major importance, and methods of hepatic vascular occlusion have been 
developed over the years to reduce the bleeding during elective liver resection.66 By 
using different techniques to control the hepatic blood inflow and outflow the surgeons 
manage to decrease the blood loss during hepatic resections resulting in decreased need 
for blood transfusion, and lower morbidity and mortality. Clamping of the portal pedicle 
(Pringle manoeuver, i.e. clamping of the hepatic artery and portal vein) is the oldest and 
commonest method of hepatic vascular occlusion and can be performed either 
continuously or intermittently during the parenchymal resection.67-69 Also, different 
methods of liver transection have been used to reduce blood loss, such as the clamp-
crush method, the Cavitron ultrasonic surgical aspirator, or the radiofrequency 
dissecting sealer. In addition, different methods of management of the cut surface of the 
liver have been used, such as the use of fibrin sealant, argon beamer, or electrocautery 
and suture material.66, 70  
 
Hepatic vascular occlusion aims to decrease operative blood loss, but, along with 
mobilization and retraction of the liver during surgery, it causes ischaemia and 
reperfusion (IR) injury to the liver. Control of the hepatic blood inflow and outflow 
have allowed major hepatic resections to be carried out with decreased blood loss but it 
has done so at the expense of liver damage from warm ischaemia and reperfusion. IR 
injury of the liver involves a number of mechanisms. Ischaemia followed by reperfusion 
results in the activation of Kupffer cells (liver macrophages) and 
polymorphonucleocytes, production of reactive oxygen species and pro-inflammatory 
cytokines, and induction of endothelial cell surface adhesion molecules, resulting in 
microvascular hypo-perfusion and liver parenchymal damage.71-74 Figure 1.2, taken 
from a study by Datta et al.,75 is a schematic diagram of the cellular mechanisms 
involved during IR injury of the liver. According to Datta et al., IR injury is initiated by 
reactive oxygen species which cause direct cellular injury and sinusoidal perfusion 
failure from platelet plugging.75 Then a cascade of molecular mediators is activated 
leading to microvascular and acute inflammatory changes. Kupffer cells activate CD4+ 
T-cells that activate natural killer T-cells which cause sinusoidal endothelial cells (SEC) 
and hepatocyte injury, followed by neutrophil activation, adhesion and transmigration, 
resulting in more necrosis and/or apoptosis of SEC and hepatocytes.75   
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Figure 1.2: A schematic diagram of the cellular mechanisms involved during IR injury 
of the liver. IR injury is initiated by reactive oxygen species which cause direct cellular 
injury and sinusoidal perfusion failure from platelet plugging. Then a cascade of 
molecular mediators is activated leading to microvascular and acute inflammatory 
changes. Kupffer cells activate CD4+ T-cells that activate natural killer T-cells which 
cause sinusoidal endothelial cells (SEC) and hepatocyte injury, followed by neutrophil 
activation, adhesion and transmigration, resulting in more necrosis and/or apoptosis of 
SEC and hepatocytes (taken from Datta et al.75). 
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Patients with cirrhotic liver are more sensitive to IR injury than patients with normal 
liver.76, 77 Many methods have been used to decrease IR injury during liver resection, 
including hypothermia,78 mechanical interventions such as ischaemic preconditioning,67, 
68, 76, 79, 80 ischaemic post-conditioning,81 and pharmacological interventions such as 
anti-oxidants,82 prostaglandins,83 steroids,84, 85 different anaesthetic agents,86, 87 
treatments to increase hepatocellular glycogen,88, 89 and treatments affecting the 
cardiovascular system.90, 91 These interventions can be used alone or in combination. 
Ischaemic preconditioning is the mechanism by which brief periods of ischaemia 
followed by reperfusion of the organ results in the ability of the organ to withstand a 
subsequent prolonged period of ischaemia.92 Ischaemic preconditioning may be direct 
(i.e. hepatic vascular occlusion for brief periods before liver resection) or remote (i.e. 
brief episodes of ischaemia–reperfusion applied in distant tissues or organs to render the 
liver resistant to subsequent sustained episode of ischaemia).93, 94 
 
Before major hepatic resection, assessment of the anticipated functional remnant liver is 
essential in order to avoid postoperative hepatic insufficiency. In a study by Mullen et 
al., the hepatic insufficiency-related mortality rate was 2.8%.95 Although the risk of 
postoperative hepatic insufficiency is influenced by multiple factors, a key determinant 
to ensuring adequate functional remnant liver is preoperative measurement of the future 
liver remnant (FLR) volume.96-99 Preoperative volumetric analysis of the anticipated 
FLR is an essential component of surgical planning and the expected remnant liver 
volume appears to be a good predictor for liver failure in patients who undergo 
hepatectomy.100, 101 The volume of the FLR correlates with FLR function and 
postoperative outcome.100, 102-104 Careful patient selection based on volumetric analysis 
in major hepatectomy cases ensures that sufficient functional liver parenchyma remains 
and, consequently, minimizes the risks of postoperative hepatic insufficiency and 
mortality.99-101  
  
Because CT is routinely performed for both tumour staging and preoperative surgical 
planning, 3-dimensional CT volumetry has become the standard technique for 
measuring FLR.100, 101, 104, 105 CT measurements of preoperative FLR volume have been 
found to correlate linearly with actual volumes of the resected specimens.98, 100, 106 
Using standardized liver volumetry, guidelines have been proposed regarding the 
minimal amount of functional liver necessary for successful hepatic resection, based on 
multiple studies demonstrating a correlation between standardised FLR and 
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postoperative outcome.100, 104, 107-109 Minimum standardised FLR thresholds for safe 
hepatectomy have been identified as 20% in patients with normal livers, 30% in those 
with chemotherapy-related liver injury, and 40% in those with chronic liver disease.100  
 
When the anticipated FLR is estimated to be too small for major liver resection, 
preoperative portal vein embolization (PVE) is indicated.99, 100, 106 PVE reduces the size 
of the liver to be resected and increases the volume of the remnant liver by inducing 
hypertrophy of the non-embolized liver, allowing a safer hepatectomy.96-98 The 
minimum standardized FLR and indications for PVE are tailored to each patient and 
depend on many factors, including the complexity of the anticipated resection, 
simultaneous procedures, patients’ comorbidities, and underlying liver disease.97, 100 The 
hypertrophy of FLR induced by PVE has beneficial effects on the postoperative course 
in patients with normal liver and in patients with chronic liver disease.97, 100, 108 
 
For patients with synchronous liver metastases, traditionally most surgeons perform a 
‘sequential’ resection, whereby the primary colorectal tumour is resected first followed 
by liver resection at a later stage.110 More recently, surgeons have started performing 
‘combined’ resections whereby the primary tumour and liver resection are performed 
concurrently.11 Nevertheless, there remain concerns regarding combined resections 
about both the safety and the long-term oncological effects, and surgeons perform 
combined resections in a selected group of patients with an easily resectable primary, 
limited metastatic disease, and few comorbidities.111-113  
 
Liver resection for CLM in the presence of hepatic lymph node involvement is 
controversial. Hepatic node involvement detected pre-operatively or during surgery is 
considered as a poor prognostic factor114-116 and has been labelled as a contraindication 
to surgery.115 Both macroscopic and microscopic lymph node involvement have been 
shown to have a negative impact on survival.116-119 Nevertheless, with significant 
improvements in perioperative cross sectional imaging, patient selection for liver 
resection, the safety of surgical techniques and chemotherapeutic agents in recent years, 
the previous contraindication to surgery in patients with hepatic node involvement is 
being challenged. 
 
After liver resection for CLM, patients need to be followed up for a period of years in 
order to properly assess their response to treatment. Survival and disease recurrence are 
21 
 
the main outcomes when comparing treatments for CLM, and long period of follow-up 
is required to assess these outcomes. The optimal follow-up period in comparing 
treatments in patients with CLM with regards to survival benefit is not known. While 
following these patients for a long period will provide definitive answers, a long follow-
up period will increase the trial costs and delay the adoption of treatment whereas a 
short period of follow-up may not be informative.  
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1.3 EVIDENCE BASED APPROACH 
 
Evidence-based medicine (EBM) is the application of scientific method and the use of 
evidence from well designed and conducted research in healthcare decision-making.120  
EBM advocates that to the greatest extent possible, decisions and policies should be 
based on scientific evidence, not just the beliefs of healthcare practitioners, experts, or 
administrators.120 EBM promotes the use of formal, explicit methods to analyse 
scientific evidence and make it available to healthcare decision makers.120 Sackett et al. 
defined evidence-based medicine as "the conscientious, explicit, and judicious use of 
current best evidence in making decisions about the care of individual patients. The 
practice of evidence based medicine means integrating individual clinical expertise with 
the best available external clinical evidence from systematic research."121 Greenhalgh 
provided a definition emphasizing the use of quantitative methods in EBM: "the use of 
mathematical estimates of the risk of benefit and harm, derived from high-quality 
research on population samples, to inform clinical decision-making in the diagnosis, 
investigation or management of individual patients".122 
 
The five steps of EBM in practice were first described in 1992,123 and a consensus 
statement developed by the delegates at the second international conference of 
Evidence-Based Health Care Teachers and Developers held in Sicily in September 2003 
summarised the five steps of EBM as shown in Table 1.2.124 
 
 
 
Table 1.2: The five steps of EBM.124 
 
1. Translation of uncertainty to an answerable question 
2. Systematic retrieval of best evidence available 
3. Critical appraisal of evidence for validity, clinical relevance, and applicability 
4. Application of results in practice 
5. Evaluation of performance 
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To help identify the best evidence, the levels of evidence in the medical literature have 
been categorised according to the strength of their freedom from the various biases that 
beset medical research. An example of a system for grading evidence for a treatment is 
the Oxford (UK) Centre of Evidence Based Medicine Levels of Evidence shown in 
Table 1.3.125 
 
 
 
 
 
Table 1.3: The Oxford (UK) Centre of Evidence Based Medicine Levels of 
Evidence.125 
 
1a: Systematic reviews (with homogeneity) of randomised controlled trials 
1b: Individual randomised controlled trials (with narrow confidence interval) 
1c: All or none randomised controlled trials 
2a: Systematic reviews (with homogeneity) of cohort studies 
2b: Individual cohort study or low quality randomised controlled trials (e.g. <80% follow-up) 
2c: "Outcomes" Research; ecological studies 
3a: Systematic review (with homogeneity) of case-control studies 
3b: Individual case-control study 
4: Case-series (and poor quality cohort and case-control studies) 
5: Expert opinion without explicit critical appraisal, or based on physiology, bench research or 
"first principles" 
 
 
 
 
 
The current system used for grading the level of evidence is the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) system.126 The 
GRADE working group began in 2000 with the aim to develop a common, sensible 
approach to grading quality of evidence and strength of recommendation. According to 
the GRADE working group, it is essential to know whether a recommendation is strong 
(we can be confident about the recommendation) or weak (we cannot be confident), 
because poor quality evidence can lead to recommendations that are not in the patients’ 
best interests.126 Some grading systems are based on study design alone without explicit 
consideration of other important factors in determining quality of evidence, and other 
systems are excessively complex.126 The GRADE system categorizes the quality of the 
evidence as high (further research is very unlikely to change our confidence in the 
estimate of effect), moderate (further research is likely to have an important impact on 
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our confidence in the estimate of effect and may change the estimate), low (further 
research is very likely to have an important impact on our confidence in the estimate of 
effect and is likely to change the estimate), and very low (any estimate of effect is very 
uncertain). The GRADE working group developed a software application that facilitates 
the use of the approach and allows the development of summary tables.126 
 
Because the randomised trial, and especially the systematic review of several 
randomised trials, is so much more likely to inform us and so much less likely to 
mislead us, it has become the “gold standard” for judging whether a treatment does 
more good than harm.121 If several studies address the same clinical question, the 
evidence may be summarised in ‘evidence tables’, or the results of the studies may be 
synthesized in the form of meta-analyses.127 If the studies have similar design and 
assess the same quantitative outcomes, a meta-analysis can be performed to statistically 
combine and compare quantitative results from several similar studies and produce 
effect estimates for each outcome. If the exposure and/or outcome differ too much 
between studies, it may not be possible to conduct a meta-analysis combining results 
from individual studies, and the researchers may do a systematic review only and 
produce the results as ‘evidence tables’. Systematic reviews or meta-analyses of the 
published medical literature is a major part of the evaluation of various medical 
treatments and are important in deciding the medical or surgical management of 
patients. 
 
Liver surgery can cure metastatic colorectal cancer although in only a small proportion 
(10 to 20%) of patients who are eligible for surgery.43, 44 However, with advances in 
technique and better understanding of the natural history of the condition, more patients 
can have safe, potentially curative surgery. The management of colorectal liver 
metastases has changed significantly over the years due to major advances in 
technology, radiological imaging, surgery, and chemotherapy. There is a vast amount of 
research available on this subject offering opportunities for systematic reviews and 
meta-analyses to be performed. 
 
There are many unanswered questions in the surgical management of CLM. Liver 
resection is a major surgery with significant risk of mortality and morbidity, with 
excessive blood loss from the cut surface of the liver being a major reason. Various 
methods have been attempted to decrease the blood loss and hence the complications 
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during liver resection. These methods include temporary occlusion of the blood vessels 
that supply the liver at the time of resection; different methods of liver transection; and 
different methods of management of cut surface of the liver. However, the benefit or 
efficacy of these different methods is not known. 
 
In addition, blocking the blood vessels supplying the liver in order to reduce 
haemorrhage during resection, can affect the liver that is not removed by causing IR 
injury, resulting in significant postoperative morbidity and mortality. Many 
interventions have been attempted to decrease the damage to the remnant liver including 
hypothermia,78 mechanical interventions such as repeated cycles of brief blockage of 
blood supply to the liver which 'conditions' or 'primes' the liver cells to withstand 
prolonged periods of blockage of blood supply,67, 68, 76, 79, 80, and medicines such as anti-
oxidants82 or steroids.84, 85 Whether any of these interventions to decrease IR injury 
during liver resection are beneficial is not known, and currently, none of these 
interventions is considered standard practice. 
 
Apart from the method of performing liver resection, various other controversies related 
to the surgical management of CLM exist. In people with synchronous liver metastases, 
the options are bowel resection and liver resection at the same time (simultaneous liver 
and bowel resection), or bowel resection initially followed by liver resection at a later 
time (sequential resection). The dilemma is because both bowel resection and liver 
resection are major operations and performing both simultaneously may be more 
challenging than performing each operation separately. Another major controversy is 
whether liver resection should be performed in patients with hepatic lymph node 
metastases. Furthermore, it is important to identify potential sources of bias in 
comparative trials comparing treatments for CLM, for example, whether not reporting 
the follow-up in a comparative trial is a possible source of bias.  
 
This thesis includes a series of systematic reviews or meta-analyses, attempting to find 
answers to the above questions based on the current evidence in the medical literature. 
Network meta-analysis will also be used, a recent development in meta-analysis. 
Network meta-analysis is performed when multiple interventions are available for the 
treatment of a disease and have been compared in different head-to-head comparisons. 
No previous network meta-analyses have been published in the field of 
HepatoPancreatoBiliary (HPB) surgery, and it is important to evaluate this new method 
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of meta-analysis in HPB surgery because it is a valuable research tool with important 
advantages, as discussed in Chapter 3. The topics identified for systematic reviews, 
pairwise meta-analyses, and network meta-analyses in this thesis are shown in Table 
1.4.  
 
 
Table 1.4: Topics identified for systematic review in this thesis. 
 
Theme Aim Comparison 
Timing of liver 
resections 
Identify the best timing for liver resections in 
patients presenting with synchronous CLM 
Combined liver and bowel 
resection versus sequential 
resection for synchronous CLM 
Liver resection 
in the presence 
of hepatic node 
metastases 
Compare survival and disease recurrence in 
node positive versus node negative disease, 
assess whether liver resection should be 
performed in patients with hepatic lymph 
node metastases, and whether there is a 
survival benefit from lymphadenectomy 
Survival and disease recurrence 
of lymph node positive versus 
lymph node negative disease 
Decrease blood 
loss during 
elective liver 
resection 
Identify the best combination of methods to 
decrease blood loss during elective liver 
resection 
Assess the comparative benefits 
and harms of different 
treatment strategies aiming to 
decrease blood loss 
Reporting the 
follow-up 
period in a trial 
Investigate whether not reporting the follow-
up period in comparative trials of patients 
with CLM is a potential source of bias 
Compare time-to-event 
outcomes (survival, disease 
recurrence) of trials reporting 
versus not reporting period of 
follow-up 
Decrease IR 
injury during 
elective liver 
resection 
Identify the best methods to decrease IR 
injury during elective liver resection 
Compare the benefits and 
harms of different methods 
aiming to decrease IR injury 
 
 
 
Performing the above systematic reviews will benefit, most importantly, the patients 
suffering with CLM. With the above meta-analyses, the best methods of liver resection 
will be identified, aiming to decrease the mortality and morbidity related to the 
operation. The timing of liver resection for patients with synchronous CLM, and 
whether liver resection is indicated in patients with CLM and hepatic node metastases, 
will benefit these two important subgroups of patients with CLM. Furthermore, these 
systematic reviews will provide information to surgeons about the best methods of 
performing liver resection for CLM, the best timing for resection of synchronous CLM, 
and indications for liver resections. Identification of new areas of research and possible 
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sources of bias in comparative trials will benefit the researchers involved in trials 
comparing treatments for CLM and liver resection. In addition, the above systematic 
reviews will assist healthcare managers by providing information as to whether special 
equipment can improve the results of liver resection surgery and decrease the hospital 
costs. Finally, the review of the literature on such an important topic related to a large 
number of publications will assist guideline developers in developing guidelines for the 
management of patients with CLM. 
 
 
 
 
 
1.4 THESIS HYPOTHESIS AND AIM 
 
 
Hypothesis:  
The hypothesis of the current thesis is that the optimal and effective approach for 
management of colorectal liver metastases can be identified by using the available 
published data through the application of an evidence based methodology. 
 
Aim:  
Through a series of systematic reviews, pairwise meta-analyses, and network meta-
analyses of published data, this thesis aims to identify the best approach to optimal 
surgical management of CLM in order to provide patients suffering with CLM the best 
possible care. The above hypothesis will be tested by assessing the quality of the 
available evidence and by assessing whether further research is necessary and how this 
should be conducted. 
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CHAPTER 2 
 
 
PAIRWISE META-ANALYSIS 
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2.1 DEFINITION 
 
Meta-analysis is a statistical and analytical technique designed to integrate and 
summarise the results of multiple independent studies.128 
 
 
2.2 ADVANTAGES AND DISADVANTAGES 
 
There is a vast array of information and diversity of evidence in the medical 
literature. CLM is an example of a medical condition where many thousands of 
medical papers have been published on its pathogenesis, diagnosis, treatment, and 
prognosis. The amount of information in the medical literature has become 
overwhelming, resulting in a need for review articles which summarise the large 
volumes of information available and allow conclusions to be drawn. A systematic 
review has a formal approach to gathering, evaluating, and presenting the medical 
evidence. A meta-analysis is similar to a systematic review article, with the added 
step of using formal statistical methods to calculate a summary result or results. 
Therefore, a meta-analysis has the added advantage of a systematic qualitative and 
quantitative analysis to support its findings or arguments. 
 
There are many situations where multiple studies may have been published on a 
medical topic, but due to their small individual size, they may have not been able to 
demonstrate with statistical significance a difference which does exist between two 
medical modalities. This is known as a type II error, which occurs when the null 
hypothesis (H0: no difference between interventions) is false, but erroneously fails to 
be rejected. The power of a statistical test is the probability that it correctly rejects 
the null hypothesis when the null hypothesis is false, and is equal to 1-β, where β is 
the probability of a Type II error occurring. By combining many studies of small 
size, a meta-analysis increases the overall sample size of the statistical analysis, and 
thus increases the power to study effects of interest.128 Therefore, a meta-analysis has 
more power than individual studies to identify a true difference that exists between 
two interventions, especially for outcomes that require larger sample sizes. In 
addition, a meta-analysis not only has more power to identify statistical difference, 
but also, increases the precision in estimating the size of the effects of difference 
30 
 
between treatments.128 As more data is included in a meta-analysis, the precision and 
accuracy of estimates can be improved, and this, in turn, may increase the statistical 
power to detect an effect. 
 
Instead of performing large expensive randomised controlled trials (RCTs) to answer 
important clinical questions, or in situations where an RCT cannot be performed due 
to practical or ethical concerns, meta-analyses can be an inexpensive alternative and 
can in this way shape healthcare policies.128 A well-designed meta-analysis can 
provide valuable information for clinicians, researchers, managers, and 
policymakers.128 Often, meta-analyses may form the initial step of a cost-
effectiveness analysis, decision analysis, or grant application. Meta-analyses can be 
used to design future research, to provide evidence in the regulatory process, and to 
modify clinical practice.129 
 
The role of meta-analytic techniques has been a source of extensive debate amongst 
epidemiologists. Summarizing large amounts of varied information using a single 
number is a controversial aspect of meta-analysis.128 There is a concern that all biases 
inherent to the individual studies, are brought into the meta-analysis. Critics argue 
that the effect of meta-analysis is to “reinforce the inherent systematic biases of the 
studies, produce spurious statistical stability and discourage further research.”130, 131 
Another argument against meta-analysis is that it may include and compare studies of 
different methodology and with different inclusion criteria for participants, therefore 
comparing different groups of participants with different characteristics. If studies are 
clinically diverse then a meta-analysis may be meaningless, and genuine differences 
in effects may be obscured. 
 
Compared with single RCTs, meta-analysis not only improves the power to detect 
differences between treatments, but also facilitates the examination of the extent to 
which there are important differences in treatment effects across RCTs.132 This 
between-study variability in a group of studies is frequently called heterogeneity. 
With a meta-analysis, inconsistency or variation in results across studies can be 
identified, quantified, and analysed. Identifying heterogeneity between studies raises 
more questions and promotes further research to identify the source of heterogeneity 
between studies. On the other hand, large, unexplained heterogeneity may reduce a 
reader’s confidence in estimates of treatment effects of a meta-analysis.132  
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Multiple studies may have been published on a medical topic with conflicting results. In 
these situations, meta-analyses can help resolve medical controversies or uncertainties 
caused by conflicting studies by pooling all the results of the individual studies and 
produce a summary result. Pooling the results of conflicting studies in order to produce 
a summary result can be done only in the absence of clinical or methodological 
heterogeneity. If there are conflicting results because of clinical or methodological 
heterogeneity, it is usually inappropriate to perform a meta-analysis. 
 
Distinction should be made between “synthetic” meta-analysis, in which a single 
summary is reported while heterogeneity is ignored, and “comparative” meta-
analysis, in which heterogeneity is taken into account and attempts are made to 
explain it.133 The latter serves as an aid in critical comparison between studies, and 
there seems to be general agreement that the “comparative” approach has a place in 
medical literature and may complement qualitative reviews.130, 134 Proponents of 
meta-analysis argue that statistical quantification and pooling of results from many 
studies provide an excellent tool for identifying reasons for variability and 
inconsistency, and that the finding of heterogeneity sets the stage for further research 
on a given topic.135  
 
Moreover, a meta-analysis allows the evaluation of the effects in subsets of 
patients.128 If there is a difference between groups of participants in a meta-analysis 
(e.g. cirrhotic vs non-cirrhotic livers), which may act as a confounding factor or 
moderator, a meta-analysis allows sensitivity analysis to be performed on a specific 
subset of patients. Also, moderators can be included in a meta-analysis to explain 
variation between studies. Metaregression is a useful tool used in meta-analysis to 
identify confounding factors or moderators and examine their impact on study effect 
size using regression-based techniques. Furthermore, publication bias occurs because 
studies with a statistically significant outcome are more likely to be published that 
those that don’t. There is concern that these studies are more likely to be included in 
a meta-analysis. Nevertheless, with a meta-analysis, the presence of publication bias 
can be identified and investigated with the help of funnel plots. 
 
A meta-analysis has the potential of generating new hypotheses for future studies, 
and overall promotes and helps guide further research. On the other hand, a meta-
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analysis has the ability to determine if new studies are needed to further investigate a 
specific clinical question.128 For example, if the results of a well-conducted meta-
analysis are statistically significant with no heterogeneity between numerous high 
quality RCTs, a valid argument can be made that no further trials are required 
attempting to answer the same clinical question. First, it would be unethical to 
perform another trial on patients or animals when the research question has already 
been answered confidently, and second, with the limited funding available to 
research, the funding will be better spent on trials attempting to solve new 
unanswered research questions. 
 
Many researchers believe that meta-analyses should be conducted only on RCTs. 
Very often in surgery, due to the nature of the specialty, there are no RCTs on a 
clinical subject, and meta-analyses are performed based on non-randomised studies. 
There is an obvious disadvantage in using non-randomised studies due to their 
inherent biases which are transferred into the meta-analysis. Nevertheless, there is an 
argument to be made in performing meta-analyses on non-randomised studies when 
RCTs are not available. Deeks et al. evaluated non-randomised intervention studies 
by using resampling techniques (generated non-randomised studies from two large 
multicentre RCTs and selectively resampled trial participants according to allocated 
treatment, centre and period), and have found that “results of randomised and 
nonrandomised studies sometimes, but not always, differ and that both similarities 
and differences may often be explicable by other confounding factors”.136  They also 
argued that non-randomised studies should be undertaken when randomization is 
“unfeasible or unethical.”136 Meta-analysis of non-randomised studies is useful in the 
absence of RCTs as well as to guide further researchers toward properly informed 
randomisation, if possible, in future studies. 
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2.3 METHODS 
 
In this section, an overview of the methods followed in the meta-analyses included in 
this thesis is described. The first step was to decide the clinical question or clinical 
subject that needed to be systematically reviewed, and the research hypothesis was 
defined. 
 
 
2.3.1 Search strategy 
 
The second step was to perform a literature search to identify the studies for inclusion in 
the meta-analyses. A comprehensive literature search was performed using a 
combination of free-text terms and controlled vocabulary when applicable of the 
following electronic databases: MEDLINE, EMBASE, Science Citation Index 
Expanded, and Cochrane Central Register of Controlled Trials (CENTRAL) in The 
Cochrane Library. The specific search strategies for the meta-analyses conducted are 
described in more detail in the individual sections of this thesis. The “related articles” 
function from PubMed was used to broaden the search, and all abstracts, studies, and 
citations scanned were reviewed. The references of the identified trials were also 
searched to identify additional trials for inclusion.  
 
 
2.3.2 Studies for inclusion 
 
Two authors independently identified studies for inclusion by screening titles and 
abstracts. The two authors performing this step for each meta-analysis performed are 
named in the individual sections of this thesis. Further selection was based on full 
text. In order to select the studies for inclusion in the meta-analysis, clear inclusion 
and exclusion criteria were used. It was important to select carefully, clearly define, 
and strictly follow these criteria, in order to include studies in the meta-analysis of 
the same or similar design and methodology; otherwise the results of the meta-
analysis would not have been valid if trials of different methodology and different 
groups of patients were compared. Similarly, the outcomes to be evaluated were 
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clearly defined to allow the extraction of the necessary data from the included studies 
and to perform the appropriate statistics. 
 
 
2.3.3 Data extraction 
 
Two reviewers independently extracted the data from each included study using a 
standardized custom-designed data extraction form. The two authors extracting the data 
for each meta-analysis are named in the individual sections of this thesis. The data 
extracted from the studies included details of the study (e.g. first author, year of 
publication, country of study), study population characteristics including age and 
gender, study design, inclusion and exclusion criteria used in individual studies, 
matching criteria, number of individuals entering the study, follow-up period, lost to 
follow-up, perioperative outcomes (e.g. mortality, morbidity, operating time, operative 
blood loss, length of hospital stay). Additional information was extracted by each study 
depending on the outcomes investigated by the meta-analysis. There should be 100% 
agreement among the two reviewers in the data extraction. If a 100% agreement was not 
achieved, any discrepancies were resolved through discussion, and if there was still a 
disagreement between authors, the final decision was taken by the most senior co-
author. 
 
 
2.3.4 Data analysis 
 
Pairwise meta-analysis was conducted using Review Manager (RevMan) Versions 5.1 
and 5.2.137, 138 The meta-analyses were performed according to the recommendations 
from Preferred Reporting Items for systematic Reviews and Meta-Analyses (PRISMA) 
statement.139 The unit of analysis was the individual patient in all the reviews. All the 
analyses were performed by an intention-to-treat analysis. 
 
Statistical analysis of dichotomous or binary variables was performed using the Odds 
Ratio (OR) as the summary statistic reported with 95% Confidence Intervals (CI).140 OR 
represents the odds of an event occurring in the intervention group compared to the 
control group. An OR of less than one favours the intervention group for an adverse 
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event and the point estimate of the OR was considered to be statistically significant at 
the P < 0.05 level if the 95% confidence interval did not include the value one. Note that 
zero cells (i.e. no events in one group) cause problems with computation of estimates 
and standard errors. The RevMan software automatically adds 0.5 to each cell of the 
2×2 table for any such study.141 If there were no events for both the intervention and 
control groups, the study was discarded from the meta-analysis for that particular 
outcome. 
 
Continuous variables were analysed using the mean difference (MD) as the summary 
statistic reported with 95% CI.140 MDs summarised the differences between the 
intervention and control groups with respect to continuous variables, accounting for 
sample size. The point estimate of the MD was considered to be statistically significant 
at the P < 0.05 level if the 95% confidence interval did not include the value zero. For 
continuous outcomes, if the data were likely to be normally distributed, the median was 
used for the analysis when the mean was not available. If standard deviation (SD) was 
not available from a study, the SD was imputed from the standard error (SE), P values, 
confidence intervals (CIs), or interquartile range, according to guidance given in the 
Cochrane Handbook for Systematic Reviews of Intervention.142 If it was not possible to 
calculate the SD from the SE, P value, CIs, or interquartile range, the SD was imputed 
using the largest SD in other trials for that outcome.  
 
The hazard ratio (HR) was used for time-to-event outcomes, e.g. to compare overall 
survival and disease free survival between the intervention and control groups, and was 
reported with 95% Confidence Intervals (CI). If the HR with 95 % CI was not reported 
in the publications, the values were calculated from other information and the Kaplan–
Meier curve using methods described by Parmar et al.143 The point estimate of the HR 
was considered to be statistically significant at the P < 0.05 level if the 95% confidence 
interval did not include the value one. 
 
The Mantel–Haenszel (MH) method and the DerSimonian Laird method were used to 
combine the binary outcomes, and the generic inverse variance method was used to 
combine the time-to event outcomes. The random-effects model140 and the fixed-
effect model144 were used for the meta-analyses. Where there was no difference 
between the results of random-effects and fixed-effect models that would change 
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interpretation of the results, the results of the fixed-effect model were reported; 
otherwise, both the results were reported. 
 
The fixed-effect model assumes that all included studies investigate the same 
population, use identical methods, use the same variable and outcome definitions, 
and should produce identical results.141 Any differences noted between the studies, is 
sampling variation according to the fixed-effect model. The Peto and Mantel-
Haenszel (MH) statistical methods are both based on a fixed effects model. With the 
fixed-effect model larger studies have more weight because the inverse of a study’s 
estimate variance is used as study weight.  
 
The random-effects model takes into consideration both between-study and within-
study variability, and it assumes that the different studies are estimating different, yet 
related, intervention effects.140, 141 The random-effects model is based on the inverse-
variance approach, making an adjustment to the study weights according to the extent 
of heterogeneity between the varying intervention effects.141 The amount of 
heterogeneity, and hence the adjustment, can be estimated from the intervention 
effects and standard errors of the studies included in the meta-analysis.141 The 
DerSimonian Laird statistic is based on a random effects model.140  
 
The random-effects and the fixed-effect models give identical results if there is no 
heterogeneity between the studies, whereas in the presence of heterogeneity, the CI 
of the meta-analysed measure of effect will be wider if the random-effects model is 
used rather than the fixed-effect model.141 Therefore, the random-effects model is 
thought to provide a more conservative value because it assumes that there is a 
variation between studies due to heterogeneity, and generates a wider CI.140, 145 The 
random-effects model is preferable by some researchers when meta-analytical 
techniques are undertaken in surgical research for a given surgical technique in which 
each study centre has differing patient selection criteria and patient risk profiles.  
 
Heterogeneity between the included studies was crudely assessed by examining the 
forest plot. If confidence intervals for the results of individual studies (depicted 
graphically using horizontal lines) had no overlap or poor overlap, this indicated the 
presence of statistical heterogeneity. In addition, if the effect estimates of the individual 
studies lied on either side of the line of no effect (Figure 2.1), then the heterogeneity 
37 
 
was in the direction of the effect which meant that the beneficial or harmful effect of the 
intervention was not consistent across studies. On the other hand, if all the point effect 
estimates of the individual studies lied on the same side but at different distances from 
the line of no effect, then the heterogeneity was in the magnitude of the effect which 
meant that all the studies consistently reported that the intervention was beneficial or 
harmful but there was variation in how beneficial or harmful the intervention was. 
 
Moreover, heterogeneity was assessed with the chi-squared (Χ2 or Chi2) test, which was 
included in the forest plots with its P value. Figure 2.1 shows an example of a forest 
plot. Heterogeneity between studies was suggested if the P value was low or the chi-
squared was large. Because the chi-squared test has low power when studies have small 
sample size or are few in number, heterogeneity among the individual studies was 
considered to be statistically significant at the more conservative value of P < 0.10 
level.141  
 
The effect of heterogeneity was also quantified by means of I-square (I2), where the 
higher the I-square value, the higher was the risk for heterogeneity between studies.142 I-
square describes the percentage of total variation across studies that is due to 
heterogeneity rather than chance, and it can be calculated using the formula 
I2=100%×(Q - df)/Q, where Q is Cochran's heterogeneity statistic and df the degrees of 
freedom.146 A rough guide to the interpretation of I-square value is as follows:142 
• 0% to 40%: might not be important 
•30% to 60%: may represent moderate heterogeneity 
•50% to 90%: may represent substantial heterogeneity 
•75% to 100%: considerable heterogeneity 
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Figure 2.1: Forest plot for a binary outcome. Each study represented by a line. The left-
hand column lists the surnames of the first authors of the studies included in the analysis 
in alphabetical order from the top downwards. The middle columns provide the 
summary data entered for each study, which in this example, show the number of events 
and the total number of patients in each group separately. Also, it provides the effect 
measure with 95% CI for each study, the method, and the model used to perform the 
meta-analysis. In this example, the effect measure is the odds ratio (OR), the statistical 
method used is the Mantel-Haenszel (MH) method, and the model used is the random-
effects model. The right-hand column is a plot of the measure of effect (in this case OR) 
for each of these studies. The mid-point of the box represents the point effect estimate, 
that is, the mean effect estimate for each study, and the horizontal lines represent the 
95% CI. The area of the square is proportional to the study's weight in the meta-
analysis. The vertical line represents no effect. For a bad event, as in this example, the 
left of the vertical line favours the experimental or intervention group, and the right of 
the vertical line favours the control group. If the confidence intervals for individual 
studies overlap with this line, it demonstrates that there is no significant difference 
between the two groups for this outcome. The diamond below the studies represents the 
overall meta-analysed measure of effect, the width of which indicates the 95% CI for 
the overall effect estimate. If the points of the diamond overlap the line of no effect, the 
overall meta-analysed result shows that there is no significant difference between the 
two groups for this outcome. Assessment of heterogeneity is demonstrated in the values 
of I-square and chi-squared with its P value. 
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Three further strategies were used to quantitatively assess heterogeneity. First, 
sensitivity analyses were undertaken using subgroups, e.g. studies of higher quality, 
more recent studies, whether chemotherapy was used in studies etc. Second, data were 
analysed using both random-effects and fixed-effect models. Third, graphical 
exploration with funnel plots was used to evaluate publication bias.145, 147 Figure 2.2 
shows an example of a funnel plot.  
 
 
 
 
 
 
 
 
Figure 2.2: Funnel plot for the same binary outcome as in Figure 2.1. A funnel plot is a 
scatterplot of the treatment effect (represented as OR estimated from individual studies) 
plotted on the horizontal axis, against a measure of study size (represented as the 
standard error of the estimate) shown on the vertical axis (SE[logOR]). In the absence 
of publication bias, it assumes that the largest studies will be plotted near the average, 
and smaller studies will be spread evenly on both sides of the average, creating a 
roughly funnel-shaped distribution. Deviation from this shape can indicate publication 
bias. The blue lines represent the overall effect estimate and the 95% CI. 
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2.3.5 Other details 
 
The bias, quality of evidence of included studies, inclusion and exclusion criteria for 
each review, and the requirement for further trials are mentioned in detail in the relevant 
chapters. 
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CHAPTER 3 
 
 
NETWORK META-ANALYSIS 
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3.1 DEFINITION 
 
A network meta-analysis uses meta-analytical techniques to compare multiple 
treatments which have been used and compared for the same disease and outcomes in 
different head-to-head comparisons. 
 
 
3.2 ADVANTAGES AND DISADVANTAGES 
 
On one medical topic, there may have been hundreds of studies comparing surgical 
interventions for the same outcomes, e.g. trials comparing different methods aiming to 
decrease blood loss during liver resections, or interventions aiming to decrease IR injury 
during liver resection. Dozens of pairwise meta-analyses may have been carried out to 
bring together and analyse the results of all the individual interventions. But, one of the 
disadvantages of a pairwise meta-analysis is that it can only compare two treatments at a 
time, i.e. it only permits comparison of the effects of one intervention versus one 
comparator, rather than all available surgical treatments simultaneously.  
 
Furthermore, if two treatments have not been compared directly against each other in 
trials, it is not possible to calculate the relative effects of the two treatments. Yet, for 
many medical or surgical conditions, there are numerous treatments which have been 
compared with a no treatment control group, but not with one another.132 For example, 
many interventions have been tested aiming to decrease ischaemic reperfusion injury 
during liver resection for CLM but have not been compared against one another. 
Sometimes, to overcome these problems, pairwise meta-analyses group together 
interventions that should not be grouped together due to their different mechanisms of 
action, in order to be able to perform a pairwise comparison. 
 
Network meta-analysis, is a new method of comparison of different treatments, and is 
ideal when multiple interventions have been used and compared for the same disease 
and outcomes in different head-to-head comparisons. An advantage of network meta-
analysis over standard pairwise meta-analysis is that it combines direct evidence within 
trials and indirect evidence across trials facilitating indirect comparisons of multiple 
interventions that have not been studied in a head-to-head fashion.132, 148 Therefore, a 
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network meta-analysis provides estimates of effect sizes for all possible pairwise 
comparisons that may or may not have been evaluated directly against each other, and 
allows inferences into the comparative effectiveness of different treatments to be 
assessed even if they have not been compared directly in individual RCTs.  
 
An example of a direct comparison between two interventions is shown in Figure 3.1, in 
this case A and B. A standard pairwise meta-analysis could be performed on trials 
comparing treatments A and B. An example of a simple indirect comparison for B and 
C is shown in Figure 3.2, when no trials are available comparing treatments B and C. 
An example of a simple closed loop is shown in Figure 3.3, where interventions A, B, 
and C, have all been compared against each other at some point in previous trials. A 
network meta-analysis could be performed to compare the treatments in examples 3.2 
and 3.3 by combining direct evidence within trials and indirect evidence across trials. 
An example of a network meta-analysis plot (or network plot) is shown in Figure 3.4, 
with the comparisons between treatments. 
 
 
 
 
 
Figure 3.1: Example of a direct comparison. A and B are examples of two interventions 
and the continuous arrow represents a direct comparison between the two interventions.  
 
 
                                                    A                             B 
 
 
 
 
 
 
Figure 3.2: Example of a simple indirect comparison. A, B, and C, are examples of 
three interventions. The continuous arrows represent a direct comparison between the 
interventions in previous trials.  The intermittent arrow represents a simple indirect 
comparison for B and C, when no trials are available comparing treatments B and C. 
 
 
                                                             A 
 
 
 
 
                                       B                 C 
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Figure 3.3: Example of a simple closed loop. A, B, and C are examples of 
interventions. The continuous arrows represent a direct comparison between the 
interventions. In this example all interventions have been compared against each other 
at some point in previous trials. 
 
 
                                                        A 
 
 
 
 
                                  B            C 
 
 
 
 
 
 
Figure 3.4: Example of a network plot. A to G are examples of interventions. The 
continuous arrows represent a direct comparison between the interventions in previous 
trials. 
 
 
 
                                  D                   A      E 
 
 
 
 
                                 B                      C 
 
 
 
  
     F                             G 
 
 
 
 
 
Visualising the geometry of a network plot permits the reader to understand the larger 
picture and see what is compared with what.149 The presence of direct evidence 
increases confidence in the estimates of interest, and the extent to which the treatments 
are connected in the network is an important determinant in the quality of the 
evidence.132, 149 For example, a star network plot (Figure 3.5) occurs when different 
interventions have only been compared with a single common comparator (e.g., no 
intervention or placebo), and only allows for indirect comparison between interventions, 
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which reduces confidence in effects, particularly if there are a limited number of trials, 
patients, and events.132, 150 On the other hand, in a connected network plot all 
interventions have been compared against each other. In a complex network plot (Figure 
3.6), which is the most common, data is available using a mixture of direct and indirect 
evidence. An example of a star network plot is shown in Figure 3.5. Figure 3.6 shows 
an example of a complex network plot. 
 
 
 
 
 
Figure 3.5: An example of a star network plot involving interventions aiming to reduce 
hepatic IR injury during liver surgery taken from Chapter 7. Circles represent the 
intervention as a node in the network; size of circles represents the number of RCTs 
reporting on the intervention; lines represent direct comparisons using RCTs; thickness 
of lines represents the number of RCTs included in each comparison, also represented 
by the numbers. 
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Figure 3.6: An example of a complex network plot involving treatment strategies 
during liver resection aiming to reduce blood loss and blood transfusion. The codes of 
the treatment strategies (e.g. V1P4R1) will be explained in detail in Chapter 6. Circles 
represent the treatment strategy as a node in the network; size of circles represents the 
number of RCTs reporting on the treatment strategy; lines represent direct comparisons 
using RCTs; thickness of lines represents the number of RCTs included in each 
comparison; . 
 
 
 
 
 
 
 
 
A network meta-analysis allows us to visualize and interpret a wider picture of the 
available evidence, and to calculate treatment rankings with probabilities.132, 148 Also, an 
advantage of a network meta-analysis compared to large RCTs, is that a very high 
number of participants is required to show a significant benefit or harm of a treatment 
for a clinical outcome if all the different interventions have to be compared in a single 
multiple arm RCT, and RCTs of this magnitude are unlikely to be funded. 
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By including evidence from both direct and indirect comparisons, a network meta-
analysis may increase the precision in estimates of the relative effects of treatments, and 
it may yield more reliable and definitive results compared to a pairwise meta-
analysis.132, 148 Because network meta-analyses include evidence from both direct and 
indirect comparisons, power may be better than in standard pairwise meta-analyses that 
include only direct evidence. Nevertheless, where direct and indirect evidence exists in 
a network meta-analysis, it has to be ensured that the findings are sufficiently consistent 
between direct and indirect comparisons. In the face of large incoherence between direct 
and indirect evidence in a particular comparison the GRADE working group suggested 
to focus attention on the direct or indirect estimate warranting greater confidence, rather 
than the network meta-analysis estimate, as the best estimate of effect. Or, alternatively, 
to focus on the network meta-analysis estimate but rate down the quality of that 
estimate due to incoherence.151 
 
An important assumption made in network meta-analyses in order to allow direct and 
indirect comparisons, is that all the included trials in the comparisons are sufficiently 
homogeneous, especially regarding essential features, for example, patient 
characteristics, definitions and measurements of outcomes, period of follow-up, and risk 
of bias in the studies.132 It is important to avoid broad inclusion criteria for the trials, in 
order to avoid heterogeneity. For example, in this thesis there was a strict inclusion 
criterion for studies to be RCTs to be included in the network meta-analysis in order to 
minimise the inherent biases and differences in methodology between the included 
studies. Nevertheless, RCTs are difficult to carry out in the field of surgery as the 
speciality is largely craft based and dependent on operator skills. 
 
The different RCTs included in a network meta-analysis are at different risk of bias. If 
significant clinical variability or statistical heterogeneity is present between trials, 
subgroup analysis or meta-regression can be performed to attempt to explain the 
heterogeneity. Due to the greater number of RCTs in network meta-analyses, there are 
more opportunities for subgroup analysis, as long as all the trials are still connected in 
the network plot of the subgroup analysis. 
 
 
 
 
48 
 
3.3 METHODS 
 
The methods for literature search, identification of studies for inclusion, and data 
extraction used for network meta-analysis are similar to those used for pairwise meta-
analysis as described in Chapter 2. Sections 2.2.1 (Search strategy), 2.2.2 (Studies for 
inclusion), and 2.2.3 (Data extraction), are applicable to the methods used for network 
meta-analysis. There are differences in the data analysis between network and pairwise 
meta-analyses, and these differences are described next in Section 3.3.1 (Data analysis). 
 
 
3.3.1 Data analysis 
 
For binary data, based on the number of patients developing the adverse event, a 
binomial model was used for the analysis and the odds ratio (OR) was calculated. For 
outcomes where some patients may develop multiple adverse events, the total number 
of adverse events rather than the number of patients was imputed in the analysis, and a 
Poisson model was used. An arbitrary constant of 1 was added to the denominator and 
0.5 to the numerator for trials with zero-event outcomes. For continuous outcomes the 
mean difference (MD) was calculated, and if the data were likely to be normally 
distributed, the median was used for the analysis when the mean was not available. 
 
For each outcome of interest, Stata/IC 11 (StataCorp LP) was used to draw a network 
plot of all the interventions assessed for that specific outcome. Circles represented the 
intervention as a node in the network, lines represented direct comparisons using RCTs, 
and thickness of lines represented the number of RCTs included in each comparison. 
Any interventions that were not connected to the other interventions through the 
network plot were excluded from the analysis of that outcome. Therefore, the trials 
reporting on those interventions that were not connected to the network plot were also 
excluded from the network meta-analysis of that outcome.  
 
A Bayesian network meta-analysis was conducted using the Markov chain Monte Carlo 
method in WinBUGS 1.4. A treatment contrast means a pairwise comparison between 
two treatments expressed as OR for binary outcomes and MD for continuous outcomes. 
The treatment contrast for any two interventions was modelled as a function of 
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comparisons between each individual intervention and an arbitrarily selected reference 
group.152 Choice of the reference group was based on ease of interpretation, with 
placebo or standard treatment usually taken as the reference group (or Treatment 1). In 
larger networks, Treatment 1 was chosen to be the treatment that is in the “centre” of 
the network, i.e. the treatment that has been trialled against the highest number of other 
treatments.  
 
The network analysis was performed as per the guidance from The National Institute for 
Health and Clinical Excellence (NICE) Decision Support Unit (DSU) documents.153 
The influence of study design and other potential sources of heterogeneity on effect 
estimates were assessed by metaregression. Details of the codes used and the raw data 
included in WinBUGS 1.4 are shown in sections 3.3 and 3.4. The codes allow handling 
of trials with multiple arms to be dealt in the same way as two-arm trials and take into 
account the correlation between effect sizes introduced by multi-arm studies. One can 
enter the data from all the arms in a trial as number of events and the number of people 
exposed to the event for binary outcomes or the mean and standard error for continuous 
outcomes. 
 
The posterior probabilities (effect estimates or values) of the treatment contrast (i.e., log 
odds ratio or mean difference) may vary depending upon the initial values to start the 
simulations in WinBUGS. In order to control the random error due to the choice of 
initial values, the network meta-analysis was performed for three different initial values 
(priors) as per the guidance from the NICE DSU documents.153 If the results from three 
different priors are similar (convergence), then the results are reliable. It was important 
to discard the results of the initial simulations as they can be significantly affected by 
the choice of the priors, and only the results of the simulations obtained after the 
convergence were included. The discarding of the initial simulations is called ’burn in’. 
The models for all binary and continuous outcomes were run for 10,000 simulations 
(i.e. the number of times that the values are calculated by the software, the values being 
sampled from a distribution based on the data from the studies) for ’burn in’ for three 
different chains (a set of initial values). The models were run for another 20,000 
simulations to obtain the effect estimates. The exceptions to this were when the model 
did not converge for a variable, and further simulations were run until they converged. 
The effect estimates from the results of all the three chains (different initial values) were 
obtained. The results in the three different chains were examined to ensure that they 
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were similar in order to control for random error due to the choice of priors. This was 
done in addition to the visual inspection of convergence obtained after simulations in 
the burn in. 
 
Three different models were run for each outcome: fixed-effect model, random-effects 
model, and random-effects inconsistency model. Fixed-effect model assumes that the 
treatment effect is the same across studies. The random-effects consistency model 
assumes that the treatment effect is distributed normally across the studies but assumes 
that the transitivity assumption is satisfied (i.e., the population studied, the definition of 
outcomes, and the methods used were similar across studies and that there is 
consistency between the direct comparison and indirect comparison). The between-
study random-effects was considered to be the same across treatment comparisons. A 
random-effects inconsistency model does not assume transitivity assumption. If the 
inconsistency model resulted in a better model fit than the consistency model, the 
results of the network meta-analysis can be unreliable and so should be interpreted with 
extreme caution. If there was evidence of inconsistency, we planned to identify areas in 
the network where substantial inconsistency might be present in terms of clinical and 
methodological diversities between trials and, when appropriate, limit network meta-
analysis to a more compatible subset of trials.  
 
Heterogeneity may be characterised as between-trial variation within treatment 
contrasts, and inconsistency as variation between contrasts. The residual deviance and 
DIC were used for assessing between study heterogeneity as per the guidance from the 
NICE DSU Technical Support Documents.153, 154 The between trial SD was also 
calculated and reported if random-effects model was used. The model fit was assessed 
by deviance residuals and Deviance Information Criteria (DIC) according to NICE DSU 
guidelines.153 The treatment contrasts (OR for binary outcomes and MD for continuous 
outcomes) of the different treatments in relation to the reference treatment, the deviance 
residuals, number of effective parameters, and DIC for fixed-effect model and random-
effects model were reported for each outcome. Also, the parameters used to assess the 
model fit (i.e. deviance residuals, number of effective parameters, and DIC) for the 
inconsistency model were reported. The choice of the model between fixed-effect model 
and random-effects model was based on the model fit. A lower DIC indicates a better 
model fit, but a difference of three or five in the DIC is not generally considered 
important.154 The simpler model, which is the fixed-effect model was used if the DIC 
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were similar between the fixed-effect model and random-effects model. The random-
effects model was used if it resulted in a better model fit as indicated by a DIC lower 
than that of fixed-effect model by at least three. 
 
Network meta-analyses may be more prone to the risk of random errors than direct 
comparisons.155 Accordingly, a greater sample size is required in indirect comparisons 
than direct comparisons.156 The power and precision in indirect comparisons depends 
upon various factors such as the number of participants included under each comparison 
and the heterogeneity between the trials.156 If there was no heterogeneity across the 
trials, the sample size in indirect comparisons would be equivalent to the sample size in 
direct comparisons. The effective indirect sample size can be calculated using the 
number of participants included in each direct comparison.156 For example, a sample 
size of 2500 participants in the direct comparison A versus C (nAC) and a sample size of 
7500 participants in the direct comparison B versus C (nBC) results in an effective 
indirect sample size of 1876 participants. However, in the presence of heterogeneity 
within the comparisons, the sample size required is higher. In the above scenario, for an 
I2 statistic for each of the comparisons A versus C (IAC
2) and B versus C (IBC
2) of 25%, 
the effective indirect sample size is 1407 participants. For an I2 statistic for each of the 
comparisons A versus C and B versus C of 50%, the effective indirect sample size is 
938 participants.156 The effective indirect sample size can be calculated using the 
following generic formula:156 
 
((nAC x (1 – IAC2)) x (nBC x (1-IBC2))/((nAC x (1 - IAC2)) + (nBC x (1-IBC2)).  
 
The effect estimates of the treatment and the 95% credible intervals (CrI, similar to the 
95% CI in a frequentist method of meta-analysis) were calculated using the formulae for 
calculating the effect estimates in indirect comparisons:157 
 
ln(ORAC) = ln(ORAB) - ln(ORCB) and Var(ln ORAC) = Var (ln ORAB) + Var (ln ORCB) 
 
where ln indicates natural logarithm; OR indicates odds ratio; Var indicates variance; 
and A, B, and C are three different treatments. 
 
The effect estimates and associated 95% CrI for each pairwise comparison were 
reported in a table. Also, the probability that each intervention ranks at one of the 
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possible positions was estimated. The probability that a treatment ranks as the best 
treatment for each outcome of interest, was presented in graphs. It should be noted that 
a less than 90% (<90%) probability that the treatment is the best treatment is 
unreliable.158 The cumulative probability of the treatment ranks (i.e. the probability that 
the treatment is within the top two, the probability that the treatment is within the top 
three, etc.) was also presented in graphs. In addition, the probability that each treatment 
is best for each of the different outcomes (rankogram) was plotted, which is generally 
considered more informative.158, 159 
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3.4 WINBUGS CODES 
 
Below are the codes used in WinBUGS 1.4 for the network meta-analyses of binary and 
continuous outcomes. The codes were taken from the NICE DSU website and they have 
been previously validated by NICE DSU. The codes used are for the fixed-effect model, 
random-effects consistency model, and random-effects inconsistency model. The codes 
used for metaregression are also included.  
 
 
3.4.1 Binary outcome - fixed-effect model 
 
# Binomial likelihood, logit link 
# Fixed effects model 
model{ # *** PROGRAM STARTS 
for(i in 1:ns){ # LOOP THROUGH STUDIES 
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
for (k in 1:na[i]) { # LOOP THROUGH ARMS 
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood 
# model for linear predictor 
logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]] 
# expected value of the numerators 
rhat[i,k] <- p[i,k] * n[i,k] 
#Deviance contribution 
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) 
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) 
} 
# summed residual deviance contribution for this trial 
resdev[i] <- sum(dev[i,1:na[i]]) 
} 
totresdev <- sum(resdev[]) # Total Residual Deviance 
d[1]<-0 # treatment effect is zero for reference treatment 
# vague priors for treatment effects 
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) } 
# ranking on relative scale 
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for (k in 1:nt) { 
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good” 
rk[k] <- rank(d[],k) # assumes events are “bad” 
best[k] <- equals(rk[k],1) #calculate probability that treat k is best 
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th 
best 
} 
} # *** PROGRAM ENDS 
 
 
3.4.2 Binary outcome - random-effects consistency model 
 
# Binomial likelihood, logit link 
# Random effects model for multi-arm trials 
model{ # *** PROGRAM STARTS 
for(i in 1:ns){ # LOOP THROUGH STUDIES 
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm 
delta[i,1] <- 0 # treatment effect is zero for control arm 
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
for (k in 1:na[i]) { # LOOP THROUGH ARMS 
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood 
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor 
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators 
#Deviance contribution 
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) 
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) } 
# summed residual deviance contribution for this trial 
resdev[i] <- sum(dev[i,1:na[i]]) 
for (k in 2:na[i]) { # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
# mean of LOR distributions (with multi-arm trial correction) 
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k] 
# precision of LOR distributions (with multi-arm trial correction) 
taud[i,k] <- tau *2*(k-1)/k 
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# adjustment for multi-arm RCTs 
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
# cumulative adjustment for multi-arm trials 
sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
} 
} 
totresdev <- sum(resdev[]) # Total Residual Deviance 
d[1]<-0 # treatment effect is zero for reference treatment 
# vague priors for treatment effects 
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) } 
sd ~ dunif(0,5) # vague prior for between-trial SD 
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) 
# ranking on relative scale 
for (k in 1:nt) { 
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good” 
rk[k] <- rank(d[],k) # assumes events are “bad” 
best[k] <- equals(rk[k],1) #calculate probability that treat k is best 
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th 
best 
} 
} # *** PROGRAM ENDS 
 
 
3.4.3 Binary outcome - random-effects inconsistency model 
 
# Binomial likelihood, logit link, inconsistency model 
# Random effects model 
model{ # *** PROGRAM STARTS 
for(i in 1:ns){ # LOOP THROUGH STUDIES 
delta[i,1]<-0 # treatment effect is zero in control arm 
mu[i] ~ dnorm(0,.0001) # vague priors for trial baselines 
for (k in 1:na[i]) { # LOOP THROUGH ARMS 
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood 
logit(p[i,k]) <- mu[i] + delta[i,k] # model for linear predictor 
#Deviance contribution 
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rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators 
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) 
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) 
} 
# summed residual deviance contribution for this trial 
resdev[i] <- sum(dev[i,1:na[i]]) 
for (k in 2:na[i]) { # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
delta[i,k] ~ dnorm(d[t[i,1],t[i,k]] ,tau) 
} 
} 
totresdev <- sum(resdev[]) # Total Residual Deviance 
for (c in 1:(nt-1)) { # priors for all mean treatment effects 
for (k in (c+1):nt) { d[c,k] ~ dnorm(0,.0001) } 
} 
sd ~ dunif(0,5) # vague prior for between-trial standard deviation 
var <- pow(sd,2) # between-trial variance 
tau <- 1/var # between-trial precision 
} # *** PROGRAM ENDS 
 
 
3.4.4 Continuous outcome - fixed-effect model 
 
# Normal likelihood, identity link 
# Fixed effects model 
model{ # *** PROGRAM STARTS 
for(i in 1:ns){ # LOOP THROUGH STUDIES 
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
for (k in 1:na[i]) { # LOOP THROUGH ARMS 
var[i,k] <- pow(se[i,k],2) # calculate variances 
prec[i,k] <- 1/var[i,k] # set precisions 
y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood 
# model for linear predictor 
theta[i,k] <- mu[i] + d[t[i,k]] - d[t[i,1]] 
#Deviance contribution 
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dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] 
} 
# summed residual deviance contribution for this trial 
resdev[i] <- sum(dev[i,1:na[i]]) 
} 
totresdev <- sum(resdev[]) #Total Residual Deviance 
d[1]<-0 # treatment effect is zero for control arm 
# vague priors for treatment effects 
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) } 
# ranking on relative scale 
for (k in 1:nt) { 
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good” 
rk[k] <- rank(d[],k) # assumes events are “bad” 
best[k] <- equals(rk[k],1) #calculate probability that treat k is best 
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th 
best 
} 
} # *** PROGRAM ENDS 
 
 
3.4.5 Continuous outcome - random-effects consistency model 
 
# Normal likelihood, identity link 
# Random effects model for multi-arm trials 
model{ # *** PROGRAM STARTS 
for(i in 1:ns){ # LOOP THROUGH STUDIES 
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm 
delta[i,1] <- 0 # treatment effect is zero for control arm 
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
for (k in 1:na[i]) { # LOOP THROUGH ARMS 
var[i,k] <- pow(se[i,k],2) # calculate variances 
prec[i,k] <- 1/var[i,k] # set precisions 
y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood 
theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor 
#Deviance contribution 
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dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] 
} 
# summed residual deviance contribution for this trial 
resdev[i] <- sum(dev[i,1:na[i]]) 
for (k in 2:na[i]) { # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
# mean of LOR distributions, with multi-arm trial correction 
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k] 
# precision of LOR distributions (with multi-arm trial correction) 
taud[i,k] <- tau *2*(k-1)/k 
# adjustment, multi-arm RCTs 
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
# cumulative adjustment for multi-arm trials 
sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
} 
} 
totresdev <- sum(resdev[]) #Total Residual Deviance 
d[1]<-0 # treatment effect is zero for control arm 
# vague priors for treatment effects 
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) } 
sd ~ dunif(0,5) # vague prior for between-trial SD 
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) 
# ranking on relative scale 
for (k in 1:nt) { 
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good” 
rk[k] <- rank(d[],k) # assumes events are “bad” 
best[k] <- equals(rk[k],1) #calculate probability that treat k is best 
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th 
best 
} 
} # *** PROGRAM ENDS 
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3.4.6 Continuous outcome - random-effects inconsistency model  
 
# Normal likelihood, identity link 
# Random effects model for multi-arm trials 
model{ # *** PROGRAM STARTS 
for(i in 1:ns){ # LOOP THROUGH STUDIES 
delta[i,1] <- 0 # treatment effect is zero for control arm 
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
for (k in 1:na[i]) { # LOOP THROUGH ARMS 
var[i,k] <- pow(se[i,k],2) # calculate variances 
prec[i,k] <- 1/var[i,k] # set precisions 
y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood 
theta[i,k] <- mu[i] + delta[i,k] # model for linear predictor 
#Deviance contribution 
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] 
} 
# summed residual deviance contribution for this trial 
resdev[i] <- sum(dev[i,1:na[i]]) 
for (k in 2:na[i]) { # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
delta[i,k] ~ dnorm(d[t[i,1],t[i,k]] ,tau) 
} 
} 
totresdev <- sum(resdev[]) # Total Residual Deviance 
for (c in 1:(nt-1)) { # priors for all mean treatment effects 
for (k in (c+1):nt) { d[c,k] ~ dnorm(0,.0001) } 
} 
sd ~ dunif(0,5) # vague prior for between-trial standard deviation 
tau <- pow(sd,-2) # between-trial precision 
} # *** PROGRAM ENDS 
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3.4.7 Metaregression binary outcome – fixed-effect model 
 
# Binomial likelihood, logit link 
# Fixed effects model with continuous covariate 
model{ # *** PROGRAM STARTS 
for(i in 1:ns){ # LOOP THROUGH STUDIES 
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
for (k in 1:na[i]) { # LOOP THROUGH ARMS 
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood 
# model for linear predictor, covariate effect relative to treat in arm 1 
logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]] + (beta[t[i,k]]-beta[t[i,1]]) * (x[i]-mx) 
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators 
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) #Deviance contribution 
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) 
} 
resdev[i] <- sum(dev[i,1:na[i]]) # summed residual deviance contribution for this trial 
} 
totresdev <- sum(resdev[]) # Total Residual Deviance 
d[1] <- 0 # treatment effect is zero for reference treatment 
beta[1] <- 0 # covariate effect is zero for reference treatment 
for (k in 2:nt){ # LOOP THROUGH TREATMENTS 
d[k] ~ dnorm(0,.0001) # vague priors for treatment effects 
beta[k] <- B # common covariate effect 
} 
B ~ dnorm(0,.0001) # vague prior for covariate effect 
} # *** PROGRAM ENDS 
 
 
3.4.8 Metaregression binary outcome – random-effects consistency 
model 
 
# Binomial likelihood, logit link, continuous covariate 
# Random effects model for multi-arm trials 
model{ # *** PROGRAM STARTS 
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for(i in 1:ns){ # LOOP THROUGH STUDIES 
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm 
delta[i,1] <- 0 # treatment effect is zero for control arm 
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
for (k in 1:na[i]) { # LOOP THROUGH ARMS 
r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood 
# model for linear predictor, covariate effect relative to treat in arm 1 (centring) 
logit(p[i,k]) <- mu[i] + delta[i,k] + (beta[t[i,k]]-beta[t[i,1]]) * (x[i]-mx) 
rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators 
dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) #Deviance contribution 
+ (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) 
} 
resdev[i] <- sum(dev[i,1:na[i]]) # summed residual deviance contribution for this trial 
for (k in 2:na[i]) { # LOOP THROUGH ARMS 
delta[i,k] ~ dnorm(md[i,k],taud[i,k]) # trial-specific LOR distributions 
md[i,k] <- d[t[i,k]] - d[t[i,1]] + sw[i,k] # mean of LOR distributions (with multi-arm 
trial correction) 
taud[i,k] <- tau *2*(k-1)/k # precision of LOR distributions (with multi-arm trial 
correction) 
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) # adjustment for multi-arm RCTs 
sw[i,k] <- sum(w[i,1:k-1])/(k-1) # cumulative adjustment for multi-arm trials 
} 
} 
totresdev <- sum(resdev[]) # Total Residual Deviance 
d[1]<-0 # treatment effect is zero for reference treatment 
beta[1] <- 0 # covariate effect is zero for reference treatment 
for (k in 2:nt){ # LOOP THROUGH TREATMENTS 
d[k] ~ dnorm(0,.0001) # vague priors for treatment effects 
beta[k] <- B # common covariate effect 
} 
B ~ dnorm(0,.0001) # vague prior for covariate effect 
sd ~ dunif(0,5) # vague prior for between-trial SD 
tau <- pow(sd,-2) # between-trial precision = (1/between-trial variance) 
} # *** PROGRAM ENDS 
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3.4.9 Metaregression continuous outcome – random-effects consistency 
model 
 
# Normal likelihood, identity link 
# Random effects model for multi-arm trials 
model{ # *** PROGRAM STARTS 
for(i in 1:ns){ #   LOOP THROUGH STUDIES 
w[i,1] <- 0 # adjustment for multi-arm trials is zero for control arm 
delta[i,1] <- 0 # treatment effect is zero for control arm 
mu[i] ~ dnorm(0,.0001) # vague priors for all trial baselines 
for (k in 1:na[i]) {             #  LOOP THROUGH ARMS 
var[i,k] <- pow(se[i,k],2)   # calculate variances 
prec[i,k] <- 1/var[i,k]      # set precisions 
y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood 
theta[i,k] <- mu[i] + delta[i,k]+ (beta[t[i,k]]-beta[t[i,1]]) * (x[i]-mx) # model for linear 
predictor 
#Deviance contribution 
dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] 
} 
#  summed residual deviance contribution for this trial 
resdev[i] <- sum(dev[i,1:na[i]])        
for (k in 2:na[i]) {             # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
# mean of LOR distributions, with multi-arm trial correction 
md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] 
# precision of LOR distributions (with multi-arm trial correction) 
taud[i,k] <- tau *2*(k-1)/k 
# adjustment, multi-arm RCTs 
w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
# cumulative adjustment for multi-arm trials 
sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
} 
}    
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totresdev <- sum(resdev[]) # Total Residual Deviance 
d[1]<-0 # treatment effect is zero for control arm 
beta[1] <- 0 # covariate effect is zero for reference treatment 
# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001)  
beta[k] <- B[k] # exchangeable covariate effect 
B[k] ~ dnorm(0,.0001) # vague prior for covariate effect 
} 
sd ~ dunif(0,5)     # vague prior for between-trial SD 
tau <- pow(sd,-2)   # between-trial precision = (1/between-trial variance) 
# treatment effect when covariate = z[j] (un-centring treatment effects) 
for (k in 1:nt){ 
for (j in 1:nz) { dz[j,k] <- d[k] - (beta[k]-beta[1])*(mx-z[j]) } 
} 
# pairwise ORs and LORs for all possible pairwise comparisons, if nt>2 
for (c in 1:(nt-1)) { 
for (k in (c+1):nt) { 
MeanDifference[c,k] <- (d[k]-d[c]) 
} 
} 
# ranking on relative scale 
for (k in 1:nt) { 
# rk[k] <- nt+1-rank(d[],k) # assumes events are “good” 
rk[k] <- rank(d[],k) # assumes events are “bad” 
best[k] <- equals(rk[k],1) #calculate probability that treat k is best 
for (h in 1:nt){ prob[h,k] <- equals(rk[k],h) } # calculates probability that treat k is h-th 
best 
} 
} # *** PROGRAM ENDS 
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3.5 RAW DATA 
 
Below are examples of how the binary and continuous data were inserted into the 
WinBUGS codes for analysis. 
 
 
3.5.1 Binary outcomes 
 
# ns= number of studies; nt=number of treatments 
list(ns=7, nt=7) 
r[,1] n[,1] r[,2] n[,2] r[,3] n[,3] t[,1] t[,2] t[,3] na[] #study 
1.5 37 0.5 38 NA NA 4 6 NA 2 #Petrowsky 
2.5 26 0.5 26 0.5 26 2 3 4 3 #Lesurtel 
0.5 27 0.5 25 NA NA 1 3 NA 2 #Lupo 
0.5 42 0.5 42 NA NA 4 5 NA 2 #Smyrniotis 
1 63 1 63 NA NA 1 6 NA 2 #Capussotti 
2.5 21 0.5 21 NA NA 6 7 NA 2 #Doklestic 
0.5 26 0.5 26 NA NA 2 7 NA 2 #Park 
END 
 
 
Footnotes: # ns= number of studies; nt=number of treatments; t[,1] indicates control 
and t[,2] indicates intervention. In a three-arm trial, t[,3] indicates the second 
intervention. r[,1] indicates the number with events in the control group; n[,1] indicates 
the total number of people in the control group. r[,2], n[,2], r[,3], and n[,3] indicate the 
corresponding numbers for intervention and second intervention. In two-arm trials, r[,3] 
and n[,3] will be entered as 'NA' to indicate empty cells. If no three-arm trials were 
included under the outcome, the entire columns r[,3] and n[,3] were not included. na[] 
indicates the number of arms in the trial. Study indicates the study name and is for 
reference only. 
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3.5.2 Continuous outcomes 
 
list(ns=6, nt=7) 
t[,1] t[,2] t[,3] y[,1] y[,2] y[,3] se[,1] se[,2] se[,3] na[] # study 
4 6 NA 14.7 12.7 NA 1.6 1.4 NA 2 # Petrowsky 
2 3 4 9 9 9 1.6 1.6 1.6 3 # Lesurtel SE imputed 
4 5 NA 10 11 NA 1.6 1.6 NA 2 # Smyrniotis SE imputed 
1 6 NA 8.6 8.9 NA 0.4 0.6 NA 2 # Capussotti 
6 7 NA 10 8.5 NA 1.6 1.6 NA 2 # Doklestic SE imputed 
2 7 NA 19.3 15.8 NA 1.4 0.9 NA 2 # Park 
END 
 
 
Footnotes: # ns= number of studies; nt=number of treatments; t[,1] indicates control 
and t[,2] indicates intervention. In a three-arm trial, t[,3] indicates the second 
intervention. y[,1] indicates the mean in the control group; se[,1] indicates the standard 
error in the control group. y[,2], se[,2], y[,3], and se[,3] indicate the corresponding 
numbers for intervention and second intervention. In two-arm trials, y[,3] and se[,3] will 
be entered as 'NA' to indicate empty cells. If no three-arm trials were included under the 
outcome, the entire columns r[,3] and n[,3] were not included. na[] indicates the number 
of arms in the trial. Study indicates the study name and is for reference only. 
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CHAPTER 4 
 
 
PAIRWISE META-ANALYSIS COMPARING  
COMBINED VERSUS SEQUENTIAL RESECTION FOR 
SYNCHRONOUS COLORECTAL LIVER METASTASES 
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4.1 INTRODUCTION 
 
In some people with colorectal cancer, the liver metastases are present at the time of 
diagnosis of the primary tumour (synchronous metastases) and in others, the liver 
metastases are identified at a later stage (metachronous metastases). Approximately 
15% to 25% of patients with colorectal cancer have detectable liver metastases at the 
time of presentation (synchronous CLM) and a further 20% to 25% of patients will 
develop metastases during the course of their disease (metachronous CLM).10-13 In a 
French epidemiologic study, the proportion of patients who presented with synchronous 
CLM was 14.5%, and the 5-year cumulative metachronous liver metastasis rate was 
14.5%.160 In the same study, curative liver resection was performed in 6.3% of 
synchronous CLM and 16.9% of metachronous liver metastases.160  
 
Liver resection is the only curative option for CLM, with five-year survival for patients 
with CLM who undergo hepatectomy, ranging between 32% and 58%,19-24, 26, 27, 161 and 
10-year overall survival ranging between 22 and 28%.20-22, 26, 27, 161 The optimal timing 
of liver resection for resectable synchronous CLM is controversial. Traditionally most 
surgeons perform a ‘sequential’ (or staged, or delayed) resection, whereby the primary 
colorectal tumour is resected first followed by a hepatectomy at a later stage.110 
Between the procedures the patients often receive chemotherapy and those with disease 
progression during chemotherapy are unlikely to be considered for liver resection, thus 
selecting tumours with better prognosis for liver resection. 
 
More recently, surgeons have started performing ‘combined’ (or simultaneous) 
resections whereby the primary tumour and liver resection are performed 
concurrently.11 Combined resections became more common due to advances in the 
fields of surgery, anaesthesia, and critical care, allowing surgeons to perform more 
complex operations safely. The advantages of combined resection over sequential 
resection is thought to be the decreased operative and anaesthetic risks of one operation 
versus two operations, with shorter hospital stay and faster recovery allowing patients to 
commence adjuvant chemotherapy earlier.  
 
Nevertheless, there remain concerns regarding combined resections about both the 
safety and the long-term oncological effects. This has led surgeons to be cautious and to 
perform combined resections in a selected group of patients with an easily resectable 
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primary, limited metastatic disease, and few comorbidities.111-113 Clinically this usually 
equates with a right colon resected along with a minor liver resection (<3 segments). 
There have been previous systematic reviews comparing combined versus sequential 
resections for synchronous CLM, but they did not report on all the important outcomes 
of interest and they have missed important studies112, 162-166 some of which were 
published after the search date of those systematic reviews.  
 
 
4.1.1. Aims of this review 
 
The aims of this review were to perform an up-to-date systematic review of the 
literature to identify the best timing for liver resections in patients presenting with 
synchronous CLM.  
 
Meta-analytical techniques are used to compare the short and long-term outcomes in 
patients with synchronous CLM undergoing combined resection (whereby the primary 
tumour and liver resection are performed concurrently) versus sequential resection 
(whereby the primary colorectal tumour is resected first followed by liver resection at a 
later stage). 
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4.2 METHODS 
 
 
4.2.1 Search strategy 
 
A comprehensive literature search was performed of the following databases: 
MEDLINE, EMBASE, and CENTRAL in The Cochrane Library. The following search 
headings were used: “colorectal liver metastases”, “colorectal hepatic metastases” 
combined with the Boolean operator ‘AND’ and each of the following terms: 
“combined resection”, “simultaneous resection”, “synchronous resection”, “sequential 
resection”, “delayed resection”, and “staged resection”. The “related articles” function 
from PubMed was used to broaden the search, and all titles were initially scanned and 
the abstracts of interest were reviewed. The references of the identified trials were also 
searched to identify additional trials for inclusion. No restrictions were made based on 
language, publication year, or publication status. The latest date for this search was June 
30, 2012. 
 
 
4.2.2 Inclusion and exclusion criteria  
 
To be included in the analysis, a study had to:  
1. Clearly report CLM as synchronous in presentation. 
2. Compare combined versus sequential resections in patients with synchronous 
CLM. 
3. Report on at least one of the outcome measures of interest mentioned below in a 
format that could be used in the meta-analysis. 
4. Be either the most recent study or the highest quality study when two or more 
reports on the same patients were published by the same institution and/or 
authors. 
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4.2.3 Data extraction 
 
The following data were independently extracted by two review authors (Constantinos 
Simillis and Alistair Slesser) from each study using a custom-designed data extraction 
form: first author, language of publication, country and year(s) of conduct of the study, 
year of publication, type of study, sample size, the number of subjects undergoing 
combined and sequential resections, participant characteristics (such as age, sex, 
underlying disease, comorbidities), inclusion and exclusion criteria used in individual 
studies, matching criteria, follow-up period, patients lost to follow-up, data for the 
outcomes of interest mentioned below, and risk of bias. Any discrepancies between the 
two reviewers were resolved through discussion.  
 
The risk of bias and the quality of the included studies was assessed based on the 
Newcastle-Ottawa Scale (NOS) with some modifications to match the needs of this 
study.167-169 The quality of the studies was evaluated by the same two review authors by 
examining three factors: patient selection, comparability of the study groups, and 
assessment of outcome. Table 4.1 shows how the stars were awarded for each study 
based on the modified NOS. 
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Table 4.1: Modified Newcastle-Ottawa Scale (NOS) for assessing the quality of the 
included studies.  
 
 
Assessment of quality of included studies – Newcastle Ottawa Scale   
Selection  (tick one box in each section)  
1. Representativeness of the intervention cohort  
a) truly representative of the average, elderly, community-dwelling resident      
b) somewhat representative of the average, elderly, community-dwelling resident      
c) selected group of patients, e.g. only certain socio-economic groups/areas 
d) no description of the derivation of the cohort 
 
 
 
 
 
 
2. Selection of the non-intervention cohort 
a) drawn from the same community as the intervention cohort      
b) drawn from a different source 
c) no description of the derivation of the non-intervention cohort 
 
 
 
3. Ascertainment of intervention   
a) secure record (e.g. health care record)      
b) structured interview      
c) written self-report 
d) other / no description 
 
 
 
 
4. Demonstration that outcome of interest was not present at start of study   
a) yes      
b) no    
 
 
Comparability  (tick one or both boxes, as appropriate)  
1. Comparability of cohorts on the basis of the design or analysis 
a) study controls for age, sex, BMI/weight, ASA grade, cardiorespiratory disease (any 3 
of the 5)      
b) study controls for any additional factors (number of metastases, distribution of 
metastases, size of metastases, location of colon cancer, staging of colon cancer ) (any 2 
of 5)      
 
 
 
 
 
Outcome  (tick one box in each section)  
1. Assessment of outcome 
a) independent blind assessment      
b) record linkage      
c) self-report 
d) other / no description 
 
 
 
 
2. Was follow up long enough for outcomes to occur   
a) yes, if median duration of follow-up ≥ 3 years      
b) no, if median duration of follow-up < 3 years 
 
 
3. Adequacy of follow up of cohorts   
a) complete follow up: all subjects accounted for      
b) subjects lost to follow up unlikely to introduce bias:  number lost ≤ 20%,      
or description of those lost suggesting no different from those followed 
c) follow up rate < 80% and no description of those lost 
d) no statement 
 
 
 
 
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4.2.4 Outcomes of interest and definitions 
 
The following outcomes were used to compare patients with synchronous CLM 
undergoing combined versus sequential hepatic resections: 
1. Adverse events: perioperative mortality, overall postoperative complications, 
hepatectomy related complications, general complications, bile leak, bowel anastomotic 
leak, wound infections, cardiovascular complications, and respiratory complications 
2. Perioperative outcomes: operating time in minutes (min), operative blood loss in 
millilitres (mL), proportion of patients needing blood transfusion, and duration of 
hospital stay in days 
3. Overall survival and recurrence-free survival 
4. Quality of life 
 
 
4.2.5 Statistical analysis 
 
For detailed explanation of the statistical analysis please refer to section 2.3.4. Analysis 
was conducted using Review Manager Version 5.1.138  
 
Statistical analysis of binary variables was performed using the OR and was reported 
with 95% CI.140  The MH method was used to combine the OR for the outcomes of 
interest. OR represent the odds of an adverse event occurring in the combined group 
compared to the sequential group, and an OR of less than one favoured the combined 
resection group. 
 
Statistical analysis of continuous variables was performed using the MD and was 
reported with 95% CI.140  MDs summarise the differences between the combined and 
sequential resection groups with respect to continuous variables, accounting for sample 
size, and a negative MD favoured the combined resection group. 
 
The HR was used to compare the time-to-event outcomes ‘overall survival’ and 
‘recurrence-free survival’ between the combined and sequential resection groups. The 
generic inverse variance method was used to combine the time-to event outcomes. An 
HR of less than one favoured the combined group. 
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Statistical heterogeneity between studies was explored using the chi-squared test, with 
significance set at the P<0.10 level, and the amount of heterogeneity was determined by 
means of I-square. Three further strategies were used to quantitatively assess 
heterogeneity. First, graphical exploration with funnel plots was used to evaluate 
publication bias.145, 147 Second, data was analysed using both random-effects and fixed-
effect models. Where there was no difference between the results of random-effects and 
fixed-effect models that would change interpretation of the results, the results of the 
fixed-effect model were reported; otherwise, both the results were reported. Third, 
sensitivity analysis was undertaken based on the following factors: more recent studies 
published from 2009 onwards,112, 162-166, 170-172 studies scoring 8 or more stars on the 
modified NOS,110, 112, 162, 163, 165, 173-177 and studies including more than 60 resections in 
the combined resection group.113, 164, 170, 173, 174, 177-180 The decision to perform sensitivity 
analysis based on the above three factors was made a priori, but the cut-off points were 
decided after the studies for inclusion were identified (but before any data analysis) in 
order to ensure adequate number of studies included in each group allowing sensitivity 
meta-analyses to be performed. 
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4.3 RESULTS 
 
 
4.3.1 Eligible studies 
 
A total of 13,475 references were identified following the search strategy described 
above. Twelve more references were identified for further assessment through scanning 
reference lists of the identified studies. The duplicates excluded between databases were 
4,859. A further 8,571 clearly irrelevant references were excluded through screening 
titles and reading abstracts. Fifty-seven references were retrieved for further assessment. 
After reviewing the studies in detail, 33 were excluded for the following reasons: 7 
studies were non-comparative, 11 studies included the assessment of metachronous 
CLM, 14 studies were either reviews, editorials, letters or abstracts, 1 study was from 
the same institution and authors as another included study. In total, 24 studies110, 112, 113, 
162-166, 170-185 met the inclusion criteria and were included in the meta-analysis. This is 
summarised in the study flow diagram in Figure 4.1.  
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Figure 4.1: Study flow diagram. 
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4.3.2 Characteristics of the included studies 
 
All studies included in the meta-analysis were non-randomised retrospective (NRR) 
studies and were published between 1991 and 2010. The patients included in the 
combined and sequential resection groups were from a contemporary cohort of patients 
in 23 studies,110, 112, 113, 162-166, 170-179, 181-185 and in one study the patients in the sequential 
resection group belonged to a succeeding (more recent) cohort of patients.180 A total of 
3,159 participants were included in the analysis, of which 1,381(43.7%) had combined 
resections and 1,778 (56.3%) had sequential resections for synchronous CLM. Only 4 
studies112, 175, 178, 180 reported the number of patients belonging in the sequential 
operation group who received chemotherapy between the first and second operation.  
 
The primary tumour was in the colon for the majority of both combined and sequential 
resections, except for four studies: in three studies164, 174, 178 the majority of the primary 
tumours of the combined resection group were rectal in origin, and in one study166 all 
the primary tumours of both groups were rectal in origin. The hepatic metastatic 
distribution in both the combined and sequential resection groups was provided by nine 
studies.112, 162, 163, 174, 175, 177, 181, 182, 185 The proportion of patients with a bilobar 
metastatic distribution was higher in the combined resection group only in two 
studies174, 177 out of the nine, whereas, in the other seven studies112, 162, 163, 175, 181, 182, 185 
the proportion of patients with a bilobar metastatic distribution was higher in the 
sequential resection group.  
 
Statistical comparison of the patient characteristics included in the combined and 
sequential resection groups showed no significant difference between the two groups in 
age (P=0.58), gender (P=0.87), number of colonic primaries (P=0.65), and number of 
liver metastases (P=0.3). On the other hand, compared to the combined resection group, 
the sequential resection group had significantly higher rate of bilobar distribution of the 
liver metastases (P=0.01), significantly greater proportion of major liver resections 
performed (P<0.001), and significantly larger size of liver metastases (P<0.001). These 
statistically significant differences were favouring the combined resection group, 
suggesting a selection bias towards a lower metastatic burden in the patients belonging 
in this group. The characteristics of the included studies and patient demographic data 
are shown in Table 4.2. The number of colon primary tumours and the burden of 
metastatic disease are shown in Table 4.3.  
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Table 4.2: Characteristics of the included studies and patient demographic data.  
 
 
Author Year Study 
Design 
No of 
patients 
C        S 
Agea 
 
C           S 
Male (n [%]) 
 
C           S 
Study 
Quality 
(max: 9) 
Brouquet, et al 2010 NRR 43 72 58(m) 56(m) 23(53) 44(61) 8 
Capussotti, et al 2007 NRR 70 57 64.9 60.8 40(57) 35(61) 8 
Chua, et al 2004 NRR 64 32 63 61 39(61) 18(56) 8 
de Hass, et al 2010 NRR 55 173 56 58 28(51) 107(62) 8 
Jaeck, et al 1999 NRR 28 31 56 60 ---- ---- 7 
Kaibori, et al 2010 NRR 32 42 65 62.3 17(53) 27(64) 9 
Luo, et al 2010 NRR 129 276 58 60 76(59) 156(57) 7 
Martin, et al 2009 NRR 70 160 58(m) 61(m) 38(54) 91(57) 7 
Minagawa, et al 2006 NRR 142 18 ---- ---- ---- ---- 5 
Moug, et al 2010 NRR 32 32 69 67 18(56) 21(66) 8 
Petri, et al 2010 NRR 14 29 60 64.2 8(57) 17(59) 6 
Reddy, et al 2007 NRR 135 475 57 58 84(62) 277(58) 6 
Scheele, et al 1991 NRR 90 42 ---- ---- ---- ---- 6 
Slupski, et al 2009 NRR 28 61 59.4 60.2 18(64) 34(56) 7 
Tanaka, et al 2004 NRR 39 37 ---- ---- 20(51) 25(68) 7 
Taniai, et al 2006 NRR 37 8 ---- ---- ---- ---- 6 
Thelen, et al 2007 NRR 40 179 60.5 59.7 24(60) 96(54) 8 
Turrini, et al 2007 NRR 57 62 60 59 ---- ---- 8 
Van der Pool, et 
al 
2010 NRR 8 29 ---- ---- ---- ---- 6 
Vassiliou, et al 2007 NRR 25 78 63 61 15(60) 47(60) 8 
Vogt, et al 1991 NRR 19 17 ---- ---- ---- ---- 5 
Weber, et al 2003 NRR 35 62 58 60 18(51) 31(50) 7 
Yan, et al 2007 NRR 73 30 60 59 33(45) 15(50) 8 
Yoshidome, et 
al 
2008 NRR 116 21 ---- ---- 83(72) 12(57) 6 
 
 
 
Footnotes: NRR=Non-Randomised Retrospective, am=median values all other values 
given as means, C=combined resection group, S=sequential resection group. 
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Table 4.3: Number of colon primary tumours and burden of metastatic disease for each 
included study.  
 
 
Author Colon 
(n [%]) 
C               S 
Bilobar 
(n [%]) 
 C                S 
Pre-op metastatic 
size (cm)a 
C                S 
Major liver 
resection % 
C                S 
Brouquet, et al 25(58) 37(51) 13(30) 43(60) 2(m) 3(m) 35 67 
Capussotti, et al 43(61) 37(65) ---- ---- ---- ---- 34 56 
Chua, et al 27(46) 15(54) 16(25) 13(41) 3.7 3.9 16 40 
de Hass, et al 43(78) 140(82) 17(31) 75(43) 3.9 3.8 ---- ---- 
Jaeck, et al 22(78) 19(61) 10(36) 18(58) ---- ---- 32 52 
Kaibori, et al 27(84) 28(67) 7(22) 20(48) ---- ---- ---- ---- 
Luo, et al 60(47) 139(50) ---- ---- ---- ---- 32 38 
Martin, et al 49(70) 123(77) ---- ---- 3.7(m) 4(m) 47 40 
Minagawa, et al 70(49) 14(78) ---- ---- ---- ---- 11 38 
Moug, et al 17(53) 17(53) ---- ---- ---- ---- 22 22 
Petri, et al ---- ---- ---- ---- 2.6 4.6 0 21 
Reddy, et al 81(60) 367(77) ---- ---- 2.5 3.5 26 61 
Scheele, et al ---- ---- ---- ---- ---- ---- ---- ---- 
Slupski, et al 18(64) 47(77) ---- ---- 3.5 4.1 29 48 
Tanaka, et al 24(65) 20(53) 14(36) 24(65) 2.4 5.0 13 59 
Taniai, et al ---- ---- ---- ---- ---- ---- ---- ---- 
Thelen, et al 34(85) 107(60) 15(38) 88(49) ---- ---- 38 79 
Turrini, et al 33(58) 42(68) ---- ---- ---- ---- ---- ---- 
Van der Pool, et al 0b 0b ---- ---- ---- ---- ---- ---- 
Vassiliou, et al 22(88) 70(89) ---- ---- ---- ---- ---- ---- 
Vogt, et al ---- ---- ---- ---- ---- ---- 32 53 
Weber, et al 25(71) 38(61) 8(23) 42(68) ---- ---- 31 52 
Yan, et al 58(79) 18(60) 50(68) 10(33) 3.8 5.9 74 73 
Yoshidome, et al 67(58) 11(52) ---- 15(71) ---- ---- ---- ---- 
 
 
 
Footnotes: C=combined resection group, S=sequential resection group, am=median 
values all other values given as means, ball cases were rectal primaries. 
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4.3.3 Overall results of meta-analysis 
 
4.3.3.1. Adverse events 
 
The overall meta-analysis comparing combined versus sequential resections for 
synchronous CLM showed no significant difference for any of the postoperative adverse 
events. Also, analysis with funnel plots showed no evidence of significant publication 
bias for these outcomes. The adverse events reported were: 
 
 Perioperative mortality: no significant difference (Figure 4.2; combined 1.5%, 
sequential 1.2%; OR=1.67, 95% CI 0.86, 3.24; P=0.13), with no evidence of 
heterogeneity (P=0.31; I-square 15%) and no evidence of publication bias (Figure 4.3). 
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Figure 4.2: Overall meta-analysis - forest plot for the outcome perioperative mortality. 
There was no statistically significant difference in the proportion of people with 
perioperative mortality between the combined versus sequential operations. 
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Figure 4.3: Overall meta-analysis - funnel plot for the outcome perioperative mortality. 
There was no evidence of publication bias.  
 
 
 
 
 
 
 
 
 
 
 
 Overall postoperative complications: no significant difference (Figure 4.4; 
combined 36%, sequential 37%; OR=0.94, 95% CI 0.78, 1.12; P=0.47), with evidence 
of heterogeneity (P=0.02; I-square 47%) and no evidence of publication bias (Figure 
4.5). 
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Figure 4.4: Overall meta-analysis - forest plot for the outcome overall postoperative 
complications. There was no statistically significant difference in the number of overall 
postoperative complications between the combined and sequential procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83 
 
Figure 4.5: Overall meta-analysis - funnel plot for the outcome overall postoperative 
complications. There was no evidence of publication bias.   
 
 
 
 
 
 
 
 
 
 
 
 Hepatectomy related complications: no significant difference (Figure 4.6; 
combined 11%, sequential 11%; OR=0.99, 95% CI 0.69, 1.43; P=0.97), with no 
evidence of heterogeneity (P=0.36; I-square 9%) and no evidence of publication bias 
(Figure 4.7). 
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Figure 4.6: Overall meta-analysis - forest plot for the outcome hepatectomy related 
complications. There was no statistically significant difference in the number of 
hepatectomy related complications between the combined and sequential procedure. 
 
 
 
 
Figure 4.7: Overall meta-analysis - funnel plot for the outcome hepatectomy related 
complications. There was no evidence of publication bias.   
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 General complications: no significant difference (Figure 4.8; combined 17%, 
sequential 13%; OR=1.10, 95% CI 0.81, 1.50; P=0.54), with evidence of heterogeneity 
(P=0.02; I-square 56%) and no evidence of publication bias (Figure 4.9). 
 
 
 
 
 
 
 
 
Figure 4.8: Overall meta-analysis - forest plot for the outcome general complications. 
There was no statistically significant difference in the number of general complications 
between the combined and sequential group, with evidence of heterogeneity. 
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Figure 4.9: Overall meta-analysis - funnel plot for the outcome general complications. 
There was no evidence of publication bias. 
 
 
 
 
 
 
 
 
 
 
 
 Bile leak: no significant difference (Figure 4.10; combined 4.1%, sequential 
6.3%; OR=0.76, 95% CI 0.42, 1.39; P=0.37), with no evidence of heterogeneity 
(P=0.55; I-square 0%) and no evidence of publication bias (Figure 4.11). 
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Figure 4.10: Overall meta-analysis - forest plot for the outcome bile leak. There was no 
statistically significant difference in the number of patients having a bile leak between 
the combined and sequential resection group. 
 
 
 
 
Figure 4.11: Overall meta-analysis - funnel plot for the outcome bile leak. There was 
no evidence of publication bias. 
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 Bowel anastomotic leak: no significant difference (Figure 4.12; combined 2.4%, 
sequential 2.1%; OR=1.15, 95% CI 0.47, 2.82; P=0.77), with no evidence of 
heterogeneity (P=0.42; I-square 0%) and no evidence of publication bias (Figure 4.13). 
 
 
Figure 4.12: Overall meta-analysis - forest plot for the outcome bowel anastomotic 
leak. There was no statistically significant difference in the number of patients having a 
bowel anastomotic leak between the combined and sequential resection group. 
 
 
 
 
Figure 4.13: Overall meta-analysis - funnel plot for the outcome bowel anastomotic 
leak. There was no evidence of publication bias. 
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 Wound infections: no significant difference (Figure 4.14; combined 8.7%, 
sequential 4.6%; OR 1.41, 95% CI 0.82, 2.41; P=0.22), with no evidence of 
heterogeneity (P=0.79; I-square 0%) and no evidence of publication bias (Figure 4.15). 
 
 
Figure 4.14: Overall meta-analysis - forest plot for the outcome wound infections. 
There was no statistically significant difference in the number of patients having a 
wound infection between the combined and sequential resection group. 
 
 
 
Figure 4.15: Overall meta-analysis - funnel plot for the outcome wound infections. 
There was no evidence of publication bias. 
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 Cardiovascular complications: no significant difference (Figure 4.16; combined 
6.6%, sequential 6.6%; OR 1.16, 95% CI 0.65, 2.07; P=0.62), with no evidence of 
heterogeneity (P=0.42; I-square 0%) and no evidence of publication bias (Figure 4.17). 
 
 
Figure 4.16: Overall meta-analysis - forest plot for the outcome cardiovascular 
complications. There was no statistically significant difference in the number of 
cardiovascular complications between the combined and sequential group. 
 
 
 
 
 
Figure 4.17: Overall meta-analysis - funnel plot for the outcome cardiovascular 
complications. There was no evidence of publication bias. 
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 Respiratory complications: no significant difference (Figure 4.18; combined 
9.3%, sequential 10.7%; OR 0.85, 95% CI 0.58, 1.27; P=0.43), with no evidence of 
heterogeneity (P=0.23; I-square 25%) and no evidence of publication bias (Figure 4.19). 
 
 
Figure 4.18: Overall meta-analysis - forest plot for the outcome respiratory 
complications. There was no statistically significant difference in the number of 
respiratory complications between the combined and sequential resection group. 
 
Figure 4.19: Overall meta-analysis - funnel plot for the outcome respiratory 
complications. There was no evidence of publication bias. 
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4.3.3.2. Perioperative outcomes 
 
Operating time was reported by eight studies.110, 164, 170, 172, 175, 181, 182, 185 The operating 
time was the total operating time for both procedures of the sequential resection group. 
Meta-analysis of this outcome using a random-effects model showed no significant 
difference between the combined and sequential resection groups (Figure 4.20; MD -
23.83 min, 95% CI -85.04, 37.38; P=0.45); whereas meta-analysis using the fixed-effect 
model showed the combined resection group to have significantly shorter operating time 
compared to the sequential resection group (Figure 4.21; MD -37.94 min, 95% CI -
47.08, -28.80, P<0.001). The reason for the difference between the two models was the 
significant heterogeneity between studies for this outcome (P<0.001, I-square 98%). 
Although, the studies are symmetrical around the vertical axis on the funnel plot for 
operating time (Figure 4.22), they are much spread and all of them fall out of the 95% 
CI lines. The random-effects model was used for the interpretation of this outcome 
because it takes into consideration the heterogeneity between studies and gives a more 
conservative effect estimate. 
 
 
Figure 4.20: Overall meta-analysis - forest plot for the outcome operating time using 
the random-effects model. There was no statistically significant difference in operating 
time between the combined and sequential resection groups using the random-effects 
model, with significant heterogeneity between studies. 
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Figure 4.21: Overall meta-analysis - forest plot for the outcome operating time using 
the fixed-effect model. The combined resection group had significantly shorter 
operating time compared to the sequential resection group using the fixed-effect model, 
with significant heterogeneity between studies. 
 
 
 
Figure 4.22: Overall meta-analysis - funnel plot for the outcome operating time. 
Although the studies are much spread and all of them fall out of the 95% CI lines, there 
is no evidence of publication bias. 
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Hepatic vascular occlusion time was reported by four studies.172, 175, 181, 185 The hepatic 
vascular occlusion time was the total hepatic vascular occlusion time for both 
procedures of the sequential resection group. Meta-analysis of this outcome using a 
random-effects model showed no significant difference between the combined and 
sequential resection groups (Figure 4.23; MD -2.56 min, 95% CI -11.15, 6.03; P=0.56); 
whereas meta-analysis using the fixed-effect model showed the combined resection 
group to have significantly shorter hepatic vascular occlusion time compared to the 
sequential resection group (Figure 4.24; MD -5.90 min, 95% CI -7.85, -3.96, P<0.001). 
The reason for the difference between the two models was the significant heterogeneity 
between studies for this outcome (P<0.001, I-square 93%). Three studies are 
symmetrical around the vertical axis on the funnel plot for hepatic vascular occlusion 
time (Figure 4.25) but one study is an outlier and falls out of the 95% CI lines. The 
random-effects model was used for the interpretation of this outcome because it takes 
into consideration the heterogeneity between studies and gives a more conservative 
effect estimate. 
 
 
Figure 4.23: Overall meta-analysis - forest plot for the outcome hepatic vascular 
occlusion time using the random-effects model. There was no statistically significant 
difference in hepatic vascular occlusion time between the combined and sequential 
resection groups using the random-effects model, with significant heterogeneity 
between studies. 
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Figure 4.24: Overall meta-analysis - forest plot for the outcome hepatic vascular 
occlusion time using the fixed-effect model. The combined resection group had 
significantly shorter hepatic vascular occlusion time compared to the sequential 
resection group using the fixed-effect model, with significant heterogeneity between 
studies. 
 
 
 
Figure 4.25: Overall meta-analysis - funnel plot for the outcome hepatic vascular 
occlusion time. Three studies are symmetrical around the vertical axis on the funnel plot 
for hepatic vascular occlusion time, but one study is an outlier and falls out of the 95% 
CI lines. 
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Operative blood loss was reported by seven studies112, 163-165, 170, 172, 182. The operative 
blood loss was the total operative blood loss for both surgeries of the sequential 
resection group. Meta-analysis using the random-effects model showed no significant 
difference between the two groups for this outcome (Figure 4.26; MD -128.37 mL, 95% 
CI -279.28, 22.53, P=0.10); using the fixed-effect model showed the combined 
resection group to have significantly lower operative blood loss compared to the 
sequential resection group (Figure 4.27; MD -221.46 mL, 95% CI -257.59, -185.32; 
P<0.001). The reason for the difference between the two models was the significant 
heterogeneity between studies for this outcome (P<0.001, I-square 85%). The funnel 
plot showed one study,172 which favoured the sequential resection group for this 
outcome, to be well out of the 95% CI lines (Figure 4.28). The random-effects model 
was preferred for the interpretation of this outcome because it gives a more conservative 
effect estimate. 
 
 
Figure 4.26: Overall meta-analysis - forest plot for the outcome operative blood loss 
using the random-effects model. There was no statistically significant difference in 
operative blood loss between the combined and sequential resection groups when using 
the random-effects model, with significant heterogeneity between studies. 
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Figure 4.27: Overall meta-analysis - forest plot for the outcome operative blood loss 
using the fixed-effect model. The combined resection group had significantly lower 
operative blood loss compared to the sequential resection group when using the fixed-
effect model, with significant heterogeneity between studies. 
 
 
Figure 4.28: Overall meta-analysis - funnel plot for the outcome operative blood loss. 
One study,172 which favoured the sequential resection group for this outcome, is well 
out of the 95% CI lines. There was no evidence of publication bias. 
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The number of patients requiring blood transfusion was reported by six studies.162, 163, 
170, 175, 181, 185 The total number of patients transfused for both procedures of the 
sequential resection group was used for comparison. There was no significant difference 
between the two groups (Figure 4.29; OR 1.29, 95% CI 0.93, 1.80; P=0.13), with no 
evidence of heterogeneity (P=0.36, I-square 8%) or publication bias for this outcome 
(Figure 4.30). 
 
 
 
 
Figure 4.29: Overall meta-analysis - forest plot for the outcome number of patient 
requiring blood transfusion. There was no statistically significant difference in the 
proportion of patients transfused between the combined and sequential resection groups. 
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Figure 4.30: Overall meta-analysis - funnel plot for the outcome number of patient 
requiring blood transfusion. There was no evidence of publication bias. 
 
 
 
 
 
 
 
 
 
Duration of hospital stay was reported by ten studies.164-166, 170, 172, 174, 175, 177, 181, 182 The 
total length of hospital stay for both surgeries of the sequential resection group was used 
in the analysis. The combined resection group was found to have significantly shorter 
duration of hospital stay compared to the sequential resection group (Figure 4.31; MD -
5.52 days, 95% CI -5.94, -5.10; P<0.001), with significant heterogeneity between 
studies (P<0.001, I-square 95%). There was evidence of publication bias as shown by 
the asymmetry of the funnel plot (Figure 4.32). 
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Figure 4.31: Overall meta-analysis - forest plot for the outcome duration of hospital 
stay. The combined resection group had significantly shorter duration of hospital stay 
compared to the sequential resection group, with significant heterogeneity identified. 
 
 
Figure 4.32: Overall meta-analysis - funnel plot for the outcome duration of hospital 
stay. There was evidence of publication bias based on the asymmetry of the funnel plot. 
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4.3.3.3. Overall survival and recurrence-free survival 
 
The overall survival rate was reported by sixteen studies.110, 112, 162, 172-179, 181-185 Meta-
analysis with the random-effects model showed no significant difference in overall 
survival between the combined and the sequential resection groups (Figure 4.33; HR 
1.00, 95% CI 0.86, 1.15; P=0.96); meta-analysis with the fixed-effect model showed the 
combined resection group to have significantly better overall survival rate compared to 
the sequential resection group (Figure 4.34; HR 0.95, 95% CI 0.92, 0.98; P=0.004). The 
reason for the difference between the two models was the significant heterogeneity 
between studies for this outcome (P<0.001, I-square 94%). The asymmetry of the funnel 
plot for this outcome also suggested evidence of publication bias (Figure 4.35). The 
random-effects model was preferred for the interpretation of this outcome because it 
takes into consideration the heterogeneity between studies and gives a more 
conservative effect estimate. 
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Figure 4.33: Overall meta-analysis - forest plot for the outcome overall survival using 
the random-effects model. There was no statistically significant difference in overall 
survival between combined and sequential procedure using the random-effects model. 
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Figure 4.34: Overall meta-analysis - forest plot for the outcome overall survival using 
the fixed-effect model. The combined resection group had significantly better overall 
survival rate compared to the sequential resection group using the fixed-effect model. 
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Figure 4.35: Overall meta-analysis - funnel plot for the outcome overall survival. The 
asymmetry of the funnel plot suggested evidence of publication bias. 
 
 
 
 
 
 
 
 
Recurrence-free survival was reported by six studies.163, 174, 177, 179, 180, 182 Meta-analysis 
using the random-effects model showed no significant difference in recurrence-free 
survival between the combined and the sequential resection groups (Figure 4.36; HR 
0.85, 95% CI 0.71, 1.02; P=0.08); meta-analysis using the fixed-effect model showed 
the combined resection group to have significantly better disease free survival rate 
compared to the sequential resection group (Figure 4.37; HR 0.86, 95% CI 0.83, 0.90; 
P<0.001). There was significant heterogeneity between studies (P<0.001, I-square 91%) 
which explains the difference in outcomes between the two models. The random-effects 
model was used for the interpretation of this outcome due to its more conservative 
value. There was no significant evidence of publication bias (Figure 4.38). None of the 
included studies reported on quality of life. 
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Figure 4.36: Overall meta-analysis - forest plot for the outcome recurrence-free 
survival using the random-effects model. There was no statistically significant 
difference in recurrence-free survival between the combined and sequential procedures 
when using the random-effects model. 
 
 
 
 
Figure 4.37: Overall meta-analysis - forest plot for the outcome recurrence-free 
survival using the fixed-effect model. The combined resection group was found to have 
significantly better disease free survival rate compared to the sequential resection group 
when using the fixed-effect model. 
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Figure 4.38: Overall meta-analysis - funnel plot for the outcome recurrence-free 
survival. There was no evidence of publication bias. 
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4.3.4 Sensitivity analysis 
 
4.3.4.1. More recent studies 
 
The only difference in the results of the sensitivity analysis including more recent 
studies compared to the results of the overall meta-analysis was regarding recurrence-
free survival which was reported by only one study163 in this sensitivity analysis, and 
this study reported better disease free survival in the combined resection group 
compared to the sequential resection group. All the other results of the sensitivity 
analysis of more recent studies were the same with the overall meta-analysis. Sensitivity 
analysis of the nine studies112, 162-166, 170-172 published during or after 2009 demonstrated 
no significant difference between the combined and sequential resection groups in 
perioperative mortality (OR 0.92, 95% CI 0.31, 2.69; P=0.87), overall complications 
(OR 1.19, 95% CI 0.91, 1.56; P=0.20), hepatectomy related complications (OR 1.02, 
95% CI 0.65, 1.60; P=0.93), general complications (OR 1.17, 95% CI 0.82, 1.69; 
P=0.39),  proportion of patients transfused (OR 1.31, 95% CI 0.84, 2.04; P=0.23), and 
overall survival (HR 1.05, 95% CI 0.95, 1.15; P=0.33).  
 
Similar to the overall meta-analysis, sensitivity analysis of more recent studies, found 
operative blood loss to be significantly less in the combined resection group during 
analysis with the fixed-effect model (MD -221.24 mL, 95% CI -257.48, -185.00; 
P<0.001), but the difference disappeared when the random-effects model was used for 
the analysis (MD -118.14 mL, 95% CI -277.44, 41.15; P=0.15). There was significant 
heterogeneity for operative blood loss (P<0.001, I-square 88%). Operating time was 
found to be significantly shorter in the combined resection group during analysis with 
the fixed-effect model (MD -55.49 min, 95% CI -68.89, -42.10; P<0.001), but the 
difference disappeared when the random-effects model was used for the analysis (MD -
75.82 min, 95% CI -211.83, 60.18; P=0.27), and there was significant heterogeneity for 
this outcome (P<0.001, I-square 99%). The length of hospital stay was significantly 
shorter in the combined resection group compared to the sequential resection group 
(MD -5.61 days, 95% CI -6.05, -5.16; P<0.001), during analysis with both the fixed-
effect and random-effects models, with significant heterogeneity between studies 
(P<0.001; I-square 97%).  
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4.3.4.2. Studies scoring 8 or more stars 
 
The results of the sensitivity analysis of the studies which scored 8 or more stars on the 
modified NOS,110, 112, 162, 163, 165, 173-177 were all similar to the overall meta-analysis, 
except for blood transfusion, where the sequential resection group was found to have 
significantly fewer patients transfused compared to the combined resection group (OR 
1.69, 95% CI 1.01, 2.83; P=0.04), with no significant heterogeneity between studies 
(P=0.31, I-square 14%). Similar to the overall meta-analysis, this sensitivity analysis 
showed no significant difference between the combined and sequential resection groups 
in perioperative mortality (OR 2.24, 95% CI 0.82, 6.11; P=0.12), general complications 
(OR 0.86, 95% CI 0.55, 1.33; P=0.49), hepatectomy related complications (OR 0.68, 
95% CI 0.38, 1.21; P=0.19), and overall survival (HR 0.99, 95% CI 0.95, 1.04; P=0.75).  
 
The combined resection group was found to have significantly fewer overall 
complications compared to the sequential resection group when compared using the 
fixed-effect model (OR 0.72, 95% CI 0.54, 0.96; P=0.02), but no significant difference 
was found between the two groups when using the random-effects model (OR 0.72, 
95% CI 0.50, 1.06; P=0.09). There was significant heterogeneity for overall 
complications (P=0.10, I-square 39%). Recurrence-free survival of the combined 
resection group was found to be significantly better during analysis with the fixed-effect 
model (HR 0.93, 95% CI 0.87, 0.99; P=0.03), but there was no significant difference 
with the random-effects model (HR 0.81, 95% CI 0.57, 1.14; P=0.22). There was 
significant heterogeneity for recurrence free survival (P<0.001, I-square 95%). 
 
Similar to the overall meta-analysis, operating time was found to be significantly shorter 
in the combined resection group during analysis with the fixed-effect model (MD -42.50 
min, 95% CI -57.52, -27.47; P<0.001), but the difference disappeared when the random-
effects model was used for the analysis (MD -14.53 min, 95% CI -143.77, 114.70; 
P=0.83). There was significant heterogeneity for operating time (P<0.001, I-square 
98%). Operative blood loss was found to be significantly less in the combined resection 
group during analysis with the fixed-effect model (MD -221.46 mL, 95% CI -257.59, -
185.32; P<0.001), but the difference disappeared when the random-effects model was 
used for the analysis (MD -128.37 mL, 95% CI -279.28, 22.53; P=0.10), and there was 
significant heterogeneity for this outcome (P<0.001, I-square 85%). The length of 
hospital stay was significantly shorter in the combined resection group compared to the 
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sequential resection group (MD -7.22 days, 95% CI -8.74, -5.71; P<0.001), during 
analysis with both the fixed-effect and random-effects models, with significant 
heterogeneity between studies (P<0.001; I-square 78%). 
 
 
4.3.4.3. Studies reporting on more than 60 resections in the combined resection 
group  
 
Sensitivity analysis of the 9 studies113, 164, 170, 173, 174, 177-180 reporting on more than 60 
resections in the combined resection group, had similar results with the overall meta-
analysis except for operative blood loss and operating time. Operative blood loss was 
found to be significantly reduced in the combined resection group compared to the 
sequential resection group (MD -239.90 mL, 95% CI -278.18, -201.62; P<0.001), 
during analysis with both the fixed-effect and random-effects models, with no 
significant heterogeneity between studies (P=0.24; I-square 28%). Operating time was 
found to be significantly shorter in the combined resection group compared to the 
sequential resection group (MD -141.45 min, 95% CI -159.50, -123.41; P<0.001), with 
significant heterogeneity between studies (P=0.02, I-square 81%). 
 
Similar to the overall meta-analysis, no significant difference was demonstrated 
between the combined and the sequential resection groups in perioperative mortality 
(OR 1.40, 95% CI 0.54, 3.59; P=0.49), overall complications (OR 1.08, 95% CI 0.86, 
1.36; P=0.50), hepatectomy related complications (OR 1.18, 95% CI 0.74, 1.87; 
P=0.49), and proportion of patients transfused (OR 1.22, 95% CI 0.70, 2.15; P=0.48). 
There was no significant difference between the two groups regarding the general 
complications (OR 1.32, 95% CI 0.88, 1.98; P=0.18), but there was significant 
heterogeneity between studies for this outcome (P=0.09, I-square 58%). The length of 
hospital stay was significantly shorter in the combined resection group compared to the 
sequential resection group (MD -6.20 days, 95% CI -6.65, -5.75; P<0.001), during 
analysis with both the fixed-effect and random-effects models, with significant 
heterogeneity between studies (P=0.02; I-square 70%). 
 
Overall survival of the combined resection group was found to be significantly better 
during analysis with the fixed-effect model (HR 0.87, 95% CI 0.82, 0.91; P<0.001), but 
there was no significant difference with the random-effects model (HR 0.93, 95% CI 
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0.73, 1.19; P=0.58). There was significant heterogeneity for overall survival (P<0.001, 
I-square 95%). Regarding recurrence-free survival, the combined resection group was 
found to do significantly better during analysis with the fixed-effect model compared to 
the sequential resection group (HR 0.87, 95% CI 0.83, 0.91; P<0.001), but there was no 
significant difference between the two groups using the random-effects model for the 
analysis (HR 0.93, 95% CI 0.76, 1.16; P=0.53), and there was significant heterogeneity 
for this outcome (P<0.001, I-square 92%). 
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4.4 DISCUSSION 
 
This review used meta-analytical techniques to compare combined versus sequential 
resection for synchronous CLM. Twenty-four non-randomised retrospective 
comparative studies were included in this meta-analysis. This meta-analysis found no 
significant difference between the combined and sequential resection groups in 
perioperative mortality and morbidity. Specifically, there was no significant difference 
between the two groups in overall complications, hepatectomy related complications, 
general complications, bile leak, bowel anastomotic leak, cardiovascular complications, 
and respiratory complications. Operative blood loss and perioperative blood transfusion 
are two of the most important factors affecting perioperative morbidity and mortality 
during liver resection,45, 46, 64, 65 and the current meta-analysis found no significant 
difference between the two groups in operative blood loss, and proportion of patients 
requiring blood transfusion. The above results, would suggest that combined resection is 
at least as safe as sequential resection in selected cases, and did not increase the rate of 
postoperative complications. In addition, the combined resection group was found to 
have a significantly shorter length of hospital stay compared to the sequential resection 
group, and this has important financial implications. Finally, the current meta-analysis 
demonstrated that combined resection is associated with comparable survival rates and 
recurrence-free rates as sequential resection. 
 
Similar to the other meta-analyses comparing combined to sequential resections for 
synchronous CLM,186-189 one of the major findings of the current meta-analysis was the 
significant heterogeneity between studies for important outcomes of interest. This 
heterogeneity persisted during sensitivity analysis of subgroups of studies. Importantly, 
when heterogeneity was identified, the heterogeneity was in the direction of the effect 
rather than its magnitude. This is important because when there is heterogeneity in the 
direction of the effect, it means that the beneficial or harmful effect of the intervention 
is not consistent across all studies. Whereas, if there is heterogeneity in the magnitude 
of the effect, it means that all the studies consistently report that the intervention is 
beneficial or harmful, but there is variation in how beneficial or harmful the intervention 
is. The current meta-analysis demonstrated how heterogeneity can affect the overall 
results of a meta-analysis depending on the model used to perform the meta-analysis. In 
the current meta-analysis, the fixed effect model demonstrated significant benefit for the 
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combined resection group compared to the sequential resection group for important 
outcomes of interest, e.g. operating time, operative blood loss, overall survival rate, and 
recurrence-free survival rate. For the same outcomes, the random-effects model found 
no significant difference between the two groups.  
 
A researcher should be aware of the benefits and limitations of the different models 
available to perform a meta-analysis, and should understand how to choose the correct 
one. Choosing the wrong model for a meta-analysis may result in completely different 
outcomes reported by the meta-analysis, thus resulting into making the wrong 
recommendations which may significantly affect the overall management and care of 
patients. The difference in results between the fixed-effect and the random-effects 
model was due to the significant heterogeneity between studies. If there was no 
significant heterogeneity between the studies, the results between the fixed-effect and 
random-effects models would have been similar. In the presence of heterogeneity, the 
CI of the meta-analysed measure of effect is wider when the random-effects model is 
used.141 Therefore, the random-effects model provides a more conservative value, and 
when there was disagreement in the results between fixed-effect and random-effects 
models, the random-effects model was chosen for the interpretation of results in the 
presence of heterogeneity. 
 
When statistical heterogeneity between studies is discovered, it is important to attempt 
to identify the source of heterogeneity. The studies included in the current meta-analysis 
were all non-randomised retrospective comparative studies. Retrospective studies have 
inherent biases, most important of which, is, selection bias. Comparison between 
combined and sequential resection groups identified significant difference between the 
two groups in the hepatic metastatic burden of the included patients. Specifically, the 
sequential resection group had significantly higher rate of bilobar distribution of the 
liver metastases, greater proportion of major liver resections needed to be performed, 
and larger size of liver metastases. These statistically significant differences were 
favouring the combined resection group, suggesting a selection bias towards a lower 
metastatic burden in the patients belonging in this group. This selection bias may have 
led to results that favoured the combined resection group. 
 
Furthermore, although there was no significant difference between combined and 
sequential resection groups in the number of colonic primaries, there was significant 
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variation between studies in the location of the primary, with one study including only 
rectal primaries, other studies including more rectal primaries in the combined or the 
sequential resection group, and other studies including mainly colonic primaries for 
both groups. This may be a source of heterogeneity for the outcomes reported by the 
included studies because, for example, a right hemicolectomy is technically easier to 
perform with lower risk of complications compared to an anterior resection or an 
abdominoperineal resection. A sensitivity analysis could not have been performed to 
test this possible source of heterogeneity because the included studies did not report 
their results separately for colonic or rectal tumours, and only one study166 included 
only rectal primaries. The heterogeneity between studies may have also resulted due to 
the other potentially confounding variables, such as demographic characteristics, patient 
selection criteria, interim treatments (e.g. type of chemotherapy), surgeon’s experience, 
and surgical technique used for liver resection and/or colorectal resection.  
 
Meta-analysis of non-randomised studies, is useful in the absence of RCTs, and together 
with identifying the source of heterogeneity between the included studies, it may guide 
further researchers toward properly informed randomisation in future studies. 
Importantly, selection criteria should be established for patients who may be suitable for 
combined resection, besides simply comparing the safety and efficacy of the two 
resection strategies.189 In addition, only limited hepatic disease should be assessed in 
both groups to avoid any bias related to the disease severity. 
 
After resection of the primary tumour, patients undergoing sequential resection, would 
typically undergo chemotherapy and would be monitored for a period of 2-3 months. 
Those patients who did not exhibit disease progression during this period, would 
progress to liver resection. This ‘test of time’ approach, or interval re-evaluation, is 
strongly advocated to observe the biological behaviour of the metastatic disease 
following primary tumour resection, in order to select patients who will benefit from 
hepatic resection, and to avoid unnecessary major operation in patients who develop 
distant or an increased number of metastases during this period.190 This interval re-
evaluation approach may have biased the results favouring the sequential resection 
group by selecting tumours with better prognosis for liver resection. On the other hand, 
the postoperative immunodeficiency following the primary resection in sequential 
resections has been suggested to increase the risk of liver metastatic growth.162, 191 
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Over the last few years, there has been a major change to practise which is the switch to 
laparoscopic approach to resect the primary disease. The laparoscopic approach allows 
chemotherapy shortly after the primary resection. Because of this, a trial comparing 
sequential laparoscopic bowel resection followed by open liver resection versus 
combined resection by open surgery will not be suitable. In this case, a RCT comparing 
laparoscopic bowel resection followed by laparoscopic liver resection versus combined 
laparoscopic resection of primary and hepatic disease will be more suitable. For this 
RCT, only limited hepatic disease amenable to laparoscopic resection should be 
assessed in both groups.  
 
Neoadjuvant chemotherapy prior to hepatectomy may facilitate the resectability of the 
liver lesions and treat occult metastases, but it may also lead to hepatic parenchyma 
damage. There have been concerns that patients who undergo combined resection 
without neoadjuvant chemotherapy may have a higher recurrence rate (currently 
unproven), and that combined resections run the risk of leaving behind undetected 
occult micro-metastases in the remnant liver.180 Whether combined resection results in 
increased disease recurrence due to undetected micro-metastases, which did not have 
time to grow and be detected, is questionable, since the metastatic disease is present in 
the liver for a long period before diagnosis. On the other hand, shorter hospital stay and 
faster recovery after combined resection, allows patients to commence adjuvant 
chemotherapy without delay as opposed to patients undergoing sequential resections.176  
 
This meta-analysis, did not find a significant difference between combined and 
sequential resections with regard to overall survival and recurrence-free survival. 
Despite the limitations of this meta-analysis, it is still important, as it has confirmed that 
in the presence of limited hepatic disease, combined resection is safe and produces the 
same oncological outcomes as sequential resection for patients with synchronous CLM. 
Therefore, combined resection of synchronous CLM would be justifiable in the 
presence of limited hepatic disease based on the findings of the current meta-analysis. 
Nevertheless, in cases of a higher burden of metastatic liver disease, combined resection 
is not yet justifiable, until further trials are produced with more severe, but importantly 
comparable, hepatic disease burden between combined and sequential resections. 
 
There have been previous systematic reviews on this topic, but they did not report on all 
the important outcomes of interest and they have missed important studies112, 162-166 
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which were published after the search date of those systematic reviews. One previous 
meta-analysis published in Chinese included 7 studies, and reported a significantly 
increased mortality rate for the combined resection group compared to the sequential 
resection group, but no difference in morbidity between the two groups.192  
 
A systematic review published by Hillingso et al. in 2009 included 16 retrospective 
studies, and suggested a tendency towards a shorter hospital stay and lower morbidity in 
the combined resection group, lower perioperative mortality in the sequential resection 
group, and similar 5-year survival between the two groups.187 Hillingso et al. did not 
proceed to perform a meta-analysis of the outcomes and odds ratios were not calculated 
because of the following reasons: no RCTs were identified;  the studies were biased 
because the sequential procedure was significantly more often undertaken in patients 
with left-sided primary tumours and with larger, more numerous, bi-lobar metastases; 
significant statistical heterogeneity between studies was identified.187 The study 
concluded that combined resections can be undertaken in selected patients, provided 
that surgeons specialized in colorectal and hepatobiliary surgery are available.187 
 
A meta-analysis published by Chen et al. in 2011, included 14 studies and reported 
significant statistical heterogeneity between the studies.186 Chen et al. demonstrated 
similar operating time and operative blood loss between the two groups, a shorter length 
of hospital stay and lower morbidity rate with the combined resection group, and similar 
1-year, 3-year, and 5-year survival rates between the two groups using the OR as the 
effect estimate for survival.186 The authors concluded that combined resection is safe 
and efficient in the treatment of patients with synchronous CLM and recommended 
caution in interpretation of the results of their study due to the heterogeneity detected.186 
 
After the current meta-analysis was performed, two more meta-analyses were published 
on the same subject in 2013,188, 189 and another meta-analysis in 2014.193 In their meta-
analysis published in 2013, Li et al. found statistical heterogeneity between studies, and 
demonstrated a shorter hospital stay and lower total complication rate with the 
combined resection group, and no significant difference between the two groups in 
perioperative mortality, operative blood loss, 1-year, 3-year and 5-year recurrence-free 
and overall survival rate.188 The study concluded that there is evidence that combined 
resection is an acceptable and safe option with carefully selected conditions and 
recommended future RCTs to confirm this conclusion.188 
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The other meta-analysis published in 2013, by Yin et al., showed statistical 
heterogeneity between studies and reported fewer postoperative complications in the 
combined group, and no difference between the two groups in perioperative mortality, 
overall survival, and recurrence-free survival (HR was the effect estimate for the latter 
two outcomes).189 The authors concluded that combined resection is safe and efficient in 
the treatment of patients with synchronous CLM and commented that their findings 
have to be carefully interpreted due to the lower level of evidence and the existence of 
heterogeneity.189 
 
Finally, the meta-analysis published in 2014 by Feng et al. included 22 retrospective 
studies and found the number of liver metastases to be a major confounding factor.193 
After correction of baseline imbalances, the meta-analysis demonstrated no significant 
difference in postoperative mortality, morbidity, overall and disease-free survival 
between the two groups.193 The study concluded that without baseline imbalances 
between the combined and sequential resection groups, the combined group had no 
statistical significant advantage in safety and efficacy.193 
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4.5 CONCLUSIONS 
 
This meta-analysis demonstrated that combined resection for synchronous CLM is 
associated with comparable perioperative mortality and morbidity, operative blood loss, 
and blood transfusion requirements as sequential resection. It also demonstrated that the 
length of hospital stay is significantly reduced in patients after combined resection. 
Survival rates and recurrence-free rates were found to be similar between the two 
groups. However, the findings of this meta-analysis are limited by significant 
differences in metastatic disease severity between the two groups, the retrospective 
nature of the included studies, and the heterogeneity identified between studies. 
Therefore, this data should be used to justify a well-designed RCT with appropriate 
selection criteria comparing combined versus sequential resection in patients with 
comparable metastatic disease severity, and with both primary and hepatic disease 
amenable to laparoscopic resection. 
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CHAPTER 5 
 
 
PAIRWISE META-ANALYSIS COMPARING THE 
SURVIVAL OF NODE POSITIVE VERSUS NODE 
NEGATIVE DISEASE AFTER HEPATECTOMY FOR 
COLORECTAL LIVER METASTASES 
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5.1 INTRODUCTION 
 
The liver produces a large amount of lymph, which is estimated to be 25 to 50 % of the 
lymph flowing through the thoracic duct.194 The hepatic lymph primarily comes from 
the hepatic sinusoids, and the hepatic lymphatic vessels fall into three categories 
depending on their locations: portal, sublobular, and superficial lymphatic vessels.194 
The portal lymphatic vessels are the most important with more than 80% of the hepatic 
lymph draining into them, while the remainder lymph drains through the sublobular and 
capsular lymphatic vessels.194 Lymphatic vessels are abundant in the immediate vicinity 
of liver metastases,194 and it is thought that lymphatic dissemination from hepatic 
metastases is the mechanism of tumour spread to extrahepatic lymph nodes.195-197 
Lymph node involvement in patients with CLM is believed to constitute a tertiary 
lymphatic metastasis or a ‘metastasis of a metastasis’.195, 196, 198 
 
Liver resection for CLM in the presence of hepatic lymph node involvement is 
controversial. Involvement of hepatic lymph nodes during liver resection is considered 
as a poor prognostic factor114-116 and has been labelled as a contraindication to 
surgery.115 The 5-year survival rate after liver resection in the presence of hepatic lymph 
node involvement varies between 0 and 4.3%.117, 118, 199 
 
Macroscopic positive lymph node involvement may be evident preoperatively by 
radiological imaging or intraoperatively by identifying enlarged, firm, irregular lymph 
nodes, with obvious tumour infiltration. Also, positive lymph node involvement may be 
identified microscopically by examining the histology of the resected lymph nodes. 
Both macroscopic and microscopic lymph node involvement have been shown to have a 
negative impact on survival.116-119 In about 14% to 15% of lymph nodes draining the 
liver considered uninvolved macroscopically, when examined closer histologically, they 
were found microscopically to be infiltrated by cancer cells.117, 118 
 
The position of the positive lymph nodes has been suggested to affect prognosis. 
Patients who have involvement of common hepatic artery nodes and coeliac artery 
nodes (considered as group 2 nodes)73, 200 have been reported to have a poorer prognosis 
than patients with involvement of the hepatoduodenal or retropancreatic  group of nodes 
(considered as group 1 nodes).73, 200 Approximately half of the microscopic disease is in 
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the hepatoduodenal and the retro-pancreatic group, which may be amenable to radical 
lymphadenectomy.73, 200 
 
Hepatic node involvement detected pre-operatively or during surgery is generally 
considered a contraindication to hepatectomy for CLM. After adjusting for different 
factors such as tumour number,117, 199, 201, 202 size,117, 201, 202 distribution,117, 202 and 
surgical resection margin,201 survival rates for people with positive lymph nodes after 
hepatectomy, are similar to those in patients with unresectable CLM who underwent 
hepatic infusion chemotherapy,200, 203, 204 suggesting that there is no benefit to these 
patients undergoing the mortality risk and morbidity associated with major liver 
surgery.  
 
A Cochrane review published in 2010 aiming to compare curative liver resection with 
lymphadenectomy versus other treatments, concluded that there was no evidence in the 
literature to assess the role of surgery (liver resection alone or in combination with 
radiofrequency ablation or cryoablation) versus other treatments (neo-adjuvant 
chemotherapy, chemotherapy, or radiofrequency ablation) for patients with CLM with 
hepatic node involvement.205 A systematic review published in 2008 assessed the role of 
lymphadenectomy during liver resection for CLM and concluded that here was no 
evidence of survival benefit for routine or selective lymphadenectomy.200 The review 
also found that the survival rates were low in patients with positive lymph nodes 
draining the liver irrespective of whether they were detected by routine 
lymphadenectomy or by macroscopic involvement.200 A case series by Carpizo et al. of 
patients undergoing liver resection for CLM with concomitant resection of extrahepatic 
disease, demonstrated that patients with hepatic portal lymph node metastases had 
worse survival than those with lung or ovarian metastases from colorectal cancer.206  
 
On the other hand, other studies have shown that long-term survival can be achieved in 
highly selected patients undergoing liver resection along with resection of hepatic 
lymph node metastases. Adam et al. reported a 5-year disease-free survival rate of 11% 
and a 5-year overall survival rate of 18% after combined liver resection and 
lymphadenectomy in a cohort of patients with CLM who had preoperatively diagnosed 
hepatic lymph node involvement and had responded to neoadjuvant chemotherapy.28 
The same study also showed a difference in survival depending on the site of nodal 
metastases: the 5-year survival rate for patients who had metastases in the hepatic 
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pedicle lymph nodes and underwent hepatectomy and lymphadenectomy was better 
(25%) than for those undergoing hepatectomy along with resection of involved coeliac 
and para-aortic lymph nodes (0%).28 Pulitano et al. evaluated the long-term outcomes of 
patients undergoing liver resection for CLM in the presence of extrahepatic disease, and 
found an overall 5-year survival rate of 18% in patients with lymph node involvement, 
most of whom had received preoperative as well as adjuvant chemotherapy.207 Jaeck et 
al. reported a 3-year survival rate of 38% in patients who had nodal involvement in the 
hepatoduodenal ligament compared with 0% in patients who had nodal involvement 
around the hepatic artery and coeliac trunk.117 Lymph node involvement in this study 
was diagnosed after routine lymphadenectomy, and the study demonstrated no survival 
advantage with routine lymphadenectomy.117 
 
With significant improvements in perioperative cross sectional imaging, patient 
selection for resection, the safety of surgical techniques and chemotherapeutic agents in 
recent years, the previous contraindication to surgery in patients with hepatic node 
involvement is being challenged. Chemotherapy regiments have significantly improved 
over the years for the treatment of CLM. Adjuvant or neoadjuvant chemotherapy may 
play a role in patients undergoing resection where positive lymph nodes have been 
identified macroscopically preoperatively or during surgery, or microscopically on 
histology postoperatively.  
 
There is a potential advantage in performing routine hepatic lymphadenectomy at the 
time of hepatectomy for CLM by removing microscopically involved lymph nodes and 
providing adjuvant chemotherapy in patients who do not have other poor prognostic 
factors. With more effective chemotherapy regimens, routine hepatic lymphadenectomy 
concurrent with liver resection for CLM could have a role in improving staging to guide 
adjuvant chemotherapy regimens.119, 208 However, there have been no studies comparing 
hepatectomy alone with hepatectomy along with routine lymphadenectomy, and there is 
no consensus on whether routine hepatic lymphadenectomy or node sampling should be 
performed.119, 208  
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5.1.1. Aims of this review 
 
The aims of this systematic review and meta-analysis are: 
1. Determine the prognostic significance of hepatic lymph node status in patients 
undergoing hepatectomy for CLM by comparing survival and disease recurrence 
of patients with node positive versus node negative disease using meta-
analytical techniques. 
2. Investigate whether survival of patients with nodal involvement is improved by 
lymphadenectomy and if the extent of lymphadenectomy affects prognosis. 
3. Investigate whether there might be a survival benefit from routine hepatic 
lymphadenectomy. 
4. Determine whether hepatectomy is indicated in patients with proven 
macroscopic nodal involvement.  
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5.2 METHODS 
 
 
5.2.1 Search strategy 
 
The following databases were searched: MEDLINE from PubMed (January 1990 to 
November 2012), EMBASE (January 1990 to November 2012), and CENTRAL in The 
Cochrane Library (issue 1, 2012 from 1990). The following search strategy was used in 
MEDLINE: ("Neoplasm Metastasis"[MeSH] OR metasta* OR secondar* OR spread 
OR cancer OR carcinoma OR tumour OR tumor OR neoplasm) AND (colon OR 
colonic OR colorect* OR rectal OR rectum OR gut OR intestine OR bowel OR 
"Intestine, Large"[MeSH] OR "Colorectal Surgery"[MeSH] OR "Intestinal 
Neoplasms"[MeSH]) AND (("Liver"[MeSH] OR "Liver Neoplasms"[MeSH] OR "Liver 
Diseases"[MeSH] OR liver OR hepatic) AND (segmentectomy OR resection) OR 
"Hepatectomy"[MeSH]) AND "humans"[MeSH Terms] AND English[Lang] AND 
("1990"[PDAT] : "3000"[PDAT]). Equivalent search strategies were used in EMBASE 
and CENTRAL. 
 
 
5.2.2 Inclusion and exclusion criteria  
 
The inclusion criteria for studies were as follows: 
1. RCTs or comparative series 
2. Published in journals from January 1990 onwards 
3. Full text in English language 
4. Clearly reported on hepatectomy for CLM 
5. Clearly reported on the hepatic lymph node status 
6. Reported survival or cancer recurrence data 
7. Had a minimum duration of follow-up of 1 year 
 
The exclusion criteria for studies were as follows:  
1. Included liver resection for cancers other than CLM (primary or secondary) 
2. Included repeat or multistage liver resections 
3. Reported on combined excision of liver and lung metastases 
124 
 
4. Less than 10 patients underwent hepatectomy 
5. Hepatic lymph node status was not clearly reported 
6. Mentioned extrahepatic disease but not clearly stated as involving hepatic lymph 
nodes 
7. Mentioned regional lymph nodes but not clearly stated whether the lymph nodes 
drain the primary tumour or the metastases 
8. Not possible to identify the survival or recurrence data for hilar node positive 
and negative status separately 
9. No controls reported (i.e. survival reported only in node negative and node 
positive patients who did not undergo hepatectomy) 
10. More than 10 %  of patients lost to follow-up  
 
 
5.2.3 Data extraction 
 
The following data were independently extracted by two review authors (Constantinos 
Simillis and Michael Jacovides) from each study using a custom-designed data 
extraction form: first author, language of publication, country and year(s) of conduct of 
the study, year of publication, type of study, sample size, participant characteristics 
(such as age, sex, underlying disease, comorbidities), study design, inclusion and 
exclusion criteria used in individual studies, length of follow up, patients lost to follow-
up, tests performed during follow-up period, any adjuvant or neoadjuvant therapy given, 
indications for chemotherapy, hepatic lymph node involvement and how it was 
diagnosed (microscopic or macroscopic or both), whether routine or selective hepatic 
lymphadenectomy was performed, group of nodes dissected, survival and mortality 
data, time to recurrence data, type of recurrence (including local or regional or remote in 
relation to liver and the actual sites of recurrence). Any discrepancies between the two 
reviewers were resolved through discussion. 
 
 
5.2.4 Risk of bias  
 
The risk of bias of the included trials was assessed based on the following bias risk 
domains: allocation sequence generation, allocation concealment, blinding of 
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participants and personnel, blinding of outcome assessors, incomplete outcome data, 
selective outcome reporting, and vested interest bias. These bias risk domains were 
chosen based on the advice of The Cochrane Collaboration,141 and the Cochrane 
Hepato-Biliary Group Module.209 For each of these risk domains of bias the studies 
were categorized as low risk, uncertain risk, and high risk of bias. A trial was 
considered at low risk of bias if the trial was assessed as at low risk of bias for all 
domains. Trials with uncertain risk of bias or with high risk of bias for one or more 
domains were considered trials with high risk of bias.  
 
In detail, the risk of bias of the included trials was assessed for the following 
domains:210-216 
 
Allocation sequence generation 
• Low risk of bias: sequence generation was achieved using computer random number 
generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and 
throwing dice were adequate if performed by an independent adjudicator. 
• Uncertain risk of bias: the trial was described as randomised, but the method of 
sequence generation was not specified.  
• High risk of bias: the sequence generation method was not, or may not have been, 
random. This includes quasi-randomised studies, i.e. those studies using dates, names, 
or admittance numbers to allocate participants. 
 
Allocation concealment 
• Low risk of bias: allocation was controlled by a central and independent randomisation 
unit, sequentially numbered, opaque and sealed envelopes, or something similar, so that 
intervention allocations could not have been foreseen in advance of, or during, 
enrolment. 
• Uncertain risk of bias: the trial was described as randomised, but the method used to 
conceal the allocation was not described, so that intervention allocations may have been 
foreseen in advance of, or during, enrolment. 
• High risk of bias: if the allocation sequence was known to the investigators who 
assigned participants or the study was quasi-randomised.  
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Blinding of participants and personnel 
• Low risk of bias: blinding was performed adequately, or the outcome measurement 
was not likely to be influenced by lack of blinding. 
• Uncertain risk of bias: information was insufficient to allow assessment of whether the 
type of blinding used was likely to induce bias on the estimate of effect. 
• High risk of bias: no blinding or incomplete blinding and the outcome or the outcome 
measurements were likely to be influenced by lack of blinding. 
 
Blinding of outcome assessors 
• Low risk of bias: blinding was performed adequately, or the outcome measurement 
was not likely to be influenced by lack of blinding. 
• Uncertain risk of bias: information was insufficient to allow assessment of whether the 
type of blinding used was likely to induce bias on the estimate of effect. 
• High risk of bias: no blinding or incomplete blinding and the outcome or the outcome 
measurements were likely to be influenced by lack of blinding. 
 
Incomplete outcome data 
• Low risk of bias: the underlying reasons for missing data were unlikely to make 
treatment effects depart from plausible values, or proper methods have been employed 
to handle missing data. 
• Uncertain risk of bias: information was insufficient to allow assessment of whether the 
missing data mechanism in combination with the method used to handle missing data 
was likely to induce bias on the estimate of effect. 
• High risk of bias: the crude estimate of effects (e.g., complete case estimate) was 
clearly biased because of the underlying reasons for missing data, and the methods used 
to handle missing data were unsatisfactory. 
 
Selective outcome reporting 
• Low risk of bias: pre-defined or clinically relevant and reasonably expected outcomes 
were reported. 
• Uncertain risk of bias: not all pre-defined or clinically relevant and reasonably 
expected outcomes were reported, or they were not reported fully, or it was unclear 
whether data on these outcomes were recorded. 
• High risk of bias: one or more clinically relevant and reasonably expected outcomes 
were not reported; data on these outcomes were likely to have been recorded. 
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Vested interest bias 
• Low risk of bias: the trial was conducted by a party with no vested interests (i.e., a 
party benefiting from the results of the trial) in the outcome of the trial. 
• Uncertain risk of bias: It was not clear if the trial was conducted by a party with vested 
interest in the outcome of the trial. 
• High risk of bias: the trial was conducted by a party with vested interests in the 
outcome of the trial (such as a drug manufacturer). 
 
 
5.2.5 Outcomes of interest and definitions 
 
The following outcomes were used to compare patients found to have positive lymph 
nodes versus patients with negative lymph nodes: 
1. Survival at 1 year postoperatively 
2. Survival at 3 years postoperatively 
3. Survival at 5 years postoperatively 
4. Overall survival expressed as time-to-event outcome 
 
The following definitions were used in this meta-analysis: 
 Hepatic lymph nodes: The term ‘hepatic’ has been used to maintain 
consistency and includes all subgroups of hepatic regional lymph nodes. The 
different terms used by different authors to define subgroups were as follows: hilar 
nodes, portal nodes, hepatoduodenal ligament nodes, hepatic pedicle nodes (nodes 
along the hepatoduodenal ligament, retropancreatic, common hepatic artery and 
celiac artery), perihepatic nodes, retropancreatic nodes, pedicular nodes (distal to 
gastroduodenal artery branch), common hepatic artery nodes, celiac nodes, para-
aortic nodes and regional nodes. 
 Primary site: Primary site of origin in the colon or rectum 
 Local recurrence in liver: Recurrence at the site of liver resection. This has no 
relation to the recurrence of the tumour at the primary site.  
 Regional nodal recurrence: Perihepatic area including porta hepatis. Again, 
this has no relation to the regional lymph nodes draining the primary tumour site.  
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 Remote recurrence: Recurrence of cancer in sites not included in the above 
two categories. In most cases (except in hepatic flexure tumours), recurrence at the 
primary site will be included in this category. 
 Macroscopic lymph node involvement: Lymph node involvement as detected 
radiologically (preoperatively or perioperatively) or by visual and tactile assessment.  
 Microscopic lymph node involvement: Lymph node involvement not detected 
radiologically or by visual and tactile assessment, but detected by microscopic 
examination of resected lymph nodes. 
 Lymph node involvement: Macroscopic or microscopic lymph node 
involvement or both. 
 No lymph node involvement: Neither macroscopic nor microscopic lymph 
node involvement. 
 Routine lymphadenectomy: Lymphadenectomy (of nodes draining the liver) 
performed routinely in the presence or absence of lymph node involvement.  
 
 
5.2.6 Statistical analysis 
 
For detailed explanation of the statistical analysis please refer to section 2.3.4. 
Analysis was conducted using Review Manager Version 5.1.138  
 
Statistical analysis of the binary outcomes (1-year, 3-year, and 5-year survival) was 
performed using the OR and was reported with 95% CI.140 The MH method was used 
to combine the OR for these outcomes. OR represents the odds of a patient surviving 
in the positive lymph node group of patients compared to the negative lymph node 
group of patients at 1 year, 3 years, and 5 years. An OR of less than one favoured 
patients with negative lymph nodes. 
 
The HR was used to compare the time-to-event outcome ‘overall survival’ between 
the lymph node positive and lymph node negative groups of patients. The generic 
inverse variance method was used to combine the time-to event outcomes. An HR of 
less than one favoured the negative lymph node group. 
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Heterogeneity was explored using the chi-squared test, with significance set at the 
P<0.10 level, and the amount of heterogeneity was determined by means of I-square. 
Three further strategies were used to quantitatively assess heterogeneity. First, 
graphical exploration with funnel plots was used to evaluate publication bias.145, 147 
Second, data was analysed using both random-effects and fixed-effect models. Where 
there was no difference between the results of random-effects and fixed-effect 
models that would change interpretation of the results, the results of the fixed-effect 
model were reported; otherwise, both the results were reported. Third, sensitivity 
analysis was undertaken based on the following factors: whether the studies included 
nodes involved macroscopically or microscopically, whether routine 
lymphadenectomy or selective lymphadenectomy was performed, whether 
chemotherapy was used, and whether only the lymph nodes along the hepatoduodenal 
ligament were removed (as compared with the removal of the other groups of nodes).  
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5.3 RESULTS 
 
 
5.3.1 Eligible studies 
 
A total of 5,316 references were identified following the search strategy described 
above. Seven more references were identified for further assessment through scanning 
reference lists of the identified studies. The duplicates excluded between databases were 
1,486.  A further 3,795 clearly irrelevant references were excluded through screening 
titles and reading abstracts. The remaining 42 studies were reviewed in detail, and 21 of 
them were excluded because they did not meet the inclusion criteria. In total, 21 
studies28, 117-119, 197, 199, 201, 206-208, 217-227 met the inclusion criteria and were included in the 
meta-analysis. This is summarised in the study flow diagram in Figure 5.1.  
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Figure 5.1: Study flow diagram. 
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5.3.2 Characteristics of the included studies 
 
No studies were identified in the literature comparing hepatectomy alone, with 
hepatectomy along with lymphadenectomy in patients with involved nodes. Therefore, a 
meta-analysis could not be performed comparing lymphadenectomy versus no 
lymphadenectomy in patients having liver resection for colorectal liver metastases with 
involved lymph nodes. Also, there were no studies comparing hepatectomy alone, with 
hepatectomy along with routine lymphadenectomy. Furthermore, there were no studies 
comparing hepatectomy with non-surgical treatments, such as chemotherapy or 
radiofrequency ablation, in patients with node positive disease who were otherwise 
suitable for hepatectomy.  
 
Twenty-one non-randomised studies28, 117-119, 197, 199, 201, 206-208, 217-227 reporting on 
patients who had undergone hepatectomy for CLM, and comparing the survival of node 
positive patients versus node negative patients, were included in the meta-analysis in 
order to determine the prognostic significance of hepatic lymph node status in patients 
undergoing hepatectomy for CLM. The studies were published between 1992 and 2013. 
In total, 4,618 patients undergoing hepatectomy for CLM were included in the meta-
analysis: 391 patients were node positive and 4,227 patients were node negative. All 
included studies were at high risk of bias according to the criteria set in this meta-
analysis. The risk of bias in the included studies is summarised in Figure 5.2 and Figure 
5.3.  
 
The characteristics of the included studies are shown in Table 5.1. The survival data of 
the individual studies is shown in Table 5.2. Routine lymphadenectomy was performed 
in 12 studies.117-119, 199, 208, 217, 219-221, 223, 224, 227 Neoadjuvant chemotherapy was given in 
patients in 6 studies,28, 207, 208, 221, 224, 226 and adjuvant chemotherapy in 15 studies.28, 118, 
119, 201, 206-208, 217-221, 223, 224, 226  
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Figure 5.2: Risk of bias summary - review authors' judgments about each risk of bias 
item for each included study. 
 
 
 
Footnotes: green plus sign = low risk of bias, yellow question mark = unclear risk of 
bias, red minus sign = high risk of bias. 
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Figure 5.3: Risk of bias graph - review authors' judgments about each risk of bias item 
presented as percentages across all included studies. 
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Table 5.1: Characteristics of the included studies reporting on patients who had undergone hepatectomy for CLM, and comparing the 
survival of node positive patients versus node negative patients. 
 
 
 
 
 
Authors 
 
 
 
 
Year 
 
Total 
number 
of 
patients 
 
Number of 
node positive 
cases 
(percentage) 
 
 
Routine or 
selective 
lymphadenectomy 
Microscopic or 
macroscopic 
node 
involvement or 
both 
 
 
 
 
Group of nodes dissected 
 
 
 
 
Chemotherapy 
 
 
 
Indications for 
chemotherapy 
Adam et al. 2008 763 47 (6.2) Selective Both Pedicular, coeliac, para-aortic Selective neoadjuvant and 
adjuvant 
Poor prognostic 
factors 
Ambiru et al. 1999 149 8 (5.4) Routine Both Hepatoduodenal ligament Adjuvant local or none Not stated 
Aoki et al. 2008 187 9 (4.8) Selective Both Hepatoduodenal ligament Adjuvant local or systemic 
or none 
Not stated 
Beckhurts et 
al. 
1997 126 35 (27.8) Routine Both Hepatoduodenal ligament Not stated Not stated 
Bennett et 
al. 
2008 45 8 (13.6) Routine Microscopic Portocaval, pancreaticoduodenal, common 
hepatic artery 
Selective neoadjuvant or 
adjuvant 
Not stated 
Carpizo et al. 2009 127 27 (21.3) Not stated Both Portal lymph nodes (hepatoduodenal 
ligament, hepatic artery) 
Adjuvant local or systemic 
or none 
Not stated 
Harms et al. 1999 155 39 (25.2) Routine Both Hepatoduodenal ligament Adjuvant local or systemic 
or none 
Poor prognostic 
factors 
Ishida et al. 2011 43 12 (27.9) Routine Both Common hepatic, proper hepatic artery, 
superior border of pancreas 
Adjuvant local or systemic All 
Jaeck et al. 2002 160 17 (10.6) Routine Both Hepatic pedicle (hepatoduodenal ligament, 
retropancreatic, coeliac axis, hepatic 
artery) 
Not stated Not stated 
Jonas et al. 2007 204 27 (13.2) Routine Both Hepatoduodenal ligament Adjuvant or neoadjuvant 
or none 
Not stated 
Kokudo et 
al. 
1998 94 7 (7.4) Not stated Not stated Hepatoduodenal ligament Adjuvant local or systemic 
or none 
Not stated 
Laurent et 
al. 
2004 156 23 (14.7) Routine Microscopic Hepatic pedicle (hepatoduodenal, hepatic 
artery) 
Adjuvant systemic Not stated 
Lupinacci et 
al. 
2013 26 5 (19.2) Routine Microscopic Hepatic hilum Adjuvant All 
Minagawa  
et al. 
2000 235 6 (2.6) Selective Both Hepatic hilum Not stated Not stated 
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Table 5.1 continued 
Nakamura  
et al. 
1992 22 6 (27.3) Routine Microscopic Hepatic pedicle (hepatoduodenal ligament, 
retropancreatic, coeliac axis) 
Adjuvant systemic All 
Oussoultzogl
ou et al. 
2008 132 12 (9.1) Routine Both Hepatic pedicle Adjuvant or neoadjuvant 
or none 
Not stated 
Pulitano et 
al. 
2012 1519 61 (4.0) Selective Both Hepatoduodenal ligament and 
retropancreatic area, common hepatic 
artery and celiac axis, para-aortic 
Neoadjuvant and adjuvant Not stated 
Rosen et al. 1992 40 9 (22.5) Selective Both Not stated Not stated Not stated 
Sanchez-
Cespedes et 
al. 
1999 16 8 (50) Not stated Microscopic Perihepatic Not stated Not stated 
Settmacher 
et al. 
2011 382 18 (4.7) Not stated Not stated Not stated Adjuvant or neoadjuvant 
or none 
Not stated 
Yasui et al. 1995 52 8 (15.4) Routine Both Hepatic pedicle (hepatoduodenal ligament, 
retropancreatic, hepatic artery) 
Not stated Not stated 
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Table 5.2: Survival data of the included studies reporting on patients who had undergone hepatectomy for CLM, and comparing node 
positive patients versus node negative patients. 
 
 
 
 
Author 
 
 
 
Year  
Total number 
of patients 
followed up 
for outcome 
Node positive followed up Node negative followed up 
Total 1-year 
survival 
3-year 
survival 
5-year 
survival 
Total 1-year 
survival 
3-year survival 5-year 
survival 
Adam et al. 2008 757 47 ---- 18 (38%) 8 (18%) 710 ---- 483 (68%) 376 (53%) 
Ambiru et al. 1999 149 8 ---- 1 (12.5%) 1 (12.5%) 141 ---- 63 (44.7%) 38 (27.0%) 
Aoki et al. 2008 187 9 ---- 5 (55.6%) 0 (0%) 178 ---- 87 (48.9%) 55 (30.9%) 
Beckhurts et al. 1997 119 35 ---- 1 (2.9%) 0 (0%) 84 ---- 40 (47.6%) 19 (22.6%) 
Bennett et al. 2008 45 8 ---- 2 (25%) ---- 37 ---- 28 (75%) ---- 
Carpizo et al. 2009 127 27 ---- 8 (29.6%) 3 (11.1%) 100 ---- 67 (67%) 49 (49%) 
Harms et al. 1999 155 39 ---- 1 (2.6%) 0 (0%) 116 ---- 52 (44.8%) 24 (20.7%) 
Ishida et al. 2011 43 12 ---- ---- ---- 31 ---- ---- ---- 
Jaeck et al. 2002 160 17 3 (17.6%) 3 (17.6%) 0 (0%) 143 135 (94.4%) 89 (62.2%) 67 (46.9%) 
Jonas et al. 2007 204 27 ---- 7 (25.9%) ---- 177 ---- 96 (54.2%) ---- 
Kokudo et al. 1998 94 7 6 (85.7%) 2 (28.6%) 0 (0%) 87 84 (96.6%) 57 (65.5%) 47 (54.0%) 
Laurent et al. 2004 156 23 16 (69.6%) 6 (26.1%) 1 (4.3%) 133 117 (88%) 74 (55.6%) 57 (42.9%) 
Lupinacci et al. 2013 26 5 ---- ---- ---- 21 ---- ---- ---- 
Minagawa et al. 2000 235 6 0 (0%) 0 (0%) 0 (0%) 229 119 (52.0%) 89 (38.9%) 62 (27.1%) 
Nakamura et al. 1992 21 5 ---- 2 (40%) ---- 16 ---- 10 (62.5%) ---- 
Oussoultzoglou 
et al. 
2008 132 12 ---- 4 (33.3%) 0 (0%) 120 ---- 88 (73.3%) 48 (40.0%) 
Pulitano et al. 2012 1519 61 52 (85.2%) 21 (34.4%) 11 (18.0%) 1458 ---- ---- 831 (57.2%) 
Rosen et al. 1992 40 9 ---- 1 (11.1%) 0 (0%) 31 ---- 17 (54.8%) 11 (35.5%) 
Sanchez-
Cespedes et al. 
1999 15 8 2 (25%) 0 (0%) ---- 7 7 (100) 2 of 4 (50%) ---- 
Settmacher 
et al. 
2011 382 18 ---- ---- ---- 364 ---- ---- ---- 
Yasui et al. 1995 52 8 ---- 2 (25%) 0 (0%) 44 ---- 26 (59.1%) 18 (40.9%) 
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5.3.3 Overall results of meta-analysis 
 
In total, 4,618 patients from 21 non-randomised studies28, 117-119, 197, 199, 201, 206-208, 217-227 
undergone hepatectomy for CLM were included in the meta-analysis: 391 patients had  
node positive disease and 4,227 patients had node negative disease. 
 
The overall prevalence of positive hilar lymph nodes in the included studies was 8.5%, 
and the prevalence of patients with positive lymph nodes reported by all studies ranged 
between 2.6% and 50%. In patients who underwent hepatectomy for CLM along with 
routine lymphadenectomy the overall prevalence of positive lymph nodes was 15.7%, 
with a range between 5.4% and 27.9%. In studies where patients underwent 
hepatectomy for CLM along with selective lymphadenectomy the overall prevalence of 
positive lymph nodes was 4.8%, with a range of 2.6% to 22.5% (Table 1). 
 
The overall 1-year, 3-year, and 5-year survival rates of patients who had undergone 
hepatectomy for CLM with positive lymph nodes were 64.8%, 23.6%, and 7.8%, 
respectively. The overall 1-year, 3-year, and 5-year survival rates of patients who had 
undergone hepatectomy for CLM with negative lymph nodes were 77.1%, 58.1% and 
47.6%, respectively. 
 
The odds of overall survival were significantly lower in the group of patients who had 
undergone hepatectomy for CLM with positive lymph nodes compared to the group of 
patients who had undergone hepatectomy for CLM with negative lymph nodes at 1 year 
(OR 0.09, 95% CI 0.05, 0.19; P<0.001), 3 years (OR 0.20, 95% CI 0.15, 0.27; P<0.001), 
and 5 years (OR 0.13, 95% CI 0.08, 0.19) (Figures 5.4, 5.5, and 5.6). There was 
significant heterogeneity between studies for overall survival at 1 year (P=0.008, I-
square 71%), but only five studies were included in the analysis of that outcome. There 
was no significant heterogeneity between studies for overall survival at 3 years (P=0.31, 
I-square 12%) and 5 years (P=0.96, I-square 0%). Also, there was no evidence of 
publication bias based on visual assessment of the funnel plots (Figures 5.7, 5.8, and 
5.9). 
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Figure 5.4: Overall meta-analysis - forest plot for the odds of overall survival at one 
year. Five studies reported on this outcome. The odds of overall survival at one year 
after hepatectomy for CLM were significantly lower in the group of patients with 
positive lymph nodes compared to the group of patients with negative lymph nodes. 
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Figure 5.5: Overall meta-analysis - forest plot for the odds of overall survival at three 
years. The odds of overall survival at three years after hepatectomy for CLM were 
significantly lower in the group of patients with positive lymph nodes compared to the 
group of patients with negative lymph nodes. 
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Figure 5.6: Overall meta-analysis - forest plot for the odds of overall survival at five 
years. The odds of overall survival at five years after hepatectomy for CLM were 
significantly lower in the group of patients with positive lymph nodes compared to the 
group of patients with negative lymph nodes. 
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Figure 5.7: Overall meta-analysis - funnel plot for the odds of overall survival at one 
year after hepatectomy for CLM. There was no evidence of publication bias. 
 
 
 
 
 
Figure 5.8: Overall meta-analysis - funnel plot for the odds of overall survival at three 
years after hepatectomy for CLM. There was no evidence of publication bias. 
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Figure 5.9: Overall meta-analysis - funnel plot for the odds of overall survival at five 
years after hepatectomy for CLM. There was no evidence of publication bias. 
 
 
 
 
 
 
 
 
 
The overall survival rate of patients undergoing liver resection for CLM was found to 
be significantly lower in the group of patients with lymph nodes metastases compared to 
the group of patients with negative lymph nodes (fixed-effect model; HR 0.29, 95% CI 
0.29, 0.29; P<0.001) with significant heterogeneity between studies (P<0.001, I-square 
100%). The result was the same for the random-effects model (HR 0.35, 95% CI 0.25, 
0.49; P<0.001) (Figure 5.10). As shown in Figure 5.10 the heterogeneity was in the 
magnitude of the effect rather than the direction. There was no evidence of publication 
bias as shown by the funnel plot in Figure 5.11. 
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Figure 5.10: Overall meta-analysis - forest plot for overall survival rate. The overall 
survival rate was significantly lower after hepatectomy for CLM in the group of patients 
with positive lymph nodes compared to the group of patients with negative lymph nodes 
with significant heterogeneity. 
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Figure 5.11: Overall meta-analysis - funnel plot for overall survival rate after 
hepatectomy for CLM. There was no evidence of publication bias. 
 
 
 
 
 
 
 
5.3.4 Sensitivity analysis 
 
The results of all the sensitivity analyses performed were similar to the overall meta-
analysis results, demonstrating a significantly lower overall survival rate after 
hepatectomy for CLM for patients with node positive disease compared to patients with 
node negative disease.  
 
Sensitivity analysis of studies including only patients with microscopic nodal 
involvement, showed a significantly lower overall survival rate after hepatectomy for 
CLM for node positive patients compared to node negative patients (HR 0.36, 95% CI 
0.35, 0.37; P<0.001) with no significant heterogeneity between studies (P=0.98, I-
square 0%) (Figure 5.12).  
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Sensitivity analysis of studies which included only patients in whom routine hepatic 
lymphadenectomy was performed, demonstrated a significantly lower overall survival 
rate after liver resection for CLM for patients with node positive disease compared to 
node negative disease (HR 0.11, 95% CI 0.11, 0.11; P<0.001), with significant 
heterogeneity in the magnitude of the effect (P<0.001, I-square 100%) (Figure 5.13).  
 
In studies where adjuvant or neoadjuvant chemotherapy was used, the overall survival 
rate was significantly lower after liver resection for CLM for node positive patients 
compared to node negative patients (HR 0.32, 95% CI 0.32, 0.32; P<0.001), with 
significant heterogeneity in the magnitude of the effect (P<0.001, I-square 99%) (Figure 
5.14). 
 
Sensitivity analysis of more recent studies published after 2006, demonstrated a 
significantly lower overall survival rate after hepatectomy for CLM for patients with 
node positive disease compared to patients with node negative disease (HR 0.41, 95% 
CI 0.41, 0.42; P<0.001), with significant heterogeneity in the magnitude of the effect 
(P<0.001, I-square 93%) (Figure 5.15). 
 
 
 
Figure 5.12: Sensitivity analysis of studies including only patients with microscopic 
nodal involvement - forest plot for overall survival rate. Node positive patients had 
significantly lower overall survival rate after hepatectomy for CLM compared to node 
negative patients. 
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Figure 5.13: Sensitivity analysis of studies including only patients in whom routine 
hepatic lymphadenectomy was performed - forest plot for overall survival rate. Node 
positive patients had significantly lower overall survival rate after hepatectomy for 
CLM compared to node negative patients with significant heterogeneity between studies 
in the magnitude of the effect. 
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Figure 5.14: Sensitivity analysis of studies only where adjuvant or neoadjuvant 
chemotherapy was used - forest plot for overall survival rate. The overall survival rate 
was significantly lower after hepatectomy for CLM for node positive patients compared 
to node negative patients with significant heterogeneity in the magnitude of the effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
Figure 5.15: Sensitivity analysis of studies published after 2006 - forest plot for overall 
survival rate. Patients with node positive disease had significantly lower overall survival 
rate after hepatectomy for CLM compared to patients with node negative disease, with 
significant heterogeneity between studies in the magnitude of the effect. 
 
 
 
 
 
 
 
In the subgroups classified by the extent/location of lymph node dissection, the overall 
survival rate of node positive patients was significantly lower compared to node 
negative patients, in patients who underwent: 
 clearance of hilar or perihepatic lymph nodes only (HR 0.48, 95% CI 0.48, 0.49; 
P<0.001), with no significant heterogeneity between studies (P=0.92, I-square 0%) 
(Figure 5.16) 
 clearance of hepatoduodenal lymph nodes only (HR 0.32, 95% CI 0.32, 0.32; 
P<0.001), with significant heterogeneity in the magnitude of the effect (P<0.001, I-
square 100%) (Figure 5.17) 
 clearance of hepatic pedicle lymph nodes only (HR 0.10, 95% CI 0.10, 0.10; 
P<0.001) with significant heterogeneity in the magnitude of the effect (P<0.001, I-
square 100%) (Figure 5.18) 
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Figure 5.16: Sensitivity analysis of studies where patients underwent hepatectomy for 
CLM with clearance of hilar or perihepatic lymph nodes only - forest plot for overall 
survival rate. The overall survival rate of node positive patients was significantly lower 
compared to node negative patients. 
 
 
 
 
 
 
 
 
Figure 5.17: Sensitivity analysis of studies where patients underwent hepatectomy for 
CLM with clearance of hepatoduodenal lymph nodes only - forest plot for overall 
survival rate. The overall survival rate of node positive patients was significantly lower 
compared to node negative patients. 
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Figure 5.18: Sensitivity analysis of studies where patients underwent hepatectomy for 
CLM with clearance of hepatic pedicle lymph nodes only - forest plot for overall 
survival rate. The overall survival rate of node positive patients was significantly lower 
compared to node negative patients. 
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5.4 DISCUSSION 
 
This meta-analysis included 21 non-randomised studies comparing patients who 
underwent hepatectomy for CLM with node positive disease versus patients with node 
negative disease. The meta-analysis has clearly demonstrated that the long-term survival 
was considerably higher in those undergoing hepatectomy with no involved hepatic 
lymph nodes than in those with hepatic lymph node metastases. The survival in the 
group of patients with positive lymph nodes was significantly reduced compared to 
patients with no nodal involvement, regardless of whether the nodal involvement was 
microscopic or macroscopic, and whether the nodal involvement was found at the time 
of routine or selective lymphadenectomy. Also, the survival of node positive patients 
compared to node negative patients was significantly reduced regardless of the use of 
adjuvant or neoadjuvant chemotherapy, and regardless of the extent/location of the 
lymph node dissection (i.e. hilar or perihepatic lymph nodes, hepatoduodenal lymph 
nodes, hepatic pedicle lymph nodes). 
 
There have been no studies comparing liver resection along with lymphadenectomy 
versus nonsurgical treatments such as chemotherapy in patients with macroscopic 
evidence of node positive disease who were otherwise suitable for liver resection. Also, 
there have been no studies comparing liver resection alone versus liver resection along 
with lymphadenectomy in those with macroscopically involved nodes (selective 
lymphadenectomy). Similarly, there have been no studies comparing liver resection 
alone versus liver resection along with routine lymphadenectomy, and therefore, a 
survival analysis of liver resection for CLM with, versus without routine 
lymphadenectomy, could not be performed. Routine lymphadenectomy is generally 
performed in order to remove the microscopically involved lymph nodes draining the 
liver and provide cancer clearance, and also in order to guide adjuvant chemotherapy 
regimens. The studies which involved routine lymphadenectomy117-119, 199, 208, 217, 219-221, 
223, 224, 227 reported very poor or no 5-year survival in patients with nodal disease 
compared with node negative patients.  
 
Unfortunately, there was no morbidity data directly related to lymphadenectomy by the 
included studies available for meta-analysis. It would be important to know the 
additional risks to the patient by routine or selective lymphadenectomy. Although 
lymphadenectomy is generally considered to be a safe procedure in experienced hands, 
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it is associated with potential risks and complications such as portal vein injury, 
duodenal injury, lymphatic leakage and bleeding.228 Two studies28, 117 compared 
morbidity in those who underwent lymphadenectomy with those who did not, and they 
reported no difference in morbidity between the two groups. None of the included 
studies reported complications directly related to hepatic lymphadenectomy, and none 
of the included studies reported higher mortality with lymphadenectomy.  Furthermore, 
there was no data available by the included studies on the extent of recurrent disease, as 
it would have been important to know how recurrent disease presents (i.e. more 
extensive disease, more liver metastases or more extensive lymphatic dissemination) 
and whether there would be a difference in recurrent disease between patients who had 
resection of nodal metastases.  
 
The overall prevalence of positive lymph nodes identified in the current review was 
8.5%. However, the prevalence reported by the included studies varied between 2.6% 
and 50%. Some surgeons remove only the lymph nodes along the hepatoduodenal 
ligament,199, 217, 219 whilst others remove nodes along the common hepatic artery, coeliac 
artery, and the retropancreatic area.117 The prevalence of positive lymph nodes in the 
eight studies119, 199, 201, 217-219, 221, 222 which reported hepatoduodenal/hepatic hilum lymph 
node dissection ranged between 2.6% and 27.8%, and the prevalence of positive lymph 
nodes in the ten studies28, 117, 118, 206-208, 220, 223, 224, 227 which reported more extensive 
lymph node dissection of the hepatic pedicle and retropancreatic area, ranged between 
4% and 27.9%. Therefore, the extent of the lymphadenectomy was not the main factor 
that causes the difference in the prevalence rate of node positive disease between 
studies. 
 
The prevalence of patients with positive lymph nodes in the twelve studies117-119, 199, 208, 
217, 219-221, 223, 224, 227 reporting routine lymphadenectomy ranged between 5.4% and 
27.9%, and the prevalence of positive nodal disease in the five studies28, 207, 218, 222, 225 
which reported selective lymphadenectomy ranged between 2.6% and 22.5%. Thus, the 
routine or selective approach for lymphadenectomy appears also not to be the main 
factor causing the variation in prevalence of disease positive lymph nodes between the 
included studies.  
 
The wide variation in prevalence of disease positive lymph nodes may be influenced by 
other factors, for example, patient selection for surgery, the adequacy of pre-operative 
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staging, preoperative and intraoperative assessment, the number of nodes examined, the 
number of sections per node, and neoadjuvant chemotherapy. Another factor which may 
influence the prevalence of node positive disease is the use of special techniques to 
identify microscopic involvement to detect positive lymph node disease. Two studies 
found increased sensitivity for detection of micrometastases in perihepatic lymph nodes 
by adding immunohistochemistry analysis208 and molecular-based techniques.197 Larger 
studies are required to assess the value and relevance of these techniques of detecting 
nodal disease in routine clinical practice.  
 
Three studies28, 117, 207 compared survival of patients with positive nodes in different 
locations and all three found better outcome in patients with hepatoduodenal lymph 
node involvement against those with coeliac and para-aortic lymph node involvement. 
Importantly, Adam et al.28 and Pulitano et al.207 found exceptionally poor survival in 
patients with coeliac and para-aortic node involvement despite preoperative 
chemotherapy. Adam et al.28 found a better 5-year survival rate (25%) for patients who 
underwent hepatectomy and lymphadenectomy of involved hepatic pedicle lymph nodes 
than for those undergoing hepatectomy along with resection of involved coeliac and 
para-aortic lymph nodes (0%). Jaeck et al.117 reported that in their cohort of 17 patients 
in whom lymph node involvement was diagnosed after routine lymphadenectomy 
during liver resection, the 3-year survival rate was 38% in patients who had nodal 
involvement in the hepatoduodenal ligament compared with 0% in patients who had 
nodal involvement around the hepatic artery and coeliac trunk. Involvement of common 
hepatic artery and coeliac artery nodes carries a worse prognosis compared to 
hepatoduodenal ligament nodal involvement, and coeliac and para-aortic lymph node 
disease should be considered an absolute contraindication to surgery. Whereas, selected 
patients with hepatoduodenal ligament nodal involvement only, who responded to 
neoadjuvant treatment, may be candidates for surgery, and future trials should further 
investigate this hypothesis. 
 
There is variation between studies in the reported benefit of adjuvant chemotherapy in 
patients already undergone hepatectomy for CLM and were found to have nodal 
metastases on a routine or selective lymphadenectomy. In the study by Nakamura et 
al.223, all the patients in the study received chemotherapy. The 3-year survival in the 6 
patients with positive hepatic lymph node was 33.3% (the study did not report the 5-
year survival).223 In the study by Harms et al.219 in which chemotherapy was given in 
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patients with poor prognostic factors, the 3-year and 5-year survival of hepatic node-
positive patients was 2.6% and 0%. Pulitano et al.207 found 3-year and 5-year overall 
survival rates of 34% and 18%, respectively, in 61 patients with node positive disease, 
most of whom had received neoadjuvant as well as adjuvant chemotherapy. Adam et 
al.28 suggested that the 5-year survival rate of 18% in node positive patients reported in 
their study may be related to neoadjuvant chemotherapy and patient selection based on 
absence of progression of nodal disease preoperatively. The survival benefit was seen in 
patients with pedicular lymph node involvement and not in patients with coeliac and 
para-aortic node involvement. There is a possibility that hepatectomy along with 
resection of metastatic lymph nodes in highly selected patients based on their response 
to neoadjuvant chemotherapy and based on the extent/location of the lymph node 
dissection (pedicular lymph nodes instead of coeliac/para-aortic lymph nodes) may 
benefit from surgical resection and chemotherapy. Nevertheless, to justify this statement 
a study should be performed comparing the outcome of node positive patients selected 
for hepatectomy based on their response to neoadjuvant chemotherapy versus node 
positive patients who had undergone hepatectomy for CLM without neoadjuvant 
chemotherapy. 
 
Sensitivity analysis of more recent studies published after 2007 still showed a 
significant decrease in survival rate after hepatectomy for CLM for patients with node 
positive disease compared to patients with node negative disease. Nevertheless, it is 
interesting that three studies with significantly improved 5-year survival rates were 
published more recently. Adam et al. with 5-year survival rate of 18% was published in 
2008, Carpizo et al. with 5-year survival rate of 11.1% was published in 2009, and 
Pulitano et al. with 5-year survival rate of 18% was published in 2012. It is possible that 
modern chemotherapy has an impact on survival in hepatic pedicular lymph node 
positive patients, but this needs to be demonstrated in large and properly designed 
clinical trials. In the past, with 5-fluorouracil and leucovorin based chemotherapy for 
CLM, the response rate was 20% to 30%, with a median survival time of 11 to 12 
months.229 With the advent of more effective systemic agents such as oxaliplatin, 
irinotecan, cetuximab and bevacizumab, improved response rates of 33% to 62%, 
median overall survival time of more than 20 months, and improved progression-free 
survival are now seen in patients with CLM.229, 230 
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These developments in modern chemotherapy may have an impact on results of surgical 
resection in patients with extrahepatic disease, and with more effective therapies there 
may be an indication for both liver resection and lymphadenectomy in those with 
chemotherapy-sensitive disease.230 Neoadjuvant chemotherapy has been used to 
downstage previously non-resectable metastatic colorectal cancer (the reasons for non-
resectability included extra-hepatic disease in the lungs and lymph nodes) with 
reasonable three-year results.16, 28, 29 Neoadjuvant chemotherapy is being used in other 
node-positive tumours including oesophageal cancers231, 232 and rectal cancers233, 234 for 
downstaging the disease preoperatively and may improve the median survival.231 It is 
not clear whether neoadjuvant chemotherapy will be useful in improving the survival in 
people with CLM and node positive disease. The role of neo-adjuvant chemotherapy in 
patients with CLM with hepatic node involvement needs to be evaluated in a 
prospective trial.  
 
Surgeons offering hepatectomy along with hepatic lymphadenectomy for resectable 
CLM associated with hepatic lymph node metastases must inform their patients that the 
surgery is without evidence of a survival advantage. The alternative to surgery for 
patients with resectable CLM in the face of known hepatic nodal metastases is to 
undergo systemic chemotherapy, and currently, there is no evidence that liver resection 
is superior to chemotherapy. Patients in whom liver resection along with 
lymphadenectomy is being considered should be counselled and should be made aware 
that the procedure is not part of routine clinical practice and is unlikely to be curative. 
The procedure would ideally be performed as part of a clinical study or trial. Patients 
with prior response to systemic chemotherapy, with resectable CLM combined with 
hilar nodal involvement could be considered for an RCT offering surgical resection 
(liver resection and lymphadenectomy) and chemotherapy versus chemotherapy alone. 
Also, patients with CLM and hepatic nodal involvement could be considered for a RCT 
comparing liver resection along with lymphadenectomy and chemotherapy versus 
radiofrequency ablation of CLM along with chemotherapy.  
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5.5 CONCLUSIONS 
 
This meta-analysis has clearly demonstrated that the survival rates of patients who had 
undergone hepatectomy for CLM are lower in patients with positive hepatic lymph 
nodes compared to patients with negative lymph nodes. This is irrespective of whether 
they are detected by routine or selective lymphadenectomy, or whether the nodal 
involvement was microscopic or macroscopic. Also, the decreased survival of node 
positive patients compared to node negative patients is regardless of the use of adjuvant 
or neoadjuvant chemotherapy, and of the extent/location of the lymph node dissection. 
Currently, there is no evidence of survival benefit from routine lymphadenectomy in 
patients with resectable CLM. Furthermore, in patients with CLM associated with 
hepatic nodal metastases, liver resection and lymphadenectomy is of no proven benefit 
and has not been compared with systemic chemotherapy or with radiofrequency 
ablation. Further trials in this patient group are required. 
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CHAPTER 6 
 
 
A NETWORK META-ANALYSIS COMPARING 
TREATMENT STRATEGIES USED DURING LIVER 
RESECTION AIMING TO DECREASE BLOOD LOSS  
AND BLOOD TRANSFUSION 
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6.1 INTRODUCTION 
 
Liver resection is the only curative option for people with CLM, but is a major surgical 
procedure with significant mortality of around 4% and morbidity of around 40%.45, 46, 63 
As the liver is a very well-vascularized organ, there is an inherent risk of bleeding 
during liver resection. Intraoperative haemorrhage remains one of the major risks during 
liver resections, and operative blood loss and perioperative blood transfusion are two of 
the most important factors affecting perioperative morbidity and mortality.45, 46, 64, 65 
Variable estimates of blood loss, ranging from 200 mL to 2 litres, have been reported.66 
Major blood loss during surgery or in the immediate postoperative period may result in 
death of the patient.  
 
Even small differences in operative blood loss and perioperative blood transfusion may 
result in increased morbidity and mortality. In a study by Ibrahim et al. hepatic donors 
with complications had a mean operative blood loss of 170±79 ml (mean ± standard 
deviation) compared to hepatic donors without complications who had a mean operative 
blood loss of 95±77 ml.64 Also, Poon et al. demonstrated a significant decrease in 
morbidity from 37.3% to 30.0% and a significant decrease in mortality from 7.5% to 
3.7%, in a group of patients who had undergone hepatectomy with a median operative 
blood loss of 750 ml and 17.3% perioperative transfusion, compared to another group 
with a median operative blood loss of 1450 ml and 67.7% perioperative transfusion.46 
Furthermore, Yang et al. demonstrated that increased intraoperative blood loss (≥ 800 
ml) during major hepatic resection is an independent risk factor of postoperative 
morbidity.65 Therefore, minimizing operative blood loss and perioperative blood 
transfusion is of major importance, and various interventions have been attempted to 
decrease blood loss during liver resection. 
 
Interventions aiming to decrease blood loss during elective liver resection include 
methods of temporary occlusion of the blood vessels that supply the liver. Clamping of 
the portal pedicle (Pringle manoeuver, i.e. clamping of the hepatic artery and portal 
vein) is the oldest and commonest method of hepatic vascular occlusion during liver 
resection, and can be performed either continuously or intermittently during the 
parenchymal resection.67-69 Also, different methods of liver transection (the way that the 
liver parenchyma is divided) have been used to reduce blood loss, such as the clamp-
crush method, the Cavitron Ultrasonic Surgical Aspirator (CUSA), or the 
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radiofrequency dissecting sealer. In addition, different methods of management of the 
cut surface of the liver (the way that the resection plane of the remnant liver is 
managed) have been used, such as the use of fibrin sealant, argon beamer, or 
electrocautery and suture material.66, 70 Commonly used surgical techniques under each 
of the above categories are listed in Table 6.1, Table 6.2, and Table 6.3. 
 
Interventions selected to decrease blood loss and blood transfusion can be used alone or 
in various combinations. Usually surgeons at different centres follow their own protocol 
for decreasing blood loss during elective liver resection, and may use a particular 
combination of the different methods of vascular occlusion, of the different methods of 
parenchymal transection, and of the different methods of dealing with the raw surface of 
the liver after transection. Therefore, in liver resection, a surgeon typically uses one 
item from Table 6.1, one item from Table 6.2, and one item from Table 6.3. In practice, 
any intervention in Table 6.1 can be used in combination with an intervention from 
Table 6.2 or Table 6.3. Any intervention in Table 6.2 can be used in combination with 
an intervention from Table 6.1 or Table 6.3, etc. Together, one can consider this 
combination of one method from each table as a treatment strategy. Altogether, the goal 
of these interventions is to decrease blood loss and blood transfusion, and the associated 
morbidity and mortality.  
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Table 6.1: Different methods of vascular occlusion aiming to decrease blood loss 
during liver resection. 
 
No vascular occlusion 
Portal triad clamping (continuous)  
(occlusion of inflow alone) 
Portal triad clamping (intermittent) 
(occlusion of inflow alone) 
Hepatic vascular exclusion  
(occlusion of inflow and outflow) 
Selective vascular occlusion  
(occlusion of inflow to the hemi-liver that is being resected) 
Selective hepatic artery occlusion 
(occlusion of hepatic artery supplying the hemi-liver that is being resected) 
Selective portal vein occlusion  
(occlusion of portal vein supplying the hemi-liver that is being resected) 
Selective hepatic vascular exclusion  
(occlusion of inflow to the hemi-liver and outflow from the hemi-liver that is being 
resected) 
 
 
 
 
Table 6.2: Different methods of parenchymal transection aiming to decrease blood loss 
during liver resection. 
 
Finger-fracture method 
Clamp-crush method 
Cavitron Ultrasonic Surgical Aspirator (CUSA) 
Sharp dissection 
Radiofrequency dissecting sealer 
Hydrojet 
Ultrasonic shears 
 
 
 
 
Table 6.3: Different methods of dealing with raw surface aiming to decrease blood loss 
during liver resection. 
 
Suturing for large and medium vessels and ducts and performing 
electrocauterisation of small vessels and ducts 
Suturing for large vessels and performing ultrasonic shears for medium-sized 
and small vessels and ducts 
Suturing and argon beam coagulator 
Suturing and fibrin sealant 
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Previous studies published in the literature compared individual components aiming to 
decrease operative blood loss and perioperative blood transfusion. Nuzzo et al. 
compared liver resections with or without hepatic pedicle clamping and found 
significantly fewer people requiring blood transfusion and significantly lower number 
of blood units transfused per patient when hepatectomy was performed with hepatic 
pedicle clamping.235 Tan et al. compared different methods of hepatic inflow occlusion 
aiming to decrease blood loss and blood transfusion.236 The three different methods 
were: intermittent total hepatic pedicle occlusion (or Pringle manoeuvre or portal triad 
clamping, i.e. clamping of portal vein and hepatic artery), hemihepatic vascular 
occlusion (or selective vascular occlusion, i.e. occlusion of the lesion-lateral portal vein 
and hepatic artery), and selective hepatic artery occlusion (i.e. occlusion of the portal 
vein and the lesion-lateral hepatic artery). A schematic drawing of these three different 
methods of hepatic inflow occlusion is shown in Figure 6.1. The study showed no 
significant difference in blood loss, clamping time, or operative time, between the three 
different methods of hepatic inflow occlusion. Hemihepatic vascular occlusion and 
selective hepatic artery occlusion caused significantly less liver remnant ischemia injury 
compared to intermittent total pedicle occlusion.236 The authors concluded that 
hemihepatic vascular occlusion is easy to do for left lateral lobe or resection of the left 
half of the liver, and selective hepatic artery occlusion is suitable for right lobe 
resection.236 
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Figure 1: Schematic drawing of hepatic inflow occlusion: (A) Intermittent total pedicle 
occlusion, (B) hemihepatic vascular occlusion, and (C) selective hepatic artery 
occlusion (taken from Tan et al.).236 Footnotes: A=hepatic artery; B=biliary duct; 
L=liver lesions; P=portal vein. 
 
 
 
 
 
 
 
 
 
A RCT by Fu et al. compared Pringle manoeuver, hemihepatic vascular inflow 
occlusion, and main portal vein inflow occlusion during partial hepatectomy, and 
demonstrated no significant differences between the three groups in intraoperative blood 
loss, perioperative mortality.237 The degree of postoperative liver injury and 
complication rates were significantly higher in the Pringle manoeuver group, resulting 
in a significantly longer hospital stay.237 A study by Narita et al. included patients with 
chemotherapy-associated liver injury undergoing major hepatectomy for CLM, and 
compared patients who underwent intermittent portal triad clamping versus patients 
who did not undergo portal triad clamping.238 The study showed that intraoperative 
blood transfusion and postoperative liver function were comparable between the two 
groups, and that prolonged portal triad clamping (>30 minutes) is related to increased 
postoperative biliary and septic complications.238 A RCT by van den Broek et al. 
compared the effect of 15 versus 30 minute intermittent Pringle manoeuver during liver 
surgery using liver fatty acid-binding protein (L-FABP) as a sensitive marker of 
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hepatocellular damage.239 The trial found no significant differences between 15 and 30 
minute Pringle manoeuver in cumulative L-FABP level or L-FABP level at any time 
point (p=0.149).239 Also, there was no significant difference between the two groups in 
operative blood loss, remnant liver function, or morbidity.239 Furthermore, Wang et al. 
compared intermittent Pringle manoeuver versus continuous Pringle manoeuver coupled 
with in situ hypothermic perfusion, and demonstrated no difference between the two 
groups in operative time, blood loss, postoperative hospital stay, morbidity rate, and 
postoperative liver function.240 
 
Mbah et al. compared bipolar compression and ultrasonic devices used for parenchymal 
transection during laparoscopic liver resection and noted no significant differences 
between the two device groups for blood loss, complications of any type, or liver-
specific complications.241 The bipolar compression device was found to result in 
significantly shorter time of parenchymal transection compared to the ultrasonic 
device.241 A RCT by Doklestic et al. compared three different parenchyma transection 
techniques of liver resection: clamp crushing technique, ultrasonic dissection (CUSA), 
or bipolar device (LigaSure). The overall surgery duration was 295 vs. 270 vs. 240 
minutes for LigaSure, CUSA and clamp crush, respectively; the transection duration 
was 85 vs. 52.5 vs. 40 minutes, respectively.242 There were no significant differences 
between the three different resection techniques in terms of intraoperative blood loss, 
blood transfusion, postoperative complications, and mortality.242 Moreover, Richter et 
al. compared liver resection using either ultrasonic dissection, hydrojet dissection, or 
radiofrequency dissecting sealer, and found the dissection was slower with the 
radiofrequency dissecting sealer; otherwise, the three devices were equally safe in terms 
of blood loss, transfusions, and postoperative complications.243  
 
Kobayashi et al. compared the application of a fibrin sealant with polyglycolic acid on 
the transection plane of the liver after hepatectomy versus no fibrin sealant, and 
demonstrated no significant difference between the two groups in operation time, 
leukocyte count, serum C-reactive protein, and drain bilirubin concentrations.244 Also, 
no cases of postoperative bleeding or biliary leakage occurred in either group.244 Noun 
et al. performed a RCT to compare the use of fibrin glue versus no fibrin glue and found 
that although postoperative morbidity and mortality were not different between the two 
groups, the mean total fluid drainage during the three postoperative days and bilirubin 
concentration were significantly lower in the group with fibrin glue.245 Figueras et al. 
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performed a RCT to compare fibrin glue application versus no fibrin glue and 
demonstrated no significant difference in postoperative morbidity, blood loss, blood 
transfusion, overall drainage volumes, days of postoperative drainage, or incidence of 
biliary fistula between the two groups.246 A RCT by Fischer et al. compared the use of 
TachoSil (a fixed combination tissue sealant) versus argon beam coagulator on the cut 
surface of the liver after hepatectomy, and showed that the mean time to haemostasis 
was significantly shorter when TachoSil was used compared with argon beam 
coagulation.247 Postoperative morbidity and mortality, drainage volume, drainage fluid, 
and drainage duration did not differ between the two groups.247 
 
Each category of interventions has been systematically reviewed previously. A meta-
analysis of trials comparing hepatic vascular occlusion versus no vascular occlusion 
demonstrated no difference in mortality, liver failure, or other morbidities.66 The blood 
loss was significantly lower in vascular occlusion compared with no vascular occlusion, 
but the liver enzymes were significantly elevated in the vascular occlusion group 
compared with no vascular occlusion.66 Another meta-analysis compared different 
techniques for liver parenchymal transection and found significantly fewer infective 
complications and lower transection blood loss with the clamp-crush method compared 
to the radiofrequency dissecting sealer.248 Also, the blood transfusion requirements were 
significantly lower with the clamp-crush technique compared to CUSA and hydrojet, 
and the clamp-crush technique was shown to be quicker than CUSA, hydrojet, and the 
radiofrequency dissecting sealer.248 A meta-analysis comparing portal triad clamping 
with other methods of vascular control during liver resection, demonstrated no 
statistically significant differences in mortality, morbidity, blood transfusion, and length 
of hospital stay, between portal triad clamping and other forms of vascular control.249 
 
No previous review has been conducted to assess and synthesise the comparative 
effectiveness of specific combinations (i.e. treatment strategies) of interventions during 
liver resection when used together to decrease operative blood loss and perioperative 
blood transfusion. Also, there has not been a previous published network meta-analysis. 
In this review, each combination of interventions was assessed as a treatment strategy, 
that is, a combination of several interventions. The purpose of this network meta-
analysis was to identify the overall treatment effect of a treatment strategy rather than 
the contribution of each component intervention towards the overall effect. This 
systematic review is intended as a useful guide for patients and healthcare providers as 
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they seek to understand the role of different combinations of interventions (treatment 
strategies) in decreasing blood loss and blood transfusion requirements in people 
undergoing elective liver resection.  
 
 
6.1.1. Aims of this review 
 
The overall aim of this network meta-analysis is to identify the best combination of 
methods (treatment strategy) to decrease blood loss during elective liver resection and to 
assess the comparative benefits and harms of the different treatment strategies used in 
order to decrease operative blood loss and perioperative blood transfusion during 
elective liver resection. 
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6.2 METHODS 
 
6.2.1 Search strategy 
 
A comprehensive literature search using a combination of free-text terms and controlled 
vocabulary when applicable was performed of the following databases: MEDLINE, 
EMBASE, Science Citation Index Expanded, CENTRAL in The Cochrane Library, and 
World Health Organization International Clinical Trials Registry Platform. The detailed 
search strategy is provided in Table 6.4. The “related articles” function from PubMed 
was used to broaden the search, and all abstracts, studies, and citations scanned were 
reviewed. The references of the identified trials were also searched to identify additional 
trials for inclusion. Because subsets of all available interventions on this topic have 
been reviewed comprehensively in existing Cochrane systematic reviews,66, 248 we also 
used these reviews as a way to identify trials. No restrictions were made based on 
language, publication year, or publication status. The latest date for this search was July 
16, 2012. 
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Table 6.4: Detailed search strategy. 
 
Database Time 
span 
Search strategy 
The Cochrane Hepato-
Biliary Group Controlled 
Trials Register and Central 
Register of Controlled 
Trials (CENTRAL) in The 
Cochrane Library (Wiley) 
July 16, 
2012 
1. Blood loss OR bleeding OR hemorrhage OR haemorrhage 
OR hemorrhages OR haemorrhages OR hemostasis OR 
haemostasis OR transfusion 
2. MeSH descriptor Hemorrhage explode all trees 
3. MeSH descriptor Blood Transfusion explode all trees 
4. (#1 OR #2 OR #3) 
5. Liver OR hepatic OR hepato* 
6. MeSH descriptor Liver explode all trees 
7. (5 OR 6) 
8. Resection OR resections OR segmentectomy OR 
segmentectomies 
9. (7 AND 8) 
10. Hepatectomy OR hepatectomies 
11. MeSH descriptor Hepatectomy explode all trees 
12. (9 OR 10 OR 11) 
13. (4 AND 12) 
MEDLINE (PubMed) January 
1947 to 
July 
2012 
(Blood loss OR bleeding OR hemorrhage OR haemorrhage OR 
hemorrhages OR haemorrhages OR hemostasis OR 
haemostasis OR transfusion OR "Hemorrhage" [MeSH] OR 
"Blood Transfusion" [MeSH]) AND (((liver OR hepatic OR 
hepato* OR "liver" [MeSH]) AND (resection OR resections 
OR segmentectomy OR segmentectomies)) OR hepatectomy 
OR hepatectomies OR "hepatectomy" [MeSH]) AND 
((randomised controlled trial [pt] OR controlled clinical trial 
[pt] OR randomised [tiab] OR placebo [tiab] OR drug therapy 
[sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT 
(animals [mh] NOT humans [mh])) 
EMBASE (OvidSP) Janurary 
1974 to 
July 
2012 
1. (Blood loss or bleeding or hemorrhage or haemorrhage or 
hemorrhages or haemorrhages or hemostasis or haemostasis or 
transfusion).af  
2. Exp bleeding/or exp blood transfusion/  
3 .1 or 2 
4. (Liver or hepatic or hepato*).af 
5. (Resection or resections or segmentectomy or 
segmentectomies).af 
6. 4 and 5 
7. (Hepatectomy or hepatectomies).af 
8. Exp Liver Resection/ 
9. 6 or 7 or 8 
10. 3 and 9 
11. Exp crossover-procedure/or exp double-blind procedure/or 
exp randomised controlled trial/or single-blind procedure/  
12. (Random* OR factorial* OR crossover* OR cross over* 
OR cross-over* OR placebo* OR double* adj blind* OR 
single* adj blind* OR assign* OR allocat* OR volunteer*).af 
13. 11 OR 12 
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14. 10 AND 13 
Science Citation Index 
Expanded 
(http://portal.isiknowledge.
com/portal.cgi?DestApp=
WOS&Func=Frame) 
January 
1945 to 
July 
2012 
1. TS=(Blood loss OR bleeding OR hemorrhage OR 
haemorrhage OR hemorrhages OR haemorrhages OR 
hemostasis OR haemostasis OR transfusion) 
2. TS=((liver OR hepatic OR hepato*) AND (resection OR 
resections OR segmentectomy OR segmentectomies) OR 
hepatectomy OR hepatectomies) 
3. TS=(random* OR rct* OR crossover OR masked OR blind* 
OR placebo* OR meta-analysis OR systematic review* OR 
meta-analys*) 
4. 1 AND 2 AND 3 
World Health Organization 
International Clinical 
Trials Registry Platform 
Search Portal 
(http://apps.who.int/trialsea
rch/Default.aspx) 
July 
2012 
Liver resection OR hepatectomy 
 
 
 
 
 
 
6.2.2 Inclusion and exclusion criteria  
 
Only RCTs were considered for this network meta-analysis. Studies of other design 
were excluded because of the risk of bias in such trials and because it is not appropriate 
to perform network meta-analysis on studies of different study designs as this will make 
the interpretation more difficult. The participants of the included RCTs underwent 
elective liver resection using different types of vascular occlusion or no vascular 
occlusion, different types of parenchymal transection, or different types of management 
of the liver cut surface, irrespective of the method of vascular occlusion or the nature of 
the background liver (i.e., normal or cirrhotic). RCTs in which participants underwent 
liver resection combined with other major surgical procedures (e.g., combined liver and 
bowel resection for synchronous metastases from colorectal tumours) were excluded. 
 
RCTs that assessed one or more of the following interventions were included in this 
review: 
1. Methods of vascular occlusion (including no vascular occlusion). 
2. Methods of liver parenchymal transection. 
3. Methods of management of the cut surface (resection plane) of the liver. 
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The RCTs should clearly state the method of vascular occlusion, method of 
parenchymal transection, and method of management of the cut surface to be included. 
 
 
6.2.3 Data extraction 
 
The trials for inclusion were independently identified by two review authors 
(Constantinos Simillis and Jessica Vaughan) by screening the titles and abstracts. Full 
text was sought for any references which were identified for potential inclusion by at 
least one of the authors, and made further selection for inclusion based on the full text. 
Any discrepancies between the two review authors were resolved through discussion, 
and if there was still a disagreement between authors, the final decision was taken by a 
senior co-author. 
 
The following data were independently extracted by the two review authors from each 
study:  
1. First author 
2. Year and language of publication 
3. Country of conduct of the trial 
4. Year(s) in which the trial was conducted 
5. Inclusion and exclusion criteria for participants 
6. Sample size 
7. Participant characteristics such as age, gender, underlying disease, comorbidity, 
number and proportion of participants with cirrhosis, and number and proportion of 
participants undergoing major versus minor liver resection. 
8. Details of the intervention and treatment strategy that aimed to decrease blood 
loss and blood transfusion requirements (e.g., surgical technique, procedure and co-
intervention, concurrent surgery, and medications). 
9. Outcomes (primary outcomes, secondary outcomes). 
10. Follow-up time points. 
11. Risk of bias 
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6.2.4 Risk of bias  
 
The risk of bias of the included trials was assessed based on the following bias risk 
domains: allocation sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessors, incomplete outcome data, 
selective outcome reporting, and vested interest bias. These bias risk domains were 
chosen based on the advice of The Cochrane Collaboration,141 the Cochrane Hepato-
Biliary Group Module,209 and reviews published on network meta-analyses.132 For 
further details on the individual bias risk domains please review section 5.2.4. For each 
of these risk domains of bias the studies were categorized as low risk, uncertain risk, 
and high risk of bias. A trial was considered at low risk of bias if the trial was assessed 
as at low risk of bias for all domains. Trials with uncertain risk of bias or with high risk 
of bias for one or more domains were considered trials with high risk of bias. 
 
 
6.2.5 Outcomes of interest and definitions 
 
The comparative effectiveness of available treatment strategies that aimed to decrease 
blood loss during liver resection, was assessed for the following outcomes: 
 
Primary outcomes  
 
 Mortality, evaluated both as short term (30-day mortality or in-hospital 
mortality) and long term (at maximal follow-up). 
 Serious adverse events, defined as any event that would increase mortality, is 
life-threatening, requires inpatient hospitalization, results in a single organ or multi-
organ dysfunction, or requires surgical, endoscopic or radiological intervention to treat 
it. Serious adverse events correspond to Grade III or above of the Clavien-Dindo 
classification (Table 6.5) and in cases where the authors did not classify the severity of 
adverse events this classification was followed.250, 251 
 Quality of life. 
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Secondary outcomes  
 
 Blood transfusion requirements (proportion of patients requiring red cell or 
whole blood heterologous blood transfusion, mean quantity of units of blood 
transfusion). 
 Operative blood loss in millilitres (mL). 
 Number of participants who had major operative blood loss. 
 Operative time in minutes (min).  
 Length of hospital stay in days. 
 Length of Intensive Therapy Unit (ITU) stay in days. 
 Time needed to return to work in days. 
 
 
 
 
 
Table 6.5: Clavien-Dindo classification of post-operative complications.250, 251 
 
Grades Definitions Examples 
I 
Any deviation from the normal post-
operative course without the need for 
pharmacological treatment or surgical, 
endoscopic, and radiological 
interventions 
Drugs such as antiemetics, 
antipyretics, analgesics, diuretics, 
and electrolytes; physiotherapy; 
wound infections opened at the 
bedside 
II 
Requiring pharmacological treatment 
with drugs other than those allowed for 
grade I complications 
Blood transfusions, total parenteral 
nutrition 
III 
Requiring surgical, endoscopic or 
radiological intervention 
Bile leak requiring endoscopic stent; 
reoperation for any cause; drainage 
of infected intra-abdominal 
collection 
IV 
Life-threatening complication requiring 
high dependency or intensive care 
management 
Dialysis 
V Death of patient 
 
Suffix 
d 
If the patient suffers from a complication 
at the time of discharge and needs further 
follow-up to fully evaluate the 
complication 
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6.2.6 Statistical analysis 
 
For detailed description of the statistical methods used to perform the network meta-
analysis please review section 3.2.1. For binary outcomes (mortality, serious adverse 
events, patients requiring blood transfusion), the OR was calculated. For continuous 
outcomes (quantity of blood transfused, operative blood loss, hospital stay, ITU stay, 
operating time), the MD was calculated. A network plot was obtained to ensure that the 
trials were connected by treatments using Stata/IC 11 (StataCorp LP). Any trials that 
were not connected to the network were excluded. The network meta-analysis was 
performed as per the guidance from the NICE DSU documents.153 
 
A Bayesian network meta-analysis was conducted using the Markov chain Monte Carlo 
method in WinBUGS 1.4. The treatment contrast (OR for binary outcomes, MD for 
continuous outcomes) for any two interventions was modelled as a function of 
comparisons between each individual intervention and an arbitrarily selected reference 
group.152 The reference group in this network meta-analysis was selected on the basis of 
the ‘least intervention’, for example, if a treatment group had no vascular occlusion, 
used finger-fracture or clamp-crush method for parenchymal transection, and no fibrin 
sealant for dealing with the cut surface, this treatment was used as the reference 
category. Details of the codes used in WinBUGS 1.4 for the network meta-analyses of 
binary and continuous outcomes and examples of the binary and continuous ‘raw data’ 
inserted into the WinBUGS codes for analysis, are shown in sections 3.3 and 3.4 
respectively. 
 
The 95% credible intervals (CrI, similar to 95% confidence intervals in a frequentist 
method of meta-analysis) were calculated, and the effect estimates and associated 95% 
CrI for each pairwise comparison were reported in a table. The probability that a 
treatment ranks as the best treatment for each outcome of interest, was presented in 
graphs. The cumulative probability of the treatment ranks (i.e. the probability that the 
treatment is within the top two, the probability that the treatment is within the top three, 
etc.) was also presented in graphs. In addition, the illustrative risk or absolute 
proportion of people at risk for an outcome of interest, calculated based on the treatment 
effects of the network meta-analysis, was presented in tables. 
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Clinical and methodological heterogeneity was assessed by carefully examining the 
characteristics and design of included trials. Major sources of clinical heterogeneity 
included cirrhotic compared to non-cirrhotic livers and major compared to minor liver 
resections. In addition, considerable heterogeneity was anticipated in the way the 
intervention was performed. For example, intermittent portal triad clamping may be 
performed with different time periods of occlusion and non-occlusion. In addition, 
different doses of fibrin sealant may be used. Different study design and risk of bias 
may contribute to methodological heterogeneity. Subgroup analysis was not performed 
because of the paucity of data. The residual deviance and DIC were used for assessing 
statistically between study heterogeneity as per the guidance from the NICE DSU 
Technical Support Documents.153, 252 The between trial SD was also calculated and 
reported if random-effects model was used. 
 
 
6.2.7 Treatment strategy 
 
In order to decrease blood loss during elective liver resection, a surgeon may use a 
particular combination of the different methods of vascular occlusion, of the different 
methods of parenchymal transection, and of the different methods of dealing with the 
raw surface of the liver after transection. Therefore, in liver resection, a surgeon 
typically uses one item from Table 6.1, one item from Table 6.2, and one item from 
Table 6.3. For example, one surgeon may perform liver resection using intermittent 
vascular occlusion, clamp crush technique as the method of liver parenchymal 
transection, and a fibrin sealant on the cut surface; while another surgeon may perform 
liver resection without using any method of vascular occlusion, with the CUSA as the 
method of liver parenchymal transection, and without any fibrin sealant on the cut 
surface. Together, one can consider this combination of one method from each table as a 
treatment strategy, that is, a combination of several interventions. In terms of network 
meta-analysis, each unique treatment strategy can be defined as a ’node’. The purpose 
of this network meta-analysis was to identify the overall treatment effect of a treatment 
strategy rather than the contribution of each component intervention towards the overall 
effect.  
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Not every node was anticipated to be represented in the included trials. Some methods 
are more commonly practiced than others. From Table 6.1, no vascular occlusion, 
intermittent portal triad clamping, and continuous portal triad clamping are used more 
often than other techniques.66 From Table 6.2, clamp-crush method and CUSA are more 
commonly applied.248 The clamp-crush method and the finger-fracture method do not 
require any special equipment, but the remaining methods do require special equipment. 
From Table 6.3, common methods of managing cut surface include suturing for large 
and medium vessels and ducts and performing electrocauterisation of small vessels and 
ducts.248 Because of the large number of possible treatment strategies (eight methods of 
vascular occlusion × six methods of parenchymal transection × four methods of 
treatment of cut surface, i.e., 192 potential treatment strategies or nodes), a more sparse 
network graph was constructed based on the treatment strategies used in the trials 
included. Not all 192 nodes were expected to be represented in the trials available in the 
literature.  
 
Because of the few trials that could be included for network meta-analysis in this 
review, the treatments were revised into fewer categories by having only three methods 
of vascular occlusion (no vascular occlusion, continuous vascular occlusion, or 
intermittent vascular occlusion) and by having only two methods of treatment of cut 
surface (fibrin sealant used or no fibrin sealant used). The allocated treatment codes and 
the revised categories of vascular occlusion, method of parenchymal transection, and 
dealing with the cut surface are shown in Table 6.6. This reduced the categories to 36 
treatment strategies or nodes (three methods of vascular occlusion × six methods of 
parenchymal transection × two methods of treatment of cut surface). 
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Table 6.6: Allocated treatment codes and different categories of vascular occlusion, 
parenchymal transection, and methods of dealing with raw surface used in this review. 
 
 
Vascular occlusion 
No vascular occlusion (V1) 
Continuous vascular occlusion (V2) 
Intermittent vascular occlusion (V3) 
Parenchymal transection 
Finger-fracture method (P1) 
Clamp-crush method (P2) 
Cavitron ultrasonic surgical aspirator (CUSA) (P3) 
Sharp dissection (P4) 
Radiofrequency dissecting sealer (P5) 
Ultrasonic shears (P6) 
Methods of dealing with raw surface 
No fibrin sealant used (R1) 
Fibrin sealant used (R2) 
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6.3 RESULTS 
 
6.3.1 Eligible studies 
 
A total of 1347 references were identified through electronic searches of CENTRAL 
(n=170), MEDLINE (n=370), EMBASE (n=442), Science Citation Index Expanded 
(n=364), and RCTs registers (n=1). Four hundred and ninety four duplicates between 
databases were excluded. A further 768 clearly irrelevant references were excluded 
through screening titles and reading abstracts. Eighty five references were retrieved for 
further assessment. No more references were identified through scanning reference lists 
of the identified randomised trials. Seventy six references (73 studies) were excluded 
after reviewing the studies in detail, for the reasons listed under Table 6.6. For 
inclusion, a trial should have given a clear definition of the method used for vascular 
occlusion (including no vascular occlusion), transection method, and method of 
managing the liver cut surface. In total, nine references of nine completed RCTs met the 
inclusion criteria.29, 242, 253-259 
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Figure 6.2: Study flow diagram.  
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6.3.2 Excluded studies 
 
Seventy six references (73 studies) were excluded after reviewing the studies in detail, 
for the reasons listed under Table 6.7. Of the 73 studies excluded, 24 studies were 
excluded because they were not RCTs.240, 260-282 One report was the protocol of a trial.283 
Seven trials did not compare different methods of vascular occlusion or parenchymal 
transection or method of management of cut surface.284-290 One trial included 
participants undergoing liver resection along with other major procedures.246 Four trials 
compared variations of methods of vascular occlusion that would have been classified 
under the same treatment categories included in this review.237, 239, 291, 292 The remaining 
36 trials included comparisons of one aspect of different methods of vascular occlusion 
or parenchymal transection or management of cut surface. However, one or more 
aspects of methods of vascular occlusion or parenchymal transection or management of 
cut surface not being compared were either not stated or were chosen in a non-random 
manner. Therefore, these trials were excluded.67, 70, 243, 245, 247, 253, 293-322 
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Table 6.7: Reasons for excluded studies. 
 
 
Study Reason for exclusion 
Aldrighetti 2006 260 Not a randomised clinical trial 
Arita 2005 293  Two methods of vascular occlusion used, separate data not reported 
Belghiti 1996  253 Two methods of parenchymal transection used, separate data 
unavailable 
Campagnacci 2007 294 Methods of management of raw surface not reported 
Capussotti 2012 295 Separate data for method of vascular occlusion not clearly reported 
(intermittent pringle manouvre was used only in case of significant 
bleeding) 
Chapman 2000 296, 323 Methods of vascular occlusion and parenchymal transection not 
reported 
Chapman 2007 297 Methods of vascular occlusion and parenchymal transection not 
reported 
Chau 2005 261 Not a randomised clinical trial 
Chen 2006 291 Compares different variations of vascular occlusion which will fall under 
the same category of vascular occlusion in our review 
Cherqui 1999 262 Not a randomised clinical trial 
Chiappa 2007 263  Not a randomised clinical trial 
Chouker 2004 67 Methods of parenchymal transection and management of raw surface 
not reported 
Cresswell 2009 264 Not a randomised clinical trial 
Dello 2011 298, 324 Methods of parenchymal transection and raw surface management not 
reported 
El-Kharboutly 2004 299 Methods of vascular occlusion and parenchymal transection not 
reported 
El-Moghazy 2009 300 Method of raw surface management not included in methods of dealing 
with raw surface in our review protocol 
Esaki 2006 301 Method of management of raw surface not reported 
Felekouras 2006265 Not a randomised clinical trial 
Figueras 2003 303 Two methods of parenchymal transection used, separate data not 
reported 
Figueras 2005 302 Method of parenchymal transection not reported 
Figueras 2007 246 Patients underwent liver resections combined with other major surgical 
procedures 
Fischer 2011 247 Methods of parenchymal transection and method of vascular occlusion 
not reported 
Frilling 2005 70 Separate data for method of vascular occlusion not clearly reported (in 
some cases the Pringle manoeuvre was used). Method of parenchymal 
transection not reported 
Fu 2010 266 Not a randomised clinical trial 
Gugenheim 2011 304 Method of vascular occlusion not reported 
Guo 2010 284 Not comparing methods of vascular occlusion or parenchymal 
transection or raw surface 
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Hasegawa 2002 285 Not comparing methods of vascular occlusion or parenchymal 
transection or raw surface 
Hashimoto 2007 286 Not comparing methods of vascular occlusion or parenchymal 
transection or raw surface 
Ikeda 2009 305 Two methods of vascular occlusion used, separate data not available 
Izzo 2008 306 Multiple methods of parenchymal transection used, separate data 
unavailable 
Johnson 1998 267 Not a randomised clinical trial 
Kato 2008 287 Not comparing methods of vascular occlusion or parenchymal 
transection or raw surface 
Kim 2007 268 Not a randomised clinical trial 
Kim 2008 307 Method of raw surface management not included in methods of dealing 
with raw surface in our review protocol 
Kohno 1992 308 Method of vascular occlusion not reported 
Koo 2005 309 Method of raw surface management not reported 
Lentschener 1997 288, 
325 
Not comparing methods of vascular occlusion or parenchymal 
transection or raw surface 
Liang 2009 310 Method of parenchymal transection and management of raw surface not 
reported 
Liu 1993 326 No report on method of vascular occlusion and method of parenchymal 
transection 
Lodge 2005 311 Not comparing methods of vascular occlusion or parenchymal 
transection or raw surface 
Man 1997 312 Method of parenchymal transection and management of raw surface not 
reported 
Man 2002 269 Not a randomised clinical trial 
Man 2003 313 Management of raw surface not reported 
Matot 2002 289 Not comparing methods of vascular occlusion, parenchymal transection 
or management of raw surface 
Mirza 2011 314 Method of vascular occlusion and method of parenchymal transection 
not reported 
Nagano 2005 270 Not a randomised clinical trial 
Noritomi 2005 271 Not a randomised clinical trial 
Noun 1996 245 Two methods of vascular occlusion and parenchymal transection used. 
Separate data not available 
Palibrk 2012 272 Not a randomised clinical trial 
Pietsch 2010 273 Not a randomised clinical trial 
Rahbari 2009 283 Protocol only 
Rahbari 2011 327 Two methods of parenchymal transection used, separate data 
unavailable 
Rau 1995 274 Not a randomised clinical trial 
Richter 2009 243 Method of vascular occlusion not reported 
Saiura 2006 316 Method of raw surface management not included in methods of dealing 
with raw surface in our review protocol 
Scatton 2011 317 Method of parenchymal transection was left to surgeons discretion 
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Schmidt 2008 318 Parenchymal transection performed according to surgeon's preference 
and local standards. Separate data not reported 
Schwartz 2004 319 Method of parenchymal transection not reported 
Shimada 1994 275 Not a randomised clinical trial 
Si-Yuan 2011 328 Compares different variations of vascular occlusion which will fall under 
the same category of vascular occlusion in our review 
Smyrniotis 2002 277 Quasi-randomised (random sequence generated by hospital number). 
This was discovered following correspondence with authors when it was 
included in a previous review 
Smyrniotis 2003 276 Quasi-randomised (random sequence generated by hospital number) 
Sugo 2005 278 Not a randomised clinical trial 
Takayama 2001 320 Two methods of vascular occlusion used, separate data unavailable 
Taniguchi 1992 279 Not a randomised clinical trial 
Van Den Broek 2011 239 Compares different variations of vascular occlusion which will fall under 
the same category of vascular occlusion in our review 
Wang 2006 321 Methods of vascular occlusion or parenchymal transection or raw 
surface not reported 
Wang 2011 240 Not a randomised clinical trial 
Wong 2003 322 Methods of parenchymal transection and management of raw surface 
not reported 
Wu 2002 292 Compares different variations of vascular occlusion which will fall under 
the same category of vascular occlusion in our review 
Wu 2006 280 Not a randomised clinical trial 
Xia 2008 281 Not a randomised clinical trial 
Yao 2006 290 Not comparing methods of vascular occlusion or parenchymal 
transection or raw surface 
Yokoo 2012 282 Not a randomised clinical trial 
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6.3.3 Characteristics of the included studies 
 
As discussed in the methodology section of this chapter (section 6.2.7), in order to 
decrease blood loss during elective liver resection, a surgeon may use a particular 
combination of the different methods of vascular occlusion, of the different methods of 
parenchymal transection, and of the different methods of dealing with the raw surface of 
the liver after transection. Together, one can consider this combination as a treatment 
strategy, that is, a combination of several interventions. Because of the few trials that 
could be included for network meta-analysis in this review, the treatments were revised 
into fewer categories by having only three methods of vascular occlusion (no vascular 
occlusion, continuous vascular occlusion, or intermittent vascular occlusion) and by 
having only two methods of treatment of cut surface (fibrin sealant used or no fibrin 
sealant used). The allocated treatment codes and the revised categories of vascular 
occlusion, method of parenchymal transection, and dealing with the cut surface are 
shown in Table 6.6.  
 
The individual characteristics and the treatments used in each of the nine RCTs included 
in this network meta-analysis are shown in Tables 6.8 to 6.16. All the included trials 
assessed different methods of open liver resection by using different combinations of 
vascular occlusion, parenchymal transection, and management of the liver cut surface, 
in order to decrease blood loss during liver resection. Seven trials were two-arm trials.29, 
254, 256-259, 329 There was one three-arm trial,242 and one four-arm trial.255 However, one 
arm in each of the latter two trials was excluded because the methods of parenchymal 
transection used in these trials (parenchymal transection using bipolar cautery and water 
jet, respectively) were not included in this review.242, 255 
 
Eleven different treatment strategies out of 36 possible treatment strategies were used in 
the trials included in this review. A total of 617 participants were randomised to the 11 
different treatment strategies in these trials. However, four treatment strategies in two 
trials were not connected to the network in any of the outcomes (i.e. they were not 
compared directly with any of the other treatment strategies for any of the outcomes of 
interest).254, 329 Thus, 496 participants were included in the network meta-analysis, 
randomised to seven different treatment strategies in the seven trials that contributed 
data for the network meta-analysis.29, 242, 255-259 A summary of the treatments used and 
types of participants included in all the included studies is shown in Table 6.17.  
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Table 6.8: Characteristics of study by Belghiti et al.329 
 
Methods Randomised clinical trial 
Participants Country: France. 
Number randomised: 86. 
Post-randomisation drop-outs: 0 (0%). 
Revised sample size: 86. 
Average age: 51 years. 
Females: 39 (45.3%). 
Major hepatic resection: 39 (45.3%). 
Cirrhosis: 25 (29.1%) 
Inclusion criteria 
1. Elective resection. 
2. Total vascular exclusion not required. 
3. No bilioenteric anastomosis. 
4. No associated gastrointestinal procedures. 
Interventions Participants were randomly assigned to two groups. 
Group 1: Intermittent vascular occlusion with cavitron ultrasonic surgical 
aspirator (CUSA) and fibrin sealant (n = 44). 
Group 2: Continuous vascular occlusion with CUSA and fibrin sealant (n 
= 42). 
Outcomes The outcomes reported were peri-operative mortality, morbidity, blood 
loss, blood transfusion requirements, and hospital stay. 
 
 
 
Table 6.9: Characteristics of study by Capusotti (2003) et al.254 
 
Methods Randomised clinical trial 
Participants Country: Italy. 
Number randomised: 35. 
Post-randomisation drop-outs: 0 (0%). 
Revised sample size: 35. 
Average age: 63 years. 
Females: 8 (22.9%). 
Major hepatic resection: 8 (22.9%). 
Cirrhosis: 35 (100%) 
Inclusion criteria 
1. < 75 years. 
2. HCC. 
3. Cirrhotic. 
4. Child A. 
Interventions Participants were randomly assigned to two groups. 
Group 1: Intermittent vascular occlusion with clamp-crush and fibrin sealant (n 
= 18). 
Group 2: Continuous vascular occlusion with clamp-crush and fibrin sealant (n 
= 17). 
Outcomes The outcomes reported were peri-operative mortality, morbidity, blood loss, 
blood transfusion requirements, and operating time. 
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Table 6.10: Characteristics of study by Capusotti (2006) et al.29 
 
Methods Randomised clinical trial 
Participants Country: Italy. 
Number randomised: 126. 
Post-randomisation drop-outs: 0 (0%). 
Revised sample size: 126. 
Average age: 51 years. 
Females: 51 (40.5%). 
Major hepatic resection: 56 (44.4%). 
Cirrhosis: 19 (15.1%) 
Inclusion criteria 
1. Hepatic resection. 
2. Resectable tumour on intraoperative ultrasound. 
3. No concomitant bowel or bile duct resection. 
4. No total vascular exclusion 
Interventions Participants were randomly assigned to two groups. 
Group 1: Intermittent vascular occlusion with clamp-crush and no fibrin 
sealant (n = 63). 
Group 2: No vascular occlusion with clamp-crush and no fibrin sealant (n = 
63). 
Outcomes The outcomes reported were peri-operative mortality, morbidity, blood loss, 
blood transfusion requirements, and hospital stay. 
 
Table 6.11: Characteristics of study by Doklestic et al.242 
 
Methods Randomised clinical trial 
Participants Country: Serbia. 
Number randomised: 40. 
Post-randomisation drop-outs: not stated. 
Revised sample size: 40. 
Average age: 59 years. 
Females: 27 (67.5%). 
Major hepatic resection: 20 (50.0%). 
Cirrhosis: 0 (0%). 
Inclusion criteria 
Patients undergoing liver resection. 
Exclusion criteria 
1. Liver cirrhosis. 
Interventions Participants were randomly assigned to two groups. 
Group 1: Intermittent vascular occlusion with CUSA and no fibrin sealant (n 
= 20). 
Group 2: Continuous vascular occlusion with clamp-crush and no fibrin 
sealant (n = 20). 
Outcomes The outcomes reported were mortality, operating time, blood loss, 
transfusion requirements, and hospital stay. 
Notes Another group in which liver resection was performed using bipolar cautery 
was not included in the review since this was not a method of parenchymal 
transection that we included in this review. 
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Table 6.12: Characteristics of study by Lesurtel et al.255 
Methods Randomised clinical trial 
Participants Country: Switzerland. 
Number randomised: 75. 
Post-randomisation drop-outs: not stated. 
Revised sample size: 75. 
Average age: 55 years. 
Females: 38 (50.7%). 
Major hepatic resection: 42 (56.0%). 
Cirrhosis: 0 (0%). 
Inclusion criteria 
1. More than 2 segments. 
2. Tumours 
3. Platelet count > 100000/ml. 
4. Prothrombin activity >60%. 
Exclusion criteria 
1. Cirrhotic. 
2. Cholestatic (serum bilirubin > 100 mumol/L). 
Interventions Participants were randomly assigned to two groups. 
Group 1: No vascular occlusion with CUSA and no fibrin sealant (n = 25). 
Group 2: No vascular occlusion with dissecting sealer and no fibrin sealant (n 
= 25). 
Group 3: Vascular occlusion with clamp-crush and no fibrin sealant (n = 25). 
Outcomes The outcomes reported were mortality, serious adverse events, hospital stay, 
transfusion requirements, and blood loss. 
Notes Another group in which parenchymal transection was performed using water 
jet was excluded since this was not one of the parenchymal transection 
methods assessed in this review. 
 
 
Table 6.13: Characteristics of study by Lupo et al.256 
Methods Randomised clinical trial 
Participants Country: Italy. 
Number randomised: 51. 
Post-randomisation drop-outs: 1 (2%). 
Revised sample size: 50. 
Average age: 62 years. 
Females: 14 (28%). 
Major hepatic resection: 21 (42.0%) 
Cirrhosis: 7 (14.0%) 
Inclusion criteria 
Interventions Participants were randomly assigned to two groups. 
Group 1: No vascular occlusion with radiofrequency dissecting sealer and 
no fibrin sealant (n = 24). 
Group 2: No vascular occlusion with clamp-crush and no fibrin sealant (n 
= 26). 
Outcomes The outcomes reported were mortality, serious adverse events, and 
transfusion requirements. 
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Table 6.14: Characteristics of study by Park et al.257 
Methods Randomised clinical trial 
Participants Country: Korea. 
Number randomised: 50. 
Post-randomisation drop-outs: not stated. 
Revised sample size: 50. 
Average age: 31 years. 
Females: 11 (22%). 
Major hepatic resection: not stated 
Cirrhosis: not stated 
Inclusion criteria 
1. Age >18 years. 
Exclusion criteria 
1. The recipient had experienced fulminant hepatic failure. 
2. The graft-to-recipient body weight ratio (GRWR) was <0.9%. 
3. A frozen biopsy sample from the donor liver showed >30% 
macrovesicular steatosis before donor hemihepatectomy. 
4. The transplant was ABO-incompatible. 
5. The recipient had previously undergone organ transplantation. 
6 Recipient had undergone or was scheduled to undergo multiorgan 
transplantation. 
Interventions Participants were randomly assigned to two groups. 
Group 1: Intermittent vascular occlusion with CUSA and no fibrin sealant (n 
= 25). 
Group 2: No vascular occlusion with CUSA and no fibrin sealant (n = 25). 
Outcomes The outcomes reported were mortality, operating time, blood loss, and 
hospital stay. 
 
Table 6.15: Characteristics of study by Petrowsky et al.258 
Methods Randomised clinical trial 
Participants Country: Switzerland. 
Number randomised: 73. 
Post-randomisation drop-outs: not stated. 
Revised sample size: 73. 
Average age: 57 years. 
Females: 35 (47.9%). 
Major hepatic resection: 73 (100%). 
Cirrhosis: 0 (0%) 
Inclusion criteria 
1. Major hepatectomies. 
2. No cirrhosis 
Interventions Participants were randomly assigned to two groups. 
Group 1: Intermittent vascular occlusion with clamp-crush and no fibrin 
sealant (n = 36). 
Group 2: Continuous vascular occlusion with clamp-crush and no fibrin 
sealant (n = 37). 
Outcomes The outcomes reported were mortality, serious adverse events, hospital 
stay, transfusion requirements, blood loss and operating time. 
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Table 6.16: Characteristics of study by Smyrniotis et al.259 
 
Methods Randomised clinical trial 
Participants Country: Greece 
Number randomised: 82 
Post-randomisation drop-outs: not stated 
Revised sample size: 82 
Average age: 63 years 
Females: 17 (20.7%) 
Major hepatic resection: 60 (73.2%) 
Cirrhosis: 12 (14.6%) 
Inclusion criteria 
Interventions Participants were randomly assigned to two groups. 
Group 1: Continuous vascular occlusion with sharp dissection and no 
fibrin sealant (n = 41). 
Group 2: Continuous vascular occlusion with clamp-crush and no 
fibrin sealant (n = 41). 
Outcomes The outcomes reported were mortality, serious adverse events, 
transfusion requirements, hospital stay, operating time, and blood loss. 
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Table 6.17: Summary of treatments used and types of participants included in all the included studies. 
 
Study Vascular occlusion Parenchymal transection 
Liver 
raw 
surface 
Codes of the comparisons 
Number of 
participants 
Major 
liver 
resections 
Cirrhosis 
Belghiti 
1999 
intermittent vascular occlusion 
versus 
continuous vascular occlusion 
cavitron ultrasonic surgical 
aspirator (CUSA) 
fibrin 
sealant 
V3P3R2 versus V2P3R2 86 
39 
(45.3%) 
25 
(29.1%) 
Capussotti 
2003 
intermittent vascular occlusion 
versus 
continuous vascular occlusion 
clamp-crush 
fibrin 
sealant 
V3P2R2 versus V2P2R2 35 
8 
(22.9%) 
35 
(100%) 
Capussotti 
2006 
intermittent vascular occlusion 
versus 
no vascular occlusion 
clamp-crush 
no fibrin 
sealant 
V3P2R1 versus V1P2R1 126 
56 
(44.4%) 
19 
(15.1%) 
Doklestic 
2012 
intermittent vascular occlusion 
CUSA versus 
clamp-crush 
no fibrin 
sealant 
V3P3R1 versus V3P2R1 40 
20 
(50.0%) 
0  
(0%) 
Lesurtel 
2005 
no vascular occlusion versus 
no vascular occlusion versus 
continuous vascular occlusion 
CUSA versus radiofrequency 
dissecting sealer versus 
clamp-crush method 
no fibrin 
sealant 
V1P3R1 versus V1P5R1 
versus V2P2R1 
75 
42 
(56.0%) 
0  
(0%) 
Lupo 2007 no vascular occlusion 
radiofrequency dissecting 
sealer versus 
clamp-crush 
no fibrin 
sealant 
V1P5R1 versus V1P2R1 50 
21 
(42.0%) 
7  
(14.0%) 
Park 2012 
intermittent vascular occlusion 
versus no vascular occlusion 
CUSA 
no fibrin 
sealant 
V3P3R1 versus V1P3R1 50 Not stated Not stated 
Petrowsky 
2006 
intermittent vascular occlusion 
versus  
continuous vascular occlusion 
clamp-crush 
no fibrin 
sealant 
V3P2R1 versus V2P2R1 73 
73 
(100%) 
0 
(0%) 
Smyrniotis 
2005 
continuous vascular occlusion 
sharp dissection versus 
clamp-crush 
no fibrin 
sealant 
V2P4R1 versus V2P2R1 82 
60 
(73.2%) 
12 
 (14.6%) 
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Footnotes for Table 6.17: Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin, V1P3R1=no vascular occlusion with 
CUSA and no fibrin, V1P5R1= no vascular occlusion with radiofrequency dissecting sealer and no fibrin, V2P2R1=continuous vascular 
occlusion with clamp-crush and no fibrin, V2P2R2= continuous vascular occlusion with clamp-crush and fibrin, V2P3R2=continuous 
vascular occlusion with CUSA and fibrin, V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin, 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin, V3P3R1=intermittent vascular occlusion with CUSA and no 
fibrin, V3P2R2= intermittent vascular occlusion with clamp-crush and fibrin, V3P3R2=intermittent vascular occlusion with CUSA and 
fibrin.
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The quality of the liver and the type of hepatectomy can influence the outcome of liver 
resection. Table 6.18 shows the seven treatment strategies included in the network meta-
analysis and the number of participants included in each strategy, along with the 
proportion of major resections performed and cirrhotic livers included in each treatment 
strategy. Major liver resection was defined as a right or left hemihepatectomy (or 
lobectomy), or extended hemihepatectomy (or extended lobectomy), or resection of 
three or more liver segments. 
 
 
 
 
 
Table 6.18: Summary of the seven treatment strategies included in the network meta-
analysis and the number of participants included in each strategy, along with the 
proportion of major resections performed and cirrhotic livers included in each treatment 
strategy.   
 
 
Treatment 
strategy 
Total number 
of participants 
Major resections 
performed 
Cirrhotic livers 
included 
V1P2R1 89 
41  
(46.1%) 
6 
(6.7%) 
V1P3R1 50 
13 out of 25 reported 
(52%) 
0 out of 25 reported 
(0%) 
V1P5R1 49 
24 
(49.0%) 
3 
(6.1%) 
V2P2R1 103 
84 
(81.6%) 
6 
(5.8%) 
V2P4R1 41 
29 
(70.7%) 
6 
(14.6%) 
V3P2R1 119 
71 
(59.7%) 
6 
(5.0%) 
V3P3R1 45 
10 out of 20 reported 
(50.0%) 
0 out of 20 reported 
(0%) 
Overall 496 
272 out of 446 reported 
(61.0%) 
38 out of 446 reported 
(8.5%) 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin, V1P3R1=no 
vascular occlusion with CUSA and no fibrin, V1P5R1= no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin, V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin, V2P4R1= continuous vascular occlusion with sharp 
dissection and no fibrin, V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin, V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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6.3.4 Risk of bias in included studies 
 
The risk of bias in the included trials is summarised in Figure 6.3 and Figure 6.4. All 
trials were at high risk of bias. The risk of bias of the included trials was assessed for 
the following domains: 
 Allocation: Four trials (44%) had adequate sequence generation.29, 254, 256, 257 
Two trials (22%) had adequate allocation concealment.242, 258 Thus, no trials (0%) had 
low risk of bias due to allocation. 
 Blinding: None of the trials reported any blinding. 
 Incomplete outcome data: Eight of the nine trials (89%) were free from bias 
due to incomplete outcome data.29, 242, 255-259, 329 
 Selective reporting: Seven trials (78%) reported mortality and serious adverse 
events and hence were considered to be free from bias.29, 254-256, 258, 259, 329 
 Other potential sources of bias: Only one trial reported the source of funding 
and the vested interest bias was rated to be low in this trial.242 The remaining trials were 
at unclear risk of bias. 
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Figure 6.3: Risk of bias summary - review authors' judgments about each risk of bias 
item for each included study.  
 
 
 
 
Footnotes: green plus sign = low risk of bias, yellow question mark = unclear risk of 
bias, red minus sign = high risk of bias. 
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Figure 6.4: Risk of bias graph - review authors' judgments about each risk of bias item 
presented as percentages across all included studies. 
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6.3.5 Overall results of network meta-analysis 
 
6.3.5.1. Mortality 
 
All the seven trials (496 participants) provided data for the network meta-analysis on 
short-term mortality.29, 242, 255-259 There were seven deaths in the included studies giving 
an overall mortality of 1.4%. The network plot for this outcome is shown in Figure 6.5. 
The results and model-fit of the fixed-effect model and random-effects model along 
with the model-fit of the inconsistency model is provided in Table 6.18. The between-
study standard deviation (tau) was 0.60. As indicated in Table 6.19, the fixed-effect 
model was preferred based on the DIC statistics. There was no evidence of 
inconsistency in the network. The pairwise ORs for the different treatment comparisons 
are shown in Table 6.20. As shown in Table 6.20, there was no evidence of any 
significant difference in mortality between the different treatments. The absolute 
proportion of people with mortality based on an illustrative risk of 3.5%330 is shown in 
the summary of findings for this outcome in Table 6.21. As shown in Figure 6.6, none 
of the treatment strategies ranked best with more than 90% probability. Also, none of 
the treatment strategies ranked worst with more than 90% probability. As shown in 
Figure 6.7, there is more than 90% probability that V3P3R1 (intermittent vascular 
occlusion with CUSA and no fibrin) is within the five best treatments (of seven 
treatments). All the remaining treatments other than V2P4R1 (continuous vascular 
occlusion with sharp dissection and no fibrin) are within the six best treatments. There 
is substantial uncertainty about the treatment strategy with the lowest or highest 
mortality. 
 
 
 
 
 
 
 
 
 
 
 
196 
 
Figure 6.5: Network plot of the treatment strategies for the outcome mortality.  
 
 
 
 
 
 
Footnotes: circles represent the treatment strategy as a node in the network; size of 
circles represents the number of RCTs reporting on the treatment strategy; lines 
represent direct comparisons using RCTs; thickness of lines represents the number of 
RCTs included in each comparison; V1P2R1=no vascular occlusion with clamp-crush 
and no fibrin; V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no 
vascular occlusion with radiofrequency dissecting sealer and no fibrin; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Table 6.19: Results and model fit of the fixed-effect model and random-effects model 
along with the model-fit of the inconsistency model for the outcome mortality.  
 
 
 
Fixed-effect model Random-effects model 
Inconsistency model 
(random-effects) 
d[2] 1.92 (95% CI -2.29 to 6.13) 1.7 (95% CI -5.33 to 8.73) - 
d[3] -0.18 (95% CI -4.2 to 3.84) -0.21 (95% CI -6.29 to 5.88) - 
d[4] 0.6 (95% CI -3.29 to 4.5) 0.6 (95% CI -6.08 to 7.27) - 
d[5] 0.6 (95% CI -6.68 to 7.89) 0.62 (95% CI -9.85 to 11.09) - 
d[6] 0.09 (95% CI -2.99 to 3.18) 0.16 (95% CI -5.25 to 5.58) - 
d[7] -1.23 (95% CI -5.45 to 2.98) -0.89 (95% CI -8.12 to 6.33) - 
Dbar 42.93 42.82 44.28 
pD 11.07 11.68 12.06 
DIC 54 54.49 56.35 
 
 
 
Footnotes: d[2] indicates the log odds ratio between treatment 2 and treatment 1, d[3] 
indicates the log odds ratio between treatment 3 and treatment 1, etc.; Dbar indicates the 
posterior mean of the residual deviance; pD indicates the effective number of 
parameters (leverage); DIC indicates the 'Deviance Information Criterion'. A lower 
Dbar indicates a better model fit. However, a model with lower DIC is generally chosen 
to aid better interpretation as it takes the model complexity into account. A lower DIC 
indicates a better model fit. Differences of less than 3 to 5 between the models are not 
considered important. Based on the information, fixed-effect model is the preferred 
model. There is no evidence of inconsistency since the difference in DIC between 
consistency and inconsistency models was not significant. 
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Table 6.20: Pairwise odds ratios of the different treatment comparisons for the outcome mortality. There was no statistically significant 
difference between the treatment strategies for the outcome mortality. 
 
 
 
V1P3R1 V1P5R1 V2P2R1 V2P4R1 V3P2R1 V3P3R1 
V1P2R1 
OR 6.83;  
95% CI 0.1 to 459.49 
OR 0.84; 
95% CI 0.02 to 46.5 
OR 1.83; 
95% CI 0.04 to 89.57 
OR 1.83;  
95% CI 0 to 2660.48 
OR 1.1;  
95% CI 0.05 to 23.98 
OR 0.29;  
95% CI 0 to 19.67 
V1P3R1 - 
OR 0.12;  
95% CI 0 to 41.17 
OR 0.27;  
95% CI 0 to 82.55 
OR 0.27;  
95% CI 0 to 1202.95 
OR 0.16;  
95% CI 0 to 29.61 
OR 0.04;  
95% CI 0 to 16.43 
V1P5R1 - - 
OR 2.19;  
95% CI 0.01 to 587.54 
OR 2.18;  
95% CI 0 to 8952.18 
OR 1.31;  
95% CI 0.01 to 207.83 
OR 0.35;  
95% CI 0 to 117.53 
V2P2R1 - - - 
OR 1;  
95% CI 0 to 3850.15 
OR 0.6;  
95% CI 0 to 85.91 
OR 0.16;  
95% CI 0 to 49.23 
V2P4R1 - - - - 
OR 0.6;  
95% CI 0 to 1634.74 
OR 0.16;  
95% CI 0 to 718.88 
V3P2R1 - - - - - 
OR 0.27;  
95% CI 0 to 49.19 
 
 
 
Footnotes: OR=odds ratio; 95% CI=95% confidence intervals; V1P2R1=no vascular occlusion with clamp-crush and no fibrin; 
V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and no 
fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; V3P3R1=intermittent vascular occlusion 
with CUSA and no fibrin. 
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Table 6.21: Summary of findings for the outcome mortality, including: quality of 
evidence, treatment strategies compared, the treatment effect for each treatment strategy 
from the network meta-analysis performed, and the corresponding illustrative risk for 
each treatment strategy. 
 
 
Methods to decrease blood loss during liver resection (mortality) 
Patient or population: people undergoing open liver resection 
Settings: secondary or tertiary 
Intervention and control: various treatments 
Number of trials (participants) 7 trials (496 participants) 
Overall quality of evidence Very low i.e. we are very uncertain about the estimate 
Groups Illustrative risk Treatment effect 
Assumed risk in control group 
(V1P2R1)* 
35 per 1000 - 
Corresponding risk in V1P3R1 
199 per 1000 
(4 to 943) 
OR 6.83 (95% CI 0.1 to 459.49) 
Corresponding risk in V1P5R1 
30 per 1000 
(1 to 628) 
OR 0.84 (95% CI 0.02 to 46.5) 
Corresponding risk in V2P2R1 
62 per 1000 
(1 to 765) 
OR 1.83 (95% CI 0.04 to 89.57) 
Corresponding risk in V2P4R1 
62 per 1000 
(0 to 1000) 
OR 1.83 (95% CI 0 to 2660.48) 
Corresponding risk in V3P2R1 
38 per 1000 
(2 to 465) 
OR 1.1 (95% CI 0.05 to 23.98) 
Corresponding risk in V3P3R1 
10 per 1000 
(0 to 416) 
OR 0.29 (95% CI 0 to 19.67) 
*The basis for the assumed risk was from literature. The corresponding risk (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect 
of the intervention (and its 95% CI). 
 
 
 
Footnotes: OR=odds ratio; 95% CI=95% confidence intervals; V1P2R1=no vascular 
occlusion with clamp-crush and no fibrin; V1P3R1=no vascular occlusion with CUSA 
and no fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and 
no fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.6: Probability of being best treatment strategy for the outcome mortality. None 
of the treatment strategies ranked best with more than 90% probability, and there is a lot 
of uncertainty about the treatment strategy with the lowest mortality. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.7: Cumulative probability of ranks of different treatment strategies for the 
outcome mortality. There is more than 90% probability that V3P3R1 is within the five 
best treatments (of seven treatments). All the remaining treatments other than V2P4R1 
are within the six best treatments. There is substantial uncertainty about the treatment 
strategy with the lowest or highest mortality. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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6.3.5.2. Serious adverse events 
 
Five trials (406 participants) provided data for the network meta-analysis on serious 
adverse events.29, 255, 256, 258, 259 Two trials reported on total adverse events (of any 
severity), but did not clearly report on serious adverse events.242, 257 There were 35 
people with serious adverse events in the included studies (8.6%). The network plot is 
shown in Figure 6.8. The results and model fit of the fixed-effect model and random-
effects model along with the model-fit of the inconsistency model is provided in Table 
6.22. The between-study standard deviation (tau) was 0.03. As indicated in Table 6.22, 
the fixed-effect model was preferred based on the DIC statistics. There was no evidence 
of inconsistency in the network. The pairwise ORs for the different treatment 
comparisons are shown in Table 6.23. As shown in Table 6.23, there was no evidence of 
any significant difference between the different treatments except for a significant 
increase in the proportion of people with serious adverse events in V1P5R1 (no vascular 
occlusion with radiofrequency dissecting sealer and no fibrin) compared with V1P2R1 
(no vascular occlusion with clamp-crush and no fibrin) (OR 7.13; 95% CrI 1.77 to 
28.65). The absolute proportion of people with serious adverse events based on an 
illustrative risk of 6.7% in the reference treatment is shown in the summary of findings 
for this outcome in Table 6.24. As shown in Figure 6.9, none of the treatment strategies 
ranked best with more than 90% probability. Also, none of the treatments ranked worst 
with more than 90% probability. As shown in Figure 6.10, there is more than 90% 
probability that V1P2R1 (no vascular occlusion with clamp-crush method and no fibrin) 
and V3P2R1 (intermittent vascular occlusion with clamp-crush and no fibrin) are within 
the three best treatments (of six treatments). This suggests that there is a high 
probability that these two treatment strategies are better than other treatment strategies 
with regards to serious adverse events. There is substantial uncertainty about the best or 
worst treatment strategy with regards to serious adverse events. 
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Figure 6.8: Network plot of the treatment strategies for the outcome serious adverse 
events.  
 
 
 
 
 
 
Footnotes: circles represent the treatment strategy as a node in the network; size of 
circles represents the number of RCTs reporting on the treatment strategy; lines 
represent direct comparisons using RCTs; thickness of lines represents the number of 
RCTs included in each comparison; V1P2R1=no vascular occlusion with clamp-crush 
and no fibrin; V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no 
vascular occlusion with radiofrequency dissecting sealer and no fibrin; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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Table 6.22: Results and model fit of the fixed-effect model and random-effects model 
along with the model-fit of the inconsistency model for the outcome serious adverse 
events.  
 
 
 
Fixed-effect model Random-effects model 
Inconsistency model 
(random-effects) 
d[2] 1 (95% CI -1.33 to 3.33) 0.77 (95% CI -6.22 to 7.76) - 
d[3] 1.96 (95% CI 0.57 to 3.36) 1.78 (95% CI -3.2 to 6.76) - 
d[4] 1.54 (95% CI -0.3 to 3.38) 1.22 (95% CI -4.57 to 7.01) - 
d[5] 1.54 (95% CI -2.49 to 5.58) 1.2 (95% CI -7.51 to 9.91) - 
d[6] 0.05 (95% CI -1.51 to 1.6) 0.1 (95% CI -4.91 to 5.11) - 
Dbar 44.12 41.43 41.4 
pD 9.65 10.64 10.64 
DIC 53.77 52.08 52.04 
 
 
 
 
Footnotes: d[2] indicates the log odds ratio between treatment 2 and treatment 1, d[3] 
indicates the log odds ratio between treatment 3 and treatment 1, etc.; Dbar indicates the 
posterior mean of the residual deviance; pD indicates the effective number of 
parameters (leverage); DIC indicates the 'Deviance Information Criterion'. A lower 
Dbar indicates a better model fit. However, a model with lower DIC is generally chosen 
to aid better interpretation as it takes the model complexity into account. A lower DIC 
indicates a better model fit. Differences of less than 3 to 5 between the models are not 
considered important. Based on the information, fixed-effect model is the preferred 
model. There is no evidence of inconsistency since the difference in DIC between 
consistency and inconsistency models was not significant. 
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Table 6.23: Pairwise odds ratios of the different treatment comparisons for the outcome serious adverse events. Statistically significant 
results are in bold. There was no evidence of any significant difference between the different treatments except for a significant increase in 
the proportion of people with serious adverse events in V1P5R1 compared with V1P2R1. 
 
 
 
V1P3R1 V1P5R1 V2P2R1 V2P4R1 V3P2R1 
V1P2R1 
OR 2.72; 
95% CI 0.27 to 27.92 
OR 7.13; 
 95% CI 1.77 to 28.65 
OR 4.68;  
95% CI 0.74 to 29.47 
OR 4.68;  
95% CI 0.08 to 264.19 
OR 1.05;  
95% CI 0.22 to 4.96 
V1P3R1 - 
OR 2.62;  
95% CI 0.17 to 39.46 
OR 1.72;  
95% CI 0.09 to 33.46 
OR 1.72;  
95% CI 0.02 to 181.18 
OR 0.39;  
95% CI 0.02 to 6.33 
V1P5R1 - - 
OR 0.66;  
95% CI 0.07 to 6.59 
OR 0.66;  
95% CI 0.01 to 46.8 
OR 0.15;  
95% CI 0.02 to 1.18 
V2P2R1 - - - 
OR 1;  
95% CI 0.01 to 84.13 
OR 0.22;  
95% CI 0.02 to 2.49 
V2P4R1 - - - - 
OR 0.22;  
95% CI 0 to 16.89 
 
 
 
Footnotes: OR=odds ratio; 95% CI=95% confidence intervals; V1P2R1=no vascular occlusion with clamp-crush and no fibrin; 
V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and no 
fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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Table 6.24: Summary of findings for the outcome serious adverse events, including: 
quality of evidence, treatment strategies compared, the treatment effect for each 
treatment strategy from the network meta-analysis performed, and the corresponding 
illustrative risk for each treatment strategy. 
 
 
Methods to decrease blood loss during liver resection (serious adverse events) 
Patient or population: people undergoing open liver resection 
Settings: secondary or tertiary 
Intervention and control: various treatments 
Number of trials (participants) 5 trials (406 participants) 
Overall quality of evidence Very low i.e. we are very uncertain about the estimate 
Groups Illustrative risk Treatment effect 
Assumed risk in control group 
(V1P2R1)* 
67 per 1000 - 
Corresponding risk in V1P3R1 
163 per 1000 
(19 to 667) 
OR 2.72 (95% CI 0.27 to 27.92) 
Corresponding risk in V1P5R1 
339 per 1000 
(113 to 673) 
OR 7.13 (95% CI 1.77 to 28.65) 
Corresponding risk in V2P2R1 
252 per 1000 
(50 to 679) 
OR 4.68 (95% CI 0.74 to 29.47) 
Corresponding risk in V2P4R1 
252 per 1000 
(6 to 950) 
OR 4.68 (95% CI 0.08 to 264.19) 
Corresponding risk in V3P2R1 
70 per 1000 
(16 to 263) 
OR 1.05 (95% CI 0.22 to 4.96) 
*The basis for the assumed risk was from the mean proportion with serious adverse 
events in control group. The corresponding risk (and its 95% confidence interval) is 
based on the assumed risk in the comparison group and the relative effect of the 
intervention (and its 95% CI). 
 
 
 
Footnotes: OR=odds ratio; 95% CI=95% confidence intervals; V1P2R1=no vascular 
occlusion with clamp-crush and no fibrin; V1P3R1=no vascular occlusion with CUSA 
and no fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and 
no fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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Figure 6.9: Probability of being best treatment strategy for the outcome serious adverse 
events. None of the treatment strategies ranked best with more than 90% probability, 
and there is a lot of uncertainty about the treatment strategy with the lowest mortality. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin. 
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Figure 6.10: Cumulative probability of ranks of different treatment strategies for the 
outcome serious adverse events. There is more than 90% probability that V1P2R1 and 
V3P2R1 are within the three best treatments (of six treatments). This suggests that there 
is a high probability that these two treatment strategies are better than other treatment 
strategies with regards to serious adverse events. There is substantial uncertainty about 
the worst treatment strategy with regards to serious adverse events. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin. 
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6.3.5.3. Proportion of patients transfused 
 
Six trials (446 participants) provided data for the network meta-analysis on proportion 
of patients needed to be transfused.29, 242, 255, 256, 258, 259 One trial did not report on the 
number of patients requiring allogeneic blood transfusion.257 The network plot is shown 
in Figure 6.11. The results and model-fit of the fixed-effect model and random-effects 
model along with the model-fit of the inconsistency model is provided in Table 6.25. As 
indicated in Table 6.25, the random-effects model was preferred based on the DIC 
statistics. The between study standard deviation (tau) was 0.61. There was no evidence 
of inconsistency in the network. The pairwise ORs for the different treatment 
comparisons are shown in Table 6.26. As shown in Table 6.26, there is no evidence of 
any significant difference in the proportion of people transfused between the different 
treatments. The absolute proportion of people requiring blood transfusion based on an 
illustrative risk of 15.7% in the reference treatment is shown in the summary of findings 
for this outcome in Table 6.27. As shown in Figure 6.12, none of the treatments ranked 
best with more than 90% probability. Also, none of the treatments ranked worst with 
more than 90% probability. As shown in Figure 6.13, there is substantial uncertainty 
about the treatment strategy resulting in the lowest or the highest proportion of people 
needed to be transfused. For example, there was more than 90% probability that 
V2P2R1 (continuous vascular occlusion with clamp-crush and no fibrin) was within the 
five best treatments (of seven treatments) and that V1P2R1 (no vascular occlusion with 
clamp-crush and no fibrin) was within the six best treatments (of seven treatments).  
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Figure 6.11: Network plot of the treatment strategies for the outcome proportion of 
patients transfused. 
 
 
 
 
 
 
Footnotes: circles represent the treatment strategy as a node in the network; size of 
circles represents the number of RCTs reporting on the treatment strategy; lines 
represent direct comparisons using RCTs; thickness of lines represents the number of 
RCTs included in each comparison; V1P2R1=no vascular occlusion with clamp-crush 
and no fibrin; V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no 
vascular occlusion with radiofrequency dissecting sealer and no fibrin; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Table 6.25: Results and model fit of the fixed-effect model and random-effects model 
along with the model-fit of the inconsistency model for the outcome proportion of 
patients transfused.  
 
 
 
Fixed-effect model Random-effects model 
Inconsistency model 
(random-effects) 
d[2] 1.29 (95% CI -0.32 to 2.9) 1.8 (95% CI -5.75 to 9.35) - 
d[3] -0.03 (95% CI -1.08 to 1.01) 0.49 (95% CI -4.94 to 5.92) - 
d[4] -0.04 (95% CI -1.43 to 1.36) -0.24 (95% CI -6.63 to 6.15) - 
d[5] -0.26 (95% CI -1.93 to 1.41) -0.46 (95% CI -9.32 to 8.41) - 
d[6] 0.8 (95% CI -0.46 to 2.07) 1.22 (95% CI -4.4 to 6.85) - 
d[7] 1.36 (95% CI -1.1 to 3.82) 1.8 (95% CI -6.77 to 10.36) - 
Dbar 63.46 56.44 56.61 
pD 12.02 13.01 12.89 
DIC 75.48 69.45 69.51 
 
 
 
Footnotes: d[2] indicates the log odds ratio between treatment 2 and treatment 1, d[3] 
indicates the log odds ratio between treatment 3 and treatment 1, etc.; Dbar indicates the 
posterior mean of the residual deviance; pD indicates the effective number of 
parameters (leverage); DIC indicates the 'Deviance Information Criterion'. A lower 
Dbar indicates a better model fit. However, a model with lower DIC is generally chosen 
to aid better interpretation as it takes the model complexity into account. A lower DIC 
indicates a better model fit. Differences of less than 3 to 5 between the models are not 
considered important. Based on the information, random-effects model is the preferred 
model. There is no evidence of inconsistency since the difference in DIC between 
consistency and inconsistency models was not significant. 
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Table 6.26: Pairwise odds ratios of the different treatment comparisons for the outcome proportion of patients transfused. There is no 
evidence of any significant difference in the proportion of people transfused between the different treatment strategies. 
 
 
 
V1P3R1 V1P5R1 V2P2R1 V2P4R1 V3P2R1 V3P3R1 
V1P2R1 
OR 6.06; 
 95% CI 0 to 11486.87 
OR 1.64;  
95% CI 0.01 to 373.55 
OR 0.79;  
95% CI 0 to 469.31 
OR 0.63;  
95% CI 0 to 4494.19 
OR 3.4;  
95% CI 0.01 to 941.28 
OR 6.03;  
95% CI 0 to 31671.1 
V1P3R1 - 
OR 0.27;  
95% CI 0 to 2950.65 
OR 0.13;  
95% CI 0 to 2563.91 
OR 0.1;  
95% CI 0 to 11933.13 
OR 0.56;  
95% CI 0 to 6873.03 
OR 1;  
95% CI 0 to 90479.42 
V1P5R1 - - 
OR 0.48;  
95% CI 0 to 2111.73 
OR 0.39;  
95% CI 0 to 12705.22 
OR 2.08;  
95% CI 0 to 5166.35 
OR 3.68;  
95% CI 0 to 93690.74 
V2P2R1 - - - 
OR 0.81;  
95% CI 0 to 44995.95 
OR 4.32;  
95% CI 0 to 21534.25 
OR 7.66;  
95% CI 0 to 336044.28 
V2P4R1 - - - - 
OR 5.37;  
95% CI 0 to 194906 
OR 9.51;  
95% CI 0 to 2152551.81 
V3P2R1 - - - - - 
OR 1.77;  
95% CI 0 to 50000.24 
 
 
 
Footnotes: OR=odds ratio; 95% CI=95% confidence intervals; V1P2R1=no vascular occlusion with clamp-crush and no fibrin; 
V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and no 
fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; V3P3R1=intermittent vascular occlusion 
with CUSA and no fibrin. 
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Table 6.27: Summary of findings for the outcome proportion of patients transfused, 
including: quality of evidence, treatment strategies compared, the treatment effect for 
each treatment strategy from the network meta-analysis performed, and the 
corresponding illustrative risk for each treatment strategy. 
 
 
Methods to decrease blood loss during liver resection (Blood transfusion proportion) 
Patient or population: people undergoing open liver resection 
Settings: secondary or tertiary 
Intervention and control: various treatments 
Number of trials (participants) 6 trials (446 participants) 
Overall quality of evidence Very low i.e. we are very uncertain about the estimate 
Groups 
Illustrative 
risk 
Treatment effect 
Assumed risk in control group 
(V1P2R1) 
157 per 1000 - 
Corresponding risk in V1P3R1 
530 per 1000 
(0 to 1000) 
OR 6.06; 95% CI 0 to 11486.87 
Corresponding risk in V1P5R1 
234 per 1000 
(2 to 986) 
OR 1.64; 95% CI 0.01 to 373.55 
Corresponding risk in V2P2R1 
128 per 1000 
(0 to 989) 
OR 0.79; 95% CI 0 to 469.31 
Corresponding risk in V2P4R1 
105 per 1000 
(0 to 999) 
OR 0.63; 95% CI 0 to 4494.19 
Corresponding risk in V3P2R1 
388 per 1000 
(2 to 994) 
OR 3.4; 95% CI 0.01 to 941.28 
Corresponding risk in V3P3R1 
529 per 1000 
(0 to 1000) 
OR 6.03; 95% CI 0 to 31671.1 
*The basis for the assumed risk was from the mean proportion with blood transfusion in 
control group. The corresponding risk (and its 95% confidence interval) is based on the 
assumed risk in the comparison group and the relative effect of the intervention (and its 95% 
CI). 
 
 
 
Footnotes: OR=odds ratio; 95% CI=95% confidence intervals; V1P2R1=no vascular 
occlusion with clamp-crush and no fibrin; V1P3R1=no vascular occlusion with CUSA 
and no fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and 
no fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.12: Probability of being best treatment strategy for the outcome proportion of 
patients transfused. None of the treatment strategies ranked best with more than 90% 
probability, and there is a lot of uncertainty about the treatment strategy with the lowest 
proportion of patients transfused. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.13: Cumulative probability of ranks of different treatment strategies for the 
outcome proportion of patients transfused. There was more than 90% probability that 
V2P2R1 was within the five best treatments (of seven treatments) and that V1P2R1 was 
within the six best treatments (of seven treatments). There is substantial uncertainty 
about the treatment strategy resulting in the lowest or the highest proportion of people 
needed to be transfused. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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6.3.5.4. Quantity of blood transfused 
 
Two trials (155 participants) provided data for the network meta-analysis on quantity of 
blood transfused.258, 259 The other five trials 29, 242, 255-257 did not report on the quantity of 
perioperative blood transfusion required. The network plot for this outcome is shown in 
Figure 6.14, and it demonstrates only the three treatment strategies included in the two 
trials258, 259 providing data on the quantity of perioperative blood transfusion. The results 
and model-fit of the fixed-effect model and random-effects model is provided in Table 
6.28. The between-study standard deviation (tau) was 0. As indicated in Table 6.28, the 
fixed-effect model was preferred based on the DIC statistics. The model-fit of the 
inconsistency model was not reported because there was no closed loop in the network. 
The pairwise MDs for the different treatment comparisons are shown in Table 6.29. As 
shown in Table 6.29, people undergoing liver resection by V3P2R1 (intermittent 
vascular occlusion with clamp-crush and no fibrin) had significantly higher amounts of 
blood transfused than people undergoing liver resection by V2P2R1 (continuous 
vascular occlusion with clamp-crush and no fibrin) (MD 1.2 units; 95% CrI 0.08 to 
2.32). There were no significant differences in the other comparisons. As shown in 
Figure 6.15, none of the treatment strategies ranked best with more than 90% 
probability. As shown in Figure 6.16, there was more than 90% probability that 
V2P2R1 (continuous vascular occlusion with clamp-crush and no fibrin) and V2P4R1 
(continuous vascular occlusion with sharp dissection and no fibrin) are within the two 
best treatments. This suggests that these two treatment strategies are better than 
V3P2R1 (intermittent vascular occlusion with clamp-crush and no fibrin) with regards 
to the quantity of blood transfused. There was a 90.2% probability that V3P2R1 
(intermittent vascular occlusion with clamp-crush and no fibrin) was the worst treatment 
strategy with regards to the quantity of blood transfused, out of the three treatment 
strategies compared for this outcome. 
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Figure 6.14: Network plot of the treatment strategies for the outcome quantity of blood 
transfused. It demonstrates only the three treatment strategies included in the two 
trials258, 259 providing data on the quantity of perioperative blood transfusion. 
 
 
 
 
 
 
Footnotes: circles represent the treatment strategy as a node in the network; size of 
circles represents the number of RCTs reporting on the treatment strategy; lines 
represent direct comparisons using RCTs; thickness of lines represents the number of 
RCTs included in each comparison; V2P2R1=continuous vascular occlusion with 
clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin. 
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Table 6.28: Results and model fit of the fixed-effect model and random-effects model 
for the outcome quantity of blood transfused. The model-fit of the inconsistency model 
was not reported because there was no closed loop in the network. 
 
 
 
Fixed-effect model Random-effects model 
d[2] 0 (95% CI -1.36 to 1.36) 0 (95% CI -5.83 to 5.83) 
d[3] 1.2 (95% CI 0.08 to 2.32) 1.2 (95% CI -4.57 to 6.96) 
Dbar 4.66 4.67 
pD 4 4 
DIC 8.65 8.67 
 
 
Footnotes: d[2] indicates the log odds ratio between treatment 2 and treatment 1, d[3] 
indicates the log odds ratio between treatment 3 and treatment 1; Dbar indicates the 
posterior mean of the residual deviance; pD indicates the effective number of 
parameters (leverage); DIC indicates the 'Deviance Information Criterion'. A lower 
Dbar indicates a better model fit. However, a model with lower DIC is generally chosen 
to aid better interpretation as it takes the model complexity into account. A lower DIC 
indicates a better model fit. Differences of less than 3 to 5 between the models are not 
considered important. Based on the information, fixed-effect model is the preferred 
model. 
 
 
 
 
 
 
 
Table 6.29: Pairwise mean differences of the different treatment comparisons for the 
outcome quantity of blood transfused. Statistically significant results are in bold. People 
undergoing liver resection by V3P2R1 had significantly higher amounts of blood 
transfused than people undergoing liver resection by V2P2R1. 
 
 
 
V2P4R1 V3P2R1 
V2P2R1 MD 0; 95% CI -1.36 to 1.36 MD 1.2; 95% CI 0.08 to 2.32 
V2P4R1 - MD 1.2; 95% CI -0.56 to 2.96 
 
 
Footnotes: MD=mean difference; 95% CI=95% confidence intervals; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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Figure 6.15: Probability of being best treatment strategy for the outcome quantity of 
blood transfused. None of the treatment strategies ranked best with more than 90% 
probability. 
 
 
 
 
 
 
Footnotes: V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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Figure 6.16: Cumulative probability of ranks of different treatments for the outcome 
quantity of blood transfused. There was more than 90% probability that V2P2R1 and 
V2P4R1 are within the two best treatments. There was a 90.2% probability that 
V3P2R1 was the worst treatment strategy with regards to the quantity of blood 
transfused, out of the three treatment strategies compared for this outcome. 
 
 
 
 
 
 
 
Footnotes: V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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6.3.5.5. Operative blood loss 
 
Four trials reported on operative blood loss during hepatectomy.29, 257-259 The other three 
trials did not report on operative blood loss.242, 255, 256 One trial257 reporting on operative 
blood loss had to be excluded from the analysis of this outcome because the treatment 
strategies it reported on were not directly compared with the treatment strategies of the 
other trials reporting on this outcome (i.e. not connected to the network plot for this 
outcome). Therefore, three trials (281 participants) provided data for the network meta-
analysis on operative blood loss. 29, 258, 259 The network plot for this outcome is shown in 
Figure 6.17. The results and model-fit of the fixed-effect model and random-effects 
model is provided in Table 6.30. The between-study standard deviation (tau) was 0.02. 
As indicated in Table 6.30, the fixed effect model was preferred based on the DIC 
statistics. The model-fit of the inconsistency model was not reported because there was 
no closed loop in the network. The pairwise MDs for the different treatment 
comparisons are shown in Table 6.31. As shown in Table 6.31, people undergoing liver 
resection by V2P2R1 (continuous vascular occlusion with clamp crush and no fibrin) 
had significantly lower blood loss than those undergoing liver resection by V1P2R1 (no 
vascular occlusion with clamp-crush and no fibrin) (MD -130.9 mL; 95% CrI -255.89 to 
-5.91). There were no significant differences in the other comparisons. As shown in 
Figure 6.18 and Figure 6.19, V2P2R1 (continuous vascular occlusion with clamp-crush 
and no fibrin) was ranked the best treatment strategy with regards to operative blood 
loss with more than 90% probability (96.0% probability). There is substantial 
uncertainty about the worst treatment strategy with regards to operative blood loss. 
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Figure 6.17: Network plot of the treatment strategies for the outcome operative blood 
loss.  
 
 
 
 
 
 
Footnotes: circles represent the treatment strategy as a node in the network; size of 
circles represents the number of RCTs reporting on the treatment strategy; lines 
represent direct comparisons using RCTs; thickness of lines represents the number of 
RCTs included in each comparison; V1P2R1=no vascular occlusion with clamp-crush 
and no fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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Table 6.30: Results and model fit of the fixed-effect model and random-effects model 
for the outcome operative blood loss. The model-fit of the inconsistency model was not 
reported because there was no closed loop in the network. 
 
 
 
Fixed-effect model Random-effects model 
d[2] -130.9 (95% CI -255.89 to -5.91) -127.9 (95% CI -255.59 to -0.21) 
d[3] 39.59 (95% CI -111.37 to 190.55) 37.61 (95% CI -113.21 to 188.43) 
d[4] 3.62 (95% CI -64.31 to 71.56) 3.45 (95% CI -64.7 to 71.6) 
Dbar 70.77 70.65 
pD 4.24 4.24 
DIC 75.01 74.89 
 
 
Footnotes: d[2] indicates the log odds ratio between treatment 2 and treatment 1, d[3] 
indicates the log odds ratio between treatment 3 and treatment 1, etc.; Dbar indicates the 
posterior mean of the residual deviance; pD indicates the effective number of 
parameters (leverage); DIC indicates the 'Deviance Information Criterion'. A lower 
Dbar indicates a better model fit. However, a model with lower DIC is generally chosen 
to aid better interpretation as it takes the model complexity into account. A lower DIC 
indicates a better model fit. Differences of less than 3 to 5 between the models are not 
considered important. Based on the information, fixed-effect model is the preferred 
model. 
 
 
 
 
Table 6.31: Pairwise mean differences of the different treatment comparisons for the 
outcome operative blood loss. Statistically significant results are in bold. People 
undergoing liver resection by V2P2R1 had significantly lower blood loss than those 
undergoing liver resection by V1P2R1. There were no significant differences in the 
other comparisons. 
 
 
 
V2P2R1 V2P4R1 V3P2R1 
V1P2R1 
MD -130.9; 95% CI -
255.89 to -5.91 
MD 39.59; 95% CI -
111.37 to 190.55 
MD 3.62; 95% CI -64.31 
to 71.56 
V2P2R1 - 
MD 170.49; 95% CI -
25.5 to 366.48 
MD 134.52; 95% CI -
7.73 to 276.78 
V2P4R1 - - 
MD -35.97; 95% CI -
201.51 to 129.57 
 
 
Footnotes: MD=mean difference; 95% CI=95% confidence intervals; V1P2R1=no 
vascular occlusion with clamp-crush and no fibrin; V2P2R1=continuous vascular 
occlusion with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with 
sharp dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-
crush and no fibrin. 
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Figure 6.18: Probability of being best treatment strategy for the outcome operative 
blood loss. V2P2R1 was ranked the best treatment strategy with regards to operative 
blood loss with 96.0% probability. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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Figure 6.19: Cumulative probability of ranks of different treatments for the outcome 
operative blood loss. V2P2R1 ranked the best treatment strategy with regards to 
operative blood loss with more than 90% probability. There is substantial uncertainty 
about the worst treatment strategy with regards to operative blood loss. 
 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin. 
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6.3.5.6. Length of hospital stay 
 
Six trials (446 participants) provided data for the network meta-analysis on length of 
hospital stay.29, 242, 255, 257-259 One trial did not report the postoperative length of hospital 
stay.256 The network plot is shown in Figure 6.20. The results and model-fit of the 
fixed-effect model and random-effects model along with the model-fit of the 
inconsistency model is provided in Table 6.32. The between study standard deviation 
(tau) was 0.01. As indicated in Table 6.32, the fixed-effect model was preferred based 
on the DIC statistics. There was no evidence of inconsistency in the network. The 
pairwise MDs for the different treatment comparisons are shown in Table 6.33. As 
shown in Table 6.33, there was no evidence of any significant difference in the length of 
hospital stay between the different treatments. As shown in Figure 6.21, none of the 
treatment strategies ranked best with more than 90% probability. Also, none of the 
treatment strategies ranked worst with more than 90% probability. As shown in Figure 
6.22, there is more than 90% probability that V3P3R1 (intermittent vascular occlusion 
with CUSA and no fibrin) is within the three best treatments (of seven treatments). 
There is more than 90% probability that V1P2R1 (no vascular occlusion with clamp-
crush and no fibrin) and V3P2R1 (intermittent vascular occlusion with clamp-crush and 
no fibrin) are within the five best treatments. There is substantial uncertainty about the 
treatment strategy with the lowest or highest length of hospital stay. 
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Figure 6.20: Network plot of the treatment strategies for the outcome length of hospital 
stay. 
 
 
 
 
 
 
Footnotes: circles represent the treatment strategy as a node in the network; size of 
circles represents the number of RCTs reporting on the treatment strategy; lines 
represent direct comparisons using RCTs; thickness of lines represents the number of 
RCTs included in each comparison; V1P2R1=no vascular occlusion with clamp-crush 
and no fibrin; V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no 
vascular occlusion with radiofrequency dissecting sealer and no fibrin; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Table 6.32: Results and model fit of the fixed-effect model and random-effects model 
along with the model-fit of the inconsistency model for the outcome length of hospital 
stay.  
 
 
 
Fixed-effect model Random-effects model 
Inconsistency model 
(random-effects) 
d[2] 2.29 (95% CI -2.03 to 6.61) 2.28 (95% CI -5.82 to 10.39) - 
d[3] 2.29 (95% CI -3.01 to 7.58) 2.29 (95% CI -6.94 to 11.51) - 
d[4] 2.29 (95% CI -1.57 to 6.15) 2.29 (95% CI -5.18 to 9.75) - 
d[5] 3.28 (95% CI -2.59 to 9.15) 3.29 (95% CI -6.64 to 13.22) - 
d[6] 0.3 (95% CI -1.11 to 1.71) 0.29 (95% CI -4.77 to 5.35) - 
d[7] -1.21 (95% CI -5.19 to 2.78) -1.21 (95% CI -8.77 to 6.34) - 
Dbar 41.68 42.11 42.7 
pD 11.99 12.41 13.01 
DIC 53.67 54.52 55.7 
 
 
 
Footnotes: d[2] indicates the log odds ratio between treatment 2 and treatment 1, d[3] 
indicates the log odds ratio between treatment 3 and treatment 1, etc.; Dbar indicates the 
posterior mean of the residual deviance; pD indicates the effective number of 
parameters (leverage); DIC indicates the 'Deviance Information Criterion'. A lower 
Dbar indicates a better model fit. However, a model with lower DIC is generally chosen 
to aid better interpretation as it takes the model complexity into account. A lower DIC 
indicates a better model fit. Differences of less than 3 to 5 between the models are not 
considered important. Based on the information, fixed-effect model is the preferred 
model. There is no evidence of inconsistency since the difference in DIC between 
consistency and inconsistency models was not significant. 
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Table 6.33: Pairwise mean differences of the different treatment comparisons for the outcome length of hospital stay. There was no 
evidence of any significant difference in the length of hospital stay between the different treatment strategies.  
 
 
 
V1P3R1 V1P5R1 V2P2R1 V2P4R1 V3P2R1 V3P3R1 
V1P2R1 
MD 2.29;  
95% CI -2.03 to 6.61 
MD 2.29;  
95% CI -3.01 to 7.58 
MD 2.29;  
95% CI -1.57 to 6.15 
MD 3.28;  
95% CI -2.59 to 9.15 
MD 0.3;  
95% CI -1.11 to 1.71 
MD -1.21;  
95% CI -5.19 to 2.78 
V1P3R1 - 
MD 0;  
95% CI -6.84 to 6.83 
MD 0;  
95% CI -5.79 to 5.79 
MD 0.99;  
95% CI -6.3 to 8.28 
MD -1.99;  
95% CI -6.54 to 2.55 
MD -3.5;  
95% CI -9.37 to 2.38 
V1P5R1 - - 
MD 0;  
95% CI -6.55 to 6.55 
MD 0.99;  
95% CI -6.91 to 8.9 
MD -1.99;  
95% CI -7.47 to 3.49 
MD -3.5;  
95% CI -10.12 to 3.13 
V2P2R1 - - - 
MD 0.99;  
95% CI -6.03 to 8.02 
MD -1.99;  
95% CI -6.1 to 2.12 
MD -3.5;  
95% CI -9.04 to 2.05 
V2P4R1 - - - - 
MD -2.98;  
95% CI -9.02 to 3.06 
MD -4.49;  
95% CI -11.58 to 2.61 
V3P2R1 - - - - - 
MD -1.51;  
95% CI -5.73 to 2.72 
 
 
 
Footnotes: MD=mean difference; 95% CI=95% confidence intervals; V1P2R1=no vascular occlusion with clamp-crush and no fibrin; 
V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and no 
fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; V3P3R1=intermittent vascular occlusion 
with CUSA and no fibrin. 
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Figure 6.21: Probability of being best treatment for the outcome length of hospital stay. 
None of the treatment strategies ranked best with more than 90% probability.  
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.22: Cumulative probability of ranks of different treatment strategies for the 
outcome length of hospital stay. These is more than 90% probability that V3P3R1 is 
within the three best treatments (of seven treatments). These is more than 90% 
probability V1P2R1 and V3P2R1 are within the five best treatments. There is 
substantial uncertainty about the treatment strategy with the lowest or highest length of 
hospital stay. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V1P5R1=no vascular occlusion with 
radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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6.3.5.7. ITU stay 
 
Four trials (261 participants) provided data for the network meta-analysis on ITU 
stay.242, 255, 258, 259 The other three trials did not report the ITU stay of their patients.29, 256, 
257 The network plot is shown in Figure 6.23. The results and model-fit of the fixed-
effect model and random-effects model along with the model-fit of the inconsistency 
model is provided in Table 6.34. The between-study standard deviation (tau) was 0. As 
indicated in Table 6.34, the fixed-effect model was preferred based on the DIC 
statistics. There was no evidence of inconsistency in the network. The pairwise MDs for 
the different treatment comparisons are shown in Table 6.35. As shown in Table 6.35, 
there is no evidence of any significant difference in ITU stay between the different 
treatments. As shown in Figure 6.24, none of the treatment strategies ranked best with 
more than 90% probability. Also, none of the treatment strategies ranked worst with 
more than 90% probability. As shown in Figure 6.25, V3P3R1 (intermittent vascular 
occlusion with CUSA and no fibrin) was within the three best treatments (of six 
treatments) with more than 90% probability. V3P2R1 (intermittent vascular occlusion 
with clamp-crush method and no fibrin) was within the four best treatments with a more 
than 90% probability. This suggests that these two treatment strategies may be better 
than other treatment strategies with regards to ITU stay.  
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Figure 6.23: Network plot of the treatment strategies for the outcome ITU stay.  
 
 
 
 
 
 
Footnotes: circles represent the treatment strategy as a node in the network; size of 
circles represents the number of RCTs reporting on the treatment strategy; lines 
represent direct comparisons using RCTs; thickness of lines represents the number of 
RCTs included in each comparison; V1P3R1=no vascular occlusion with CUSA and no 
fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and no 
fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Table 6.34: Results and model fit of the fixed-effect model and random-effects model 
along with the model-fit of the inconsistency model for the outcome ITU stay 
 
 
 
Fixed effect model Random-effects model 
Inconsistency model 
(random-effects) 
d[2] 0 (95% CI -3.32 to 3.33) -0.01 (95% CI -6.56 to 6.55) - 
d[3] 0.01 (95% CI -3.32 to 3.34) -0.01 (95% CI -6.55 to 6.53) - 
d[4] 0.01 (95% CI -4.69 to 4.71) -0.01 (95% CI -9.27 to 9.24) - 
d[5] -2.18 (95% CI -6.38 to 2.01) -2.2 (95% CI -11.19 to 6.79) - 
d[6] -3.68 (95% CI -9.04 to 1.68) -3.7 (95% CI -14.81 to 7.41) - 
Dbar 27.07 27.07 27.07 
pD 9 9 9 
DIC 36.07 36.07 36.06 
 
 
 
Footnotes: d[2] indicates the log odds ratio between treatment 2 and treatment 1, d[3] 
indicates the log odds ratio between treatment 3 and treatment 1, etc.; Dbar indicates the 
posterior mean of the residual deviance; pD indicates the effective number of 
parameters (leverage); DIC indicates the 'Deviance Information Criterion'. A lower 
Dbar indicates a better model fit. However, a model with lower DIC is generally chosen 
to aid better interpretation as it takes the model complexity into account. A lower DIC 
indicates a better model fit. Differences of less than 3 to 5 between the models are not 
considered important. Based on the information, fixed-effect model is the preferred 
model. There is no evidence of inconsistency since the difference in DIC between 
consistency and inconsistency models was not significant. 
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Table 6.35: Pairwise mean differences of the different treatment comparisons for the outcome ITU stay. There is no evidence of any 
significant difference in ITU stay between the different treatments.  
 
 
 
V1P5R1 V2P2R1 V2P4R1 V3P2R1 V3P3R1 
V1P3R1 
MD 0;  
95% CI -3.32 to 3.33 
MD 0.01;  
95% CI -3.32 to 3.34 
MD 0.01;  
95% CI -4.69 to 4.71 
MD -2.18;  
95% CI -6.38 to 2.01 
MD -3.68;  
95% CI -9.04 to 1.68 
V1P5R1 - 
MD 0.01;  
95% CI -4.7 to 4.71 
MD 0.01;  
95% CI -5.75 to 5.76 
MD -2.19;  
95% CI -7.54 to 3.17 
MD -3.68;  
95% CI -9.99 to 2.62 
V2P2R1 - - 
MD 0;  
95% CI -5.76 to 5.76 
MD -2.19; 
95% CI -7.55 to 3.16 
MD -3.69;  
95% CI -10 to 2.62 
V2P4R1 - - - 
MD -2.19;  
95% CI -8.49 to 4.11 
MD -3.69;  
95% CI -10.82 to 3.44 
V3P2R1 - - - - 
MD -1.5;  
95% CI -8.3 to 5.31 
 
 
 
Footnotes: MD=mean difference; 95% CI=95% confidence intervals; V1P3R1=no vascular occlusion with CUSA and no fibrin; 
V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion with clamp-
crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; V3P2R1=intermittent vascular occlusion 
with clamp-crush and no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.24: Probability of being best treatment strategy for the outcome ITU stay. 
None of the treatment strategies ranked best with more than 90% probability.  
 
 
 
 
 
 
Footnotes: V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no 
vascular occlusion with radiofrequency dissecting sealer and no fibrin; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.25: Cumulative probability of ranks of different treatments for the outcome 
ITU stay. V3P3R1 was within the three best treatments (of six treatments) with more 
than 90% probability. V3P2R1 was within the four best treatments with a more than 
90% probability. This suggests that these two treatment strategies may be better than 
other treatment strategies with regards to ITU stay. 
 
 
 
 
 
 
Footnotes: V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no 
vascular occlusion with radiofrequency dissecting sealer and no fibrin; 
V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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6.3.5.8. Operating time 
 
Five trials reported on operating time.242, 256-259  The other two trials did not report the 
operating time of their patients.29, 255 One trial256 reporting on operating time had to be 
excluded from the analysis of this outcome because the treatment strategies it reported 
on were not directly compared with the treatment strategies of the other trials reporting 
on this outcome (i.e. not connected to the network plot for this outcome). Therefore, 
four trials (245 participants) provided data for the network meta-analysis on operating 
time.255, 257-259 The network plot for this outcome is shown in Figure 6.26. The results 
and model-fit of the fixed-effect model and random-effects model along with the model-
fit of the inconsistency model is provided in Table 6.36. The between-study standard 
deviation (tau) was 0.01. As indicated in Table 6.36, the fixed-effect model was 
preferred based on the DIC statistics. The model-fit of the inconsistency model was not 
reported because there was no closed loop in the network. The pairwise MDs for the 
different treatment comparisons are shown in Table 6.37. As shown in Table 6.37, 
people undergoing liver resection by the V3P3R1 method (intermittent vascular 
occlusion with CUSA and no fibrin) had significantly longer operating time than people 
undergoing liver resection by V1P3R1 (no vascular occlusion with CUSA and no fibrin) 
(MD 49.61 min; 95% CrI 29.81 to 69.41). There is no evidence of any significant 
difference in the operating time between the other comparisons. As shown in Figure 
6.27, none of the treatments ranked best with more than 90% probability. As shown in 
Figure 6.28, there is substantial uncertainty about the treatment strategy with least 
operating time. There is more than 90% probability that V1P3R1 (no vascular occlusion 
with CUSA and no fibrin), V2P2R1 (continuous vascular occlusion with clamp-crush 
method and no fibrin), and V3P2R1 (intermittent vascular occlusion with clamp-crush 
method and no fibrin) are within the four best treatments (of five treatments). There is 
substantial uncertainty about the best or worst treatment strategy for operating time. 
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Figure 6.26: Network plot of the treatment strategies for the outcome operating time.  
 
 
 
 
 
 
Footnotes: circles represent the treatment strategy as a node in the network; size of 
circles represents the number of RCTs reporting on the treatment strategy; lines 
represent direct comparisons using RCTs; thickness of lines represents the number of 
RCTs included in each comparison; V1P3R1=no vascular occlusion with CUSA and no 
fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; 
V3P2R1=intermittent vascular occlusion with clamp-crush and no fibrin; 
V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Table 6.36: Results and model fit of the fixed-effect model and random-effects model 
for the outcome operating time. The model-fit of the inconsistency model was not 
reported because there was no closed loop in the network.  
 
 
 
Fixed-effect model Random-effects model 
d[2] 8.41 (95% CI -61.25 to 78.07) 7.94 (95% CI -62.15 to 78.03) 
d[3] 10.42 (95% CI -74.02 to 94.86) 9.33 (95% CI -75.48 to 94.14) 
d[4] 7.25 (95% CI -47.15 to 61.64) 6.83 (95% CI -47.78 to 61.43) 
d[5] 49.61 (95% CI 29.81 to 69.41) 49.35 (95% CI 28.83 to 69.87) 
Dbar 67.38 67.4 
pD 7.47 7.5 
DIC 74.85 74.9 
 
 
 
Footnotes: d[2] indicates the log odds ratio between treatment 2 and treatment 1, d[3] 
indicates the log odds ratio between treatment 3 and treatment 1, etc.; Dbar indicates the 
posterior mean of the residual deviance; pD indicates the effective number of 
parameters (leverage); DIC indicates the 'Deviance Information Criterion'. A lower 
Dbar indicates a better model fit. However, a model with lower DIC is generally chosen 
to aid better interpretation as it takes the model complexity into account. A lower DIC 
indicates a better model fit. Differences of less than 3 to 5 between the models are not 
considered important. Based on the information, fixed-effect model is the preferred 
model. 
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Table 6.37: Pairwise mean differences of the different treatment comparisons for the outcome operating time. Statistically significant 
results are in bold. People undergoing liver resection by the V3P3R1 had significantly longer operating time than people undergoing liver 
resection by V1P3R1. There is no evidence of any significant difference in the operating time between the other comparisons.  
 
 
 
 
V2P2R1 V2P4R1 V3P2R1 V3P3R1 
V1P3R1 
MD 8.41;  
95% CI -61.25 to 78.07 
MD 10.42;  
95% CI -74.02 to 94.86 
MD 7.25;  
95% CI -47.15 to 61.64 
MD 49.61;  
95% CI 29.81 to 69.41 
V2P2R1 - 
MD 2.01;  
95% CI -107.45 to 111.47 
MD -1.17;  
95% CI -89.55 to 87.21 
MD 41.2;  
95% CI -31.22 to 113.61 
V2P4R1 - - 
MD -3.18;  
95% CI -103.61 to 97.26 
MD 39.19;  
95% CI -47.54 to 125.92 
V3P2R1 - - - 
MD 42.37; 
95% CI -15.52 to 100.25 
 
 
 
Footnotes: MD=mean difference; 95% CI=95% confidence intervals; V1P2R1=no vascular occlusion with clamp-crush and no fibrin; 
V1P3R1=no vascular occlusion with CUSA and no fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no fibrin; 
V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.27: Probability of being best treatment strategy for the outcome operating 
time. None of the treatments ranked best with more than 90% probability.  
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Figure 6.28: Cumulative probability of ranks of different treatments for the outcome 
operating time. There is more than 90% probability that V1P3R1, V2P2R1, and 
V3P2R1 are within the four best treatments (of five treatments). V3P3R1 has 76.4% 
probability of ranking the worst treatment strategy for operating time. There is 
substantial uncertainty about the best or worst treatment strategy for operating time. 
 
 
 
 
 
 
Footnotes: V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no 
vascular occlusion with CUSA and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp 
dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-crush and 
no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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6.3.5.9. Outcomes not reported 
 
None of the included trials reported on long-term mortality, quality of life, time needed 
to return to work, and the proportion of people who developed major blood loss. In one 
trial, two participants after undergoing liver resection with V2P4R1 (continuous 
vascular occlusion with sharp dissection and no fibrin sealant) were reoperated due to 
significant post-operative bleeding.259 The authors stated that this was related to the 
sharp dissection method of parenchymal transection.259 In another trial, one participant 
post hepatectomy with V1P3R1 (no vascular occlusion with CUSA and no fibrin 
sealant) underwent re-operation for significant post-operative bleeding.257  
 
 
6.3.5.10. Summary of results 
 
As shown in Figure 6.29, none of the treatments appear clearly superior to others when 
all the outcomes are considered together. We did not give any specific weighting to the 
different outcomes. However, if serious adverse events are considered more important 
than all the outcomes other than mortality, V1P2R1 (no vascular occlusion with clamp-
crush and no fibrin) and V3P2R1 (intermittent vascular occlusion with clamp-crush and 
no fibrin) are better than the other treatment strategies with regards to serious adverse 
events. V1P5R1 (no vascular occlusion with radiofrequency dissecting sealer and no 
fibrin) and V2P2R1 (continuous vascular occlusion with clamp-crush and no fibrin) 
appear to be the worse in terms of serious adverse events. On the other hand, V2P2R1 
(continuous vascular occlusion with clamp-crush and no fibrin) was the best treatment 
with regard to operative blood loss. There does not seem to be much correlation 
between a treatment being best in reducing blood loss and blood transfusion and being 
best in reducing serious adverse events and mortality. V3P3R1 (intermittent vascular 
occlusion with CUSA and no fibrin) provided the best results with regards to hospital 
stay and ITU stay.  
 
All statistically significant results of the pairwise comparisons of the different treatment 
strategies for all outcomes of interest are shown in Table 6.38. The treatment strategies 
with the highest probability of ranking from best to worst (1st to 7th) for the outcomes 
of interest are summarised in Table 6.39. 
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Figure 6.29: Rankogram showing the probability that a treatment strategy is best for each outcome.  
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Table 6.38: Statistically significant pairwise odds ratios (yellow treatment over blue treatment) and mean differences (yellow treatment 
minus blue treatment) of the different treatment strategy comparisons for all outcomes of interest. There was no statistically significant 
difference between the treatment strategies for the outcomes: mortality, proportion of patients transfused, length of hospital stay, and ITU 
stay. Statistically significant results were reported for the outcomes: 1=serious adverse events; 2=quantity of blood transfusion; 3= operative 
blood loss; 4=operating time. 
 
 
 
TREATMENT 
STRATEGIES V1P3R1 V1P5R1 V2P2R1 V2P4R1 V3P2R1 V3P3R1 
V1P2R1 
NO OR 7.13 (1.77 to 28.65)1 MD -130.9 (-255.89 to -5.91)3 NO NO NO 
V1P3R1 
NA NO NO NO NO MD 49.61 (29.81 to 69.41)4 
V1P5R1 
NA NA NO NO NO NO 
V2P2R1 
NA NA NA NO MD 1.2 (0.08 to 2.32)2 NO 
V2P4R1 
NA NA NA NA NO NO 
V3P2R1 
NA NA NA NA NA NO 
 
 
 
Footnotes: OR=odds ratio; MD=mean difference; (95% credible intervals); NA=not applicable; NO=no statistically significant outcomes 
for this pairwise comparison; V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no vascular occlusion with CUSA 
and no fibrin; V1P5R1=no vascular occlusion with radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion 
with clamp-crush and no fibrin; V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; V3P2R1=intermittent vascular 
occlusion with clamp-crush and no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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Table 6.39: Treatment strategies with the highest probability of ranking from best to worst (1st to 7th) for the outcomes of interest.  
 
 
 
TREATMENT 
STRATEGIES 
RANKS 
1st 2nd  3rd  4th  5th  6th  7th  
Mortality V3P3R1 
P=0.412 
V3P3R1  
P=0.236 
V3P2R1 
P=0.236 
V2P2R1 
P= 0.203 
V2P2R1 
P= 0.270 
V1P3R1 
P=0.275 
V1P3R1  
P= 0.469 
Serious adverse events V1P2R1 
P=0.373 
V1P2R1 
P=0.401 
V1P3R1 
P=0.295 
V2P2R1 
P=0.350 
V2P2R1 
P=0.346 
V1P5R1 
P=0.427 
NA 
1 
Proportion of patients 
transfused 
V2P4R1 
P=0.328 
V2P2R1 
P=0.262 
V2P2R1 
P=0.216 
V1P5R1 
P=0.181 
V3P2R1 
P=0.214 
V3P2R1 
P=0.244 
V3P3R1 
P=0.339 
Quantity of blood 
transfusion 
V2P4R1  
P=0.450 
V2P2R1 
P=0.502 
V3P2R1 
P=0.902 
NA 
2 
NA NA NA 
Operative blood loss V2P2R1  
P=0.960 
V1P2R1  
P=0.382 
V1P2R1 
P=0.451 
V2P4R1 
P=0.621 
NA 
3 
NA NA 
Length of hospital stay V3P3R1 
P=0.633 
V1P2R1 
P=0.338 
V3P2R1 
P=0.363 
V1P3R1 
P=0.211 
V2P2R1 
P=0.296 
V2P2R1 
P=0.299 
V2P4R1 
P=0.465 
ITU stay V3P3R1 
P=0.733 
V3P2R1 
P=0.589 
V2P4R1 
P=0.215 
V1P3R1 
P=0.202 
V2P2R1 
P=0.319 
V2P4R1 
P=0.312 
NA 
4 
Operating time V1P3R1 
P=0.395 
V3P2R1 
P=0.304 
V2P2R1 
P=0.287 
V2P4R1 
P=0.230 
V3P3R1 
P=0.764 
NA 
5 
NA 
 
 
Footnotes: P=probability of ranking; NA=not applicable because less than 7 treatments were analysed for this outcome;  
Treatment strategies not included in the analysis for individual outcomes of interest: 1=V3P3R1; 2=V1P2R1, V1P3R1, V1P5R1, V3P3R1; 
3=V1P3R1, V1P5R1, V3P3R1; 4=V1P2R1; 5=V1P2R1, V1P5R1; 
V1P2R1=no vascular occlusion with clamp-crush and no fibrin; V1P3R1=no vascular occlusion with CUSA and no fibrin; V1P5R1=no 
vascular occlusion with radiofrequency dissecting sealer and no fibrin; V2P2R1=continuous vascular occlusion with clamp-crush and no 
fibrin; V2P4R1=continuous vascular occlusion with sharp dissection and no fibrin; V3P2R1=intermittent vascular occlusion with clamp-
crush and no fibrin; V3P3R1=intermittent vascular occlusion with CUSA and no fibrin. 
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6.4 DISCUSSION 
 
This is the first network meta-analysis comparing the common combination of 
techniques aimed at decreasing blood loss during liver resection. The advantages of a 
network meta-analysis have been discussed in section 3.1. Importantly, a network meta-
analysis combines direct evidence within trials and indirect evidence across trials 
facilitating indirect comparisons of multiple interventions that have not been studied in 
a head-to-head fashion. Therefore, a network meta-analysis provides estimates of effect 
sizes for all possible pairwise comparisons that may or may not have been evaluated 
directly against each other, and allows inferences into the comparative effectiveness of 
different treatments to be assessed even if they have not been compared directly in 
individual RCTs. This advantage of a network meta-analysis, allowed, in the current 
study, the comparison of different treatment strategies aiming to decrease blood loss 
during liver resection which have not been compared directly in trials before. 
 
Another novel aspect of this study is the method of combining interventions aiming to 
decrease blood loss during liver resection, which is a new method of addressing the 
problem and can be used in future trials. In order to decrease blood loss during elective 
liver resection, a surgeon may use a particular combination of the different methods of 
vascular occlusion, of the different methods of parenchymal transection, and of the 
different methods of dealing with the raw surface of the liver after transection. 
Together, one can consider this combination of interventions as a treatment strategy. 
There have been no previous studies which attempted to address the problem of blood 
loss during liver resection, through comparison of treatment strategies defined by set 
criteria as in the current study. Future studies comparing interventions aiming to 
decrease blood loss during liver resection should attempt to follow this approach of 
combining interventions aiming to decrease blood loss into clearly defined treatment 
strategies for comparison. 
 
Many published trials did not follow this approach and did not clearly define the 
method of vascular occlusion, parenchymal transection, and dealing with the raw 
surface in their trials. This resulted in the high number of excluded trials, and in the 
difficulty in identifying trials which would meet the inclusion criteria. Thirty six RCTs 
which included comparisons of one aspect of different methods of vascular occlusion or 
parenchymal transection or management of cut surface, had to be excluded because one 
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or more aspects of methods of vascular occlusion or parenchymal transection or 
management of cut surface not being compared were either not stated or were chosen in 
a non-random manner.67, 70, 243, 245, 247, 253, 293-322 An important concern is the source of 
bias of those RCTs excluded, which did not clearly state on one or more aspects of 
methods of vascular occlusion or parenchymal transection or management of the liver 
cut surface. Also, if any of these three methods were chosen in a non-random manner, it 
would remove the element of randomisation of a trial meant to be a RCT, and would 
introduce selection bias into the trial. It is recommended that researchers performing 
future trials to investigate interventions aiming to decrease blood loss during liver 
resection should take this source of bias into consideration in order to minimise their 
study bias. 
 
Due to the few trials that could be included for network meta-analysis in this review and 
the sparsity of data, the individual interventions included in the treatment strategies had 
to be revised into fewer categories by comparing only three methods of vascular 
occlusion (no vascular occlusion, continuous vascular occlusion, or intermittent 
vascular occlusion) and by having only two methods of treatment of the cut surface 
(fibrin sealant used or no fibrin sealant used). Nine RCTs met the inclusion criteria,29, 
242, 253-259 but only seven trials contributed data for the network meta-analysis.29, 242, 255-
259 This is because four treatment strategies in two trials were not connected to the 
network in any of the outcomes. In addition, one arm of a three-arm trial,242 and one 
arm of a four-arm trial255 had to be excluded because the methods of parenchymal 
transection used in these trials (parenchymal transection using bipolar cautery and water 
jet, respectively) were not included in this review. Furthermore, the treatment strategies 
from the trials that used fibrin sealant for management of the raw liver surface could not 
be connected to the network for any outcomes. Thus, the trials included in the network 
meta-analysis varied only in their approaches to vascular exclusion and parenchymal 
transection, and none used fibrin sealant. This is one of the disadvantages of a network 
meta-analysis, which can only compare treatments which are connected through a 
network plot.  
 
Seven trials contributed data for the network meta-analysis,29, 242, 255-259, including 496 
participants randomised to seven different treatment strategies. Overall, no major 
advantage of one combination of techniques was identified over another, and none of 
the treatment strategies showed persistently poor outcomes. It was noted that some end 
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points could be worse and some better with any particular treatment strategy. There was 
no significant difference in mortality between the different treatment strategies. 
Mortality was generally low in all the groups compared to that reported in previous 
studies.330 This may be because of the careful selection of participants included in RCTs 
compared to a consecutive case series330 where the results of all liver resections were 
reported. There was no evidence to suggest that patients of lower anaesthetic risk were 
selectively recruited in the included RCTs. 
 
It is not surprising that a significant reduction in mortality was not demonstrated by any 
of the treatment combinations. Even when the strategies are compared with the 
mortality of 3.5% observed in consecutive published series of liver resection for 
CLM,330 to achieve a 20% relative reduction in mortality (20% relative risk reduction) 
from 3.5% to 2.8%, for a single comparison 20,116 participants are required based on 
type I error of 5%, and type II error of 20%. The number of participants compared 
between treatment strategies in this network meta-analysis was 496. As discussed in 
section 3.2.1, network meta-analyses may be more prone to the risk of random errors 
than direct comparisons.155  Accordingly, a greater sample size is required in indirect 
comparisons than direct comparisons.156 The effective sample size in an indirect 
comparison involving just three treatments is only a fraction of the number of 
participants included in direct comparisons in trials. In the example shown in section 
3.2.1, 10,000 (7,500 + 2,500) participants included in the indirect comparisons was 
equivalent to 1,876 participants in the absence of heterogeneity and 938 participants in 
the presence of moderate heterogeneity. Even without these calculations, it is possible 
to observe that the confidence intervals in this study were very wide, which means a 
significant benefit or harm cannot be ruled out by using different treatments. Given the 
number of participants required to show a significant benefit of treatment with relation 
to mortality and serious adverse events, trials of this magnitude are unlikely to be 
funded. 
 
Regarding serious adverse events, V1P5R1 (no vascular occlusion with radiofrequency 
dissecting sealer and no fibrin) was found to have significantly more serious adverse 
events compared to V1P2R1 (no vascular occlusion with clamp-crush and no fibrin). In 
more simple terms, serious adverse events were significantly higher with 
radiofrequency dissecting sealer compared to clamp-crush method in the absence of 
vascular occlusion or use of fibrin. Also, there was a high probability that V1P2R1 (no 
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vascular occlusion with clamp-crush and no fibrin) and V3P2R1 (intermittent vascular 
occlusion with clamp-crush and no fibrin) treatment strategies were better than other 
treatments with regards to serious adverse events. However, based on wide credible 
intervals, there was considerable uncertainty about the benefit of these methods over the 
methods other than radiofrequency dissecting sealer. Furthermore, the use of these 
treatment strategies was not justified by any of the other outcomes reported. None of 
these treatments significantly reduced ITU or hospital stay, which would be anticipated 
if an intervention made a significant reduction in serious adverse events. The network 
meta-analysis found no evidence of any significant difference in the length of hospital 
stay or ITU stay between any of the different treatment strategies. V3P3R1 (intermittent 
vascular occlusion with CUSA and no fibrin) which had the best outcomes with regards 
to hospital stay and ITU stay, was not included in the analysis for serious adverse 
events. 
 
Intraoperative haemorrhage remains one of the major risks during liver resections, and 
operative blood loss and perioperative blood transfusion are two of the most important 
factors related to perioperative morbidity and mortality.45, 46, 64, 65 People undergoing 
liver resection by V2P2R1 (continuous vascular occlusion with clamp crush method and 
no fibrin) were found to have significantly lower blood loss than those undergoing liver 
resection by V1P2R1 (no vascular occlusion with clamp-crush method and no fibrin). 
Importantly, V2P2R1 (continuous vascular occlusion with clamp-crush method and no 
fibrin) was ranked the best treatment with regards to operative blood loss with more 
than 90% probability.  
 
The current review found no significant difference between the different treatment 
strategies in the proportion of people transfused. There was a significant difference in 
the amount of blood transfusion though, with people undergoing liver resection by 
V3P2R1 (intermittent vascular occlusion with clamp-crush method and no fibrin) 
having significantly higher amounts of blood transfused than people undergoing liver 
resection by V2P2R1 (continuous vascular occlusion with clamp-crush method and no 
fibrin). This result would support the finding of the previous paragraph, that liver 
resection under continuous vascular occlusion with clamp-crush and no fibrin, results in 
lower operative blood loss, and therefore, lower blood transfusion requirements.  
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Despite the statistically significant decrease in operative blood loss and in the amount of 
blood transfusion, V2P2R1 (continuous vascular occlusion with clamp-crush method 
and no fibrin) did not result in a statistically significant decrease in mortality, serious 
adverse events, hospital stay, and ITU stay. Therefore, the decrease in operative blood 
loss and blood transfusion may not be important on the background of no difference in 
clinical outcomes. On the other hand, there may not have been enough patients included 
in the analysis to detect statistical significance of such possible benefit in the clinical 
outcomes reported. There may be a cost benefit from the decrease in blood loss by 
resulting in a decreased need in blood transfusion. Furthermore, operative blood loss 
and perioperative blood transfusion may be used as surrogates for outcome after liver 
resection since it has been demonstrated in the literature that they are two of the most 
important factors affecting perioperative morbidity and mortality.45, 46, 64, 65 
 
Regarding operating time, people undergoing liver resection by the V3P3R1 method 
(intermittent vascular occlusion with CUSA and no fibrin) had significantly longer 
operating time than people undergoing liver resection by V1P3R1 (no vascular 
occlusion with CUSA and no fibrin). This may have an impact on cost effectiveness on 
the background of no benefit in clinical outcomes. Moreover, none of the trials reported 
the quality of life. Quality of life is an important outcome used in assessing the cost-
effectiveness of a treatment in a state-funded healthcare system. Given that the quality 
of life would depend upon various factors including peri-operative complications, 
length of hospital stay, and time to return to work, it is likely to be easier to demonstrate 
a significant difference in the quality of life if the treatment was effective than to 
demonstrate a difference in mortality or serious adverse events. Future RCTs should 
attempt to use a validated quality of life measure to compare treatments aiming to 
decrease operative blood loss. 
 
This is the first network meta-analysis comparing methods aiming to decrease blood 
loss during elective liver resection. Previous pairwise meta-analyses compared 
individual components and concluded that intermittent vascular occlusion may decrease 
blood loss,66 and that the clamp-crush method may decrease blood loss.248 In this 
review, there was no evidence for any significant advantage of different methods of 
liver resection, and the best or worst treatment strategy aiming to decrease blood loss 
and blood transfusion could not be identified with confidence. The differences in 
conclusion with previous published reviews may be because of the exclusion of trials in 
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which the methods were not reported or when the other aspects of liver resection other 
than the component being compared were chosen in a non-random manner.  
 
The major purpose of different methods of liver resection analysed in this review is to 
decrease the blood loss and blood transfusion requirements. Various methods have been 
proposed to achieve this. Some methods do not require any additional equipment (e.g., 
vascular occlusion), while other methods require special equipment (e.g., CUSA or 
radiofrequency dissecting sealer). This review has shown that simple methods, such as 
clamp-crush method, do not appear to result in poorer outcomes than other methods 
which require special equipment. In addition, this review has suggested that special 
equipment like the radiofrequency dissecting sealer may actually result in higher 
morbidity. These results may have important financial implications, and they are useful 
for clinicians and managers, in planning treatment for patients with CLM and in 
minimising expenses in a state-funded healthcare system with limited resources.  
 
Caution is needed when interpreting the results of this network meta-analysis due to the 
low number of trials and participants included. Also, caution is needed due to the 
possible sources of heterogeneity and bias of the included trials. There was no 
significant heterogeneity in all the outcomes other than proportion of blood transfused 
as indicated by the good model-fit achieved by fixed-effect model as compared to the 
random-effects model. The effect estimates were wide with the credible intervals 
overlapping 1 and with either 20% reduction (0.80) or 20% increase (1.20) which can be 
considered a clinically significant effect. Future trials should be adequately powered to 
decrease the risk of random errors.  
 
Clinical and methodological heterogeneity was also assessed by carefully examining the 
characteristics and design of included trials. Major sources of clinical heterogeneity 
included cirrhotic compared to non-cirrhotic livers, and major compared to minor liver 
resections. A large variation in the proportion of major liver resections performed and 
the proportion of cirrhotic livers included in the different treatment strategies compared 
was identified (Table 6.18) and these may be a major source of clinical heterogeneity. 
Unfortunately, due to the low number of studies included in the analysis, a 
metaregression or sensitivity analysis based on the number of major hepatectomies or 
cirrhotic livers, could not be performed. 
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In addition, considerable heterogeneity was anticipated in the way the interventions 
aiming to decrease blood loss were performed. For example, intermittent portal triad 
clamping may be performed with different time periods of occlusion and non-occlusion. 
Likewise, there was no distinction between different maximum periods for continuous 
vascular occlusion.331 Also, for liver outflow obstruction, it was not determined whether 
the suprahepatic inferior vena cava or the hepatic veins were occluded. These practice 
variations might be a source of heterogeneity; however, evidence was insufficient to 
suggest that these variations may affect the outcome. 
 
Moreover, the overall quality of evidence in this review was low. The risk of bias was 
high in all the included trials. Using appropriate methods of randomisation and 
reporting the method of randomisation adequately will decrease selection bias. While 
the surgeons who perform the surgery cannot be blinded to the treatments, it is possible 
to blind the surgeons or healthcare provides who are involved in the day-to-day 
postoperative management of the patient and assess the postoperative outcomes of 
surgery. While it may be difficult to blind the anaesthetist to the treatment groups, using 
objective criteria for transfusion,332 may overcome the problem of bias due to lack of 
blinding with regards to intra-operative blood transfusion. The intensivist involved in 
the post-operative care of the patient can be also blinded. Objective criteria for detection 
of complications along with the postoperative management of the patient by a 
healthcare team not involved in the operation can decrease detection and performance 
bias. With regards to drop-outs, randomising the participants after confirming that the 
tumour can be removed can avoid post randomisation drop-outs due to metastatic 
spread identified at the time of laparotomy. This can decrease attrition bias. In addition, 
reporting all the important clinical outcomes can decrease selective reporting bias. 
 
It should be noted that ischaemic preconditioning was used prior to continuous vascular 
occlusion with a maximum continuous clamp period of 75 minutes in one trial,258 and in 
the other trial ischaemic preconditioning was used in the second half of the trial.259 
Ischaemic preconditioning aims to decrease ischaemic-reperfusion injury, and is the 
temporary occlusion of vessels supplying the liver to ‘condition’ the liver to blood flow 
occlusion before exposing the liver to a prolonged period of blood flow occlusion 
during liver resection. Not controlling for the application of ischaemic preconditioning 
in a trial comparing methods aiming to decrease operative blood loss is a source of bias 
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or heterogeneity between studies, because ischaemic preconditioning itself may affect 
the operative blood loss. 
 
 
 
6.5 CONCLUSIONS 
 
Liver resection is a major surgery with significant mortality and morbidity, and various 
methods have been attempted to decrease blood loss, and therefore, morbidity during 
elective liver resection. This review assessed the comparative benefits and harms of 
different treatment strategies aiming to decrease operative blood loss, by combining the 
methods of vascular occlusion, parenchymal transection, and management of the cut 
surface of the liver that a surgeon would typically use during the operation. A 
significant number of RCTs had to be excluded by the analysis because they did not 
report on all three methods aiming to decrease operative blood loss. There was no 
difference in mortality between the treatment strategies, but there was an increase in the 
proportion of people with serious adverse events when surgery was performed using 
radiofrequency dissecting sealer compared with the standard clamp-crush method in the 
absence of vascular occlusion and fibrin sealant. People undergoing liver resection by 
intermittent vascular occlusion had higher amounts of blood transfused than people with 
continuous vascular occlusion when the parenchymal transection was carried out with 
the clamp-crush method and no fibrin sealant was used for the cut surface. Furthermore, 
people undergoing liver resection using continuous vascular occlusion had lower blood 
loss than people with no vascular occlusion when the parenchymal transection was 
carried out with clamp crush method and no fibrin sealant was used for the cut surface. 
There was no difference between treatment strategies in length of hospital stay or ITU 
stay. Overall, this network meta-analysis found no evidence to prefer one treatment 
strategy over another. Simple methods, such as clamp-crush method, appear to give 
equivalent outcomes to other methods which require special equipment. Further RCTs 
are required to compare methods aiming to decrease blood loss during liver resection 
taking into consideration the possible sources of bias and heterogeneity identified in this 
review. 
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CHAPTER 7 
 
 
REVIEW OF THE LITERATURE TO ASSESS  
WHETHER NOT REPORTING THE PERIOD OF 
FOLLOW-UP IS A SOURCE OF BIAS IN TRIALS 
COMPARING LONG-TERM OUTCOMES 
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7.1 INTRODUCTION 
 
Patients suffering with CLM need to be followed up for a period of years in order to 
determine their outcome and whether the treatment they received was optimal. This 
requirement for long-term follow up is the same for most types of cancer and many 
chronic diseases. To answer some of the important controversies in the management of 
CLM therefore requires long-term prospective clinical trials of the interventions. Trials 
comparing treatments for patients with CLM should follow-up these patients for a 
sufficiently long period of time in order to reach correct conclusions about the efficacy 
or adverse effects of these treatments. Survival and disease recurrence are the main 
outcomes when comparing treatments for CLM, and both require long term follow-up to 
determine which treatments are best. The optimal follow-up period in comparing 
treatments in patients with CLM with regards to survival benefit is not known. While 
following these patients for a long period will provide definitive answers, a long follow-
up period will increase the trial costs and delay the adoption of treatment whereas a 
short period of follow-up may not be informative.  
 
The follow up period required for cancer or a chronic disease is likely to be related to 
the natural history of the disease and its response to treatment. In breast cancer where 
survival overall is excellent but recurrence after 10 years is well described, then very 
long follow up to evaluate new cancer therapies is essential.333-336 In the case of CLM, 
the median survival for untreated disease ranges between six to twelve months.14, 15 
Five-year survival for patients with CLM who undergo liver resection, ranges between 
32 and 58%,19-24, 26, 27, 161 and 10-year survival ranges between 22 and 28%.20-22, 26, 27, 161 
For patients with unresectable CLM, modern systemic neoadjuvant chemotherapy can 
be used to downsize the liver metastases so that an R-0 resection (negative tumour 
margins) is possible, and allows approximately 12.5% of patients with unresectable 
CLM to be rescued by liver surgery.16, 28, 29 Furthermore, the use of modern adjuvant 
chemotherapy for patients with CLM who underwent liver resection with curative 
intent, may result in improvement of disease-free survival and overall survival.30-34 
Given that surgery for CLM produces a good 5-year survival, this is usually taken as the 
most important outcome measure for treatments of CLM.  
 
An example where inadequate follow-up of participants gave an inappropriate answer to 
the treatment of patients undergoing liver resection for CLM was the European 
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Organization for Research and Treatment of Cancer (EORTC) intergroup trial 40983 
(EPOC).32 The EPOC trial demonstrated that perioperative FOLFOX4 (folinic acid, 
fluorouracil, and oxaliplatin) therapy (six cycles before surgery and six cycles after) 
significantly improved 3-year disease free survival compared with surgery alone for 
CLM.32 After this trial was published, perioperative chemotherapy became the standard 
of care for patients with resectable CLM, especially in western countries.337, 338 But, 
after a median follow-up of 8.5 years was carried out for the same trial, no significant 
survival advantage was demonstrated between the perioperative chemotherapy and the 
surgery alone groups.339 
 
During the course of this thesis, it was noted that the period of follow-up was 
inadequately reported by trials comparing time-to-event outcomes for CLM. Chapter 4 
of this thesis discussed whether to perform combined or sequential resection for 
synchronous CLM. Chapter 5 discussed the surgical management and survival of 
patients with CLM and positive hepatic lymph node metastases. For both chapters, the 
long-term outcomes mortality and disease recurrence were important to decide the best 
treatment for patients with CLM. In order to answer correctly the important clinical 
questions raised in both chapters, appropriate periods of follow-up were required by the 
included trials. However, from the studies included in Chapter 4, fourteen studies 
reported the period of follow-up of their participants and 10 studies did not report the 
period of follow-up. For Chapter 5, fourteen studies reported the length of follow-up 
and seven studies did not. Chapters 6 and Appendix of this thesis included trials 
assessing the short-term perioperative outcomes of different interventions aiming to 
decrease blood loss and blood transfusion during liver resection, and different 
interventions aiming to decrease ischaemic-reperfusion injury during liver resection. 
None of the included trials in Chapters 6 and Appendix reported the period of follow-up 
of the participants. Although the outcomes investigated in Chapters 6 and Appendix are 
perioperative short-term outcomes, an argument could be made that any perioperative 
interventions may have a long-term impact on survival and disease recurrence of 
patients with CLM, and the period of follow-up (and hence, reporting the period of 
follow-up) is important in these trials too. Recognising the importance of the duration of 
follow-up in trials comparing treatments for CLM, and recognising that the period of 
follow-up is not adequately reported in these trials, led to the current review.  
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There is a valid concern that that not reporting the overall period of follow-up by trials 
comparing time-to-event outcomes for CLM, would introduce significant bias in these 
trials. Researchers should always try to exclude known sources of bias in their trials, but 
they should also try to identify new possible sources of bias when designing trials. It is 
thought that adequately designed trials comparing treatments for CLM, or for any other 
type of cancer or chronic disease, should clearly report the period of follow-up of the 
participants in the trials. This is important when evaluating outcomes requiring long 
period of time to be assessed, such as survival and disease recurrence. Not reporting the 
period of follow-up may result in bias of the results of comparative trials. 
 
There has been no previous study examining whether reporting or not reporting the 
length of follow-up, in comparative trials investigating time-to-event outcomes, is a 
potential source of bias. The method used in this study was to identify RCTs included in 
meta-analyses published in Cochrane, and compare the time-to-event outcomes of trials 
reporting versus trials not reporting the follow-up period of their participants.  
 
 
7.1.1. Aims of this review 
 
The aim of this review is to investigate whether not reporting the period of follow-up in 
comparative trials comparing time-to-event outcomes (survival, disease recurrence) of 
patients with CLM is a potential source of bias. In order to achieve this aim, the time-to-
event outcomes of trials reporting versus trials not reporting the follow-up period of 
their participants were to be compared. Nevertheless, the number of RCTs published 
comparing time-to-event outcomes of patients with CLM is very limited to allow a 
meta-analysis to be performed.  
 
Because of the limited number of RCTs comparing time-to-event outcomes of patients 
with CLM, in order to meet the aim of this review, RCTs included in meta-analyses 
published in Cochrane on any type of cancer were identified, and the time-to-event 
outcomes of trials reporting versus trials not reporting the follow-up period of their 
participants were compared. 
 
 
 
260 
 
7.2 METHODS 
 
In summary, the methods used in this review to assess whether reporting the period of 
follow-up is a source of bias in trials comparing long-term outcomes were as follows: 
- identify RCTs comparing long-term outcomes (survival and disease recurrence) 
included in meta-analyses published in the Cochrane Library 
- for each meta-analysis identify which included RCTs reported and which RCTs 
did not report the period of follow-up  
- for each meta-analysis compare the long-term outcomes found by RCTs 
reporting and not reporting the period of follow-up, and calculate a relative 
Hazard ratio (HR) for each meta-analysis 
- combine the results of all meta-analyses to test if the long-term outcomes of 
studies reporting and not reporting the period of follow-up were significantly 
different 
 
 
7.2.1 Search strategy 
 
An electronic database search was performed of MEDLINE from PubMed to identify 
published Cochrane meta-analyses of RCTs that contained hazard ratio (HR) in their 
abstract or the outcome(s) that were meta-analysed were ‘disease recurrence’ and/or 
‘survival’. Only MEDLINE from PubMed was searched because Cochrane reviews are 
all available in Pubmed. The latest date for this search was June 23, 2014.The following 
search strategy was used in MEDLINE: Cochrane Database Syst Rev [jo] AND (HR 
[tiab] OR hazard ratio*[tiab] OR mortality OR survival OR recurrence OR time-to) 
AND (2000[pdat] or 2001[pdat] or 2002[pdat] or 2003[pdat] or 2004[pdat] or 
2005[pdat] 2006[pdat] or 2007[pdat] or 2008[pdat] or 2009[pdat] or 2010[pdat] or 
2011[pdat] or 2012[pdat] or 2013[pdat]). 
 
 
7.2.2 Inclusion and exclusion criteria  
 
For studies to be included in this review, they should be meta-analyses of RCTs 
published by The Cochrane Collaboration between 2000 and 2013. The meta-analyses 
261 
 
published in Cochrane were selected because they were considered to be a reliable 
source of data for the included RCTs and allowed us to identify RCTs reporting on the 
same long-term outcomes. They should have reported on HR as the measure of effect 
for the outcomes disease recurrence or mortality (i.e. not used a different measure of 
effect, e.g. odds ratio, risk ratio, etc.). For a meta-analysis to be included in this review, 
at least two of its included trials should have reported the period of follow-up, and at 
least two of its included trials should have not reported the period of follow-up, in order 
to be able to compare the results of the trials reporting and not reporting follow-up for 
each meta-analysis included in this review. 
 
 
7.2.3 Data extraction 
 
From each Cochrane meta-analysis that met the inclusion criteria and for each 
individual RCT included in a meta-analysis that met the inclusion criteria, two review 
authors (Constantinos Simillis and Marios Zertalis) independently extracted the 
following data: name of first author, year of publication, language of publication, 
country and year(s) of conduct of the study, inclusion and exclusion criteria, sample 
size, study design, length of follow-up of the participants if reported, HR and Standard 
Error (SE) for disease recurrence and/or mortality. Any discrepancies between the two 
reviewers were resolved through discussion. The risk of bias of the meta-analyses or the 
individual trials was not assessed because it was not required for this review. 
 
 
7.2.4 Outcomes of interest and definitions 
 
For each meta-analysis the number of included RCTs reporting and not reporting the 
period of follow-up was identified. Each individual RCT, included in the meta-analyses, 
was checked to assess whether the period of follow-up for the patients included in the 
trial was reported or not reported. From individual RCTs the HR with 95% CI, lnHR, 
and SE(lnHR) for the time-to-event outcomes ‘Disease recurrence’ and ‘Mortality’ were 
collected.  
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7.2.5 Statistical analysis 
 
From each meta-analysis included in this review, the trials that reported the period of 
follow-up and the trials that did not report the period of follow-up were identified. 
For each RCT included in a meta-analysis, the HR with 95% CI, lnHR (natural 
logarithm of hazard ratio), and SE(lnHR) (standard error of natural logarithm of hazard 
ratio) for the time-to-event outcomes ‘Disease recurrence’ and "Mortality" were 
collected. Analysis was conducted using Review Manager (RevMan) Version 5.1.138 
 
RevMan was used to calculate the overall effect estimate HR, using inverse-variance 
method and a random-effects model, for ‘Disease recurrence’ and ‘Mortality’ of the 
trials within a meta-analysis that reported the period of follow-up. RevMan was 
similarly used to calculate the overall effect estimate HR for ‘Disease recurrence’ and 
‘Mortality’ of the trials within the same meta-analysis that did not report the period of 
follow-up. Then, using indirect comparison calculations, the relative HR with 95% CI, 
lnHR, and SE(lnHR) were calculated for each meta-analysis, of the trials that reported 
follow-up period [HR of studies that reported follow-up] versus the trials that did not 
report the period of follow-up [HR of studies that did not report follow up]. 
 
Relative HR for each meta-analysis = [HR of studies that reported follow-up] / [HR of 
studies that did not report follow up] 
 
The calculated relative HR for each meta-analysis was then inserted in RevMan to 
calculate the overall effect estimate of the relative HR with 95% CI of all the trials 
reporting period of follow-up versus the trials not reporting the period of follow-up for 
the outcomes ‘Disease recurrence’ and ‘Mortality’. Again, inverse-variance method and 
a random-effects model were used. Statistical significance would suggest a difference in 
outcome between trials reporting period of follow-up and trials not reporting period of 
follow-up, and therefore, not reporting the period of follow-up period would be 
considered to be a source of bias in trials assessing time-to-event outcomes (mortality 
and disease recurrence).  
 
Heterogeneity between meta-analyses was explored using the chi-squared test, with 
significance set at the P<0.10 level, and the amount of heterogeneity was determined by 
263 
 
means of I-square. Graphical exploration with funnel plots was used to evaluate 
publication bias.145, 147 Also, sensitivity analysis was undertaken using the following 
subgroups: meta-analyses published after 2010, and meta-analyses including more 10 or 
more RCTs.   
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7.3 RESULTS 
 
 
7.3.1 Eligible studies 
 
A total of 3,295 references were identified following the search strategy described 
above. No more references were identified for further assessment through scanning 
reference lists of the identified studies. The duplicates excluded were 64. A further 
3,085 clearly irrelevant references were excluded through screening titles and reading 
abstracts. The remaining 146 studies, which were Cochrane meta-analyses, were 
reviewed in detail. From the meta-analyses reviewed in detail, 125 meta-analyses were 
excluded because either less than two of their included trials reported the period of 
follow-up, or less than two of their included trials did not report the period of follow-up, 
or they did not report on HR as the measure of effect for the outcomes disease 
recurrence or mortality. In total, 21 meta-analyses340-360 met the inclusion criteria and 
were included in this review. This is summarised in the study flow diagram in Figure 
7.1. The 21 meta-analyses included in this review reported on 136 RCTs which included 
the follow-up period and 134 RCTs which did not include the follow-up period (Table 
7.1). 
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Figure 7.1: Study flow diagram. 
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Table 7.1: Meta-analyses included in the review with their numbers of trials reporting 
or not reporting on the period of follow-up. 
 
 
Cochrane  
meta-analysis  
first author 
Year of 
publication of 
meta-analysis 
Number of RCTs 
reporting period  
of follow-up 
Number of RCTs  
not reporting period  
of follow-up 
Arnott 2005 2 4 
Bohlius  2008 5 5 
Butters 2010 3 11 
Carrick 2009 10 26 
Diaz-Nieto 2013 17 17 
Furness 2011 12 13 
Gibson 2009 8 5 
Glenny 2010 12 5 
Mao 2012 2 2 
Mocellin  2009 3 7 
Mocellin 2013 15 2 
O'Rourke 2010 5 4 
Oliveri 2011 6 3 
Pidala 2011 10 3 
PORT 2005 5 3 
Ronellenfitsch 2013 10 4 
Rydzewska 2012 3 3 
Steurer 2006 2 2 
Vale 2012 2 6 
van Dalen 2009 2 7 
Wagner 2009 2 2 
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7.3.2 Overall results of meta-analysis 
 
As an example, the analysis performed in this review for the meta-analysis by Diaz-
Nieto et al.344 is shown in Figures 7.2 to 7.9. Similar analysis to the one described here, 
was performed for all the 21 meta-analyses included in this review. Figure 7.2 shows 
the analysis of the RCTs included in the meta-analysis by Diaz-Nieto et al. that reported 
the period of follow-up for the outcome mortality. Figure 7.4 shows the analysis of the 
RCTs included in the meta-analysis by Diaz-Nieto et al. that did not report the period of 
follow-up for the outcome mortality. Figure 7.6 shows the analysis of the RCTs 
included in the meta-analysis by Diaz-Nieto et al. that reported the period of follow-up 
for the outcome disease recurrence, and Figure 7.8 shows the analysis of the RCTs that 
did not report the period of follow-up for the outcome disease recurrence. There was no 
evidence of significant publication bias in the analysis of the RCTs that reported the 
period of follow-up, and the RCTs that did not report the period of follow-up, for the 
outcomes mortality and disease recurrence, as shown in Figures 7.3, 7.5, 7.7, and 7.9.  
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Figure 7.2: Forest plot of the RCTs included in the meta-analysis by Diaz-Nieto et 
al.344 that reported the period of follow-up for the outcome mortality. This forest plot 
shows that RCTs on adjuvant chemotherapy for gastric cancer reporting the follow-up 
period showed a significant benefit to adjuvant chemotherapy regarding survival. 
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Figure 7.3: Funnel plot of the RCTs included in the meta-analysis by Diaz-Nieto et 
al.344 that reported the period of follow-up for the outcome mortality. There was no 
evidence of significant publication bias in the analysis of the RCTs that reported the 
period of follow-up. 
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Figure 7.4:  Forest plot of the RCTs included in the meta-analysis by Diaz-Nieto et 
al.344 that did not report the period of follow-up for the outcome mortality. This forest 
plot shows that RCTs on adjuvant chemotherapy for gastric cancer not reporting the 
follow-up period showed a significant benefit to adjuvant chemotherapy regarding 
survival. These results are similar to Figure 8.2, for the RCTs in the same meta-analysis 
reporting the follow-up period 
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Figure 7.5:  Funnel plot of the RCTs included in the meta-analysis by Diaz-Nieto et 
al.344 that did not report the period of follow-up for the outcome mortality. There was no 
evidence of significant publication bias in the analysis of the RCTs that did not report 
the period of follow-up. 
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Figure 7.6: Forest plot of the RCTs included in the meta-analysis by Diaz-Nieto et 
al.344 that reported the period of follow-up for the outcome disease recurrence. This 
forest plot shows that RCTs on adjuvant chemotherapy for gastric cancer reporting the 
follow-up period showed a significant benefit to adjuvant chemotherapy regarding 
disease recurrence. 
 
 
Figure 7.7: Funnel plot of the RCTs included in the meta-analysis by Diaz-Nieto et 
al.344 that reported the period of follow-up for the outcome disease recurrence. There 
was no evidence of significant publication bias in the analysis of the RCTs that reported 
the period of follow-up. 
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Figure 7.8: Forest plot of the RCTs included in the meta-analysis by Diaz-Nieto et 
al.344 that did not report the period of follow-up for the outcome disease recurrence. 
This forest plot shows that RCTs on adjuvant chemotherapy for gastric cancer not 
reporting the follow-up period showed a significant benefit to adjuvant chemotherapy 
regarding disease recurrence. These results are similar to Figure 8.6, for the RCTs in the 
same meta-analysis reporting the follow-up period 
 
 
 
 
Figure 7.9: Funnel plot of the RCTs included in the meta-analysis by Diaz-Nieto et 
al.344 that did not report the period of follow-up for the outcome disease recurrence. 
There was no evidence of significant publication bias in the analysis of the RCTs that 
did not report the period of follow-up. 
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The relative HR of the trials in the meta-analysis by Diaz-Nieto et al.344 that reported 
the follow-up period versus the trials that did not report the period of follow-up for the 
outcome mortality was calculated to be HR=1, with 95% CI 0.880 to 1.137, with 
LnHR=0, and SE(LnHR)=0.065. The relative HR of the trials that reported the follow-
up period versus the trials that did not report the period of follow-up for the disease 
recurrence was calculated to be HR=1, with 95% CI 0.818 to 1.223, with LnHR=0, and 
SE(LnHR)=0.103. Then, these results for the meta-analysis by Diaz-Nieto et al., 
together with the results of the other included Cochrane meta-analyses, were used in 
RevMan for the overall analysis. 
 
The overall analysis for the outcome mortality is shown in Figure 7.10, and for the 
outcome disease recurrence is shown in Figure 7.11. No significant difference in 
mortality was found between the trials that reported the period of follow-up versus the 
trials that did not report the period of follow-up (HR 0.98, 95% CI 0.93, 1.03; P=0.43), 
with no significant heterogeneity between the included meta-analyses (P=0.69; I-square 
0%). Also, no significant difference in disease recurrence was identified between the 
trials that reported the period of follow-up versus the trials that did not report the period 
of follow-up (HR 0.88, 95% CI 0.77, 1.02; P=0.10), with significant heterogeneity 
between the meta-analyses (P=0.06; I-square 46%). 
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Figure 7.10: Overall analysis for the outcome mortality. There was no significant 
difference in mortality between the trials that reported the period of follow-up versus 
the trials that did not report the period of follow-up. 
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Figure 7.11: Overall analysis for the outcome disease recurrence. There was no 
significant difference in disease recurrence between the trials that reported the period of 
follow-up versus the trials that did not report the period of follow-up, with significant 
heterogeneity between the meta-analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
277 
 
7.3.2 Sensitivity analysis 
 
Sensitivity analysis of more recent Cochrane meta-analyses published after 2010 for the 
outcome mortality is shown in Figure 7.12, and for the outcome disease recurrence is 
shown in Figure 7.13. No significant difference in mortality was found between the 
trials that reported the period of follow-up versus the trials that did not report the period 
of follow-up (HR 0.99, 95% CI 0.92, 1.07; P=0.81), with no significant heterogeneity 
between the meta-analyses (P=0.92; I-square 0%). A significant difference in disease 
recurrence was identified between the trials that reported the period of follow-up versus 
the trials that did not report the period of follow-up (HR 0.88, 95% CI 0.80, 0.98; 
P=0.02), with no significant heterogeneity between the meta-analyses (P=0.62; I-square 
0%). The trials that reported the period of follow-up were found to have a significantly 
lower HR for disease recurrence compared to the trials that did not report the period of 
follow-up. 
 
 
 
Figure 7.12: Sensitivity analysis – meta-analyses published after 2010, for the outcome 
mortality. There was no significant difference in mortality between the trials reporting 
and not reporting the period of follow-up. 
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Figure 7.13: Sensitivity analysis – meta-analyses published after 2010, for the outcome 
disease recurrence. There was a significant difference in disease recurrence between the 
trials that reported the period of follow-up and the trials that did not report the period of 
follow-up. The trials that reported the period of follow-up were found to have a 
significantly lower HR for disease recurrence compared to the trials that did not report 
the period of follow-up. 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity analysis of Cochrane meta-analyses including 10 or more RCTs for the 
outcome mortality is shown in Figure 7.14, and for the outcome disease recurrence is 
shown in Figure 7.15. No significant difference in mortality was demonstrated between 
the trials that reported the period of follow-up versus the trials that did not report the 
period of follow-up (HR 0.97, 95% CI 0.90, 1.03; P=0.32), with no significant 
heterogeneity between the meta-analyses (P=0.22; I-square 24%). A significant 
difference in disease recurrence was found between the trials that reported the period of 
follow-up versus the trials that did not report the period of follow-up (HR 0.81, 95% CI 
0.66, 0.99; P=0.04), with significant heterogeneity between the meta-analyses (P=0.02; 
I-square 70%). The trials that reported the period of follow-up were found to have a 
significantly lower HR for disease recurrence compared to the trials that did not report 
the period of follow-up. 
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Figure 7.14: Sensitivity analysis – meta-analyses including 10 or more trials, for the 
outcome mortality. There was no significant difference in mortality between the trials 
that reported the period of follow-up versus the trials that did not report the period of 
follow-up. 
 
 
 
Figure 7.15: Sensitivity analysis – meta-analyses including 10 or more trials, for the 
outcome disease recurrence. There was a significant difference in disease recurrence 
between the trials that reported the period of follow-up versus the trials that did not 
report the period of follow-up, with significant heterogeneity. The trials that reported 
the period of follow-up were found to have a significantly lower HR for disease 
recurrence compared to the trials that did not report the period of follow-up. 
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7.4 DISCUSSION 
 
The period of follow-up of the participants included in trials comparing treatments for 
cancer or chronic diseases with time to event outcomes may make vital differences to 
the perceived efficacy of treatment. Especially when comparing treatments for cancer 
and reporting on survival and/or cancer recurrence, the length of follow-up of the 
participants is an important factor when assessing the long-term comparative benefits or 
harms of these treatments. This review was performed to analyse studies reporting on 
time-to-event outcomes (survival, disease recurrence) and to investigate if not reporting 
the period of follow-up is a potential source of bias.  
 
Overall, this review did not identify a significant difference in the time-to-event 
outcomes mortality and disease recurrence between trials that reported the period of 
follow-up and trials that did not report the period of follow-up. However, there was a 
trend towards statistical significance for a difference in disease recurrence (P=0.10), 
with trials reporting the period of follow-up to have a lower HR for disease recurrence 
compared to the trials that did not report the period of follow-up. Importantly, 
sensitivity analysis of more recent meta-analyses published after 2010 and larger meta-
analyses including 10 or more RCTs identified significant difference for the outcome 
disease recurrence between trials reporting the period of follow up and trials not 
reporting the period of follow-up. The trials that reported the period of follow-up were 
found to have a significantly lower HR for disease recurrence compared to the trials that 
did not report the period of follow-up. There was no significant heterogeneity for the 
sensitivity analysis of more recent meta-analyses, but there was significant 
heterogeneity for the sensitivity analysis of larger meta-analyses for disease recurrence. 
For the outcome mortality, sensitivity analyses of more recent and larger meta-analyses 
showed no significant difference between trials reporting and trials not reporting the 
duration of follow-up. 
 
The findings may have been statistically significant for the outcome disease recurrence 
and not for mortality, because shorter variations in time of follow-up would affect more 
significantly the outcome disease recurrence, rather than the outcome mortality. The 
significant results for disease recurrence may suggest that not reporting the duration of 
follow-up in a trial comparing treatments for a chronic disease is a possible source of 
bias. Also, the fact that the trials not reporting the period of follow-up were found to 
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have a significantly higher HR suggests that these trials may report a higher HR of the 
intervention versus control more commonly leading to a significant advantage in disease 
free survival for the control group compared to the intervention treatment group, and 
possibly leading more commonly to Type II errors (i.e. not identifying a statistically 
significant difference between the two groups when actually there is a difference). It is 
expected that a trial looking at long-term outcomes would follow the participants long-
enough to assess these outcomes correctly. Reporting the period of follow-up in a trial, 
allows the reader to confirm that participants were followed-up for an adequate period 
of time to make the results of the trial valid. 
 
Heterogeneity was identified for disease recurrence during the overall analysis and 
sensitivity analysis of larger meta-analyses. The most likely cause for heterogeneity is 
that the Cochrane reviews included in this study were investigating different types of 
chronic diseases and different types of cancers, and were comparing different types of 
treatments. Unfortunately, there were no available Cochrane reviews including only 
RCTs reporting on long-term outcomes of treatments for CLM. Other possible causes of 
heterogeneity are trial design and methodology, selection criteria for their participants, 
life expectancy, and rate of recurrence of the chronic diseases investigated by the 
reviews. To minimise bias, for a Cochrane meta-analysis to be included in this study, 
the trials included in the Cochrane review were RCTs, at least two of these trials were 
reporting the period of follow-up, and at least two of the trials were not reporting the 
period of follow up. 
 
Survival and disease recurrence are the primary outcomes in trials comparing different 
treatments in patients with cancer. In order to reach the appropriate conclusions, trials 
comparing treatments for CLM should follow patients long enough to detect differences 
in survival or cancer recurrence. It is important to remember that the conclusions and 
suggestions given by trials comparing treatments for CLM, or any other type of cancer, 
comparing survival and disease recurrence rates, may result in changes in the 
management of patients suffering and dying from cancer. Therefore, as researchers and 
clinicians designing trials, it is our duty to minimise any potential sources of bias and 
attempt to reach valid conclusions from our trials. 
 
There are numerous sources of bias in studies which can result in deviation from the 
truth, in results and inferences. Bias can vary in both magnitude and direction leading to 
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underestimation or overestimation of the observed effect in comparative trials.361 The 
importance of developing a standardised tool for assessing the risk of bias is reflected 
by the number of scales and checklists developed to assess the validity of RCTs.362, 363 
Between 2005 and 2007 the Cochrane Collaboration developed a domain-based 
evaluation for assessing risk of bias.141 The domains included were sequence 
generation, allocation concealment, blinding of participants, personnel and outcome 
assessors, incomplete outcome data, selective reporting, and other sources of bias.210-216. 
These were the domains used in Chapters 5, 6, and 7 to assess the bias of the included 
trials. In this review, the attempt was to raise the concern that not reporting the period of 
follow-up is another source of bias. The observed variability of length of follow-up in 
comparative trials, and the lack of a standardised time-scale during which unfavourable 
outcomes such as recurrence of disease and mortality are identified and reported, can act 
as a potential source of bias in comparative trials. 
 
To answer some of the important controversies in the management of CLM requires 
prospective clinical trials of the interventions. There are different ways to approach the 
question of whether different periods of follow-up can affect the results of comparative 
trials comparing treatments for CLM. One method would be to compare two trials of 
same treatment with different follow-up periods. Another way to address this problem 
would be to compare survival analysis in trials with short-term follow-up versus trials 
with long-term follow-up, e.g. compare outcomes of CLM resection trials with less than 
2-year follow-up period versus 5-year follow-up period. A further method would be to 
compare trials with actuarial survival analysis versus trials with an actual long-term 
follow-up period. 
 
The optimal follow-up period in comparing treatments in patients with CLM with 
regards to survival benefit or disease recurrence is not known. While following these 
patients for a long period will provide definitive answers, a long follow-up period will 
increase the trial costs and delay the adoption of new treatments, while a short period of 
follow-up may not be informative. At present, there is no consensus amongst surgeons 
for the ideal follow-up time period after liver resection for CLM in order to identify 
recurrence of disease. Cox proportional hazard model is generally used to compare 
treatments, but it assumes the hazard ratio of death between the intervention and control 
to be constant over time. This may be untrue in treatments comparing surgery and other 
interventions (e.g. radiofrequency ablation, chemotherapy) in patients suffering with 
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CLM. Deaths in the surgery group usually happen due to two reasons: due to the 
surgery itself and due to the cancer; while the deaths in the other treatments occur 
mainly due to the cancer. Therefore, a short follow-up period will result in bias against 
surgery since mortality is higher earlier on in surgery, whereas there is no early 
mortality in the less invasive treatment. The general belief is however that the patients 
who survive surgery for resection of cancer are more likely to have achieved cure 
compared to non-invasive treatments. But this benefit of survival by surgical treatment 
is unlikely to be seen unless the patients have been followed up for a sufficiently long 
time for the disease to recur and progress.  
 
Further research is needed to identify the required follow-up time period for patients 
with CLM to assess overall survival rates and disease free survival rates. One method to 
determine the optimal follow-up period to assess overall survival rates would be to 
calculate the overall HR and 95% CI at maximal follow-up (i.e. death of the patients) 
and different potential periods of follow-up. This will typically involve calculation of 
HR and 95% CI if every patient was followed for a period of 1 month or until death; if 
every patient was followed for a period of 2 months or until death, and so on. It is 
anticipated that the HR will not change beyond a set period of follow-up; similarly, the 
variance of the HR will not change beyond another set period of follow-up. This set 
period of follow-up for patients with CLM, would be the optimal period of follow-up, 
between short-term and long-term follow-up, at which further follow-up of patients is 
unlikely to alter the effect estimate. Until the required period of follow-up is known, 
trials comparing treatments for patients suffering with CLM should follow-up the 
patients for an adequate period of time, and should report this period of time to allow 
clinicians to critically appraise the results of the trial and to guide researchers into future 
trial design. 
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7.5 CONCLUSIONS 
 
To answer some of the important controversies in the management of CLM requires 
prospective clinical trials of the interventions, with adequate period of follow-up of the 
participants, to assess survival and disease recurrence. The aim of this review was to 
analyse studies reporting on time-to-event outcomes (survival, disease recurrence) in the 
literature and investigate if not reporting the period of follow-up in comparative trials is 
a potential source of bias. Although, overall analysis did not identify a significant 
difference in mortality and disease recurrence between trials that reported the period of 
follow-up and trials that did not report the period of follow-up, sensitivity analysis of 
more recent reviews and larger reviews showed a significant difference in disease 
recurrence between trials reporting, and trials not reporting, the period of follow up. The 
trials that reported the period of follow-up were found to have a significantly lower HR 
for disease recurrence compared to the trials that did not report the period of follow-up. 
The lack of follow-up reporting in comparative trials may be considered as a new source 
of trial bias, and it is expected by trials comparing treatments for patients suffering with 
CLM to follow-up the patients for an adequate period of time, and to report this time 
period. Further research is required into identifying the required follow-up time period 
for patients with CLM to assess overall survival rates and disease free survival rates. 
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CHAPTER 8 
 
 
OVERALL DISCUSSION AND FUTURE STUDIES 
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8.1 OVERALL DISCUSSION AND FUTURE STUDIES 
 
The overall aim of this thesis was to use an evidence based approach to answer some of 
the important controversies in the surgical management of patients suffering with CLM. 
There are many unanswered questions in the surgical management of CLM, and CLM is 
a clinical subject for which there is a vast array of information available in the medical 
literature. An evidence-based approach allows a researcher or clinician to follow formal, 
explicit methods to summarise and analyse the available scientific evidence, evaluate 
and critically appraise the evidence, and attempt to answer important clinical questions 
to improve the care of patients. These important clinical questions may not have been 
possible to be answered confidently by individual studies in the literature due to their 
small individual size or conflicting results.  
 
Meta-analyses have been used in this thesis to help resolve medical controversies or 
uncertainties in the management of patients with CLM. By pooling all the results of the 
individual studies, a meta-analysis has more power than individual studies to identify a 
true difference that exists between treatments, and increases the precision in estimating 
the size of the effects of difference between treatments. Network meta-analyses have 
also been used in this thesis, which is a new method of comparison of different 
treatments, and is ideal when multiple treatments have been used and compared for the 
same disease and outcomes in different head-to-head comparisons. A network meta-
analysis, unlike a standard pairwise meta-analysis, allows comparison of multiple 
treatments simultaneously, and combines direct evidence within trials and indirect 
evidence across trials facilitating indirect comparisons of multiple interventions that 
have not been studied in a head-to-head fashion. 
 
Currently, there is no consensus between surgeons on the optimal timing of liver 
resection for resectable synchronous CLM. A meta-analysis was performed to compare 
the short-term and long-terms outcomes in patients with synchronous CLM undergoing 
combined resection versus sequential resection. The meta-analysis demonstrated that 
combined resection is associated with reduced hospital stay and with comparable 
perioperative mortality and morbidity, operative blood loss, blood transfusion 
requirements, survival rates and recurrence-free rates as sequential resection. The meta-
analysis confirmed that in the presence of limited hepatic disease, combined resection is 
safe and produces the same oncological outcomes as sequential resection for patients 
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with synchronous CLM. However, the findings of this meta-analysis were limited by 
significant differences in metastatic disease severity and location of the primary tumour 
between the combined and sequential resection groups, the retrospective nature of the 
included studies, and the heterogeneity identified between studies. Therefore, well 
designed RCTs are required to compare combined versus sequential resection for 
synchronous CLM with appropriate selection criteria taking into consideration the 
metastatic burden and the location of the primary tumour. Also, future RCTs should 
clearly define the strategy used for the colorectal resection and for the liver resection 
(e.g. laparoscopic or open, or methods used to decrease blood loss), and should follow-
up patients for an adequate period of time to assess mortality and disease recurrence 
rates.  
 
Involvement of hepatic lymph nodes during liver resection is considered as a poor 
prognostic factor, and liver resection for CLM in the presence of hepatic lymph node 
involvement is controversial. A meta-analysis was performed to determine the 
prognostic significance of hepatic lymph node status in patients undergoing 
hepatectomy for CLM and to determine whether hepatectomy is indicated in patients 
with nodal involvement. The meta-analysis demonstrated that the survival rates are 
lower in node positive disease patients compared to node negative disease patients, 
irrespective of: the extent/location of the lymph node dissection, whether the positive 
disease nodes were detected by routine or selective lymphadenectomy, whether the 
nodal involvement was microscopic or macroscopic, and whether adjuvant or 
neoadjuvant chemotherapy was used. The meta-analysis concluded that there is no 
evidence of survival benefit from routine lymphadenectomy, and no proven benefit of 
liver resection with lymphadenectomy for CLM with nodal disease. 
 
The meta-analysis identified a wide variation between studies in the prevalence of 
disease positive lymph nodes for patients undergoing liver resection for CLM. Further 
research is required to identify the reasons for this significant variation, for example, 
patient selection for surgery, the adequacy of pre-operative staging, preoperative and 
intraoperative assessment, the number of nodes examined, the number of sections per 
node, special techniques to identify microscopic involvement, and neoadjuvant 
chemotherapy. Also, there was no data available on the extent of recurrent disease, as it 
would have been important to know how recurrent disease presents (i.e. more extensive 
disease, more liver metastases or more extensive lymphatic dissemination) and whether 
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there would be a difference in recurrent disease between patients who had resection of 
nodal metastases. Furthermore, chemotherapy regiments have significantly improved 
over the years for the treatment of CLM and adjuvant or neoadjuvant chemotherapy 
may play a role in patients undergoing resection where positive lymph nodes have been 
identified. A selected group of patients who responded to neoadjuvant chemotherapy 
with resectable CLM combined with hilar nodal involvement could be considered for an 
RCT offering surgical resection (liver resection and lymphadenectomy) and 
chemotherapy versus chemotherapy alone.  
 
Liver resection is the only curative option for people with CLM but is a major surgical 
procedure with significant mortality and morbidity. Operative blood loss and 
perioperative blood transfusion are two of the most important factors affecting 
perioperative morbidity and mortality during liver resection. A network meta-analysis 
was performed to assess the comparative benefits and harms of different treatment 
strategies aiming to decrease operative blood loss and blood transfusion, by combining 
the methods of vascular occlusion, parenchymal transection, and management of the cut 
surface of the liver that a surgeon would typically use during the operation. No 
differences between treatment strategies were identified in mortality, length of hospital 
stay or ITU stay. There were more serious adverse events when surgery was performed 
using radiofrequency dissecting sealer compared with the standard clamp-crush method 
in the absence of vascular occlusion and fibrin sealant. Liver resection with intermittent 
vascular occlusion resulted in higher amounts of blood transfusion than liver resection 
with continuous vascular occlusion when the parenchymal transection was carried out 
with the clamp-crush method and no fibrin sealant was used for the cut surface. No 
evidence was found to prefer one treatment strategy over another, but simple methods, 
such as clamp-crush method, gave equivalent outcomes to other methods which require 
special equipment.  
 
There was a difficulty in identifying trials which would meet the inclusion criteria for 
the above mentioned network meta-analysis. Many RCTs which included comparisons 
of one aspect of different methods of vascular occlusion or parenchymal transection or 
management of cut surface, had to be excluded because one or more aspects of methods 
of vascular occlusion or parenchymal transection or management of cut surface not 
being compared were either not stated or were chosen in a non-random manner. Due to 
the few trials that could be included for network meta-analysis in this review and the 
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sparsity of data, the individual interventions included in the treatment strategies had to 
be revised into fewer categories. This new method of combining interventions aiming to 
decrease blood loss during liver resection into a treatment strategy can prevent 
methodology bias in future trials. Future trials are needed to compare treatment 
strategies aiming to decrease blood loss and blood transfusion and assess patient 
outcomes after hepatectomy. Such trials should attempt to control other possible 
confounding factors, for example, cirrhotic or non-cirrhotic livers, major or minor liver 
resections, periods of occlusion and non-occlusion of intermittent portal triad clamping, 
maximum periods for continuous vascular occlusion, and use of ischaemic 
preconditioning. 
 
Many interventions have been used to decrease IR injury during liver resection. CRM 
remains by far the most common indication for liver resection. A network meta-analysis 
(in Appendix) was performed to assess the comparative benefits and harms of these 
interventions. No significant difference was identified between the different 
interventions in mortality, quantity of blood transfusion, and ITU stay. Although no 
significant evidence was found to recommend one intervention over another, ischaemic 
preconditioning showed promising results because it resulted in fewer serious adverse 
events, lower operative blood loss, fewer transfusion proportions, and shorter operative 
time compared to other interventions. Ischaemic preconditioning should be used more 
routinely to benefit patients undergoing liver resection for CLM, but further RCTs are 
needed to confirm these important findings, in order to allow ischaemic preconditioning 
to become standard practice during liver resection for CLM.  
 
In addition, a cost effectiveness study should be performed on the use of ischaemic 
preconditioning during liver resection, and a long-term study is required to examine the 
effects ischaemic preconditioning may have on the long-term cancer outcomes. 
Furthermore, sensitivity analysis suggested a decrease in serious adverse events from 
the use of sevoflurane (a volatile anaesthetic), verapamil (a calcium channel blocker), 
and gabexate mesilate (a thrombin inhibitor) during liver resection, and further RCTs 
are required to investigate the possible beneficial effects of these three drugs. This 
network meta-analysis could be used to design future RCTs related to the treatment of 
IR injury during liver resection surgery and the impact of treatment on costs, quality of 
life, and long-term outcomes. 
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To answer some of the important controversies in the management of CLM requires 
prospective clinical trials comparing treatments, with adequate period of follow-up of 
the participants, in order to reach correct conclusions about the long-term comparative 
benefits or harms of these treatments. Survival and disease recurrence are the main 
outcomes when comparing treatments for CLM, and long period of follow-up is 
required to assess these outcomes. During the course of this thesis, it was noted that the 
period of follow-up was inadequately reported by trials comparing time-to-event 
outcomes for CLM, raising the concern that not reporting the period of follow-up would 
introduce significant bias in these trials. A review of the literature was performed to 
analyse studies reporting on time-to-event outcomes (survival, disease recurrence) and 
investigate if not reporting the period of follow-up in comparative trials is a potential 
source of bias. Although overall analysis did not identify a significant difference in 
mortality and disease recurrence between trials that reported the period of follow-up and 
trials that did not report the period of follow-up, sensitivity analysis of more recent 
reviews and larger reviews showed a significant difference in disease recurrence 
between trials reporting and trials not reporting the period of follow up.  
 
Further studies could be performed to assess if different periods of follow-up affect the 
time-to-event outcomes of trials comparing treatments for CLM, and one way to address 
this problem would be to compare survival analysis in trials with short-term follow-up 
versus trials with long-term follow-up, e.g. compare outcomes of CLM resection trials 
with less than 2-year follow-up versus 5-year follow-up. It is expected that trials 
comparing treatments for patients suffering with CLM to follow-up the patients for an 
adequate period of time, and to report this period of time to allow clinicians to critically 
appraise the results of the trial and to guide researchers into future trial design. 
However, the optimal follow-up period in comparing treatments in patients with CLM 
with regards to survival benefit is not known. While following these patients for a long 
period will provide definitive answers, a long follow-up period will increase the trial 
costs and delay the adoption of treatment whereas a short period of follow-up may not 
be informative and result in bias against surgery due to the higher early mortality 
postoperatively compared to non-surgical treatments. Therefore, further research is 
needed to identify the optimal follow-up time period for patients with CLM to assess 
overall survival rates and disease free survival rates. The optimal follow-up period 
could be the time period beyond which there is no significant change in the HR and the 
variance of the HR. 
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Overall, the studies included in this thesis have met the individual objectives set and 
have answered some of the important clinical questions raised in the management of 
patients suffering with CLM. Furthermore, the importance of using optimum follow-up 
period in trials comparing treatments for patients suffering with CLM has been 
demonstrated, and the optimal follow-up period can be determined using analysis of 
existing databases such as those maintained by cancer networks in the UK. There have 
been difficulties in giving some answers and these were identified and discussed. In 
addition, new clinical questions have been raised aiming to promote further research. 
The patient should be the main focus of any clinical research performed and this thesis 
is likely to help in the improvement of care for patients suffering with CLM and 
improvement in design of trials evaluating the management of patients with CLM.  
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APPENDIX 
 
 
EFFECTIVENESS AND CLINICAL OUTCOMES OF 
INTERVENTIONS AIMING TO DECREASE  
HEPATIC ISCHAEMIA-REPERFUSION INJURY  
– A NETWORK META-ANALYSIS 
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A.1 INTRODUCTION 
 
Over the years, indications for liver resection have been broadened and the number of 
liver resections performed has increased. The number of liver resections performed in 
the UK has more than doubled over the last 10 years, from around 1000 in 2003 to 
around 2400 in 2013.61, 62 The most common reason for liver resection is the resection 
of colorectal liver metastases (CLM). Other common reasons are HCC, 
cholangiocarcinoma, and benign liver tumours.45, 46 Liver resection is a major surgical 
procedure with significant mortality of around 4% and morbidity of around 40%.45, 46, 63 
 
As discussed in Chapter 6, intraoperative haemorrhage remains one of the major risks 
during liver resections, and operative blood loss and perioperative blood transfusion are 
two of the most important factors associated with higher perioperative morbidity and 
mortality.45, 46, 64, 65 Therefore, minimizing blood loss is of major importance, and 
methods of hepatic vascular occlusion have been developed over the years to reduce the 
bleeding during elective liver resection.66 Clamping of the portal pedicle (Pringle 
manoeuver, i.e. clamping the hepatic artery and portal vein) is the oldest and 
commonest method of hepatic vascular occlusion and can be performed either 
continuously or intermittently during the parenchymal resection.67-69 Nuzzo et al. 
compared liver resections with or without hepatic pedicle clamping and found 
significantly fewer people requiring blood transfusion and significantly lower number 
of blood units transfused per patient when hepatectomy was performed with hepatic 
pedicle clamping.235 A meta-analysis of trials comparing hepatic vascular occlusion 
versus no vascular occlusion demonstrated no difference in mortality, liver failure, or 
other morbidities.66 The blood loss was significantly lower in vascular occlusion 
compared with no vascular occlusion, but the liver enzymes were significantly elevated 
in the vascular occlusion group compared with no vascular occlusion.66 Furthermore, as 
shown in Chapter 6, liver resection under continuous vascular occlusion with clamp-
crush and no fibrin, results in lower operative blood loss and lower blood transfusion 
requirements. 
 
However, hepatic vascular occlusion, along with mobilization and retraction of the liver 
during surgery, causes ischaemia and reperfusion (IR) injury to the future liver remnant 
(FLR). IR injury is more applicable to liver transplantation than liver resection, as 
majority of liver resection for CLM can be achieved without major vascular clamping, 
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and the part of the liver concerned intraoperatively from IR injury is resected/removed.  
Nonetheless, CLM remains by far the most common indication for liver resection. In 
cases of extensive liver resection where the FLR is small and in cases when the liver 
suffers from chronic diseases, such as cirrhosis, IR injury can greatly increase the risk of 
post-operative liver failure resulting in significant increase in postoperative mortality 
and morbidity.73, 74, 76, 77 Patients with cirrhotic liver and hepatic steatosis are more 
sensitive to IR injury than patients with normal liver.76, 77  
 
IR injury of the liver involves a number of mechanisms. Ischaemia followed by 
reperfusion results in the activation of Kupffer cells (liver macrophages) and 
polymorphonucleocytes, production of reactive oxygen species and pro-inflammatory 
cytokines, and induction of endothelial cell surface adhesion molecules, resulting in 
microvascular hypo-perfusion and liver parenchymal damage.72-74, 364  
 
Many interventions have been used to decrease IR injury associated with prolonged 
duration of vascular occlusion with the intention of decreasing perioperative mortality 
and morbidity.72 These interventions include hypothermia,78 mechanical interventions 
such as ischaemic preconditioning (the mechanism by which brief periods of hepatic 
vascular occlusion followed by reperfusion results in the ability of the liver to withstand 
a subsequent prolonged period of ischaemia),67, 68, 76, 79, 80 ischaemic post-conditioning (a 
prolonged period of ischaemia during liver resection is followed by brief periods of 
hepatic ischaemia and reperfusion),81 and pharmacological interventions such as anti-
oxidants,82 prostaglandins,83 steroids,84, 85 different anaesthetic agents,86, 87 treatments to 
increase hepatocellular glycogen,88, 89 and treatments affecting the cardiovascular 
system.90, 91 These interventions can be used alone or in combination.  
 
Hypothermia during liver resection reduces the metabolic rate and slows the 
degeneration of cellular components due to IR injury.78 The interventions aiming to 
increase hepatic glycogen are thought to reduce postoperative liver dysfunction by 
achieving better perioperative glucose control, by preserving liver glycogen stores 
which may protect hepatocytes, and possibly through an antiapoptotic effect.88, 365 The 
anti-inflammatory and immune modulating effects of steroids through cytokine release 
modulation are thought to be the mechanisms through which steroids may decrease 
surgical stress and IR injury.84, 85, 366, 367  
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Each individual category of interventions has been systematically reviewed 
independently previously,71, 364, 368 and no individual therapy is considered a current 
standard practice. One pairwise meta-analysis included five RCTs and compared one 
pharmacological agent versus another pharmacological agent (a total of 9 different 
pharmacological agents).71 A statistical meta-analysis of the data with forest plots could 
not be performed since indirect comparisons of the different pharmacological agents 
were not possible with a pairwise meta-analysis.71 Another meta-analysis included 
fifteen RCTs comparing any pharmacological agent versus placebo or no 
pharmacological agent.364 Similar to the previous meta-analysis, indirect comparisons 
between groups could not be performed, and the only statistical meta-analysis 
performed was of four RCTs comparing Prostaglandin E1 versus placebo and a meta-
analysis of three studies comparing Methylprednisolone versus control.364 This 
deficiency of pairwise meta-analyses (to allow only pairwise direct comparisons) has 
been addressed by the current network meta-analysis.  
 
There has been no previous network meta-analysis comparing different techniques 
aimed at decreasing IR injury during elective liver resection. A network meta-analysis is 
ideal for this topic, where multiple interventions have been used and compared for the 
same disease and outcomes in different head-to-head comparisons. Network meta-
analysis combines direct evidence within trials and indirect evidence across trials.132 
Therefore, it allows comparison of interventions that may or may not have been 
evaluated directly against each other, and allows the relative effectiveness of different 
treatments to be assessed even if they have not been compared directly in individual 
RCTs. Furthermore, with a network meta-analysis we can visualize and interpret a wide 
picture of the evidence and calculate treatment rankings with probabilities.  
 
 
A.1.1. Aims of this review 
 
The aim of this network meta-analysis is to identify the best methods to decrease IR 
injury during elective liver resection and to compare the benefits and harms of different 
interventions aimed at decreasing IR injury. 
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A.2 METHODS 
 
 
A.2.1. Search strategy 
 
A comprehensive literature search using a combination of free-text terms and controlled 
vocabulary when applicable was performed of the following databases: MEDLINE, 
EMBASE, Science Citation Index Expanded, CENTRAL in The Cochrane Library, and 
World Health Organization International Clinical Trials Registry Platform. Detailed 
search strategy is provided in Table A.1. The “related articles” function from PubMed 
was used to broaden the search, and all abstracts, studies, and citations scanned were 
reviewed. The references of the identified trials were also searched to identify additional 
trials for inclusion. No restrictions were made based on language, publication year, or 
publication status. The latest date for this search was October 6, 2013. 
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Table A.1: Detailed search strategy. 
 
Database Time 
span 
Search strategy 
Cochrane Central Register of Controlled 
Trials (CENTRAL) in The Cochrane 
Library (Wiley) 
October 
6th 2013 
#1 (ischaemia OR ischaemia OR ischaemic OR 
ischaemic OR reperfusion) AND (injury OR injuries OR 
damage OR damages) 
#2 MeSH descriptor Reperfusion Injury explode all 
trees 
#3 (#1 OR #2) 
#4 liver OR hepatic OR hepato* 
#5 MeSH descriptor Liver explode all trees 
#6 (#4 OR #5) 
#7 resection OR resections OR segmentectomy OR 
segmentectomies 
#8 (#6 AND #7) 
#9 hepatectomy OR hepatectomies 
#10 MeSH descriptor Hepatectomy explode all trees 
#11 (#8 OR #9 OR #10) 
#12 (#3 AND #11) 
MEDLINE (Pubmed) 
January 
1947 to 
October 
2013 
(((ischaemia OR ischaemia OR ischaemic OR ischaemic 
OR reperfusion) AND (injury OR injuries OR damage 
OR damages)) OR "Reperfusion Injury"[Mesh])) AND 
(((liver OR hepatic OR hepato* OR "liver"[MeSH]) 
AND (resection OR resections OR segmentectomy OR 
segmentectomies)) OR hepatectomy OR hepatectomies 
OR "hepatectomy"[MeSH]) AND ((randomised 
controlled trial [pt] OR controlled clinical trial [pt] OR 
randomised [tiab] OR placebo [tiab] OR drug therapy 
[sh] OR randomly [tiab] OR trial [tiab] OR groups 
[tiab]) NOT (animals [mh] NOT humans [mh])) 
EMBASE (OvidSP) 
Janurary 
1974 to 
October 
2013 
1 (ischaemia or ischaemia or ischaemic or ischaemic or 
reperfusion).af. 
2 (injury or injuries or damage or damages).af. 
3 1 and 2 
4 exp Reperfusion Injury/ 
5 3 or 4 
6 (liver or hepatic or hepato*).af. 
7 (resection or resections or segmentectomy or 
segmentectomies).af. 
8 6 and 7 
9 (hepatectomy or hepatectomies).af. 
10 exp Liver Resection/ 
11 8 or 9 or 10 
12 5 and 11 
13 exp crossover-procedure/ or exp double-blind 
procedure/ or exp randomised controlled trial/ or single-
blind procedure/  
14 (random* OR factorial* OR crossover* OR cross 
over* OR cross-over* OR placebo* OR double* adj 
blind* OR single* adj blind* OR assign* OR allocat* 
OR volunteer*).af. 
15 13 OR 14 
16 12 AND 15 
Science Citation Index Expanded January #1 TS=((ischaemia OR ischaemia OR ischaemic OR 
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(http://www.webofknowledge.com/ 
?DestApp=WOS) 
1945 to 
October 
2013 
ischaemic OR reperfusion) AND (injury OR injuries OR 
damage OR damages)) 
#2 TS=((liver OR hepatic OR hepato*) AND (resection 
OR resections OR segmentectomy OR 
segmentectomies) OR hepatectomy OR hepatectomies) 
#3 TS=(random* OR rct* OR crossover OR masked OR 
blind* OR placebo* OR meta-analysis OR systematic 
review* OR meta-analys*) 
#4 #1 AND #2 AND #3 
World Health Organization International 
Clinical Trials Registry Platform search 
portal 
(http://apps.who.int/trialsearch/Default.aspx) 
October 
2013 
liver resection OR hepatectomy 
 
 
 
 
 
 
 
 
 
A.2.2. Inclusion and exclusion criteria 
 
Only RCTs were considered for this network meta-analysis. Studies of other design 
were excluded because of the risk of bias in such trials and because it is not appropriate 
to perform network meta-analysis on studies of different study designs as this will make 
the interpretation more difficult.132, 148 The patients included in the analysis underwent 
elective liver resection, with or without vascular occlusion, and irrespective of the 
number of segments removed or the nature of the background liver, i.e. normal or 
cirrhotic liver. RCTs that assessed one or more of the following interventions were 
included in this review: hypothermia, ischaemic preconditioning, ischaemic 
postconditioning, and pharmacological interventions. The following comparisons were 
included: RCTs comparing one of the interventions in the above list with surgery alone, 
and RCTs comparing one of the interventions in the above list with another intervention 
in the above list. 
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A.2.3. Outcomes of interest 
 
The comparative effectiveness of different interventions aimed to decrease liver IR 
injury during elective liver resection, was assessed for the following outcomes. 
 
Primary outcomes:  
 Mortality, evaluated both as short term (30-day mortality or in-hospital 
mortality) and long term (at maximal follow-up). 
 Serious adverse events, defined as any event that would increase mortality, is 
life-threatening, requires inpatient hospitalization, results in a single organ or multi-
organ dysfunction, or requires surgical, endoscopic or radiological intervention to treat 
it. Serious adverse events correspond to Grade III or above of the Clavien-Dindo 
classification and in cases where the authors did not classify the severity of adverse 
events this classification was followed.250, 251 
 Quality of life. 
 
Secondary outcomes:  
 Blood transfusion requirements (proportion of patients requiring red cell or 
whole blood heterologous blood transfusion, proportion of patients with major blood 
loss, and mean quantity of units of blood transfusion). 
 Operative blood loss in millilitres (mL). 
 Operative time in minutes (min). 
 Length of hospital stay in days. 
 Length of ITU stay in days. 
 Time needed to return to work in days. 
 
 
A.2.4. Data collection 
 
The trials for inclusion were independently identified by two review authors 
(Constantinos Simillis and Thalia Afxentiou) by screening the titles and abstracts. Full 
text was sought for any references which were identified for potential inclusion by at 
least one of the authors, and made further selection for inclusion based on the full text. 
The following data were independently extracted by two review authors (Constantinos 
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Simillis and Francis Robertson) from each study: first author, year of publication, 
language of publication, country, year(s) of conduct of the trial, inclusion and exclusion 
criteria, sample size, participant characteristics (such as age, sex, underlying disease, 
comorbidity, number of participants with liver cirrhosis, number of participants with 
liver steatosis, number of participants undergoing major versus minor liver resection), 
study design including details of the intervention aimed at decreasing IR injury, 
outcomes described above, risk of bias. Any discrepancies were resolved through 
discussion, and if there was still a disagreement between authors, the final decision was 
taken by a more senior co-author.  
 
The risk of bias of the included trials was assessed based on the following bias risk 
domains: allocation sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessors, incomplete outcome data, 
selective outcome reporting, and vested interest bias. These bias risk domains were 
chosen based on the advice of The Cochrane Collaboration,141 the Cochrane Hepato-
Biliary Group Module,209 and reviews published on network meta-analyses.132 For 
further details on the individual bias risk domains please review section 5.2.4. For each 
of these risk domains of bias the studies were categorized as low risk, uncertain risk, 
and high risk of bias. A trial was considered at low risk of bias if the trial was assessed 
as at low risk of bias for all domains. Trials with uncertain risk of bias or with high risk 
of bias for one or more domains were considered trials with high risk of bias. 
 
 
A.2.5. Statistical analysis 
 
For detailed description of the statistical methods used to perform the network meta-
analysis please review section 3.2.1. For binary outcomes (mortality, serious adverse 
events, total adverse events, patients requiring blood transfusion), the OR was 
calculated. For continuous outcomes (quantity of blood transfused, operative blood loss, 
hospital stay, ITU stay, operating time), the MD was calculated. For each outcome of 
interest, Stata/IC 11 (StataCorp LP) was used to draw a network plot of all the 
interventions assessed for that specific outcome Any interventions that were not 
connected to the other interventions through the network plot were excluded from the 
analysis of that outcome. 
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A Bayesian network meta-analysis was conducted using the Markov chain Monte Carlo 
method in WinBUGS 1.4. The treatment contrast (OR for binary outcomes, MD for 
continuous outcomes) for any two interventions was modelled as a function of 
comparisons between each individual intervention and an arbitrarily selected reference 
group.152 The reference group in this network meta-analysis was selected to be the 
surgery alone group. The network analysis was performed as per the guidance from the 
NICE DSU documents.153 
 
The treatment contrasts (OR for binary outcomes and MD for continuous outcomes) of 
the different treatments in relation to the reference treatment, the deviance residuals, 
number of effective parameters, and DIC for fixed-effect model and random-effects 
model were reported for each outcome. Also, the parameters used to assess the model fit 
(i.e. deviance residuals, number of effective parameters, and DIC) for the inconsistency 
model were reported. The 95% credible intervals (CrI, similar to 95% confidence 
intervals in a frequentist method of meta-analysis) were calculated, and the effect 
estimates and associated 95% CrI for each pairwise comparison were reported in a table.  
 
The probability that a treatment ranks as the best treatment for each outcome of interest, 
was presented in graphs. The cumulative probability of the treatment ranks (i.e. the 
probability that the treatment is within the top two, the probability that the treatment is 
within the top three, etc.) was also presented in graphs. In addition, the probability that 
each treatment is best for each of the different outcomes (rankogram) was plotted, 
which is generally considered more informative.158, 159 The residual deviance and DIC 
were used for assessing between study heterogeneity as per the guidance from the NICE 
DSU Technical Support Documents.153, 154 The between trial SD was also calculated 
and reported if the random-effects model was used.  
 
An overall network meta-analysis was performed to compare eight classes of active 
interventions aimed at decreasing IR injury along with a control group which was 
surgery alone. The classes of intervention were grouped based on their mechanism of 
action. A sensitivity network meta-analysis was performed to compare all the individual 
interventions included in each class of intervention aimed at decreasing IR injury. 
Another sensitivity network meta-analysis was performed to compare the following 4 
larger groups: surgery alone, hypothermia, ischaemic preconditioning, and all 
pharmacological interventions. A third sensitivity network meta-analysis was performed 
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comparing only the pharmacological interventions aiming to decrease IR injury. Finally, 
a metaregression was performed based on the percentage of cirrhotic livers included in 
each trial, and a metaregression based on the percentage of major liver resections 
performed in each trial. 
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A.3 RESULTS 
 
A.3.1. Eligible studies 
 
A total of 522 references were identified through electronic searches of CENTRAL 
(n=60), MEDLINE (n=154), EMBASE (n=119), and Science Citation Index Expanded 
(n=189). Two hundred and thirty-two duplicates between databases were excluded. A 
further 220 clearly irrelevant references were excluded through screening titles and 
reading abstracts. Seventy references were retrieved for further assessment. Five more 
references were identified for further assessment through scanning reference lists of the 
identified RCTs. Thirty one references were excluded after reviewing the studies in 
detail, and in total, 44 RCTs met the inclusion criteria.67, 68, 76, 78-80, 82-91, 258, 317, 365-367, 369-
391 This is summarised in the study flow diagram Figure A.1.  
 
A total of 2457 patients undergoing liver resection were included in the analysis. The 
included trials with the treatments compared, total number of patients in each trial, and 
the number with percentages of cirrhotic livers and major liver resections that took 
place in each trial, are shown in Table A.2. Major hepatectomy was defined as a right or 
left hemihepatectomy (or lobectomy), or extended hemihepatectomy (or extended 
lobectomy), or resection of three or more liver segments according to Couinaud.392 All 
trials were at high risk of bias according to the criteria set in this analysis. The risk of 
bias in the included trials is summarised in Figure A.2 and Figure A.3. 
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Figure A.1: Study flow diagram. 
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Table A.2: Summary of studies included, showing treatments compared, total number of patients in each study, and the number with 
percentages of cirrhotic livers and major resections (NR=not reported). 
 
Study Treatments compared  Total 
N 
Cirrhotic 
n (%) 
Major 
resections 
Study Treatments compared  Total 
N 
Cirrhotic 
n (%) 
Major 
resections 
Aldrighetti 
2006 
steroids vs  
no steroids 
73 26 (36) 53 (73) Li 
 2004b 
ulinastatin vs 
no ulinastatin 
31 27 (87) NR 
Arkadopoulos 
2009 
ischaemic preconditioning vs 
no ischaemic preconditioning 
84 0 (0) 84 (100) Liang 
 2002 
ischaemic preconditioning vs 
no ischaemic preconditioning 
29 25 (86) NR 
Azoulay  
2006 
ischaemic preconditioning vs  
no ischaemic preconditioning 
60 1 (2) 60 (100) Luo 
2009 
pre-storing glycogen vs  
no pre-storing glycogen 
38 19 (50) NR 
Bartels  
2004 
vitamin E vs  
placebo 
47 0 (0) 33 (70) Marx 
2000 
dopexamine vs  
dopamine 
19 NR 19 (100) 
Beck-Schimmer 
2008 
sevoflurane vs  
no sevoflurane 
64 0 (0) 28 (44) Muratore 
2003 
steroids vs  
no steroids 
53 16 (30) 28 (53) 
Beck-Shimmer 
2012 
sevoflurane vs  
no sevoflurane 
65 0 (0) 26 (40) Nickkholgh 
2011 
melatonin vs  
placebo 
36 0 (0) 36 (100) 
Cerwenka 
1999 
antioxidant multivitamin vs  
no antioxidant multivitamin 
50 13 (26) NR Nuzzo 
2004 
ischaemic preconditioning vs  
no ischaemic preconditioning 
42 0 (0) 14 (33) 
Chouker 
2004 
ischaemic preconditioning vs  
no ischaemic preconditioning 
33 0 (0) 9 (27) Orii 
2000 
amrinone vs placebo vs 
 prostaglandin E1 
45 45 (100) 0 (0) 
Clavien 
2003 
ischaemic preconditioning vs  
no ischaemic preconditioning 
100 0 (0) 75 (75) Petrowsky 
2006 
ischaemic preconditioning vs  
no ischaemic preconditioning 
73 0 (0) 44 (60) 
Hahn 
2011 
ischaemic preconditioning vs  
no ischaemic preconditioning 
160 60 (38) 117 (73) Petrowsky 
2010 
pentoxifylline vs  
placebo 
101 0 (0) 95 (94) 
Hassanain 
2013 
insulin vs  
no insulin 
56 NR 17 (30) Scatton 
2011 
ischaemic preconditioning vs  
no ischaemic preconditioning 
84 0 (0) 78 (93) 
Hayashi 
2011 
steroids vs  
no steroids 
200 NR 26 (13) Settaf 
2001 
trimetazidine  vs  
placebo 
76 NR NR 
Heizmann 
2008 
ischaemic preconditioning vs  
no ischaemic preconditioning 
61 0 (0) 19 (31) Shirabe 
1996 
OKY046 vs  
no OKY 046 
17 NR 9 (53) 
Hou 
2009 
ischaemic preconditioning vs  
no ischaemic preconditioning 
48 24 (50) 16 (33) Smyrniotis 
2006 
ischaemic preconditioning vs  
no ischaemic preconditioning 
54 0 (0) 27 (50) 
Ishikawa 
2010 
branched chain amino acids vs  
no branched chain amino acids 
24 10 (42) 5 (21) Su 
2013 
S-adenosyl-L-methionine vs  
no S-adenosyl-L-methionine 
79 79 (100) 33 (42) 
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Table A.2 continued 
Kawano 
2005 
prostaglandin E1 vs  
no prostaglandin E1 
22 NR NR Sugawara 
1998 
prostaglandin E1 vs  
placebo 
24 24 (100) 0 (0) 
Kim 
1996 
hypothermia vs  
no hypothermia 
20 NR 18 (90) Tang 
2007 
hepatocellular glycogen vs  
no hepatocellular glycogen 
57 50 (88) 38 (67) 
Kim 
2002 
gabexate mesilate vs   
no gabexate mesilate 
66 31 (47) 27 (41) Tsujii 
2012 
sivelestat vs  
placebo 
50 NR NR 
Kim 
2006 
gabexate mesilate vs   
no gabexate mesilate 
60 40 (67) 51 (75) Vriens 
2002 
allopurinol vs  
no allopurinol 
16 0 (0) NR 
Kostopanagiotou 
2006 
mannitol vs  
placebo 
30 NR 28 (93) Winbladh 
2012 
ischaemic preconditioning vs  
no ischaemic preconditioning 
32 NR 16 (50) 
Laviolle 
2012 
propofol vs  
desflurane 
30 0 (0) 22 (73) Xia 
2009 
verapamil vs  
no verapamil 
86 86 (100) 51 (59) 
Li 
2004a 
ischaemic preconditioning vs  
no ischaemic preconditioning 
29 29 (100) 4 (14) Yamashita 
2001 
steroids vs  
no steroids 
33 0 (0) 11 (33) 
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Figure A.2: Risk of bias summary - review authors' judgments about each risk of bias 
item for each included study. 
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Figure A.3: Risk of bias graph - review authors' judgments about each risk of bias item 
presented as percentages across all included studies. 
 
 
 
 
 
 
 
 
 
A.3.2. Overall network meta-analysis 
 
A network meta-analysis was performed to compare the eight classes of active 
interventions aimed at decreasing IR injury along with the control group undergoing 
liver resection surgery alone. The classes of intervention were grouped based on their 
mechanism of action: hypothermia, ischaemic preconditioning, antioxidants, 
immunomodulators, cardiovascular modulators, steroids, treatments that increase 
hepatic glycogen, and miscellaneous therapies (Table A.3). None of the included trials 
compared ischaemic postconditioning to any other active or inactive intervention. Also, 
none of the included trials reported on quality of life, time needed to return to work, and 
the proportion of people who developed major blood loss. 
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Table A.3: Types of network meta-analyses performed. An overall network meta-
analysis was performed to compare eight classes of active interventions aimed at 
decreasing IR injury along with a control group which was surgery alone. The classes of 
intervention were grouped based on their mechanism of action. The first sensitivity 
network meta-analysis was performed to compare all the individual interventions 
included in each class of intervention aimed at decreasing IR injury. The second 
sensitivity network meta-analysis was performed to compare the following 4 larger 
groups: surgery alone, hypothermia, ischaemic preconditioning, and all pharmacological 
interventions. 
 
 
 
Overall network 
meta-analysis 
First sensitivity 
network meta-analysis 
Second sensitivity 
network meta-analysis 
Surgery alone Surgery alone Surgery alone 
Hypothermia Hypothermia Hypothermia 
Ischaemic preconditioning Ischaemic preconditioning Ischaemic preconditioning 
 
 
Antioxidants 
Allopurinol  
 
 
 
 
 
 
 
 
 
 
Pharmacological interventions 
Antioxidant multivitamin 
Mannitol 
Melatonin 
Propofol 
Vitamin E 
 
 
 
Cardiovascular modulators 
Amrinone 
Dopamine 
Dopexamine 
OKY 046 
Trimetazidine 
Verapamil 
 
Immunomodulators 
Gabexate mesilate 
Pentoxifylline 
Prostaglandin E1 
Sivelestat 
Increased hepatic glycogen Insulin 
Pre-storing hepatocellular glycogen 
Steroids Steroids 
 
 
Miscellaneous 
Branched chain amino acids 
Desflurane 
S-adenosyl-L-methionine 
Sevoflurane 
Ulinastatin 
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A.3.2.1. Mortality 
 
Thirty five trials (2132 participants; 9 groups) provided data on mortality for the 
network meta-analysis.68, 76, 78-80, 83-86, 91, 258, 317, 365, 366, 369-371, 373-385, 387-391 Nine trials, 67, 
82, 87-90, 367, 372, 386 reporting on 325 patients, did not clearly report on mortality, and were 
excluded from the analysis of this outcome. In total, there were 28 deaths in the 
included trials giving an overall mortality of 1.3%. The fixed-effect model was 
preferred based on the DIC statistics, and there was no evidence of inconsistency in the 
networks. The pairwise odds ratios of the different treatment comparisons for mortality 
are shown in Table A.4. As shown in Table A.4, no significant difference was identified 
in mortality between the different groups. The network plot for mortality is shown in 
Figure A.4. Figures A.5 and A.6 show that none of the interventions was conclusively 
the best with more than 90% probability and there was a lot of uncertainty about the 
treatment with the lowest or highest mortality. 
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Table A.4: Pairwise odds ratios (OR) of the different treatment comparisons for the outcome mortality (95% confidence intervals). There 
was no statistically significant difference between the intervention groups for the outcome mortality. 
 
 
Mortality Pairwise Odds Ratios 
  Hypothermia Ischaemic 
preconditioning 
Antioxidants Immuno-
modulators 
Cardiovascular 
modulators 
Steroids Increased 
hepatic 
glycogen 
Miscellaneous 
Surgery alone OR 1 
(0-496.69) 
OR 0.79 
(0.35-1.74) 
OR 0.57 
(0.1-3.22) 
OR 0.48 
(0.13-1.81) 
OR 0.94 
(0.11-7.77) 
OR 1.04 
(0.07-15.27) 
OR 0.92 
(0-447.76) 
OR 0.91 
(0.15-5.55) 
Hypothermia - OR 0.79 
(0-413.14) 
OR 0.57 
(0-359.89) 
OR 0.49 
(0-278.45) 
OR 0.94 
(0-665.79) 
OR 1.04 
(0-905.42) 
OR 0.93 
(0-5933.5) 
OR 0.91 
(0-588.75) 
Ischaemic 
preconditioning 
- - OR 0.72 
(0.11-4.88) 
OR 0.62 
(0.13-2.88) 
OR 1.2 
(0.12-11.44) 
OR 1.32 
(0.08-21.83) 
OR 1.18 
(0-600.13) 
OR 1.16 
(0.16-8.37) 
Antioxidants - - - OR 0.85 
(0.1-7.56) 
OR 1.65 
(0.11-25.48) 
OR 1.83 
(0.07-44.89) 
OR 1.63 
(0-1002.19) 
OR 1.6 
(0.13-19.67) 
Immuno-
modulators 
- - - - OR 1.94 
(0.16-23.38) 
OR 2.14 
(0.11-42.78) 
OR 1.9 
(0-1061.41) 
OR 1.88 
(0.2-17.61) 
Cardiovascular 
modulators 
- - - - - OR 1.1 
(0.04-33.77) 
OR 0.98 
(0-677.45) 
OR 0.97 
(0.06-15.64) 
Steroids - - - - - - OR 0.89 
(0-755.15) 
OR 0.88 
(0.03-22.41) 
Increased hepatic 
glycogen 
- - - - - - - OR 0.99 
(0-618.89) 
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Figure A.4: Network plot of the interventions aiming to decrease hepatic IR injury for 
the outcome mortality.  
 
 
 
 
 
 
Footnotes: circles represent the intervention as a node in the network; size of circles 
represents the number of RCTs reporting on the intervention; lines represent direct 
comparisons using RCTs; thickness of lines represents the number of RCTs included in 
each comparison, also represented by the numbers in this figure. 
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Figure A.5: Probability of being best intervention for the outcome mortality. None of 
the interventions ranked best with more than 90% probability, and there is a lot of 
uncertainty about the intervention with the lowest mortality. 
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Figure A.6: Cumulative probability of ranks of different interventions aiming to 
decrease hepatic IR injury for the outcome mortality. There is substantial uncertainty 
about the intervention with the lowest or highest mortality. 
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A.3.2.2. Serious adverse events 
 
Twenty-eight trials (1887 participants; 8 groups) provided data on serious adverse 
events for the network meta-analysis. 68, 76, 79, 80, 82-84, 86, 91, 258, 317, 365-367, 369-373, 375, 376, 378, 
379, 381, 382, 384, 385, 387 In total, there were 325 people with serious adverse events in the 
included trials (17.2%). Although some patients develop multiple serious adverse events 
postoperatively, most RCTs included in this review reported this outcome as number of 
patients rather than as number of events, therefore, this outcome was analysed as 
number of patients. The fixed-effect model was preferred based on the DIC statistics, 
and there was no evidence of inconsistency. The pairwise odds ratios of the different 
treatment comparisons for serious adverse events are shown in Table A.5. Significantly 
fewer serious adverse events were found in the ischaemic preconditioning group 
compared to the surgery alone group. Also, there were significantly fewer serious 
adverse events in the cardiovascular modulators group compared to surgery alone. 
Furthermore, significantly fewer serious adverse events were found in the miscellaneous 
group compared to surgery alone, ischaemic preconditioning, immunomodulators, and 
steroids. There was no significant difference in the other comparisons. The network plot 
for serious adverse events is shown in Figure A.7. Figures A.8 and A.9 show that 
although the miscellaneous group had a high probability (74.2%) of being the best 
treatment for this outcome, none of the treatment groups ranked best with more than 
90% probability and there was a lot of uncertainty about the treatment group with the 
fewest or with the most serious adverse events.  
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Table A.5: Pairwise odds ratios (OR) of the different treatment comparisons for the outcome serious adverse events (95% confidence 
intervals). Statistically significant results are in bold. Significantly fewer serious adverse events were found in the ischaemic 
preconditioning group compared to the surgery alone group. Also, there were significantly fewer serious adverse events in the 
cardiovascular modulators group compared to surgery alone. Furthermore, significantly fewer serious adverse events were found in the 
miscellaneous group compared to surgery alone, ischaemic preconditioning, immunomodulators, and steroids. There was no significant 
difference in the other comparisons.  
 
 
  Ischaemic 
preconditioning 
Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Increased hepatic 
glycogen 
Miscellaneous 
Surgery alone OR 0.66 
(0.44- 0.98) 
OR 0.54 
(0.19-1.47) 
OR 0.67 
(0.34-1.34) 
OR 0.39 
(0.18-0.87) 
OR 0.66 
(0.32-1.35) 
OR 0.69 
(0.15-3.08) 
OR 0.21 
(0.08-0.51) 
Ischaemic 
preconditioning 
- OR 0.82 
(0.27-2.43) 
OR 1.03 
(0.46-2.28) 
OR 0.6 
(0.24-1.47) 
OR 1 
(0.44-2.28) 
OR 1.05 
(0.22-4.96) 
OR 0.31 
(0.12-0.85) 
Antioxidants - - OR 1.26 
(0.37-4.28) 
OR 0.73 
(0.2-2.67) 
OR 1.23 
(0.36-4.25) 
OR 1.28 
(0.21-7.85) 
OR 0.38 
(0.1-1.5) 
Immunomodulators - - - OR 0.58 
(0.2-1.68) 
OR 0.98 
(0.36-2.65) 
OR 1.02 
(0.2-5.34) 
OR 0.31 
(0.1-0.96) 
Cardiovascular 
modulators 
- - - - OR 1.68 
(0.57-4.92) 
OR 1.75 
(0.32-9.62) 
OR 0.53 
(0.16-1.76) 
Steroids - - - - - OR 1.04 
(0.2-5.51) 
OR 0.31 
(0.1-0.99) 
Increased hepatic 
glycogen 
- - - - - - OR 0.3 
(0.05-1.74) 
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Figure A.7: Network plot of the interventions aiming to decrease hepatic IR injury for 
the outcome serious adverse events.  
 
 
Surgery_alone
Ischaemic_preconditioning
Antioxidants
Immunomodulators
Cardiovascular_modulators
Steroids
Increased_hepatic_glycogen
Miscellaneous
 
 
 
 
Footnotes: circles represent the intervention as a node in the network; size of circles 
represents the number of RCTs reporting on the intervention; lines represent direct 
comparisons using RCTs; thickness of lines represents the number of RCTs included in 
each comparison. 
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Figure A.8: Probability of being best intervention for the outcome serious adverse 
events. Although the miscellaneous group had a high probability (74.2%) of being the 
best intervention for this outcome, none of the interventions ranked best with more than 
90% probability.  
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Figure A.9: Cumulative probability of ranks of different interventions aiming to 
decrease hepatic IR injury for the outcome serious adverse events. There was a lot of 
uncertainty about the intervention group with the fewest or with the most serious 
adverse events. 
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A.3.2.3. Proportion of patients transfused perioperatively  
 
Seventeen trials provided data on the proportion of patients transfused for the network 
meta-analysis.67, 68, 76, 78-80, 85, 87, 91, 258, 317, 365, 366, 371, 372, 382, 384 One trial87 was excluded 
because it was not connected to the network plot with the other studies for this outcome. 
Thus leaving 16 trials 67, 68, 76, 78-80, 85, 91, 258, 317, 365, 366, 371, 372, 382, 384 for analysis on 1261 
participants divided in 7 groups. In total, 294 people had blood transfusion in the 
included trials (23.3%). The fixed-effect model was preferred and there was no evidence 
of inconsistency in the network. The results of the pairwise comparisons for the 
proportion of patients transfused are provided in Table A.6. Pairwise comparison of the 
interventions showed that significantly fewer people were transfused with ischaemic 
preconditioning compared to steroids. There was no significant difference in the other 
comparisons. The network plot for the proportion of patients transfused is shown in 
Figure A.10. Figures A.11 and A.12 show that none of the treatment groups ranked best 
with more than 90% probability and there was a lot of uncertainty about the treatment 
group with the lowest and with the highest proportion of patients transfused. 
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Table A.6: Pairwise odds ratios (OR) of the different treatment comparisons for the outcome proportion of patients transfused (95% 
confidence intervals). Statistically significant results are in bold. Pairwise comparison of the interventions showed that significantly fewer 
people were transfused with ischaemic preconditioning compared to steroids. There was no significant difference in the other comparisons.  
 
 
  Hypothermia Ischaemic 
preconditioning 
Immunomodulators Cardiovascular 
modulators 
Steroids Increased hepatic glycogen 
Surgery alone OR 3.16 
(0.35-28.39) 
OR 0.71 
(0.5-1) 
OR 0.65 
(0.18-2.29) 
OR 0.84 
(0.35-2.01) 
OR 1.63 
(0.79-3.38) 
OR 1.02 
(0.35-3.03) 
Hypothermia - OR 0.22 
(0.02-2.07) 
OR 0.21 
(0.02-2.59) 
OR 0.27 
(0.02-2.83) 
OR 0.52 
(0.05-5.23) 
OR 0.32 
(0.03-3.76) 
Ischaemic 
preconditioning 
- - OR 0.92 
(0.25-3.41) 
OR 1.19 
(0.46-3.05) 
OR 2.31 
(1.03-5.18) 
OR 1.45 
(0.46-4.54) 
Immunomodulators - - - OR 1.29 
(0.28-6.02) 
OR 2.51 
(0.58-10.81) 
OR 1.58 
(0.3-8.36) 
Cardiovascular 
modulators 
- - - - OR 1.94 
(0.62-6.08) 
OR 1.22 
(0.3-4.93) 
Steroids - - - - - OR 0.63 
(0.17-2.32) 
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Figure A.10: Network plot of the interventions aiming to decrease hepatic IR injury for 
the outcome proportion of patients transfused. 
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Footnotes: circles represent the intervention as a node in the network; size of circles 
represents the number of RCTs reporting on the intervention; lines represent direct 
comparisons using RCTs; thickness of lines represents the number of RCTs included in 
each comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
323 
 
 
 
Figure A.11: Probability of being best intervention for the outcome proportion of 
patients transfused. None of the interventions ranked best with more than 90% 
probability. 
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Figure A.12: Cumulative probability of ranks of different interventions aiming to 
decrease hepatic IR injury for the outcome proportion of patients transfused. There was 
a lot of uncertainty about the intervention group with the lowest and with the highest 
proportion of patients transfused. 
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A.3.2.4. Perioperative quantity of blood transfusion per patient 
 
Fourteen trials76, 79, 80, 86, 258, 260, 365, 369, 371, 375, 377, 381, 382, 387 (901 participants;  7 groups) 
were included in the analysis. On average, 1.4 units of blood were transfused per 
patient. The random-effects model was preferred based on the DIC statistics, and there 
was no evidence of inconsistency in the networks. The results of the pairwise 
comparisons for the quantity of blood transfusion per patient are provided in Table A.7. 
No evidence of any significant difference in quantity of blood transfusion per patient 
between the different interventions was found with pairwise comparison. The network 
plot for quantity of blood transfusion per patient is shown in Figure A.13. Figures A.14 
and A.15 show that none of the treatment groups ranked best with more than 90% 
probability and there was a lot of uncertainty about the treatment group with the lowest 
and with the highest quantity of blood transfusion per patient. 
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Table A.7: Pairwise mean differences (MD) of the different treatment comparisons for the outcome quantity of blood transfusion per 
patient (95% confidence intervals). There was no statistically significant difference between the intervention groups for this outcome. 
 
 
  Ischaemic 
preconditioning 
Antioxidants Immunomodulators Steroids Increased hepatic 
glycogen 
Miscellaneous 
Surgery alone  MD -0.1 
(-1.28 to 1.08) 
MD -0.54 
(-2.45 to 1.37) 
MD -0.31 
(-3.57 to 2.96) 
MD -0.79 
(-3.96 to 2.38) 
MD -0.01 
(-3.15 to 3.14) 
MD 0.01 
(-3.13 to 3.16) 
Ischaemic 
preconditioning  
- MD -0.44 
(-2.69 to 1.81) 
MD -0.21 
(-3.68 to 3.27) 
MD -0.69 
(-4.07 to 2.7) 
MD 0.09 
(-3.26 to 3.45) 
MD 0.11 
(-3.25 to 3.47) 
Antioxidants  - - MD 0.23 
(-3.55 to 4.02) 
MD -0.25 
(-3.95 to 3.45) 
MD 0.53 
(-3.15 to 4.21) 
MD 0.55 
(-3.13 to 4.23) 
Immunomodulators  - - - MD -0.48 
(-5.04 to 4.07) 
MD 0.3 
(-4.24 to 4.83) 
MD 0.32 
(-4.22 to 4.85) 
Steroids  - - - - MD 0.78 
(-3.68 to 5.24) 
MD 0.8 
(-3.67 to 5.27) 
Increased hepatic 
glycogen  
- - - - - MD 0.02 
(-4.43 to 4.46) 
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Figure A.13: Network plot of the interventions aiming to decrease hepatic IR injury for 
the outcome quantity of blood transfusion per patient. 
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Footnotes: circles represent the intervention as a node in the network; size of circles 
represents the number of RCTs reporting on the intervention; lines represent direct 
comparisons using RCTs; thickness of lines represents the number of RCTs included in 
each comparison. 
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Figure A.14: Probability of being best intervention for the outcome quantity of blood 
transfusion per patient. None of the intervention groups ranked best with more than 
90% probability. 
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Figure A.15: Cumulative probability of ranks of different interventions aiming to 
decrease hepatic IR injury for the outcome quantity of blood transfusion per patient. 
There was a lot of uncertainty about the intervention group with the lowest and with the 
highest quantity of blood transfusion per patient. 
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A.3.2.5. Operative blood loss during hepatectomy 
 
Thirty six trials67, 68, 76, 78-80, 83-86, 88, 89, 91, 258, 317, 365-367, 371-376, 378-381, 383, 384, 386-391 (2114 
participants; 9 groups) were included in the analysis of this outcome. The fixed-effect 
model was preferred based on the DIC statistics, and there was no evidence of 
inconsistency in the networks. The results of the pairwise comparisons for operative 
blood loss are provided in Table A.8. The pairwise mean differences of the different 
group comparisons showed that ischaemic preconditioning had significantly lower 
operative blood loss compared to all other groups and ranked best treatment with 99.7% 
probability. Also, the surgery alone group had significantly lower operative blood loss 
compared to all other groups except ischaemic preconditioning, and ranked second best 
treatment with 98.5% probability. In addition, the steroids and increased hepatic 
glycogen groups were found to have significantly lower operative blood loss compared 
to the hypothermia, immunomodulators, and miscellaneous groups. The network plot 
for operative blood loss is shown in Figure A.16. Figures A.17 and A.18 show that 
ischaemic preconditioning ranked best, and surgery alone ranked second best, with 
more than 90% probability for operative blood loss. There was substantial uncertainty 
about the intervention ranking worst for operative blood loss. 
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Table A.8: Pairwise mean differences (MD) of the different treatment comparisons for the outcome operative blood loss (95% confidence 
intervals). Statistically significant results are in bold. The pairwise mean differences of the different group comparisons showed that 
ischaemic preconditioning had significantly lower operative blood loss compared to all other groups. Also, the surgery alone group had 
significantly lower operative blood loss compared to all other groups except ischaemic preconditioning. In addition, the steroids and 
increased hepatic glycogen groups were found to have significantly lower operative blood loss compared to the hypothermia, 
immunomodulators, and miscellaneous groups.  
 
 
  Hypothermia Ischaemic 
preconditioning 
Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Increased  
hepatic glycogen 
Miscellaneous 
Surgery alone  MD 247.1 
(143.59 to 
350.61) 
MD -35.97 
(-53.76 to -18.18) 
MD 207 
(34.13 to 379.87) 
MD 231.2 
(145.82 to 316.58) 
MD 142.2 
(61.59 to 222.81) 
MD 69.32 
(21.46 to 117.18) 
MD 92.04 
(25.2 to 158.88) 
MD 209.7 
(118.32 to 301.08) 
Hypothermia  - MD -283.07 
(-388.09 to -
178.05) 
MD -40.1 
(-241.59 to 
161.39) 
MD -15.9 
(-150.08 to 118.28) 
MD -104.9 
(-236.1 to 26.3) 
MD -177.78 
(-291.82 to -
63.74) 
MD -155.06 
(-278.27 to -31.85) 
MD -37.4 
(-175.47 to 100.67) 
Ischaemic 
preconditioning  
- - MD 242.97 
(69.19 to 416.75) 
MD 267.17 
(179.96 to 354.38) 
MD 178.17 
(95.62 to 260.72) 
MD 105.29 
(54.23 to 156.35) 
MD 128.01 
(58.85 to 197.17) 
MD 245.67 
(152.58 to 338.76) 
Antioxidants  - - - MD 24.2 
(-168.61 to 217.01) 
MD -64.8 
(-255.54 to 125.94) 
MD -137.68 
(-317.06 to 41.7) 
MD -114.96 
(-300.3 to 70.38) 
MD 2.7 
(-192.84 to 198.24) 
Immunomodula
tors  
- - - - MD -89 
(-206.42 to 28.42) 
MD -161.88 
(-259.76 to -64) 
MD -139.16 
(-247.59 to -30.73) 
MD -21.5 
(-146.56 to 103.56) 
Cardiovascular 
modulators  
- - - - - MD -72.88 
(-166.63 to 20.87) 
MD -50.16 
(-154.88 to 54.56) 
MD 67.5 
(-54.35 to 189.35) 
Steroids  - - - - - - MD 22.72 
(-59.49 to 104.93) 
MD 140.38 
(37.23 to 243.53) 
Increased 
hepatic 
glycogen  
- - - - - - - MD 117.66 
(4.45 to 230.87) 
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Figure A.16: Network plot of the interventions aiming to decrease hepatic IR injury for 
the outcome operative blood loss. 
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Footnotes: circles represent the intervention as a node in the network; size of circles 
represents the number of RCTs reporting on the intervention; lines represent direct 
comparisons using RCTs; thickness of lines represents the number of RCTs included in 
each comparison. 
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Figure A.17: Probability of being best intervention for the outcome operative blood 
loss. Ischaemic preconditioning ranked best intervention for this outcome with 99.7% 
probability.  
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Figure A.18: Cumulative probability of ranks of different interventions aiming to 
decrease hepatic IR injury for the outcome operative blood loss. Ischaemic 
preconditioning ranked best intervention with more than 90% probability, and surgery 
alone ranked second best with more than 90% probability for operative blood loss. 
There was substantial uncertainty about the intervention ranking worst for operative 
blood loss. 
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A.3.2.6. Postoperative length of hospital stay 
 
Twenty seven trials (1610 participants; 7 groups) provided data for the network meta-
analysis on IR therapy during hepatectomy and the length of hospital stay.68, 76, 79, 80, 83-
86, 91, 258, 317, 366, 367, 369, 370, 372, 374, 377-381, 384, 385, 387, 390, 391 The average length of hospital 
stay was 13.7 days. The random-effects model was preferred based on the DIC statistics 
and there was no evidence of inconsistency in the networks. The results of the pairwise 
comparisons for length of hospital stay are provided in Table A.9. The pairwise 
comparison of the interventions showed ischaemic preconditioning to have significantly 
shorter length of hospital stay compared to surgery alone by 2.3 days (MD -2.34, 95% 
CrI -4.06 to -0.62). There was no significant difference in the other comparisons. The 
network plot for length of hospital stay is shown in Figure A.19. Figures A.20 and A.21 
show that no class of interventions ranked best with more than 90% probability, and 
there was substantial uncertainty regarding the best or worst group of interventions for 
this outcome. 
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Table A.9: Pairwise mean differences (MD) of the different treatment comparisons for the outcome length of hospital stay (95% 
confidence intervals). Statistically significant results are in bold. The pairwise comparison of the interventions showed ischaemic 
preconditioning to have significantly shorter length of hospital stay compared to surgery alone. There was no significant difference in the 
other comparisons.  
 
 
  Ischaemic 
preconditioning 
Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Miscellaneous 
Surgery alone  MD -2.34 
(-4.06 to -0.62) 
MD -1.94 
(-5.54 to 1.66) 
MD -0.61 
(-4.73 to 3.5) 
MD -2.56 
(-5.71 to 0.58) 
MD -0.3 
(-3.3 to 2.69) 
MD -2.67 
(-6.39 to 1.04) 
Ischaemic 
preconditioning 
- MD 0.41 
(-3.59 to 4.4) 
MD 1.73 
(-2.73 to 6.19) 
MD -0.22 
(-3.81 to 3.37) 
MD 2.04 
(-1.41 to 5.49) 
MD -0.33 
(-4.43 to 3.76) 
Antioxidants  - - MD 1.33 
(-4.14 to 6.79) 
MD -0.63 
(-5.41 to 4.16) 
MD 1.63 
(-3.05 to 6.32) 
MD -0.74 
(-5.91 to 4.44) 
Immunomodulators  - - - MD -1.95 
(-7.13 to 3.23) 
MD 0.31 
(-4.78 to 5.4) 
MD -2.06 
(-7.61 to 3.48) 
Cardiovascular 
modulators 
- - - - MD 2.26 
(-2.08 to 6.6) 
MD -0.11 
(-4.98 to 4.76) 
Steroids  - - - - - MD -2.37 
(-7.14 to 2.4) 
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Figure A.19: Network plot of the interventions aiming to decrease hepatic IR injury for 
the outcome length of hospital stay. 
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Footnotes: circles represent the intervention as a node in the network; size of circles 
represents the number of RCTs reporting on the intervention; lines represent direct 
comparisons using RCTs; thickness of lines represents the number of RCTs included in 
each comparison. 
 
 
 
 
 
 
 
 
 
 
338 
 
 
 
Figure A.20: Probability of being best intervention for the outcome length of hospital 
stay. No class of interventions ranked best with more than 90% probability. 
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Figure A.21: Cumulative probability of ranks of different interventions aiming to 
decrease hepatic IR injury for the outcome length of hospital stay. There was substantial 
uncertainty regarding the best or worst class of interventions for this outcome. 
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A.3.2.7. Postoperative length of ITU stay 
 
Twelve trials (736 participants; 4 groups) provided data for the network meta-analysis 
on IR therapy during hepatectomy and postoperative ITU stay.68, 76, 79, 80, 258, 317, 369, 371, 
377, 381, 384, 387 The average length of ITU stay was 2 days. The random-effects model was 
preferred based on the DIC statistics, and there was no evidence of inconsistency. The 
results of the pairwise comparisons for ITU stay are provided in Table A.10. Pairwise 
comparison of the groups showed no evidence of any significant difference in the ITU 
stay. The network plot for ITU stay is shown in Figure A.22. Figures A.23 and A.24 
show that none of the intervention groups ranked best or worst with more than 90% 
probability. 
 
 
 
 
 
 
Table A.10: Pairwise mean differences (MD) of the different treatment comparisons for 
the outcome ITU stay (95% confidence intervals). There was no statistically significant 
difference between the intervention groups for the outcome ITU stay.  
 
 
  Ischaemic 
preconditioning 
Antioxidants Immunomodulators 
Surgery alone  MD -0.81 
(-2.1 to 0.47) 
MD -0.43 
(-2.95 to 2.09) 
MD -0.99 
(-4.5 to 2.52) 
Ischaemic 
preconditioning  
- MD 0.39 
(-2.44 to 3.21) 
MD -0.18 
(-3.91 to 3.56) 
Antioxidants  - - MD -0.56 
(-4.88 to 3.75) 
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Figure A.22: Network plot of the interventions aiming to decrease hepatic IR injury for 
the outcome ITU stay. 
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Footnotes: circles represent the intervention as a node in the network; size of circles 
represents the number of RCTs reporting on the intervention; lines represent direct 
comparisons using RCTs; thickness of lines represents the number of RCTs included in 
each comparison. 
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Figure A.23: Probability of being best intervention for the outcome ITU stay. None of 
the interventions ranked best with more than 90% probability, and there is lot of 
uncertainty about the intervention with the shortest ITU stay. 
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Figure A.24: Cumulative probability of ranks of different interventions aiming to 
decrease hepatic IR injury for the outcome ITU stay. None of the intervention groups 
ranked best or worst with more than 90% probability, and there was substantial 
uncertainty about the best or worst intervention for this outcome. 
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A.3.2.8. Operative time for liver resection 
 
Thirty two trials67, 68, 76, 79, 80, 83, 84, 86, 88, 89, 258, 317, 365-367, 369-371, 373, 374, 377-384, 389-391 (1868 
participants; 8 groups) reported on operative time data included in the network meta-
analysis. The fixed-effect model was preferred based on the DIC statistics, and there 
was no evidence of inconsistency in the networks. The results of the pairwise 
comparisons for operative time are provided in Table A.11. The pairwise MDs of the 
different treatments showed ischaemic preconditioning and increased hepatic glycogen 
to have significantly shorter operative time compared to steroids by 17 and 26 minutes 
respectively. There was no significant difference in the operating time between the other 
comparisons. The network plot for operative time is shown in Figure A.25. Figures 
A.26 and A.27 show that none of the groups ranked best or worst with more than 90% 
probability. 
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Table A.11: Pairwise mean differences (MD) of the different treatment comparisons for the outcome operative time (95% confidence 
intervals). Statistically significant results are in bold. The pairwise mean differences of the different treatments showed ischaemic 
preconditioning and increased hepatic glycogen to have significantly shorter operative time compared to steroids. There was no significant 
difference in the operating time between the other comparisons.  
 
 
  Ischaemic 
preconditioning 
Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Increased 
hepatic glycogen 
Miscellaneous 
Surgery alone  MD -5.53 
(-12.47 to 1.41) 
MD -5.49 
(-41.85 to 30.87) 
MD -2.06 
(-27.31 to 23.18) 
MD 19.53 
(-59.71 to 98.77) 
MD 11.15 
(-3.14 to 25.44) 
MD -14.79 
(-31.89 to 2.31) 
MD 18.27 
(-10.11 to 46.65) 
Ischaemic 
preconditioning  
- MD 0.04 
(-36.97 to 37.06) 
MD 3.47 
(-22.71 to 29.65) 
MD 25.06 
(-54.49 to 104.61) 
MD 16.68 
(0.79 to 32.57) 
MD -9.26 
(-27.71 to 9.19) 
MD 23.8 
(-5.42 to 53.02) 
Antioxidants  - - MD 3.43 
(-40.84 to 47.69) 
MD 25.02 
(-62.17 to 112.2) 
MD 16.64 
(-22.43 to 55.7) 
MD -9.3 
(-49.48 to 30.88) 
MD 23.76 
(-22.37 to 69.88) 
Immunomodulators  - - - MD 21.59 
(-61.58 to 104.76) 
MD 13.21 
(-15.8 to 42.22) 
MD -12.73 
(-43.22 to 17.76) 
MD 20.33 
(-17.65 to 58.31) 
Cardiovascular 
modulators  
- - - - MD -8.38 
(-88.9 to 72.14) 
MD -34.32 
(-115.39 to 
46.75) 
MD -1.26 
(-85.43 to 82.91) 
Steroids  - - - - - MD -25.94 
(-48.22 to -3.66) 
MD 7.12 
(-24.66 to 38.9) 
Increased hepatic 
glycogen  
- - - - - - MD 33.06 
(-0.07 to 66.19) 
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Figure A.25: Network plot of the interventions aiming to decrease hepatic IR injury for 
the outcome operative time. 
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Footnotes: circles represent the intervention as a node in the network; size of circles 
represents the number of RCTs reporting on the intervention; lines represent direct 
comparisons using RCTs; thickness of lines represents the number of RCTs included in 
each comparison. 
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Figure A.26: Probability of being best intervention for the outcome operative time.  
None of the interventions ranked best with more than 90% probability, and there is lot 
of uncertainty about the intervention with the shortest operative time. 
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Figure A.27: Cumulative probability of ranks of different interventions aiming to 
decrease hepatic IR injury for the outcome operative time. None of the intervention 
groups ranked best or worst with more than 90% probability, and there was substantial 
uncertainty about the best or worst intervention for this outcome. 
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A.3.2.9. Summary of results of the overall network meta-analysis  
 
The overall network meta-analysis was performed to compare eight classes of active 
interventions aimed at decreasing IR injury along with a control group which was 
surgery alone. The classes of intervention were grouped based on their mechanism of 
action. Figure A.28 is a rankogram showing the probability that a class of interventions 
is best for each outcome of interest for the overall network meta-analysis. None of the 
treatment groups appear clearly superior to others when all the outcomes are considered 
together. There does not seem to be much correlation between a treatment group being 
best in reducing operative blood loss and being best in reducing serious adverse events 
and blood transfusion. No specific weighting was given to the different outcomes. 
Ischaemic preconditioning did well with most outcomes and especially in reducing 
operative blood loss. 
 
All statistically significant results of the pairwise comparisons during the overall 
network meta-analysis of the different classes of interventions for all outcomes of 
interest are shown in Table A.12. The classes of interventions with the highest 
probability of ranking from best to worst (1st to 9th) for the outcomes of interest are 
summarised in Table A.13. 
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Figure A.28: Rankogram showing the probability that a class of interventions is best treatment for each outcome of interest. 
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Table A.12: Statistically significant pairwise odds ratios (yellow treatment over blue treatment) and mean differences (yellow treatment 
minus blue treatment) of the comparisons of the classes of interventions for all outcomes of interest.  
 
 
CLASSES OF 
INTERVENTIONS 
Hypothermia Ischaemic preconditioning Antioxidants Immunomodulators 
Surgery alone MD 247.1 (143.59 to 350.61)3 OR 0.66 (0.44- 0.98)1 
MD -35.97 (-53.76 to -18.18)3 
MD -2.34 (-4.06 to -0.62)4 
MD 207 (34.13 to 379.87)3 MD 231.2 (145.82 to 316.58)3 
Hypothermia NA MD -283.07 (-388.09 to -178.05)3 NO NO 
Ischaemic 
preconditioning 
NA NA MD 242.97 (69.19 to 416.75)3 MD 267.17 (179.96 to 354.38)3 
Antioxidants NA NA NA NO 
 Cardiovascular modulators Steroids Increased hepatic glycogen Miscellaneous 
Surgery alone OR 0.39 (0.18-0.87)1 
MD 142.2 (61.59 to 222.81)3 
MD 69.32 (21.46 to 117.18)3 MD 92.04 (25.2 to 158.88)3 OR 0.21 (0.08-0.51)1 
MD 209.7 (118.32 to 301.08)3 
Hypothermia NO MD -177.78 (-291.82 to -63.74)3 MD -155.06 (-278.27 to -31.85)3 NO 
Ischaemic 
preconditioning 
MD 178.17 (95.62 to 260.72)3 OR 2.31 (1.03-5.18)2 
MD 105.29 (54.23 to 156.35)3 
MD 16.68 (0.79 to 32.57)5 
MD 128.01 (58.85 to 197.17)3 OR 0.31 (0.12-0.85)1 
MD 245.67 (152.58 to 338.76)3 
Antioxidants NO NO NO NO 
Immuno-
modulators 
NO MD -161.88 (-259.76 to -64)3 MD -139.16 (-247.59 to -30.73)3 OR 0.31 (0.1-0.96)1 
Cardiovascular 
modulators 
NA NO NO NO 
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Table 7.20 continued 
Steroids NA NA MD -25.94 (-48.22 to -3.66)5 OR 0.31 (0.1-0.99)1 
MD 140.38 (37.23 to 243.53)3 
Increased hepatic 
glycogen 
NA NA NA MD 117.66 (4.45 to 230.87)3 
 
 
 
Footnotes: OR=odds ratio; MD=mean difference; (95% credible intervals); NA=not applicable; NO=no statistically significant outcomes 
for this pairwise comparison; 1=serious adverse events; 2=proportion of patients transfused, 3=operative blood loss, 4=length of hospital 
stay, 5=operative time. There was no statistically significant difference between the interventions for the outcomes: mortality, quantity of 
blood transfusion per patient, and ITU stay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
353 
 
 
Table A.13: Classes of interventions aiming to decrease hepatic IR injury with the highest probability of ranking from best to worst (1st to 
9th) for the outcomes of interest. 
 
 
 
 
 
 
OUTCOMES 
RANKS 
1st 2nd  3rd  4th  5th  6th  7th  8th 9th  
Mortality Increased 
hepatic glycogen 
P=0.253 
Immuno-
modulators  
P=0.225 
Immuno-
modulators 
P=0.212 
Ischaemic 
preconditioning 
P=0.205 
Surgery alone 
P=0.231 
Surgery alone 
P=0.290 
Surgery alone 
P=0.221 
Steroids 
P=0.179 
Hypothermia 
P=0.292 
Serious adverse 
events 
Miscellaneous 
P=0.742 
Cardiovascular 
modulators 
P=0.374 
Cardiovascular 
modulators 
P=0.246 
Ischaemic 
preconditioning 
P=0.226 
Ischaemic 
preconditioning 
P=0.293 
Ischaemic 
preconditionin
g 
P=0.235 
Surgery alone 
P=0.404 
Surgery alone 
P=0.455 
NA 
1 
Proportion of 
patients transfused 
Immuno-
modulators 
P=0.424 
Ischaemic 
preconditioning 
P=0.395 
Ischaemic 
preconditioning 
P=0.272 
Surgery alone 
P=0.404 
Surgery alone 
P=0.280 
Steroids 
P=0.477 
Hypothermia 
P=0.665 
NA 
2 
NA 
Quantity of blood 
transfusion 
Steroids 
 P=0.318 
Antioxidants 
P=0.226 
Antioxidants 
P=0.198 
Surgery alone 
P=0.282 
Surgery alone 
P=0.317 
Surgery alone 
P=0.179 
Miscellaneous 
P=0.255 
NA 
3 
NA 
Operative blood 
loss 
Ischaemic 
preconditioning 
P=0.997 
Surgery alone 
P=0.985 
Steroids 
P=0.451 
Increased hepatic 
glycogen 
P=0.492 
Cardiovascular 
modulators  
P=0.478 
Miscellaneous 
P=0.256 
Miscellaneous 
P=0.296 
Immuno-
modulators 
P=0.316 
Hypothermia 
P=0.388 
Length of hospital 
stay 
Miscellaneous 
P=0.324 
Ischaemic 
preconditioning 
P=0.268 
Ischaemic 
preconditioning 
P=0.297 
Ischaemic 
preconditioning 
P=0.208 
Surgery alone 
P=0.226 
Surgery alone 
P=0.425 
Immuno-
modulators 
P=0.294 
NA 
4 
NA 
ITU stay Immuno-
modulators 
P=0.453 
Ischaemic 
preconditioning 
P=0.427 
Surgery alone 
P=0.427 
Surgery alone 
 P=0.426 
NA 
5 
NA NA NA NA 
Operating time Increased 
hepatic glycogen 
P=0.430 
Increased hepatic 
glycogen 
P=0.324 
Ischaemic 
preconditioning 
P=0.369 
Surgery alone 
P=0.341 
Surgery alone 
P=0.358 
Steroids  
P=0.343 
Miscellaneous 
P=0.343 
Cardiovascular 
modulators 
P=0.465 
NA 
6 
 
 
Footnotes: P=probability of ranking; NA=not applicable because less than 9 interventions were analysed for this outcome. Interventions not 
included in the analysis for this outcome: 1=hypothermia; 2=antioxidants, miscellaneous; 3=hypothermia, cardiovascular modulators; 
4=hypothermia, increased hepatic glycogen; 5=hypothermia, cardiovascular modulators, steroids, increased hepatic glycogen, 
miscellaneous, 6=hypothermia. 
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A.3.3. Sensitivity network meta-analysis – individual interventions 
 
A network meta-analysis was performed to compare the individual interventions 
included in each class of interventions aimed at decreasing IR injury during major liver 
resection surgery (Table 7.3). No significant difference was found in mortality, quantity 
of blood transfusion per patient, and ITU stay, between the different interventions 
aimed at reducing IR injury. As there is no direct measure of IR injury multiple clinical 
end points were measured which are likely to reflect the benefits or harms of a group of 
interventions aimed at reducing IR injury. Pairwise comparisons showed fewer people 
transfused with ischaemic preconditioning compared to steroids, as shown in Table 
A.14. Furthermore, ischaemic preconditioning was found to have significantly lower 
operative blood loss compared to surgery alone, hypothermia, prostaglandin E1, 
steroids, verapamil, S-adenosyl-L-methionine, pre-storing hepatocellular glycogen, 
insulin, sivelestat, branched chain aminoacids, gabexate mesilate, and melatonin. 
Surgery alone had significantly lower operative blood loss compared to hypothermia, 
prostaglandin E1, steroids, verapamil, S-adenosyl-L-methionine, insulin, branched 
chain aminoacids, gabexate mesilate, and melatonin. The pairwise comparisons for 
operative blood loss are shown in Table A.15 Part A and Part B. 
 
Ischaemic preconditioning was found to have significantly fewer serious adverse events 
compared to surgery alone. Sevoflurane was found to have significantly fewer serious 
adverse events compared to surgery alone, ischaemic preconditioning, steroids, and 
pentoxifylline. Both verapamil and gabexate mesilate had significantly fewer serious 
adverse events compared to surgery alone and pentoxifylline. The pairwise comparisons 
for serious adverse events are shown in Table A.16 Part A and Part B. 
 
Ischaemic preconditioning was found to have significantly shorter hospital stay 
compared to surgery alone. Furthermore, ischaemic preconditioning and pre-storing 
hepatocellular glycogen were found to have significantly shorter operative time 
compared to steroids; and vitamin E was found to have shorter operative time compared 
to branched chain amino acids. 
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Table A.14: Sensitivity analysis – individual interventions. Pairwise odds ratios (OR) of the different treatment comparisons for the 
outcome proportion of patients transfused (95% confidence intervals). Statistically significant results are in bold. Pairwise comparisons 
showed fewer people transfused with ischaemic preconditioning compared to steroids. There was no significant difference in the proportion 
of patients transfused between the other comparisons. 
 
 
  Hypothermia Ischaemic 
preconditioning 
Steroid Verapamil Insulin Pentoxifylline 
Surgery alone OR 3.18 
(0.35 to 28.65) 
OR 0.71 
(0.5 to 1.01) 
OR 1.63 
(0.78 to 3.38) 
OR 0.84 
(0.35 to 2.01) 
OR 1.02 
(0.35 to 3.02) 
OR 0.65 
(0.18 to 2.31) 
Hypothermia - OR 0.22 
(0.02 to 2.06) 
OR 0.51 
(0.05 to 5.2) 
OR 0.26 
(0.02 to 2.82) 
OR 0.32 
(0.03 to 3.73) 
OR 0.2 
(0.02 to 2.58) 
Ischaemic 
preconditioning 
- - OR 2.3 
(1.02 to 5.19) 
OR 1.19 
(0.46 to 3.05) 
OR 1.45 
(0.46 to 4.52) 
OR 0.91 
(0.24 to 3.43) 
Steroid - - - OR 0.52 
(0.16 to 1.62) 
OR 0.63 
(0.17 to 2.32) 
OR 0.4 
(0.09 to 1.73) 
Verapamil - - - - OR 1.22 
(0.3 to 4.91) 
OR 0.77 
(0.16 to 3.62) 
Insulin - - - - - OR 0.63 
(0.12 to 3.35) 
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Table A.15 Part A: Sensitivity analysis – individual interventions. Pairwise mean differences (MD) of the different treatment comparisons 
for the outcome operative blood loss (95% confidence intervals). Statistically significant results are in bold. Ischaemic preconditioning was 
found to have significantly lower operative blood loss compared to surgery alone, hypothermia, prostaglandin E1, steroids, verapamil, S-
adenosyl-L-methionine, pre-storing hepatocellular glycogen, insulin, sivelestat, branched chain aminoacids, gabexate mesilate, and 
melatonin. Surgery alone had significantly lower operative blood loss compared to hypothermia, prostaglandin E1, steroids, verapamil, S-
adenosyl-L-methionine, insulin, branched chain aminoacids, gabexate mesilate, and melatonin.  
  Hypothermia Ischaemic 
preconditioning 
Sevoflurane Prostaglandin 
E1 
Amrinone Steroids Ulinastatin Verapamil S-adenosyl-L-
methionine 
Surgery alone MD 245.9 
(142.35 to 
349.45) 
MD -36 
(-53.42 to -
18.58) 
MD 69.59 
(-61.95 to 
201.13) 
MD 163.5 
(34.04 to 
292.96) 
MD 101.3 
(-58.85 to 
261.45) 
MD 69.54 
(21.79 to 
117.29) 
MD 92.46 
(-43.31 to 
228.23) 
MD 111 
(26.41 to 
195.59) 
MD 174.4 
(25.69 to 
323.11) 
Hypothermia - MD -281.9 
(-386.9 to -
176.9) 
MD -176.31 
(-343.71 to -
8.91) 
MD -82.4 
(-248.17 to 
83.37) 
MD -144.6 
(-335.31 to 
46.11) 
MD -176.36 
(-290.38 to -
62.34) 
MD -153.44 
(-324.19 to 
17.31) 
MD -134.9 
(-268.61 to 
-1.19) 
MD -71.5 
(-252.7 to 
109.7) 
Ischaemic 
preconditioning 
- - MD 105.59 
(-27.09 to 
238.27) 
MD 199.5 
(68.88 to 
330.12) 
MD 137.3 
(-23.8 to 
298.4) 
MD 105.54 
(54.72 to 
156.36) 
MD 128.46 
(-8.42 to 
265.34) 
MD 147 
(60.63 to 
233.37) 
MD 210.4 
(60.68 to 
360.12) 
Sevoflurane - - - MD 93.91 
(-90.65 to 
278.47) 
MD 31.71 
(-175.53 to 
238.95) 
MD -0.05 
(-139.98 to 
139.88) 
MD 22.87 
(-166.17 to 
211.91) 
MD 41.41 
(-114.98 to 
197.8) 
MD 104.81 
(-93.72 to 
303.34) 
Prostaglandin 
E1 
- - - - MD -62.2 
(-268.13 to 
143.73) 
MD -93.96 
(-231.94 to 
44.02) 
MD -71.04 
(-258.64 to 
116.56) 
MD -52.5 
(-207.15 to 
102.15) 
MD 10.9 
(-186.26 to 
208.06) 
Amrinone - - - - - MD -31.76 
(-198.88 to 
135.36) 
MD -8.84 
(-218.8 to 
201.12) 
MD 9.7 
(-171.42 to 
190.82) 
MD 73.1 
(-145.44 to 
291.64) 
Steroids - - - - - - MD 22.92 
(-121 to 
166.84) 
MD 41.46 
(-55.68 to 
138.6) 
MD 104.86 
(-51.32 to 
261.04) 
Ulinastatin - - - - - - - MD 18.54 
(-141.43 to 
178.51) 
MD 81.94 
(-119.42 to 
283.3) 
Verapamil - - - - - - - - MD 63.4 
(-107.68 to 
234.48) 
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Table A.15 Part B: Sensitivity analysis – individual interventions. Pairwise mean differences (MD) of the different treatment comparisons 
for the outcome operative blood loss (95% confidence intervals). Statistically significant results are in bold. Ischaemic preconditioning was 
found to have significantly lower operative blood loss compared to surgery alone, hypothermia, prostaglandin E1, steroids, verapamil, S-
adenosyl-L-methionine, pre-storing hepatocellular glycogen, insulin, sivelestat, branched chain aminoacids, gabexate mesilate, and 
melatonin. Surgery alone had significantly lower operative blood loss compared to hypothermia, prostaglandin E1, steroids, verapamil, S-
adenosyl-L-methionine, insulin, branched chain aminoacids, gabexate mesilate, and melatonin.  
 
  Pre-storing 
hepatocellular 
glycogen 
Allopurinol Insulin Sivelestat Branched 
chain amino 
acids 
OKY046 Gabexate 
mesilate 
Melatonin Pentoxifylline 
Surgery alone MD 61.54 
(-7.57 to 
130.65) 
MD 37.71 
(-155.31 to 
230.73) 
MD 194.8 
(35.22 to 
354.38) 
MD 147 
(-5.92 to 
299.92) 
MD 203.2 
(45.36 to 
361.04) 
MD 75.47 
(-117.35 to 
268.29) 
MD 190.9 
(64.79 to 
317.01) 
MD 180.4 
(5.72 to 
355.08) 
MD 73.39 
(-66.08 to 
212.86) 
Hypothermia MD -184.36 
(-308.85 to -
59.87) 
MD -208.19 
(-427.23 to 
10.85) 
MD -51.1 
(-241.33 to 
139.13) 
MD -98.9 
(-283.58 to 
85.78) 
MD -42.7 
(-231.47 to 
146.07) 
MD -170.43 
(-389.3 to 
48.44) 
MD -55 
(-218.17 to 
108.17) 
MD -65.5 
(-268.56 to 
137.56) 
MD -172.51 
(-346.22 to 
 1.2) 
Ischaemic 
preconditioning 
MD 97.54 
(26.27 to 
168.81) 
MD 73.71 
(-120.1 to 
267.52) 
MD 230.8 
(70.27 to 
391.33) 
MD 183 
(29.09 to 
336.91) 
MD 239.2 
(80.4 to  
398) 
MD 111.47 
(-82.14 to 
305.08) 
MD 226.9 
(99.6 to 
354.2) 
MD 216.4 
(40.86 to 
391.94) 
MD 109.39 
(-31.17 to 
249.95) 
Sevoflurane MD -8.05 
(-156.64 to 
140.54) 
MD -31.88 
(-265.46 to 
201.7) 
MD 125.21 
(-81.6 to 
332.02) 
MD 77.41 
(-124.3 to 
279.12) 
MD 133.61 
(-71.85 to 
339.07) 
MD 5.88 
(-227.54 to 
239.3) 
MD 121.31 
(-60.91 to 
303.53) 
MD 110.81 
(-107.85 to 
329.47) 
MD 3.8 
(-187.91 to 
195.51) 
Prostaglandin E1 MD -101.96 
(-248.71 to 
44.79) 
MD -125.79 
(-358.2 to 
106.62) 
MD 31.3 
(-174.19 to 
236.79) 
MD -16.5 
(-216.86 to 
183.86) 
MD 39.7 
(-164.44 to 
243.84) 
MD -88.03 
(-320.28 to 
144.22) 
MD 27.4 
(-153.33 to 
208.13) 
MD 16.9 
(-200.52 to 
234.32) 
MD -90.11 
(-280.41 to 
100.19) 
Amrinone MD -39.76 
(-214.19 to 
134.67) 
MD -63.59 
(-314.4 to 
187.22) 
MD 93.5 
(-132.59 to 
319.59) 
MD 45.7 
(-175.73 to 
267.13) 
MD 101.9 
(-122.96 to 
326.76) 
MD -25.83 
(-276.49 to 
224.83) 
MD 89.6 
(-114.24 to 
293.44) 
MD 79.1 
(-157.88 to 
316.08) 
MD -27.91 
(-240.28 to 
184.46) 
Steroids MD -8 
(-92 to  
76) 
MD -31.83 
(-230.67 to 
167.01) 
MD 125.26 
(-41.31 to 
291.83) 
MD 77.46 
(-82.74 to 
237.66) 
MD 133.66 
(-31.24 to 
298.56) 
MD 5.93 
(-192.72 to 
204.58) 
MD 121.36 
(-13.48 to 
256.2) 
MD 110.86 
(-70.22 to 
291.94) 
MD 3.85 
(-143.57 to 
151.27) 
Ulinastatin MD -30.92 
(-183.27 to 
121.43) 
MD -54.75 
(-290.74 to 
181.24) 
MD 102.34 
(-107.18 to 
311.86) 
MD 54.54 
(-149.95 to 
259.03) 
MD 110.74 
(-97.46 to 
318.94) 
MD -16.99 
(-252.82 to 
218.84) 
MD 98.44 
(-86.86 to 
283.74) 
MD 87.94 
(-133.29 to 
309.17) 
MD -19.07 
(-213.71 to 
175.57) 
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Table A.15 Part B continued 
Verapamil MD -49.46 
(-158.69 to 
59.77) 
MD -73.29 
(-284.03 to 
137.45) 
MD 83.8 
(-96.82 to 
264.42) 
MD 36 
(-138.76 to 
210.76) 
MD 92.2 
(-86.88 to 
271.28) 
MD -35.53 
(-246.09 to 
175.03) 
MD 79.9 
(-71.95 to 
231.75) 
MD 69.4 
(-124.68 to 
263.48) 
MD -37.61 
(-200.73 to 
125.51) 
S-adenosyl-L-
methionine 
MD -112.86 
(-276.84 to 
51.12) 
MD -136.69 
(-380.35 to 
106.97) 
MD 20.4 
(-197.73 to 
238.53) 
MD -27.4 
(-240.7 to 
185.9) 
MD 28.8 
(-188.06 to 
245.66) 
MD -98.93 
(-342.43 to 
144.57) 
MD 16.5 
(-178.48 to 
211.48) 
MD 6 
(-223.4 to 
235.4) 
MD -101.01 
(-304.89 to 
102.87) 
Pre-storing 
hepatocellular 
glycogen 
- MD -23.83 
(-228.85 to 
181.19) 
MD 133.26 
(-40.64 to 
307.16) 
MD 85.46 
(-82.35 to 
253.27) 
MD 141.66 
(-30.65 to 
313.97) 
MD 13.93 
(-190.91 to 
218.77) 
MD 129.36 
(-14.44 to 
273.16) 
MD 118.86 
(-68.99 to 
306.71) 
MD 11.85 
(-143.81 to 
167.51) 
Allopurinol - - MD 157.09 
(-93.36 to 
407.54) 
MD 109.29 
(-136.96 to 
355.54) 
MD 165.49 
(-83.85 to 
414.83) 
MD 37.76 
(-235.07 to 
310.59) 
MD 153.19 
(-77.37 to 
383.75) 
MD 142.69 
(-117.63 to 
403.01) 
MD 35.68 
(-202.46 to 
273.82) 
Insulin - - - MD -47.8 
(-268.82 to 
173.22) 
MD 8.4 
(-216.05 to 
232.85) 
MD -119.33 
(-369.63 to 
130.97) 
MD -3.9 
(-207.3 to 
199.5) 
MD -14.4 
(-251 to 
222.2) 
MD -121.41 
(-333.35 to 
90.53) 
Sivelestat - - - - MD 56.2 
(-163.57 to 
275.97) 
MD -71.53 
(-317.63 to 
174.57) 
MD 43.9 
(-154.31 to 
242.11) 
MD 33.4 
(-198.75 to 
265.55) 
MD -73.61 
(-280.58 to 
133.36) 
Branched chain 
amino acids 
- - - - - MD -127.73 
(-376.92 to 
121.46) 
MD -12.3 
(-214.33 to 
189.73) 
MD -22.8 
(-258.22 to 
212.62) 
MD -129.81 
(-340.44 to 
80.82) 
OKY 046 - - - - - - MD 115.43 
(-114.97 to 
345.83) 
MD 104.93 
(-155.25 to 
365.11) 
MD -2.08 
(-240.06 to 
235.9) 
Gabexate 
mesilate 
- - - - - - - MD -10.5 
(-225.94 to 
204.94) 
MD -117.51 
(-305.54 to 
70.52) 
Melatonin - - - - - - - - MD -107.01 
(-330.54 to 
116.52) 
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Table A.16 Part A: Sensitivity analysis – individual interventions. Pairwise odds ratios (OR) of the different treatment comparisons for the 
outcome serious adverse events (95% confidence intervals). Statistically significant results are in bold. Ischaemic preconditioning was 
found to have significantly fewer serious adverse events compared to surgery alone. Sevoflurane was found to have significantly fewer 
serious adverse events compared to surgery alone, ischaemic preconditioning, steroids, and pentoxifylline. Both verapamil and gabexate 
mesilate had significantly fewer serious adverse events compared to surgery alone and pentoxifylline. 
 
 
  Ischaemic 
preconditioning 
Vitamin E Sevoflurane Prostaglandin E1 Steroids Ulinastatin Verapamil Antioxidant 
multivitamin 
Surgery alone OR 0.65 
(0.44 to 0.97) 
OR 0.77 
(0.18 to 3.28) 
OR 0.17 
(0.06 to 0.48) 
OR 1.02 
(0 to 503.71) 
OR 0.66 
(0.32 to 1.34) 
OR 0.34 
(0.04 to 2.62) 
OR 0.35 
(0.14 to 0.88) 
OR 0.06 
(0 to 6.48) 
Ischaemic 
preconditioning 
- OR 1.17 
(0.26 to 5.3) 
OR 0.25 
(0.08 to 0.8) 
OR 1.56 
(0 to 781.64) 
OR 1.01 
(0.44 to 2.29) 
OR 0.51 
(0.06 to 4.17) 
OR 0.53 
(0.19 to 1.47) 
OR 0.1 
(0 to 10.1) 
Vitamin E - - OR 0.22 
(0.04 to 1.32) 
OR 1.33 
(0 to 778.57) 
OR 0.86 
(0.17 to 4.34) 
OR 0.44 
(0.04 to 5.43) 
OR 0.45 
(0.08 to 2.56) 
OR 0.08 
(0 to 10.58) 
Sevoflurane - - - OR 6.13 
(0.01 to 3325.48) 
OR 3.96 
(1.09 to 
14.33) 
OR 2.02 
(0.2 to 20.48) 
OR 2.09 
(CI 0.51 to 
8.66) 
OR 0.38 
(0 to 44.1) 
Prostaglandin E1 - - - - OR 0.65 
(0 to 333.59) 
OR 0.33 
(0 to 227.66) 
OR 0.34 
(0 to 181.42) 
OR 0.06 
(0 to 143.58) 
Steroids - - - - - OR 0.51 
(0.06 to 4.5) 
OR 0.53 
(0.16 to 1.72) 
OR 0.1 
(0 to 10.42) 
Ulinastatin - - - - - - OR 1.03 
(0.11 to 9.88) 
OR 0.19 
(0 to 29.86) 
Verapamil - - - - - - - OR 0.18 
(0 to 20.5) 
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Table A.16 Part B: Sensitivity analysis – individual interventions. Pairwise odds ratios (OR) of the different treatment comparisons for the 
outcome serious adverse events (95% confidence intervals). Statistically significant results are in bold. Ischaemic preconditioning was 
found to have significantly fewer serious adverse events compared to surgery alone. Sevoflurane was found to have significantly fewer 
serious adverse events compared to surgery alone, ischaemic preconditioning, steroids, and pentoxifylline. Both verapamil and gabexate 
mesilate had significantly fewer serious adverse events compared to surgery alone and pentoxifylline. 
 
 
  Trimetazidine Insulin Branched chain 
amino acids 
Gabexate 
mesilate 
Melatonin Pentoxifylline 
Surgery alone OR 0.53 
(0.11 to 2.63) 
OR 0.69 
(0.15 to 3.09) 
OR 0.15 
(0 to 17.94) 
OR 0.21 
(0.06 to 0.73) 
OR 0.48 
(0.09 to 2.66) 
OR 1.34 
(0.54 to 3.35) 
Ischaemic 
preconditioning 
OR 0.81 
(0.15 to 4.24) 
OR 1.05 
(0.22 to 4.99) 
OR 0.23 
(0 to 27.95) 
OR 0.32 
(0.09 to 1.2) 
OR 0.74 
(0.13 to 4.26) 
OR 2.05 
(0.76 to 5.58) 
Vitamin E OR 0.69 
(0.08 to 6.02) 
OR 0.9 
(0.11 to 7.27) 
OR 0.19 
(0 to 29.08) 
OR 0.27 
(0.04 to 1.87) 
OR 0.63 
(0.07 to 5.93) 
OR 1.75 
(0.31 to 9.76) 
Sevoflurane OR 3.18 
(0.46 to 21.91) 
OR 4.13 
(0.65 to 26.2) 
OR 0.89 
(0.01 to 121.59) 
OR 1.26 
(0.24 to 6.56) 
OR 2.91 
(0.39 to 21.76) 
OR 8.07 
(1.98 to 33) 
Prostaglandin E1 OR 0.52 
(0 to 315.31) 
OR 0.67 
(0 to 400.1) 
OR 0.15 
(0 to 371.05) 
OR 0.21 
(0 to 115.63) 
OR 0.47 
(0 to 296.08) 
OR 1.32 
(0 to 698.36) 
Steroids OR 0.8 
(0.14 to 4.67) 
OR 1.04 
(0.2 to 5.53) 
OR 0.23 
(0 to 28.8) 
OR 0.32 
(0.08 to 1.35) 
OR 0.73 
(0.12 to 4.67) 
OR 2.04 
(0.64 to 6.53) 
Ulinastatin OR 1.57 
(0.12 to 21.34) 
OR 2.04 
(0.16 to 26.1) 
OR 0.44 
(0 to 81.47) 
OR 0.62 
(0.06 to 6.92) 
OR 1.44 
(0.1 to 20.77) 
OR 3.99 
(0.42 to 37.86) 
Verapamil OR 1.52 
(0.24 to 9.76) 
OR 1.98 
(0.34 to 11.64) 
OR 0.43 
(0 to 56.57) 
OR 0.6 
(0.13 to 2.88) 
OR 1.39 
(0.2 to 9.72) 
OR 3.86 
(1.04 to 14.3) 
Antioxidant 
multivitamin 
OR 8.29 
(0.06 to 1107.87) 
OR 10.78 
(0.08 to 1394.97) 
OR 2.33 
(0 to 1821.3) 
OR 3.29 
(0.03 to 396.21) 
OR 7.59 
(0.05 to 1048.3) 
OR 21.07 
(0.19 to 2347.95) 
Trimetazidine - OR 1.3 
(0.14 to 11.78) 
OR 0.28 
(0 to 44.24) 
OR 0.4 
(0.05 to 3.05) 
OR 0.92 
(0.09 to 9.54) 
OR 2.54 
(0.4 to 16.18) 
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Table A.16 Part B continued 
Insulin - - OR 0.22 
(0 to 32.96) 
OR 0.31 
(0.04 to 2.17) 
OR 0.7 
(0.07 to 6.85) 
OR 1.95 
(0.34 to 11.4) 
Branched chain 
amino acids 
- - - OR 1.41 
(0.01 to 201.64) 
OR 3.26 
(0.02 to 531.1) 
OR 9.06 
(0.07 to 1198.14) 
Gabexate 
mesilate 
- - - - OR 2.31 
(0.28 to 19.16) 
OR 6.4 
(1.35 to 30.29) 
Melatonin - - - - - OR 2.78 
(0.4 to 19.23) 
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A.3.4. Sensitivity network meta-analysis – larger groups 
 
A network meta-analysis was performed to compare the following 4 larger groups: 
surgery alone, hypothermia, ischaemic preconditioning, and all pharmacological 
interventions (Table A.3). There was no significant difference in mortality, proportion 
of patients transfused, quantity of blood transfusion per patient, ITU stay, and operative 
time, between the 4 groups. Ischaemic preconditioning was found to have a high 
probability (87%) of being the best treatment for operating time (Figure A.29).  
 
Ischaemic preconditioning and pharmacological interventions were found to have 
significantly fewer serious adverse events compared to surgery alone. The pairwise 
comparisons for serious adverse events are shown in Table A.17. Pharmacological 
interventions had 86% probability of being the best treatment for serious adverse events. 
Ischaemic preconditioning had significantly lower operative blood loss compared to 
surgery alone, hypothermia, and pharmacological interventions, and was confirmed best 
treatment for operative blood loss with 100% probability. In addition, hypothermia and 
pharmacological interventions had significantly higher operative blood loss compared to 
surgery alone. The pairwise comparisons for operative blood loss are shown in Table 
A.18, and the probability of being best treatment is shown in Figure A.30.  
 
Furthermore, ischaemic preconditioning and pharmacological interventions had 
significantly shorter hospital stay compared to surgery alone. Figure A.31 is a 
rankogram showing the probability that a group of treatments is best for each outcome 
of this sensitivity network meta-analysis. Ischaemic preconditioning did well with most 
outcomes and especially in reducing operative blood loss. 
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Figure A.29: Sensitivity analysis – larger groups. Probability of being best treatment 
for the outcome operating time. Ischaemic preconditioning was found to have a high 
probability (87%) of being the best treatment for operating time 
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Table A.17: Sensitivity analysis – larger groups. Pairwise odds ratios (OR) of the 
different treatment comparisons for the outcome serious adverse events. Statistically 
significant results are in bold. Ischaemic preconditioning and pharmacological 
interventions were found to have significantly fewer serious adverse events compared to 
surgery alone 
 
 
  Ischaemic preconditioning Pharmacological intervention 
Surgery alone OR 0.65;  
95% CI 0.44 to 0.98 
OR 0.49;  
95% CI 0.35 to 0.69 
Ischaemic 
preconditioning 
- OR 0.75;  
95% CI 0.44 to 1.27 
 
 
 
 
 
 
 
 
 
Table A.18: Sensitivity analysis – larger groups. Pairwise mean differences (MD) of 
the different treatment comparisons for the outcome operative blood loss. Statistically 
significant results are in bold. Ischaemic preconditioning had significantly lower 
operative blood loss compared to surgery alone, hypothermia, and pharmacological 
interventions. In addition, hypothermia and pharmacological interventions had 
significantly higher operative blood loss compared to surgery alone.  
 
 
  Hypothermia Ischaemic preconditioning Pharmacological 
intervention 
Surgery alone MD 247.4 
95% CI 143.7 to 351.1 
MD -35.9 
95% CI -53.32 to -18.48 
MD 139.2 
95% CI 107.23 to 171.17 
Hypothermia - MD -283.3 
95% CI -388.46 to -178.14 
MD -108.2 
95% CI -216.72 to 0.32 
Ischaemic 
preconditioning 
- - MD 175.1 
95% CI 138.7 to 211.5 
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Figure A.30: Sensitivity analysis – larger groups. Probability of being best treatment 
for the outcome operative blood loss. Ischaemic preconditioning was confirmed best 
treatment for operative blood loss with 100% probability. 
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Figure A.31: Sensitivity analysis – larger groups. Rankogram showing the probability that a treatment group is best for each outcome.  
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A.3.5. Sensitivity network meta-analysis – only pharmacological 
interventions 
 
A network meta-analysis was performed comparing the classes of pharmacological 
interventions, and another analysis comparing the individual pharmacological 
interventions, thus excluding ischaemic preconditioning and hypothermia from the 
analysis.  
 
Comparing the classes of pharmacological interventions aiming to decrease IR injury 
during liver resection showed no significant difference between the classes of 
pharmacological interventions in mortality, number of patients transfused, and ITU stay. 
Cardiovascular modulators were found to have significantly fewer serious adverse 
events compared to surgery alone. Also, the miscellaneous group was found to have 
significantly fewer serious adverse events compared to the surgery alone and increased 
hepatic glycogen groups. The pairwise comparisons for serious adverse events are 
shown in Table A.19. Furthermore, the antioxidants group and cardiovascular 
modulators group had a significantly shorter length of hospital stay compared to the 
surgery alone and steroid groups. The increased hepatic glycogen group had 
significantly shorter operating time compared to the steroids and miscellaneous groups. 
Regarding operative blood loss, the surgery alone group had significantly lower 
operative blood loss compared to the antioxidants, immunomodulators, cardiovascular 
modulators, steroids, increased hepatic glycogen, and miscellaneous groups. The 
surgery alone group had a high probability (99%) of being the best treatment for 
operative blood loss. The immunomodulators and miscellaneous groups had 
significantly higher operative blood loss compared to the steroids and increased hepatic 
glycogen groups. The pairwise comparisons for operative blood loss are shown in Table 
A.20, and the probability of being best treatment is shown in Figure A.32. Finally, 
steroids were found to need a significantly lower quantity of blood transfusion 
compared to the surgery alone, antioxidants, increased hepatic glycogen, and 
miscellaneous groups. 
 
Sensitivity network meta-analysis comparing the individual pharmacological 
interventions aiming to decrease IR injury found no significant difference between the 
individual interventions in mortality, number of patients transfused, and ITU stay. 
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Sevoflurane, verapamil, and gabexate mesilate had significantly fewer serious adverse 
events compared to surgery alone and pentoxifylline. Regarding hospital stay, surgery 
alone and steroids had a significantly longer hospital stay compared to trimetazidine and 
melatonin. Furthermore, vitamin E was found to have a significantly shorter operating 
time compared to amrinone and branched chain aminoacids. As in the previous analysis, 
the surgery alone group had significantly lower operative blood loss compared to 
steroids, verapamil, S-adenosyl-L-methionine, insulin, branched chain aminoacids, 
gabexate mesilate, and melatonin. Finally, vitamin E and steroids, resulted in 
significantly lower quantity of blood transfusion compared to surgery alone, 
sevoflurane, mannitol, insulin, and melatonin.  
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Table A.19: Sensitivity analysis – classes of pharmacological interventions. Pairwise odds ratios (OR) of the different treatment 
comparisons for the outcome serious adverse events (95% confidence intervals). Statistically significant results are in bold. Cardiovascular 
modulators were found to have significantly fewer serious adverse events compared to surgery alone. Also, the miscellaneous group was 
found to have significantly fewer serious adverse events compared to the surgery alone and increased hepatic glycogen groups. 
 
 
  Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Increased hepatic 
glycogen 
Miscellaneous 
Surgery alone OR 0.53 
(0.19 to 1.47) 
OR 0.67 
(0.33 to 1.34) 
OR 0.4 
(0.18 to 0.88) 
OR 0.66 
(0.32 to 1.34) 
OR 0.68  
(0.15 to 3.09) 
OR 0.21 
(0.08 to 0.51) 
Antioxidants - OR 1.26  
(0.37 to 4.31) 
OR 0.74  
(0.2 to 2.71) 
OR 1.23  
(0.36 to 4.27) 
OR 1.28  
(0.21 to 7.92) 
OR 0.39 
(0.1 to 1.51) 
Immunomodulators - - OR 0.59  
(0.2 to 1.71) 
OR 0.98  
(0.36 to 2.66) 
OR 1.02  
(0.19 to 5.38) 
OR 0.31 
(0.1 to 0.96) 
Cardiovascular 
modulators 
- - - OR 1.66 
 (0.57 to 4.85) 
OR 1.73  
(0.31 to 9.54) 
OR 0.52  
(0.15 to 1.74) 
Steroids - - - - OR 1.04  
(0.2 to 5.54) 
OR 0.31  
(0.1 to 1) 
Increased hepatic 
glycogen 
- - - - - OR 0.3  
(0.05 to 1.75) 
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Table A.20: Sensitivity analysis – classes of pharmacological interventions. Pairwise mean differences (MD) of the different treatment 
comparisons for the outcome operative blood loss (95% confidence intervals). Statistically significant results are in bold. Regarding 
operative blood loss, the surgery alone group had significantly lower operative blood loss compared to the antioxidants, 
immunomodulators, cardiovascular modulators, steroids, increased hepatic glycogen, and miscellaneous groups. The immunomodulators 
and miscellaneous groups had significantly higher operative blood loss compared to the steroids and increased hepatic glycogen groups.  
 
 
  Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Increased hepatic 
glycogen 
Miscellaneous 
Surgery alone  MD 207.8 
(34.85 to 380.75) 
MD 216.1 
(125.8 to 306.4) 
MD 137.1 
(56.82 to 217.38) 
MD 79.15 
(32.42 to 125.88) 
MD 92.08 
(25.36 to 158.8) 
MD 210.4 
(118.59 to 302.21) 
Antioxidants  - MD 8.3 
(-186.8 to 203.4) 
MD -70.7 
(-261.38 to 119.98) 
MD -128.65 
(-307.8 to 50.5) 
MD -115.72 
(-301.09 to 69.65) 
MD 2.6 
(-193.21 to 198.41) 
Immunomodulators  - - MD -79 
(-199.83 to 41.83) 
MD -136.95 
(-238.62 to -35.28) 
MD -124.02 
(-236.29 to -11.75) 
MD -5.7 
(-134.47 to 123.07) 
Cardiovascular 
modulators  
- - - MD -57.95 
(-150.84 to 34.94) 
MD -45.02 
(-149.41 to 59.37) 
MD 73.3 
(-48.66 to 195.26) 
Steroids  - - - - MD 12.93 
(-68.52 to 94.38) 
MD 131.25 
(28.24 to 234.26) 
Increased hepatic 
glycogen  
- - - - - MD 118.32 
(4.83 to 231.81) 
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Figure A.32: Sensitivity analysis – classes of pharmacological interventions. 
Probability of being best treatment for the outcome operative blood loss. The surgery 
alone group had a high probability (99%) of being the best treatment for operative blood 
loss. 
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A.3.6. Metaregression – percentage of cirrhotic livers 
 
A metaregression was performed based on the percentage of cirrhotic livers included in 
each trial. No significant difference was identified between the classes of interventions 
aiming to decrease IR during liver resection with regards to mortality, proportion of 
patients transfused, quantity of blood transfused per patient, operating time, hospital 
stay, and ITU stay. The surgery alone group was found to have significantly more 
serious adverse events compared to the ischaemic preconditioning, antioxidants, and 
miscellaneous groups. Also, the miscellaneous group had significantly fewer serious 
adverse events compared to the ischaemic preconditioning, immunomodulators, and 
cardiovascular modulators group. Moreover, the immunomodulators and miscellaneous 
groups of interventions were found to have significantly higher operative blood loss 
compared to the surgery alone, ischaemic preconditioning, steroids, and increased 
hepatic glycogen groups. The miscellaneous group also had significantly higher 
operative blood loss compared to the antioxidants and cardiovascular modulators 
groups. In addition, ischaemic preconditioning had significantly lower operative blood 
loss compared to the surgery alone group. The pairwise comparisons for the outcomes 
serious adverse events and operative blood loss are shown in Table A.21 and Table 
A.22 respectively. 
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Table A.21: Metaregression – percentage of cirrhotic livers. Pairwise odds ratios (OR) of the different treatment comparisons for the 
outcome serious adverse events (95% confidence intervals). Statistically significant results are in bold. The surgery alone group was found 
to have significantly more serious adverse events compared to the ischaemic preconditioning, antioxidants, and miscellaneous groups. 
Also, the miscellaneous group had significantly fewer serious adverse events compared to the ischaemic preconditioning, 
immunomodulators, and cardiovascular modulators group.  
 
 
  Ischaemic 
preconditioning 
Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Miscellaneous 
Surgery alone OR 0.55 
(0.36 to 0.85) 
OR 0.35 
(0.12 to 0.99) 
OR 0.63 
(0.31 to 1.29) 
OR 1.19 
(0.36 to 3.87) 
OR 0.26 
(0.06 to 1.12) 
OR 0.16 
(0.06 to 0.41) 
Ischaemic 
preconditioning 
- OR 0.62 
(0.2 to 1.94) 
OR 1.14 
(0.5 to 2.61) 
OR 2.15 
(0.61 to 7.54) 
OR 0.47 
(0.1 to 2.16) 
OR 0.29 
(0.1 to 0.81) 
Antioxidants - - OR 1.82 
(0.51 to 6.5) 
OR 3.44 
(0.71 to 16.73) 
OR 0.75 
(0.12 to 4.56) 
OR 0.46 
(0.11 to 1.9) 
Immunomodulators - - - OR 1.89 
(0.47 to 7.5) 
OR 0.41 
(0.08 to 2.1) 
OR 0.25 
(0.08 to 0.83) 
Cardiovascular 
modulators 
- - - - OR 0.22 
(0.03 to 1.43) 
OR 0.13 
(0.03 to 0.61) 
Steroids - - - - - OR 0.62 
(0.11 to 3.56) 
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Table A.22: Metaregression – percentage of cirrhotic livers. Pairwise mean differences (MD) of the different treatment comparisons for the 
outcome operative blood loss (95% confidence intervals). Statistically significant results are in bold. The immunomodulators and 
miscellaneous groups of interventions were found to have significantly higher operative blood loss compared to the surgery alone, 
ischaemic preconditioning, steroids, and increased hepatic glycogen groups. The miscellaneous group also had significantly higher 
operative blood loss compared to the antioxidants and cardiovascular modulators groups. In addition, ischaemic preconditioning had 
significantly lower operative blood loss compared to the surgery alone group.  
 
 
  Ischaemic 
preconditioning 
Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Increased hepatic 
glycogen 
Miscellaneous 
Surgery alone  MD -33.21 
(-52.33 to -14.09) 
MD -7.07 
(-189.54 to 175.41) 
MD 173.4 
(76.2 to 270.6) 
MD -2.94 
(-152.29 to 146.41) 
MD 1.57 
(-84.95 to 88.08) 
MD -81.53 
(-201.62 to 38.56) 
MD 206.9 
(113.07 to 300.73) 
Ischaemic 
preconditioning  
- MD 26.15 
(-157.33 to 209.62) 
MD 206.61 
(107.55 to 305.67) 
MD 30.27 
(-120.3 to 180.84) 
MD 34.78 
(-53.83 to 123.38) 
MD -48.32 
(-169.92 to 73.28) 
MD 240.11 
(144.36 to 335.86) 
Antioxidants  - - MD 180.47 
(-26.28 to 387.21) 
MD 4.12 
(-231.68 to 239.93) 
MD 8.63 
(-193.32 to 210.58) 
MD -74.47 
(-292.91 to 143.98) 
MD 213.97 
(8.78 to 419.15) 
Immunomodulators  - - - MD -176.34 
(-354.54 to 1.85) 
MD -171.84 
(-301.96 to -41.71) 
MD -254.93 
(-409.42 to -100.44) 
MD 33.5 
(-101.59 to 168.59) 
Cardiovascular 
modulators  
- - - - MD 4.51 
(-168.09 to 177.11) 
MD -78.59 
(-270.23 to 113.06) 
MD 209.84 
(33.46 to 386.22) 
Steroids  - - - - - MD -83.1 
(-231.1 to 64.91) 
MD 205.34 
(77.71 to 332.96) 
Increased hepatic 
glycogen  
- - - - - - MD 288.43 
(136.03 to 440.83) 
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A.3.7. Metaregression – percentage of major liver resections 
 
A metaregression was performed based on the percentage of major liver resections 
performed in each trial. No significant difference was identified between the classes of 
interventions aiming to decrease IR injury during hepatectomy with regards to 
mortality, operating time, and ITU stay. Regarding serious adverse events, ischaemic 
preconditioning, cardiovascular modulators and miscellaneous classes of interventions 
were found to have significantly fewer serious adverse events compared to surgery 
alone. Steroids had significantly more serious adverse events compared to the 
miscellaneous class. Furthermore, ischaemic preconditioning was found to have 
significantly shorter length of hospital stay compared to surgery alone. Also, the 
ischaemic preconditioning group was found to have significantly fewer patients needing 
blood transfusion compared to the surgery alone group. Moreover, ischaemic 
preconditioning was found to have significantly lower operative blood loss compared to 
the surgery alone, immunomodulators, cardiovascular modulators, steroids, and 
increased hepatic glycogen groups. Surgery alone had significantly lower operative 
blood loss compared to immunomodulators, cardiovascular modulators, and increased 
hepatic glycogen groups. In addition, the increased hepatic glycogen group had 
significantly higher operative blood loss compared to the hypothermia, antioxidants, 
steroids, and miscellaneous groups. The immunomodulators group resulted in 
significantly lower quantity of blood transfusion compared to the surgery alone, 
ischaemic preconditioning, and antioxidants groups. The pairwise comparisons for the 
outcomes serious adverse events and operative blood loss are shown in Table A.23 and 
Table A.24 respectively. 
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Table A.23: Metaregression – percentage of major liver resections. Pairwise odds ratios (OR) of the different treatment comparisons for 
the outcome serious adverse events (95% confidence intervals). Statistically significant results are in bold. Ischaemic preconditioning, 
cardiovascular modulators and miscellaneous classes of interventions were found to have significantly fewer serious adverse events 
compared to surgery alone. Steroids had significantly more serious adverse events compared to the miscellaneous class.  
 
 
 Ischaemic 
preconditioning 
Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Increased hepatic 
glycogen 
Miscellaneous 
Surgery alone OR 0.6 
(0.39 to 0.91) 
OR 0.51 
(0.16 to 1.62) 
OR 0.56 
(0.26 to 1.18) 
OR 0.34 
(0.13 to 0.87) 
OR 0.79 
(0.36 to 1.7) 
OR 0.82 
(0.18 to 3.78) 
OR 0.2 
(0.07 to 0.55) 
Ischaemic 
preconditioning 
- OR 0.86 
(0.25 to 2.93) 
OR 0.93 
(0.39 to 2.2) 
OR 0.57 
(0.2 to 1.59) 
OR 1.32 
(0.55 to 3.17) 
OR 1.37 
(0.28 to 6.7) 
OR 0.33 
(0.11 to 1) 
Antioxidants - - OR 1.08 
(0.27 to 4.27) 
OR 0.66 
(0.15 to 2.91) 
OR 1.53 
(0.38 to 6.1) 
OR 1.59 
(0.24 to 10.79) 
OR 0.38 
(0.08 to 1.79) 
Immunomodulators - - - OR 0.61 
(0.18 to 2.03) 
OR 1.41 
(0.48 to 4.14) 
OR 1.47 
(0.27 to 8.09) 
OR 0.35 
(0.1 to 1.26) 
Cardiovascular 
modulators 
- - - - OR 2.33 
(0.69 to 7.87) 
OR 2.43 
(0.4 to 14.62) 
OR 0.58 
(0.14 to 2.35) 
Steroids - - - - - OR 1.04 
(0.19 to 5.78) 
OR 0.25 
(0.07 to 0.91) 
Increased hepatic 
glycogen 
- - - - - - OR 0.24 
(0.04 to 1.51) 
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Table A.24: Metaregression – percentage of major liver resections. Pairwise mean differences (MD) of the different treatment comparisons 
for the outcome operative blood loss (95% confidence intervals). Statistically significant results are in bold. Ischaemic preconditioning was 
found to have significantly lower operative blood loss compared to the surgery alone, immunomodulators, cardiovascular modulators, 
steroids, and increased hepatic glycogen groups. Surgery alone had significantly lower operative blood loss compared to 
immunomodulators, cardiovascular modulators, and increased hepatic glycogen groups. In addition, the increased hepatic glycogen group 
had significantly higher operative blood loss compared to the hypothermia, antioxidants, steroids, and miscellaneous groups.  
 
 
  Hypothermia Ischaemic 
preconditioning 
Antioxidants Immunomodulators Cardiovascular 
modulators 
Steroids Increased hepatic 
glycogen 
Miscellaneous 
Surgery alone  MD 12.09 
(-167.5 to 
191.68) 
MD -36.18 
(-58.07 to -14.29) 
MD 26.47 
(-183.25 to 
236.19) 
MD 208.9 
(120.8 to 297) 
MD 136.1 
(54.09 to 218.11) 
MD 51.23 
(-0.02 to 102.48) 
MD 278.4 
(147.65 to 409.15) 
MD 13.66 
(-147.57 to 174.89) 
Hypothermia  - MD -48.27 
(-229.19 to 132.65) 
MD 14.38 
(-261.73 to 
290.49) 
MD 196.81 
(-3.23 to 396.85) 
MD 124.01 
(-73.42 to 321.44) 
MD 39.14 
(-147.63 to 
225.91) 
MD 266.31 
(44.16 to 488.46) 
MD 1.57 
(-239.78 to 242.92) 
Ischaemic 
preconditioning  
- - MD 62.65 
(-148.21 to 
273.51) 
MD 245.08 
(154.3 to 335.86) 
MD 172.28 
(87.4 to 257.16) 
MD 87.41 
(31.68 to 143.14) 
MD 314.58 
(182.01 to 447.15) 
MD 49.84 
(-112.87 to 212.55) 
Antioxidants  - - - MD 182.43 
(-45.04 to 409.9) 
MD 109.63 
(-115.55 to 334.81) 
MD 24.76 
(-191.13 to 
240.65) 
MD 251.93 
(4.79 to 499.07) 
MD -12.81 
(-277.34 to 251.72) 
Immunomodulators  - - - - MD -72.8 
(-193.16 to 47.56) 
MD -157.67 
(-259.6 to 
 -55.74) 
MD 69.5 
(-88.16 to 227.16) 
MD -195.24 
(-378.97 to 
 -11.51) 
Cardiovascular 
modulators  
- - - - - MD -84.87 
(-181.58 to 11.84) 
MD 142.3 
(-12.04 to 296.64) 
MD -122.44 
(-303.33 to 58.45) 
Steroids  - - - - - - MD 227.17 
(86.73 to 367.61) 
MD -37.57 
(-206.75 to 131.61) 
Increased hepatic 
glycogen  
- - - - - - - MD -264.74 
(-472.32 to -57.16) 
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A.4 DISCUSSION 
 
This network meta-analysis analysed data from 44 RCTs, comparing eight classes of 
interventions aimed at decreasing IR injury during liver resection and a control group 
which was surgery alone.  There was no statistically significant difference in mortality 
between the groups, and that was persistent during sensitivity analysis. The overall 
mortality found in this review was 1.3%, which is lower compared to the 3% to 4% 
overall mortality reported by large case series of liver resections.45, 46, 63 There is no 
clear reason why the mortality is lower in the trials included in this review, although, 
there is the possibility that the overall outcomes were better because patients were 
included in a trial, even if they were in the control group. Studies assessing whether 
there were harmful or beneficial effects to patients from participating in research trials 
gave contradictory results with some studies suggesting the outcomes of patients 
participating and not participating in trials were similar,393-395 and other studies 
suggesting that clinical trials have a positive effect on the outcome of participants.396-398 
There was no evidence to suggest that patients of lower anaesthetic risk were selectively 
recruited in the included RCTs. Nevertheless, the included trials were not powered to 
measure differences in mortality. If a trial was designed to compare short-term mortality 
after liver resection between an intervention aiming to decrease IR injury and control, a 
sample size of approximately 26,851 patients per group would be needed to detect a 
20% reduction in mortality, i.e. a reduction in mortality from 1.3% in the control group 
to 1.04% in the intervention group, based on alpha-error of 0.05 and 80% power. 
 
The rate of serious adverse events reported in this review was 17.2% which is slightly 
lower compared to other series of liver resection.45, 399, 400 The interventions aiming to 
decrease IR injury during hepatectomy are not treatments for serious adverse events, but 
through their mechanism of action and by decreasing the injury to the liver during 
surgery, may prevent or reduce the postoperative complication rate. Three groups of 
interventions – ischaemic preconditioning, cardiovascular modulators, and 
miscellaneous group – were found to have fewer serious adverse events compared to the 
surgery alone group. Sensitivity analysis confirmed ischaemic preconditioning to have 
fewer serious adverse events compared to surgery alone. The miscellaneous group had 
fewer serious adverse events compared to ischaemic preconditioning, 
immunomodulators, and steroids. Although there was a high probability that the 
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miscellaneous group of interventions was best in reducing or preventing serious adverse 
events (74% chance), sensitivity analysis performed showed none of the individual 
interventions within the miscellaneous group to have a high probability of being the best 
intervention in preventing serious adverse events. Overall, no individual intervention 
had a probability higher than 40% of being best intervention in reducing serious adverse 
events. Evaluation with sensitivity analyses showed sevoflurane (from the 
miscellaneous group of interventions) to result in fewer serious adverse events 
compared to surgery alone, ischaemic preconditioning, and pentoxifylline, possibly 
explaining the findings of the overall network meta-analysis regarding the 
miscellaneous group. Also, verapamil (from the cardiovascular modulators group) and 
gabexate mesilate (from the immunomodulators group) were found both to result in 
significantly less serious adverse events compared to surgery alone and pentoxifylline.  
 
All interventions in this review aimed at reducing IR injury during hepatectomy. But, if 
this were their sole mechanism of action we would expect all end points with a single 
intervention to be beneficial or not. Since this is not the case, it may suggest multiple 
additional actions for each intervention with multiple secondary effects. Hence, for each 
intervention there is the possibility of improvement in one complication (e.g. blood 
loss), without improvement in other outcomes (e.g. hospital stay or serious adverse 
events). For example, the antioxidant group of interventions (e.g. antioxidant 
multivitamin, allopurinol, mannitol, melatonin, propofol, vitamin E) is thought to 
decrease IR injury by reducing the amount of oxygen free radicals or reactive oxygen 
species produced during the ischaemic-reperfusion phase. Nevertheless, the beneficial 
effects of allopurinol is also thought to be mediated by improving resynthesis of ATP 
during reperfusion after ischaemia, and by preserving hepatocyte function.390, 401 
Mannitol is an osmotic diuretic with free radical–scavenging properties, which has been 
shown to reduce the extent of ischaemic injury and improve myocardial, renal, and 
cerebral function.377 Propofol, a widely used anaesthetic agent, has been shown to 
reduce free radical production under ischaemia–reperfusion conditions,87, 402 but may 
also have a protective effect against hepatic injury and improve liver metabolic function 
recovery.87 
 
Ischaemic preconditioning is the mechanism by which brief periods of ischaemia 
(hepatic vascular occlusion) followed by reperfusion of the organ results in the ability of 
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the organ to withstand a subsequent prolonged period of ischaemia.92 There have been 
trials in the literature demonstrating the beneficial effects of ischaemic preconditioning 
on the outcomes of liver resection surgery in patients with background healthy livers as 
well as those with background cirrhotic or steatotic livers by showing a decrease in 
postoperative liver enzymes which are markers for liver parenchymal injury.67, 68, 379, 380, 
403 Nevertheless, trials have not shown a significant benefit in clinical end points due to 
ischaemic preconditioning, reporting no statistically significant difference in mortality, 
morbidity, liver failure, hospital stay, or ITU stay.67, 68, 80, 368, 371 Although the exact 
mechanism of hepatic protection by ischaemic preconditioning is not known, it is 
considered to be multifactorial, including preservation of post-reperfusion adenosine 
triphosphate (ATP) content in liver tissue, inhibition of apoptosis, decrease in caspase-3 
(one of the mediators of apoptosis), activation of polymorphonuclear leukocytes, and 
release of substances such as metabolites of ATP degradation (e.g. adenosine) or nitric 
oxide (NO) by the ischaemic tissue which protect the liver against the subsequent 
prolonged ischaemic insult.68, 379, 391, 404 Furthermore, ischaemic preconditioning is 
found to result in improved cardiovascular stability by lowering the need for 
catecholamines after liver reperfusion without affecting the blood sparing benefits of the 
Pringle manoeuver.67 
 
The interventions belonging in the immunomodulators may decrease IR injury during 
hepatectomy through a range of actions: inhibition of neutrophil activation (gabexate 
mesilate, sivelestat), suppression of acute inflammatory cytokine reaction (gabexate 
mesilate, Prostaglandin E1, pentoxifylline, sivelestat), antioxidant action (gabexate 
mesilate), and anticoagulatory properties (gabexate mesilate, Prostaglandin E1, 
pentoxifylline).374-376, 384, 389, 405 Furthermore, the cardiovascular modulators group of 
interventions may reduce IR injury through a positive inotropic effect (amrinone), or 
through vasodilation enhancing splanchnic blood flow (amrinone, dopamine, 
dopexamine), or by preventing vasoconstriction and platelet aggregation (OKY 046).90, 
383, 385, 386 Verapamil is a calcium channel blocker which can maintain intracellular 
calcium homeostasis, prevent activation of Kupffer cells and release of cytokines, and 
attenuate IR injury of several organs including the liver.91, 406-409 The miscellaneous 
group contained drugs with multiple mechanisms of action. For example, sevoflurane, 
whose benefits were first shown in cardiac surgery, is thought to decrease IR injury 
through stimulation of adenosine receptors and subsequent activation of protein kinase 
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C and increased production of nitric oxide and free oxygen radicals.86, 370, 406, 410-412 
Although sevoflurane, verapamil, and gabexate mesilate were found to have fewer 
serious adverse events during sensitivity analysis, none of these treatments significantly 
reduced ITU or hospital stay, which would be anticipated if an intervention made a 
significant reduction in serious adverse events. 
 
On the other hand, ischaemic preconditioning showed multiple benefits including 
shorter hospital stay compared to the surgery alone group (i.e. versus no ischaemic 
preconditioning), decreased blood loss compared to all other interventions, shorter 
operative time (compared to steroids), and the highest probability of being best 
treatment for reducing the operative time (87%). The decreased operative time is 
perhaps counter-intuitive as the ischaemic preconditioning is in effect an additional 
operative manoeuver that takes additional time. However, ischaemic preconditioning 
used in combination with intermittent or continuous vascular occlusion, may decrease 
operative time by decreasing the time taken for parenchymal transection because of 
reduced blood loss during the surgery. The time necessary for haemostasis may be 
shortened and subsequent operative manoeuvers (such as parenchymal dissection) 
facilitated.371, 413 The reduced operative time related to ischaemic preconditioning may 
reduce the costs of surgery and possibly allow more surgeries to be performed. 
 
The main cause of IR injury during elective liver resection is blood inflow occlusion to 
the liver (e.g. with the Pringle manoeuver) which is used to decrease the blood loss and 
blood transfusion requirements. Intraoperative haemorrhage remains one of the major 
risks during liver resections, and increased operative blood loss and perioperative blood 
transfusion are directly related to higher morbidity and mortality.45, 46, 64, 65 Therefore, it 
would be important for any treatment aiming to decrease IR injury to also reduce 
operative blood loss. A decrease in blood loss with an associated decrease in blood 
transfusion, adverse events, and hospital stay, may also result in decreased costs. This 
study showed that ischaemic preconditioning had significantly lower operative blood 
loss compared to the surgery alone group and compared to all other interventions, and it 
had a high probability of being the best treatment for this outcome. These findings 
persisted during sensitivity analysis. Another important finding during analysis of this 
outcome was that the surgery alone group (control group) had significantly lower 
operative blood loss compared to all other interventions, except the ischaemic 
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preconditioning group. Therefore, not only was ischaemic preconditioning the only 
intervention to significantly reduce blood loss, but also all other interventions resulted 
in significantly higher operative blood loss compared to the surgery alone group. These 
results were persistent during sensitivity analyses and would suggest that other than 
ischaemic preconditioning the other interventions are ineffectual at reducing blood loss. 
 
The results on operative blood loss were not reciprocated on blood transfusion 
requirements (proportion of patients transfused and quantity of blood transfusion), 
where there were no significant differences between interventions, apart from a 
significantly lower proportion of patients transfused with ischaemic preconditioning 
compared to steroids. The fewer people transfused with ischaemic preconditioning 
compared to steroids is most likely due to reduced bleeding caused by ischaemic 
preconditioning as suggested in the above paragraph, rather than increased blood loss 
caused by steroids. RCTs comparing steroids versus controls showed no significant 
difference in operative blood loss and blood transfusion requirements.84, 85, 366, 367 On the 
other hand, some RCTs comparing ischaemic preconditioning versus controls showed 
no statistically significant difference in operative blood loss and blood transfusion 
requirements,68, 80, 258, 379, 391 and other RCTs demonstrated significantly reduced 
bleeding and/or significantly decreased blood transfusion requirements with ischaemic 
preconditioning compared to controls.76, 371, 387 The variance in the results of RCTs 
regarding operative blood loss for ischaemic preconditioning may be due to trial size 
(i.e. not enough patients included in the trial to show statistical significance), different 
patient selection criteria, different methods of measuring blood loss, and variability of 
ischaemic preconditioning protocols between trials (e.g. variability in the timing of 
ischaemic preconditioning and the type of vascular occlusion performed during liver 
resection). 
 
This is the first network meta-analysis of IR injury therapies in liver resection surgery, 
but previously there have been standard pairwise meta-analyses comparing individual 
components aiming to decrease IR injury. The advantage of network meta-analysis over 
standard pairwise meta-analysis is that it facilitates indirect comparisons of multiple 
interventions that have not been studied in a head-to-head fashion.148 A network meta-
analysis may also yield more reliable and definitive results than would a pairwise meta-
analysis.148 One pairwise meta-analysis included five RCTs which compared one 
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pharmacological agent versus another pharmacological agent (a total of 9 different 
pharmacological agents).71 The meta-analysis suggested that there was no significant 
difference between the groups in mortality, liver failure, or perioperative morbidity.71 
Nevertheless, a statistical meta-analysis of the data with forest plots could not be 
performed since indirect comparisons of the different pharmacological agents were not 
possible with a pairwise meta-analysis.71 This deficiency has been addressed by the 
current network meta-analysis.  
 
Another pairwise meta-analysis included fifteen RCTs comparing any pharmacological 
agent versus placebo or no pharmacological agent.364 The pharmacological agents 
included in the pairwise meta-analysis were:  methylprednisolone, multivitamin, 
antioxidant infusion, vitamin E infusion, amrinone, prostaglandin E1, pentoxifylline, 
mannitol, trimetazidine, dextrose, allopurinol, and OKY 046.364  Again, similar to the 
previous pairwise meta-analysis, indirect comparisons between groups could not be 
performed, and the only statistical meta-analysis performed was of four RCTs 
comparing Prostaglandin E1 versus placebo, and a separate meta-analysis of three 
studies comparing Methylprednisolone versus control.364 The meta-analysis showed no 
significant differences between the groups in mortality, liver failure, or perioperative 
morbidity. The authors reported that trimetazidine had a significantly shorter hospital 
stay than control, and that trimetazidine, methylprednisolone, and dextrose reduced the 
enzyme markers of liver injury compared with controls.364 Again the deficiencies of the 
pairwise meta-analysis have been addressed by the current network meta-analysis which 
has shown no significant clinical benefit for any of the pharmacological interventions 
included in the pairwise meta-analysis. 
 
A meta-analysis comparing ischaemic preconditioning versus no ischaemic 
preconditioning found no significant difference in mortality, morbidity, hospital stay, or 
ITU stay but showed reduced blood transfusion requirements with ischaemic 
preconditioning.368 Another meta-analysis comparing trials of ischaemic 
preconditioning versus intermittent vascular inflow occlusion showed, similar to this 
network meta-analysis, shorter operative time with ischaemic preconditioning, and no 
difference in mortality, morbidity, and hospital stay.414 Both previous meta-analyses368, 
414 did not show a significant decrease in blood loss with ischaemic preconditioning, 
possibly due to a lower number of RCTs included (4 RCTs368 and 5 RCTs414). 
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Furthermore, a meta-analysis evaluating ischaemic preconditioning found, similar to 
this meta-analysis, no significant difference in mortality, morbidity, liver failure, or 
length of ITU stay between ischaemic preconditioning plus continuous clamping versus 
continuous clamping, or between ischaemic preconditioning plus (continuous clamping 
or intermittent clamping) versus intermittent clamping.413 The same meta-analysis 
reported significantly shorter length of hospital stay and a significant reduction in the 
proportion of patients having blood transfusion with ischaemic preconditioning plus 
continuous clamping versus continuous clamping.413 Finally, similar to this network 
meta-analysis, shorter operative time was reported with ischaemic preconditioning plus 
(continuous clamping or intermittent clamping) versus intermittent clamping.413 
Overall, the results of this network meta-analysis agree with the results of previous 
meta-analyses and RCTs, and would suggest multiple beneficial clinical end points to 
ischaemic preconditioning treatment, indicating that ischaemic preconditioning should 
be introduced into routine clinical practise during liver resection surgery. Any small 
variations in the results may have resulted due to variation between trials possibly 
reflecting trial size (e.g. not enough patients included in a trial to show statistical 
significance), patient selection criteria and case mix, different methods of measurement 
(e.g. methods of measuring blood loss), protocols (e.g. variability in the timing of 
ischaemic preconditioning and the type of vascular occlusion performed during liver 
resection), and end points evaluated. 
 
In all the trials included in the current review, where ischaemic preconditioning was 
used to decrease IR injury, ischaemic preconditioning was performed with liver vascular 
inflow occlusion (also called Pringle manoeuver or portal triad clamping). Nevertheless, 
there was variability between trials in the timing of ischaemic preconditioning and the 
type of vascular occlusion performed during liver resection. The downside of this is that 
it does not allow for the optimal ischaemic preconditioning protocol to be determined 
accurately or even whether some protocols were ineffective. In some trials, ischaemic 
preconditioning was performed with 10 minutes of vascular inflow occlusion and 10 
minutes of reperfusion,67, 68, 76, 79, 80, 258, 317, 371, 382, 387 whereas in other trials ischaemic 
preconditioning was performed with 5 minutes of vascular inflow occlusion and 5 
minutes of reperfusion.372, 379, 380 Furthermore, in some trials ischaemic preconditioning 
was followed by vascular inflow occlusion (or Pringle manoeuver) for liver resection,67, 
68, 76, 258, 317, 371, 372, 379, 380, 382 whereas in other trials it was followed by selective hepatic 
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vascular exclusion (occlusion of inflow to the hemi-liver and outflow from the hemi-
liver that is being resected)80, 387 or hepatic vascular exclusion (i.e. simultaneous 
clamping of the portal triad and the main hepatic veins).79 
 
Sensitivity network meta-analysis comparing only pharmacological interventions (i.e. 
excluding ischaemic preconditioning and hypothermia), showed no significant 
differences between the individual pharmacological interventions in mortality, number 
of patients transfused, and ITU stay. Similar to the overall analysis, cardiovascular 
modulators and the miscellaneous group were found to have fewer serious adverse 
events compared to surgery alone. Comparison of the individual pharmacological 
interventions, showed specifically sevoflurane, verapamil, and gabexate mesilate to 
have fewer serious adverse events compared to surgery alone and pentoxifylline, similar 
to the results of the overall analysis. It is not clear how these pharmacological 
interventions reduce serious adverse events and it is not sufficient to justify their use 
based on the findings of the current literature, and, therefore, more trials are required to 
further investigate the use of these pharmacological interventions during liver resection. 
Furthermore, similar to the findings of the overall analysis, the surgery alone group had 
lower operative blood loss compared to the antioxidants, immunomodulators, 
cardiovascular modulators, steroids, increased hepatic glycogen, and miscellaneous 
groups. Without ischaemic preconditioning in the analysis, the surgery alone group had 
a high probability (99%) of being the best treatment for operative blood loss in the 
analysis of only pharmacological interventions. This suggests that the pharmacological 
agents increase blood loss, and this apparent disadvantage should be weighed against 
any apparent benefit of pharmacological interventions, e.g. in reducing serious adverse 
events. A possible explanation in the increase in operative blood loss by these 
pharmacological agents is that by increasing the microvascular flow and perfusion of 
the liver in order to decrease IR injury, they result in increased overall blood flow and 
blood loss during hepatectomy. 
 
Possible sources of bias in this network meta-analysis are the proportion of cirrhotic and 
steatotic livers included in each trial, and the proportion of patients undergoing major 
liver resections in each trial. Therefore, metaregressions were performed based on the 
proportion of cirrhotic livers and major liver resections included in each trial. 
Unfortunately, due to the low number of trials reporting on the number of steatotic 
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livers included (only 7 trials), a metaregression based on the proportion of steatotic 
livers was not possible. A metaregression based on the percentage of cirrhotic livers 
included in each trial showed no significant difference between the classes of 
interventions with regards to mortality, proportion of patients transfused, quantity of 
blood transfused per patient, operating time, hospital stay, and ITU stay. The 
metaregression based on the percentage of major liver resections performed in each trial 
showed no significant difference between the classes of interventions with regards to 
mortality, operating time, and ITU stay. Similar to the overall analysis, both 
metaregressions showed ischaemic preconditioning, cardiovascular modulators and 
miscellaneous classes of interventions to have fewer serious adverse events compared to 
surgery alone. In addition, ischaemic preconditioning was found to result in lower 
operative blood loss compared to the immunomodulators, miscellaneous, and surgery 
alone groups in the metaregression based on the number of cirrhotic livers, and 
compared to the immunomodulators, cardiovascular modulators, increased hepatic 
glycogen, and surgery alone groups in the metaregression based on the number of major 
liver resections. The latter metaregression also showed ischaemic preconditioning to 
result in fewer patients needing blood transfusion compared to surgery alone, and 
shorter length of hospital stay compared to surgery alone. 
 
The results of the network meta-analysis did not allow one superior intervention to be 
identified. However, ischaemic preconditioning, which can be achieved without any 
requirement for equipment, costs, or additional expertise, has a high likelihood of being 
beneficial to the patients undergoing liver resection. Further RCTs are needed to 
confirm clinical benefit in order to allow ischaemic preconditioning to become standard 
practice during liver resection. Sensitivity analysis identified three drugs (sevoflurane, 
verapamil, and gabexate mesilate) which may reduce serious adverse events during 
elective liver resection. This network meta-analysis could be used to design future 
RCT’s related to the treatment of IR injury during liver resection surgery and the impact 
of treatment on costs, quality of life, and long-term outcomes. RCTs comparing 
interventions aiming to decrease IR injury will require high number of patients to be 
recruited to identify statistically significant differences in outcomes (for example, 
approximately 2051 patients in each group would be needed to identify a 10% reduction 
in morbidity, i.e. reduction in morbidity from 43% in the control group to 38.7% in the 
intervention group, based on alpha-error of 0.05 and 80% power). To overcome this 
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problem, instead of a parallel design, a factorial trial design for an RCT may be used 
where multiple interventions (‘factors’) can be assessed in the same trial, reducing the 
overall sample size needed for the trial and allowing for exploration of interactions 
between multiple interventions.415 
 
 
 
 
 
 
A.5 CONCLUSIONS 
 
This network meta-analysis included 44 RCTs, and was performed to assess the 
comparative benefits and harms of different methods that aim to decrease IR injury 
during elective liver resection. There was no significant difference between the different 
interventions in mortality, quantity of blood transfusion, and ITU stay. Patients treated 
with ischaemic preconditioning, cardiovascular modulators, and miscellaneous 
interventions had significantly fewer serious adverse events compared to patients 
receiving surgery alone. Ischaemic preconditioning patients had significantly fewer 
transfusion proportions and shorter operative time than patients treated with steroids. 
Also, ischaemic preconditioning had significantly lower operative blood loss compared 
to all other interventions, and shorter length of hospital stay than surgery alone. 
Sensitivity analysis identified three drugs, sevoflurane (a volatile anaesthetic), 
verapamil (a calcium channel blocker), and gabexate mesilate (a thrombin inhibitor) 
which may reduce serious adverse events during elective liver resection, and further 
RCTs are needed to investigate these results. Importantly, ischaemic preconditioning 
showed promising results for most outcomes, and should be introduced into routine 
clinical practise during liver resection surgery. 
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